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Abstract 
 
Members of the glial cell line-derived neurotrophic factor (GDNF) family of ligands 
(GFL) comprising GDNF, neurturin and artemin, show efficacy in rat neuropathic 
pain models and promote regeneration after nerve injury. Their receptors, GFRα1-3 
respectively, are expressed by adult dorsal root ganglion (DRG) neurons and each 
have distinct central projection patterns, strongly suggesting different functions.  
Many sacral bladder afferent neurons express GFRα1- and GFRα3-immunoreactivity 
and following chronic bladder inflammatory pain, GFRα1 expression in the sacral 
dorsal horn is increased in an area receiving afferent projections from the bladder. 
Results from this study suggest that GDNF has the potential to modulate sacral 
visceral pathways during inflammation. Changes in GFR expression in the dorsal 
horn have also been reported following spinal cord injury, suggesting that altered 
GFR signalling may contribute to the mechanisms that initiate and maintain 
neuropathic pain. Other studies have demonstrated that the GFLs can sensitise 
nociceptors, which is dependent on the peripheral targets of the nociceptor as it varies 
between afferents innervating visceral or somatic (skin, muscle) tissues. Together 
these results indicate that the GFLs and their receptors can contribute to the 
mechanisms underlying nociceptor sensitisation and the development of pain 
following nerve injury and inflammation. 
 
In this thesis, I have used immunohistochemical techniques to investigate the effects 
of nerve injury and visceral inflammation on nociceptors expressing receptors for the 
GFLs in adult rats. Specifically, I have investigated the effects of somatic and visceral 
nerve injury on nociceptors and their central terminals expressing the GFRs. To 
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determine the effect of somatic (sciatic) nerve injury on nociceptors expressing the 
GFRs, two injury models were used, chronic constriction and transection, which 
differ in severity and the development of nociceptive behaviours. GFR expression 
was compared in lumbar dorsal horn following transection or constriction. DRG 
neurons expressing the GFRs were also analysed after transection. To study visceral 
nerve injury, the pelvic and/or the hypogastric nerves, that innervate the bladder and 
other pelvic viscera, were transected. The distribution of their central terminals 
expressing the GFRs were analysed in lumbar and sacral spinal cord, regions where 
axons travelling in these nerves project. Results from these experiments show that 
nerve injury has profound effects on GFR expression in DRG neurons and their 
central projections. Each population of GFR-expressing neurons respond differently 
to somatic and visceral nerve injury. Furthermore, injury to somatic and visceral 
nerves produce different effects on the central distribution of neurons expressing the 
GFRs. These results suggest that each ligand may contribute differently to plasticity 
following nerve injury that may impact regeneration or the development of pain. 
 
The second study characterised lumbar and sacral bladder afferent neurons expressing 
the GFRs and determined the impact of chronic bladder inflammation induced by 
cyclophosphamide on different populations of bladder afferent neurons. The 
distribution of their central terminals was also investigated in upper lumbar cord, an 
area of bladder afferent projection. Results from this study demonstrate that GDNF 
and artemin target different functional groups of bladder afferent neurons, potentially 
regulating different components of bladder function and modulating distinct aspects 
of bladder activity and pain during inflammation. Chronic bladder inflammation had 
no effect on immunohistochemical properties of bladder afferent neurons expressing 
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the GFRs. Each GFR had distinct central projections in lumbar cord, and in contrast 
to sacral cord, these were unaffected by chronic inflammation. This suggests that 
GDNF has the potential to mediate plasticity of sacral afferents following chronic 
inflammation, but is unlikely to effect lumbar visceral afferents in the same way. 
Induction of activated transcription factor 3 following acute bladder inflammation 
was also used to potentially identify the population of bladder afferent neurons that 
are injured or undergoing structural remodelling during inflammation. This study 
identified a subpopulation of sacral neurons expressing nitric oxide synthase that are 
likely to be undergoing structural remodelling during acute inflammation. These 
results contribute to the increased understanding of the neurons that are known to be 
involved in pain modulation and hyperreflexia during inflammation.  
 
The final study aimed to identify the potential targets of GFRα3 axons across 
different regions and tissues in the bladder of adult female rats. We also determined if 
chronic bladder inflammation altered the structure and distribution of axons 
containing GFRα3 in the bladder and how these compare to other classes of sensory 
and autonomic axons. Immunolabelling of GFRα3 was performed on bladder 
wholemounts and cryosections, comparing results with other major afferent and 
autonomic axonal populations. GFRα3 axons were widely distributed throughout the 
bladder and labelled specific populations of peptidergic afferent axons, sympathetic 
noradrenergic vasoconstrictor axons and glial cells. Chronic bladder inflammation 
had no effect on the structure of GFRα3 axons in the bladder.  
 
Together, results from this thesis provide evidence that the three populations of 
nociceptors expressing the GFRs show distinct responses to nerve injury and 
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inflammation. This has important implications for regeneration after injury and how 
pain arises from somatic and visceral origin. GDNF and artemin have the potential to 
regulate different aspects of bladder function and may also contribute to pain or 
hyperreflexia following inflammation. Results from this thesis indicate that GFLs and 
their receptors represent a promising new target for therapies aimed at regeneration 
and the development of pain.  
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 CHAPTER 1: General introduction 
 
1.1 Overview 
Pain originating from the viscera, termed visceral pain, is one of the most common 
types of pain seen in the clinical setting. Animal models of visceral inflammatory pain 
show alterations in structural, neurochemical and electrophysiological properties of 
dorsal root ganglion (DRG) neurons. These changes are thought to be responsible for 
nociceptor sensitisation and the development of pain (Callsen-Cencic and Mense, 
1997; Vizzard, 2001; Yoshimura and de Groat, 1999). Nerve growth factor (NGF), a 
member of the neurotrophin family of neurotrophic factors, is well known to have an 
important role in the development of nociceptor sensitisation and pain (Malin et al., 
2006; Woolf et al., 1994). NGF binds to the tyrosine kinase receptor, trkA and the p75 
receptor, which are expressed by adult DRG neurons (Averill et al., 1995; Bennett et 
al., 1996; Klinger et al., 2008). This group of neurons are referred to as the 
peptidergic population and express one or more neuropeptides including calcitonin 
gene-related peptide (CGRP) and substance P (SP) (Lewin, 1996; Pezet and 
McMahon, 2006).  
 
A significant proportion of DRG neurons are insensitive to NGF and do not 
synthesise neuropeptides. Most of this group are C-type neurons and are referred to as 
the non-peptidergic population and are responsive to members of the glial cell line-
derived neurotrophic factor (GDNF) family of ligands (GFLs) (Bennett et al., 1998). 
The GFLs comprise GDNF, neurturin, artemin and persephin, which signal via their 
receptors GFRα1-4 respectively and the co-receptor Ret (Airaksinen and Saarma, 
2002). The GFRs (GFRα1-3) are expressed in separate DRG populations where 
1
 GFRα1 and GFRα2 are expressed by non-peptidergic neurons, whereas GFRα3 is 
exclusively expressed in a subpopulation of peptidergic neurons (Orozco et al., 2001). 
Our laboratory has reported that two of the GFRs (GFRα1 and GFRα3) are expressed 
by one quarter of bladder afferent neurons in the rat, and further demonstrated that 
each GFR has distinct distribution patterns in sacral spinal cord (Forrest and Keast, 
2008). These results raise the possibility that each type of GFR-expressing neuron has 
a different function and supraspinal connectivity. 
 
There is accumulating evidence to suggest that members of the GFLs can influence a 
number of pain states and contribute to nociceptor sensitisation (Elitt et al., 2006; 
Gardell et al., 2003; Malin et al., 2011; Malin et al., 2006; Nagano et al., 2003; Wang 
et al., 2008). Following chronic bladder inflammatory pain in rats, GFRα1 expression 
is increased in the sacral dorsal horn (Forrest and Keast, 2008), an area receiving 
afferent projections from the bladder (Steers et al., 1991). Results from this study 
indicate that GDNF could modulate sacral visceral afferent pathways during 
inflammation. These results matched reports that GDNF is increased in the urine of 
patients with interstitial cystitis, a condition characterised by chronic pelvic pain 
(Okragly et al., 1999). Changes in GFR expression in the dorsal horn also occur 
following spinal cord injury, suggesting that GFR signalling could contribute to 
mechanisms that initiate and maintain neuropathic pain (Kalous et al., 2007; 2009). 
Following sciatic nerve injury, GDNF administration prevents the loss of non-
peptidergic fibres in the dorsal horn (Bennett et al., 2000) and reduces neuropathic 
pain responses (Nagano et al., 2003). Administration of artemin has been reported to 
promote regeneration of injured primary afferent fibres and reverse the onset of 
neuropathic pain following nerve injury (Gardell et al., 2003; Wang et al., 2008). In 
2
 addition, members of the GFLs have been shown to regulate the sensitivity of 
nociceptors to thermal stimuli and induce prolonged nociceptor sensitisation and pain 
(Malin et al., 2006a).  
 
These studies raise the possibility that the GFLs and their receptors could be regulated 
by different inflammatory and injury conditions, and that altered GFR signalling is 
likely to contribute to the mechanisms underpinning nociceptor sensitisation and the 
development of pain. The goal of this thesis was to investigate the impact of bladder 
inflammation and nerve injury on nociceptors expressing receptors for the GFLs and 
their central projections. The following literature review addresses the topics of 
bladder pain and innervation, bladder dysfunction caused by inflammation and how 
NGF can regulate bladder function. In addition, this review will outline the emerging 
evidence of how bladder function can be regulated by the GFLs. It will demonstrate 
how the GFLs have been implicated in different pain states, including neuropathic 
pain. This review will also show how the GFRs can be used as tools to investigate 
different afferent pathways that have not been previously identified. 
 
1.2 Visceral pain 
1.2.1 Overview 
Pain originating from the organs, termed visceral pain, is very different to somatic 
pain, which originates from the skin, joints and musculature. Visceral pain is one of 
the most frequent forms of pain seen in the clinical setting (Cervero and Laird, 2004; 
Giambererdino, 1999) and has many unique characteristics that set it apart from other 
types of pain. Visceral pain is poorly localised, diffuse, and often associated with 
referred pain to somatic structures, such as in angina and appendicitis (Gebhart and 
3
 Bielefeldt, 2008). Pain is not evoked from all organs, and many solid organs such as 
the liver and lungs are typically insensitive to pain where injury can go unnoticed. In 
contrast, hollow organs such as the bladder and gastrointestinal tract are very sensitive 
to pain, triggered by excessive distension and contraction, but are insensitive to most 
stimuli that cause pain in somatic structures (Cervero and Laird, 1999). For example, 
cutting, pinching, crushing and heat stimuli evoke painful sensations in somatic 
structures, but these can go unnoticed in the viscera (Robinson and Gebhart, 2008). In 
general, visceral pain is difficult to treat and resistant to many analgesic therapies that 
alleviate somatic pain (Cervero and Laird, 2004; Giambererdino, 1999; McMahon et 
al., 1995). 
 
Compared to somatic tissues, few DRG neurons project to the viscera (Robinson and 
Gebhart, 2008). These neurons are thought to contribute 5-8% of the total afferent 
input into the spinal cord (McMahon and Koltzenburg, 2006). This relatively small 
group of neurons still provide numerous terminals to the organs and to the spinal cord 
because of the wide arborisation of their peripheral and central terminals (Cervero and 
Connell, 1984; Ness and Gebhart, 1990; Robinson and Gebhart, 2008). Intracellular 
labelling of DRG neurons with Phaseolus vulgaris leucoagglutinin (PHA-L) has been 
used to visualise and compare the central projections of single somatic and visceral 
afferent fibres (Sugiura et al., 1986; Sugiura et al., 1989; Sugiura et al., 1993). 
Somatic or visceral DRG neurons were identified by responses evoked by electrical 
stimulation of the subcostal (somatic) nerve or celiac (visceral) ganglion. After 
identification (somatic or visceral) of a DRG neuron, PHA-L was injected 
iontophoretically by positive current, where only one neuron was labelled in each 
animal. After labelling, animals were allowed to survive 2-4 days before being 
4
 sacrificed, to enable the tracer to reach the central terminals (Sugiura et al., 1989; 
Sugiura et al., 1993). The central projections of labelled DRG neurons terminate in 
different laminae of Rexed, areas of spinal grey matter that are subdivided into ten 
cytoarchitecturally different divisions based on cellular structure (Rexed, 1952) 
(Figure 1.1a-c). Individual somatic afferents have a smaller terminal field than 
visceral afferents and project to the ipsilateral spinal cord. Somatic afferents primarily 
terminate in laminae I and II of the dorsal horn and are spread across fewer spinal 
segments (Figure 1.2a). Few somatic terminals extend into laminae III-V. Often 
single somatic afferents will issue several branches upon entering the dorsal horn that 
combine to produce tight nest-like terminal fields (Sugiura et al., 1986; Sugiura et al., 
1989; Sugiura et al., 1993). In comparison, visceral afferents terminate in laminae I, 
II, V and X in the ipsilateral spinal cord. Some terminals extend into laminae V and X 
on the contralateral side. Central projections of visceral afferents are closely 
associated with autonomic preganglionic motor neurons in the intermediolateral cell 
column (IML) and the dorsal grey commissure (DGC) (Figure 1.1c). Single visceral 
fibres spread across multiple spinal levels, rostral and caudal to their point of entry 
and issue side branches across the dorsal horn (McMahon and Koltzenburg, 2006; 
Sugiura et al., 1989) (Figure 1.2b). These features of visceral afferents contribute to 
many of the unique features of visceral sensation and likely contribute to the 
development of referred pain, with visceral afferents often terminating on the same 
second order neurons that receive input from somatic afferents (Robinson and 
Gebhart, 2008). 
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Figure 1.1 Organisation of laminae in the lumbar 1 and lumbar 6 spinal cord. a, b. 
Diagrammatic representation of a transverse lumbar 1 (a) and lumbar 6 (b) spinal 
segment in the rat. The spinal cord is divided into ten cytoarchitecturally different 
divisions based on cell structure and density. c. A transverse section of lumbar 6 
spinal cord in the cat showing the location of sacral parasympathetic preganglionic 
neurons (shaded areas). IML, intermediolateral cell column; LSN, lateral spinal 
nucleus; SPN, sacral preganglionic nucleus; VM, ventromedial nucleus (Onuf’s 
nucleus). Images (a) and (b) adapted from Paxinos and Watson (2005), image (c) 
adapted from Fowler et al., (2008). 
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Figure 1.2 Central terminations of somatic and visceral afferent fibres in the guinea 
pig spinal cord. a. The terminal field from one somatic afferent fibre, which has a 
localised distribution pattern in the dorsal horn, terminating in laminae I and II of the 
13th thoracic spinal segment. b. A reconstruction of the arborisation from the 10th 
thoracic to the second lumbar spinal segment of a single visceral afferent fibre traced 
from the celiac (visceral) ganglion. Visceral fibres have a widespread distribution in 
the spinal cord, terminating in laminae I, II, V, X, intermediolateral cell column 
(IML) and the dorsal grey commissure (DGC). Scale bar in (a) represents 100 µm 
(applies to both diagrams). Adapted from Sugiura et al., 1989. 
 
 
Referred pain has been reported in clinical and experimental animal studies. Patients 
with bladder pain often report altered function and pain in the bowel, and conversely, 
patients with irritable bowel syndrome will report symptoms of pelvic and / or bladder 
pain (Francis et al., 1997; Nickel et al., 2010; Whitehead et al., 2002). In addition, 
patients with irritable bowel syndrome have also reported increased pain sensitivity in 
their hands and feet (Verne et al., 2001). Together, these studies demonstrate that 
referred pain occurs between neighbouring visceral organs, and between the viscera 
and somatic structures. Referred pain originating from a visceral organ, which is then 
perceived in a neighbouring organ or somatic structure originates from viscero-
visceral, or viscero-somatic convergence, respectively (Bielefeldt et al., 2006). 
Convergence occurs when primary afferent neurons innervating one organ or tissue, 
synapse onto the same second order neuron receiving input from primary afferent 
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 neurons innervating another organ or tissue. This causes pain to be perceived in the 
other structure (Bielefeldt et al., 2006). 
 
Experimental evidence of viscero-visceral and viscero-somatic convergence 
originates from functional and anatomical animal studies. Early functional studies in 
cats (Fields et al., 1970; Foreman et al., 1984; Garrison et al., 1992; Rigamonti et al., 
1978) and rats (Ness and Gebhart, 1987) demonstrate that second order neurons can 
receive both visceral and somatic input, providing an anatomical basis for referred 
pain. Rat models of bladder inflammatory pain (discussed in detail in section 1.2.3) 
induced by protamine sulphate and potassium chloride infusion show altered 
responses to colorectal distension, indicative of a pain-like state (Pezzone et al., 
2005), and colorectal distension produces bladder pain-like symptoms (Qin and 
Foreman, 2004). Both studies suggest viscero-visceral convergence for the 
development of referred pain in neighbouring organs. Similar studies in mice 
demonstrate that bladder inflammatory pain induced by two injections of the pro-
inflammatory agent, cyclophosphamide (CYP, 50µl/kg, i.p, 3 days apart) increases 
viscero-motor responses to colorectal distension (Bielefeldt et al., 2006) indicating a 
pain-like state. This study also demonstrated that bladder inflammatory pain increases 
thermal and mechanical pain sensitivity in the hindpaw. Conversely, inflammation of 
the hindpaw by complete Freund’s adjuvant (CFA) increases responses to colorectal 
distension (Bielefeldt et al., 2006). Together, these results indicate that: 1) visceral 
inflammatory pain sensitises visceral afferent neurons innervating neighbouring 
organs, which synapse onto the same second order neurons, referred to as viscero-
visceral convergence. Sensitisation is the increased responsiveness of neurons to their 
normal inputs (Loesser and Treede, 2008) and will be discussed in more detail in 
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 section 1.4; 2) visceral inflammatory pain sensitises somatic afferent neurons, which 
synapse onto the same second order neurons, referred to as viscero-somatic 
convergence and 3) somatic inflammatory pain sensitises visceral afferent neurons, 
which converge onto the same second order neurons, referred to as somato-visceral 
convergence (Bielefeldt et al., 2006). 
 
A second mechanism for the development of referred pain arises from functional and 
anatomical data suggesting that a number of primary afferent neurons have axons 
innervating two anatomically different tissues. For example, a single DRG neuron 
innervating two different visceral organs or, a single DRG neuron innervating a 
visceral and somatic structure. These neurons are referred to as dichotomising 
afferents (Ness and Gebhart, 1990; Lamb et al., 2005), which were first proposed to 
exist by Sinclair et al., 1948 (Figure 1.3). Functional studies using intracellular 
recordings of DRG neurons in cats (Bahr and Jänig, 1981) and rats (Pierau et al., 
1982) show single neurons that innervate two visceral organs, or visceral and somatic 
targets. In DRG neurons from rats in which retrograde tracer dyes were injected into 
both the bladder and colon, up to 17% of labelled neurons contain both dyes 
(Christianson et al., 2007; Keast and deGroat, 1992) indicating these double-labelled 
neurons innervate both organs. The anatomical arrangement of dichotomising afferent 
neurons has been proposed as a potential mechanism for neuronal cross-talk between 
different visceral organs, or between visceral and somatic structures that could form 
the underlying basis of referred pain. 
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Figure 1.3 Dichotomising afferent neurons innervate two anatomically different 
tissues. Depicted here are two dorsal root ganglion (DRG) neurons with branching 
peripheral axons; one DRG neuron innervating the viscera and muscle, and the other 
innervating muscle and skin. Dichotomising afferent neurons contribute to the 
underlying basis of referred pain. Adapted from Sinclair et al., 1948. 
 
 
1.2.2 Bladder pain – clinical conditions 
Chronic pelvic pain, defined as intermittent or constant pain in the lower abdomen or 
pelvic region of at least six months duration (Vincent, 2009), negatively impacts 
quality of life and causes significant health care costs (Moutzouris and Falagas, 
2009). The cause of chronic pelvic pain is multifactorial with pathologies arising from 
gynaecological, urological, gastrointestinal, musculoskeletal, neurological origin, or 
of unknown etiology (Vercellini et al., 2009). Interstitial cystitis, also referred to as 
interstitial cystitis / painful bladder syndrome (Gebhart and Bielefeldt, 2008; 
Theoharides et al., 2008), is a common cause of chronic pelvic pain with reports 
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 suggesting that the majority (82%) of patients with chronic pelvic pain have 
interstitial cystitis (Paulson and Delgado, 2007). Most studies classify interstitial 
cystitis as a chronic inflammatory condition of the lower urinary tract causing chronic 
pelvic pain, increased urinary frequency and urgency, and decreased bladder capacity 
(Rosenberg et al., 2007). However, that interstitial cystitis is a chronic inflammatory 
condition is now seen as controversial, as more recent reports provide evidence that 
biopsies from patients show little or no inflammation, and their bladder capacity is not 
altered in the majority (~90%) of cases (Leiby et al., 2007; Potts and Payne, 2012). 
Regardless of this discrepancy, chronic pain is one of the main symptoms of 
interstitial cystitis (Potts and Payne, 2012; Rosenberg et al., 2007). 
 
Symptoms associated with interstitial cystitis are more common in females, and vary 
with the menstrual cycle (Chancellor and Yoshimura, 2004; Dawson and Jamison, 
2007; Rosenberg et al., 2007). The prevalence of interstitial cystitis in the general 
population is between 2-20%, but this varies between studies (Fall et al., 2010; French 
et al., 2009; Stanford et al., 2007). However, a recent report (Konkle et al., 2012) 
suggests that the incidence of interstitial cystitis is higher in the general population 
and is currently under-diagnosed. Part of this problem arises from the difficulty in 
diagnosing interstitial cystitis, as many of its symptoms overlap with other urological 
and gynaecological diseases (Butrick, 2007; Sant and Hanno, 2001; Sant and 
Theoharides, 1999; Stanford et al., 2007). Treatments for interstitial cystitis are 
typically not very effective and are generally aimed at symptom relief. Non-
pharmacologic approaches include educating patients about symptoms, stress 
reduction and dietary changes to help control and cope with symptoms (Rosenberg et 
al., 2007). Pharmacological approaches aim to restore bladder integrity and function, 
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 and reduce inflammation and pain. These include anti-inflammatory and anti-
muscarinic agents to alleviate symptoms of urinary frequency and urgency. The anti-
depressant, amitriptyline, is used to regulate pain and relieve symptoms of urgency, 
whereas pentosan polysulfate sodium is used to restore the damaged bladder 
urothelium in patients with interstitial cystitis (Potts and Payne, 2012; Rosenberg et 
al., 2007). Administration of a variety of drugs directly into the bladder can also help 
alleviate urinary urgency and frequency (Rosenberg et al., 2007). These treatments 
may provide some pain relief and alleviation of bladder symptoms, but they do not 
cure the disease (Potts and Payne, 2012; Rosenberg et al., 2007; Sant and 
Theoharides, 1999). 
 
1.2.3 Experimental animal models of bladder pain 
Developing adequate animal models of visceral pain is fundamental for investigating 
the mechanisms of altered visceral functions, sensory and pain transmission. Visceral 
pain is more difficult to study than somatic pain in experimental animal models, 
partly because pain is not evoked from all organs and is not always associated with 
tissue damage or injury (Cervero and Laird, 1999; Robinson and Gebhart, 2008). 
Inducing lower urinary tract inflammation with CYP is a well-characterised model of 
visceral inflammatory pain (Nishiguchi et al., 2004; Vizzard, 2000a; Vizzard, 2000b; 
Vizzard et al., 1996; Yoshimura and de Groat, 1999). In rats, CYP is used to induce 
acute or chronic bladder inflammation, producing increased micturition frequency, 
decreased bladder thresholds and compromised bladder capacity. These are 
characteristic features of bladder inflammation (Bielefeldt et al., 2006; Lagos and 
Ballejo, 2004). Some early studies used different chemical irritants injected directly 
into the bladder to induce acute visceral pain, such as acrolein (Guerios et al., 2008), 
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 acetic acid (Lanteri-Minet et al., 1993; Rodella et al., 1998), formalin (Rodella et al., 
1998), mustard oil, croton oil and turpentine (McMahon and Abel, 1987), and single, 
high doses of CYP (Bon et al., 1996; Bon et al., 1998; Lanteri-Minet et al., 1995; 
McMahon, 1988; Vizzard et al., 1996). We have selected the CYP model of bladder 
inflammation in this study as bladder histological changes have been well 
characterised, and it produces consistent inflammation (Vizzard, 2001; Yoshimura 
and de Groat, 1999).  
 
Clinically, CYP is an anti-tumour agent and when administered, is metabolised by the 
kidneys producing acrolein, which has been identified as the pro-inflammatory agent 
of the lower urinary tract (Cox, 1979). The bladder is a reservoir allowing for 
relatively long exposure of the urothelium to acrolein causing hemorrhagic cystitis in 
humans (Foad and Hess, 1976) and animals (Lanteri-Minet et al., 1995; Vizzard, 
2000a). Acrolein is urotoxic and erodes the bladder urothelium (Brock et al., 1981), a 
specialised transitional epithelium (Birder, 2010; Khandelwal et al., 2009; Young and 
Heath, 2000). This causes loss of urothelial barrier function, where acrolein and other 
toxic substances in urine enter underlying bladder tissue, causing inflammation and 
bladder pain (Birder et al., 2010; Lewis, 2000). Administration of sodium-2-
mercapto-ethane-sulphonate (mesna) is uro-protective in the bladders of rats 
(Freedman et al., 1984; Menetrey et al., 1999), guinea pigs (Etlik et al., 1997) and 
humans (Shepherd et al., 1991), preventing the destruction of bladder urothelium and 
the CYP-induced inflammation. When mesna combines with acrolein in the urine, an 
inactive compound is formed, which prevents urothelium damage after CYP 
administration (Brock et al., 1981; Etlik et al., 1997). 
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 Direct measurement of visceral pain in animals is very difficult, and the development 
of referred pain and changes in bladder activity are used to indirectly measure the 
development of visceral pain following CYP administration (Corrow and Vizzard, 
2007; Frias et al., 2013; Hu et al., 2005; McMahon et al., 1995). Following 
administration of CYP, mice develop referred pain with hypersensitivity to 
mechanical stimuli at the base of the tail (Bon et al., 2003). Similar studies in rats 
show the development of referred pain in the abdomen, base of the tail, thigh and 
hindpaw (Frias et al., 2013; Jaggar et al., 1999; McMahon et al., 1995). These 
changes correlate with pathological changes in the bladder as will be addressed 
below. 
 
1.3 Innervation of the urinary bladder 
The bladder has two main functions: elimination (voiding) and storage, both 
involving complex neural control in supraspinal nuclei, spinal cord and peripheral 
ganglia. The process of micturition undergoes postnatal development where bladder 
circuitry matures, becoming under voluntary control (Andersson and Hedlund, 2002; 
Cervero, 1994; Fowler et al., 2008; Sann et al., 1997). During voiding there is initial 
relaxation of pelvic floor muscles and the urethra, followed by subsequent contraction 
of the detrusor muscle and opening of the bladder neck to expel urine. During storage 
the bladder outlet is closed and bladder contraction is inhibited to allow for bladder 
filling (Yoshimura, 1999). Three sets of nerves mediate this activity: sacral 
parasympathetic pelvic nerves, lumbar sympathetic hypogastric and splanchnic 
nerves, and somatic pudendal motor nerves (de Groat and Yoshimura, 2009) (Figure 
1.4). The pelvic and hypogastric nerves are pure visceral nerves that contain a mixture 
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 of both afferent and preganglionic autonomic axons that innervate the bladder, bowel 
and other pelvic organs (Keast, 2006). 
 
 
 
Figure 1.4 Diagram of the afferent and efferent pathways controlling bladder 
function. Micturition is mediated by sacral parasympathetic pelvic nerves, lumbar 
sympathetic hypogastric and splanchnic nerves, and somatic pudendal nerves. In 
rodents, afferent innervation of the bladder arises from neurons located in the sacral 
(L6/S1) and lumbar (L1/L2) dorsal root ganglia (DRG). These axons pass through the 
major pelvic ganglia (MPG) and reach the bladder via accessory nerves. 
Parasympathetic preganglionic neurons are located in the sacral preganglionic nucleus 
in sacral spinal cord; their axons synapse onto post-ganglionic parasympathetic 
neurons in the MPG. Sympathetic preganglionic neurons are located in lumbar cord, 
their axons synapse onto sympathetic postganglionic neurons in the MPG. 
Postganglionic autonomic axons also leave the MPG via the accessory nerve to reach 
the bladder. Somatic motor neurons located in Onuf’s nucleus in sacral spinal cord 
innervate the external urethral sphincter (EUS). These axons travel in the pudendal 
nerve. IMG, inferior mesenteric ganglia. Adapted from Ford et al., 2006. 
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 1.3.1 Spinal and supraspinal micturition pathways  
Mechanosensitive afferent endings in the detrusor detect bladder filling and activate a 
thoracolumbar and lumbosacral spinal reflex, referred to as the guarding reflex (de 
Groat and Wickens, 2013; Drake et al., 2010). This reflex inhibits parasympathetic 
activity in the detrusor and activates sympathetic and pudendal outflow to the bladder. 
Together, this causes relaxation of the detrusor body and contraction of the bladder 
base and urethra, resulting in bladder continence and preventing involuntary voiding 
(Fowler et al., 2008; Yoshimura, 1999; Yoshimura and de Groat, 1997). These storage 
reflexes are mediated by spinal circuits, whereas voiding is mediated by both spinal 
and supraspinal pathways. During bladder filling, intravesical pressure remains 
relatively low until it reaches the threshold for micturition, triggering a cascade of 
coordinated micturition reflexes (Yoshimura and de Groat, 1999). At this time, 
activity increases in mechanosensitive fibres in the bladder. Their axons travel in the 
pelvic nerve, and synapse with interneurons in the dorsal horn and IML of sacral cord 
to initiate the micturition reflex. From here, the signal is either relayed directly to 
Barrington’s nucleus in the dorsolateral pons (referred to as the pontine micturition 
centre, PMC) or to the periaqueductal grey, which then relays the signal to 
Barrington’s nucleus (Drake et al., 2010; Holstege, 2005; Holstege and Mouton, 
2003; Yoshimura and de Groat, 1997). The PMC activates descending micturition 
pathways by exciting parasympathetic outflow to the bladder, and inhibiting 
sympathetic and pudendal outflow. Together this contracts the bladder and relaxes the 
urethra to expel urine (Fowler et al., 2008). 
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 1.3.2 Central afferent pathways 
Sensory information from the bladder including sensations of bladder fullness, 
discomfort and pain are relayed to the spinal cord by afferent axons travelling in the 
pelvic and hypogastric nerves (Fowler et al., 2008). In rodents, the afferent 
innervation of the bladder arises from neurons located in sacral (L6/S1) and lumbar 
(L1/2) DRG, their axons travel in the pelvic and hypogastric nerves respectively 
(Nadelhaft and Booth, 1984; Nadelhaft and McKenna, 1987). The central projections 
of afferent neurons innervating the bladder, and their association with spinal 
projection neurons, interneurons and preganglionic autonomic neurons have been 
investigated using tracing techniques (below).  
 
Anterograde tracing studies using horseradish peroxidase (HRP) applied to the cut 
pelvic nerve in cats (Morgan et al., 1981) and rats (Nadelhaft and Booth, 1984) have 
been used to identify DRG neurons that project in this nerve, and the distribution of 
their central projections. In the rat, this labels approximately 1500 DRG neurons, the 
majority (95%) located in the L6 and S1 DRGs (Nadelhaft and Booth, 1984). These 
axons enter Lissauer’s tract via their respective dorsal root, and travel rostrocaudally 
across multiple spinal segments with branching collateral fibres that extend from 
lamina I, and into deeper dorsal horn (laminae III, V-VII and X). Some axons extend 
laterally from Lissauer’s tract into the dorsolateral funiculus. Two main pathways 
emerge from Lissauer’s tract: a medial pathway and a more prominent lateral pathway 
(Nadelhaft and Booth, 1984).  Axons in the medial pathway travel along the medial 
border of the dorsal horn (medial collateral pathway) and terminate in dorsal half of 
the DGC. The lateral pathway comprises axons arranged into bundles that travel along 
the lateral edge of the dorsal horn (lateral collateral pathway, LCP). The most lateral 
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 axon collaterals terminate in the area of the sacral preganglionic nucleus (SPN), 
where they are in close proximity to preganglionic autonomic neurons and their 
proximal dendrites (Nadelhaft and Booth, 1984). The more medial axon bundles 
extend towards the SPN but then project medially toward the DGC, some crossing the 
midline. Some axons travelling in the pelvic nerve terminate in lamina X, just ventral 
to the central canal. These central projections are most prominent in L6/S1 spinal 
segments, but many project rostrally to L3, and caudally to S3 (Nadelhaft and Booth, 
1984). This distribution matches other studies in the guinea pig using intracellular 
labelling of single DRG neurons (Sugiura et al., 1989; Sugiura et al., 1993). Together 
these studies demonstrate that somatic afferents have a localised and restricted 
distribution within the spinal cord (above, section 1.2.1), whereas visceral afferents 
have a wider distribution pattern within the dorsal horn, extending many spinal 
segments above and below their entry point into the cord (Sugiura et al., 1989; 
Sugiura et al., 1993).  
 
Similar studies with HRP applied to the hypogastric nerve in cats (Morgan et al., 
1986) and rats (Nadelhaft and McKenna, 1987) have been used to identify DRG 
neurons that project in the hypogastric nerve and the distribution of their central 
terminals. In rats, this labels approximately 150 neurons in T11-L3 DRGs, with over 
90% localised in L1/2 DRGs, three quarters of which are labelled on the ipsilateral 
side (Nadelhaft and McKenna, 1987). Their axons enter Lissauer’s tract and project to 
lamina I, V and VII, and medial and lateral collateral pathways. Axons travelling in 
the medial and lateral collateral pathways terminate in the region of the DGC and 
IML respectively, where they are in close apposition to lumbar preganglionic 
autonomic neurons. Some axons extend laterally from Lissauer’s tract into the 
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 dorsolateral funiculus. The central projections of afferent axons in the hypogastric 
nerve are most prominent in L1/2 spinal segments but spread over T13-L3 segments 
(Hancock and Peveto, 1979a; Morgan et al., 1986; Nadelhaft and McKenna, 1987). In 
comparison to the pelvic nerve, a much smaller number of primary afferent neurons 
project in the hypogastric nerve, which corresponds to the less prevalent distribution 
of their central projections in upper lumbar cord. In addition, laminae III and IV do 
not receive projections from afferents travelling in the hypogastric nerve, areas that 
contain spinal interneurons (Basbaum et al., 2009). 
 
The central distribution of bladder specific afferents in sacral cord has also been 
addressed by injection of HRP directly into the bladder wall (Steers et al., 1991). 
Using this approach, approximately 400 neurons are labelled in L1/2 DRGs and 
approximately 900 are labelled in L6/S1 DRGs. A smaller number of neurons are 
observed in L3-5 DRGs. The majority of labelled axons are located in L6/S1 spinal 
segments, corresponding to the higher proportion of sacral bladder afferent neurons 
compared to lumbar levels (Steers et al., 1991). Bladder afferents terminate in lamina 
I, II, V-VII and X in lumbar (L1/2) and sacral (L6/S1) spinal segments, primarily on 
the ipsilateral side, but some are observed on the contralateral side (Steers et al., 
1991). The central distribution of bladder afferents show a similar pattern but are not 
as dense as those reported by Nadelhaft and Booth (1984). This is attributable to 
bladder-projecting axons only making up a proportion of pelvic visceral axons 
travelling in the pelvic nerve (Keast, 2006).  
 
Spinal neurons involved in processing information from the bladder that are involved 
in the normal micturition reflex have been identified using a combination of 
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 anterograde and retrograde tracing techniques, and immunohistochemical labelling of 
the immediate early gene product, Fos (Birder et al., 1999; Vizzard, 2000a). After 
bladder stimulation and intravesical saline infusion, Fos is up-regulated in neurons in 
the lateral and medial dorsal horn, SPN and DGC, all regions that receive input from 
bladder afferents. The majority of these neurons containing Fos were located in the 
SPN and DGC (Birder and de Groat, 1993; Vizzard, 2000a). However, only a 
relatively small proportion of neurons expressing Fos (10%) projected to the 
brainstem and hypothalamus (brain regions involved in micturition, section 1.3.1), or 
comprised autonomic preganglionic neurons in lumbar and sacral spinal cord (Birder 
et al., 1999). The majority of neurons up-regulating Fos after bladder stimulation were 
likely spinal interneurons (Birder et al., 1999).  
 
1.3.3 Characterisation of bladder afferent neurons 
DRG neurons, including bladder-projecting neurons, can be categorised by the 
conduction velocity of their axons (Lawson and Waddell, 1991) and their 
neuropeptide content (Basbaum et al., 2009). On the basis of conduction velocity, 
DRG neurons can be classified into three groups (Harper and Lawson, 1985a; b; 
Lawson and Waddell, 1991; McCarthy and Lawson, 1990): the first group are mostly 
large diameter neurons with myelinated axons containing Aα- and Aβ-fibres. Large 
diameter neurons have an average neuronal area of >800 µm2 and a diameter of >32 
µm (Fang et al., 2002; 2005; Lawson et al., 1984). This group of neurons have rapidly 
conducting fibres and respond to innocuous mechanical stimuli, including light touch 
and pressure (Lawson and Waddell, 1991). Neurons with Aα- and Aβ-fibres do not 
project to the bladder (Robinson and Gebhart, 2008). The second group have a 
medium diameter, and thinly myelinated Aδ-fibres. Medium sized neurons are 23-32 
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 µm in diameter and have a neuronal area of 400-800 µm2 (Fang et al., 2002; 2005; 
Lawson et al., 1984). The majority of neurons with Aδ-fibres are mechanosensitive 
nociceptors (Alvarez and Fyffe, 2000; Hunt and Mantyh, 2001; McCarthy and 
Lawson, 1990; Priestley et al., 2002) and comprise 20-40% of bladder afferent 
neurons (Robinson and Gebhart, 2008). The last group of neurons are small diameter 
neurons with unmyelinated C-fibres (McCarthy and Lawson, 1990). Small diameter 
neurons have an average neuronal area up to 400 µm2 and diameters of less than 23 
µm (Fang et al., 2002; 2005; Lawson et al., 1984). C-type neurons account for the 
majority (up to 80%) of neurons innervating the bladder (Robinson and Gebhart, 
2008). The majority of these neurons are polymodal nociceptors that respond to 
noxious chemical, thermal and mechanical stimuli (Basbaum et al., 2009). Aδ-type 
(and Aα- and Aβ-) neurons can be distinguished from C-type neurons by their 
neurofilament 200 (NF200) content, a marker of DRG neurons with myelinated axons 
(Lawson and Waddell, 1991). 
 
Most visceral afferent neurons are mechanosensitive, detecting changes in distension 
and contraction (Fowler et al., 2008). These neurons can be further subdivided into 
those having low and high thresholds to mechanical stimuli (Robinson and Gebhart, 
2008). Low threshold mechanoreceptors comprise approximately 80% of the 
population, and respond to innocuous mechanical stimuli in the physiological range. 
This group of neurons are responsible for the normal neuronal control of visceral 
functions that are not consciously perceived (Robinson and Gebhart, 2008). Low 
threshold mechanoreceptors can also detect stimuli in the noxious range, and sensitise 
following inflammation (Cervero, 1994; Robinson and Gebhart, 2008). High 
threshold visceral mechanoreceptors detect stimuli in the noxious range (Cervero, 
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 1994; Robinson and Gebhart, 2008; Sengupta and Gebhart, 1994). Both types of 
visceral mechanoreceptors can sensitise, contributing to the initiation and 
maintenance of pain, and visceral hyperactivity during inflammation or injury. 
Neurons with mechanosensitive Aδ-fibres are essential for detecting changes in 
bladder distension and detrusor contraction during voiding (Birder et al., 2010; 
Gabella and Davis, 1998), whereas C-fibre neurons discharge at higher physiological 
thresholds, usually when the bladder is distended (Fowler et al., 2008). This group of 
C-fibres also include many “silent afferents” that are unresponsive to mechanical 
stimuli in the normal physiological range, but become activated and awakened in the 
presence of tissue injury and inflammation (Birder et al., 2010).  
 
C-type DRG neurons are also characterised by their neuropeptide content (Basbaum 
et al., 2009). Approximately 40% of adult DRG neurons are referred to as peptidergic 
and express one or more neuropeptides including CGRP, SP and somatostatin (Pezet 
and McMahon, 2006a; Woolf and Ma, 2007a). The majority of peptidergic neurons 
also express the capsaicin receptor, transient receptor potential vanilloid 1 (TRPV1) 
(Basbaum et al., 2009), which has been the focus of a lot of pain research (Blackshaw 
et al., 2010; Caterina et al., 1997; Patapoutian et al., 2009). Neurons that do not 
synthesise CGRP or other neuropeptides, instead bind to the plant Isolectin Griffonia 
simplicifolia B4 (IB4), or express the purinergic receptor P2X3. This group of neurons 
are referred to as the non-peptidergic population (Bennet et al., 1996; Bennet et al., 
2003; Gerke and Plenderleith, 2001; Stucky and Lewin, 1999). Non-peptidergic 
neurons, including nociceptors, can also be identified by labelling with fluoride-
resistant acid phosphatase (FRAP) and Mas-related G-protein coupled receptors 
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 (Mrgprs) (Bailey and Ribeiro-da-Silva, 2006; Dong et al., 2001; Zylka et al., 2003; 
Zylka et al., 2005).  
 
The majority of studies on neuropeptides in C- and Aδ-type DRG neurons have 
focused on somatic DRGs innervating the skin or muscle. In comparison, a higher 
proportion of DRG neurons innervating the viscera contain neuropeptides 
(Christianson et al., 2006; McMahon et al., 1994; Perry and Lawson, 1998). A 
number of studies have also shown that the neuropeptide content is not uniform across 
neurons innervating different organs (Bennett et al., 2003; Christianson et al., 2010). 
The peptidergic population comprises the largest group of neurons innervating the 
bladder with approximately 60-80% of bladder afferent neurons containing CGRP-
immunoreactivity (IR) (Bennett et al., 1996; Bennett et al., 2003; Vizzard, 2001). A 
higher proportion of lumbar bladder afferent neurons express CGRP- and SP-IR than 
sacral bladder afferent neurons (Callsen-Cencic and Mense, 1997; Vizzard, 2001). 
The remaining 20-40% of bladder afferent neurons (and other visceral afferents) are 
non-peptidergic and bind IB4 (Bennett et al., 1996; Stucky and Lewin, 1999). 
 
1.3.4 Characteristics of afferents in pelvic and hypogastric nerves 
A number of early studies have shown that the two groups of bladder afferent neurons 
(lumbar and sacral) have different central projection patterns (above, section 1.3.2) 
and different peripheral targets in the bladder (below) (Floyd et al., 1976; Habler et 
al., 1988; 1990; 1993; Janig and Koltzenburg, 1990). It is estimated that 8000 afferent 
axons innervate the rat bladder (Gabella, 1999), but this number varies between 
studies (Hancock and Peveto, 1979b; Nadelhaft and Booth, 1984; Nadelhaft and 
McKenna, 1987). In rats, a much higher proportion of axons project to the bladder via 
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 the pelvic nerves compared to the proportion projecting via the hypogastric nerves 
(Hancock and Peveto, 1979b; Nadelhaft and Booth, 1984; Nadelhaft and McKenna, 
1987), which is consistent with other studies in cats (Baron et al., 1985; Hulsebosch 
and Coggeshall, 1982) and guinea pigs (McLachlan, 1985).  
 
In the pelvic nerve of rats, two thirds of bladder afferents have C-fibres and one third 
have Aδ-fibres (Sengupta and Gebhart, 1994a; Shea et al., 2000). The majority of 
mechanoreceptors in the pelvic nerve show resting activity when the bladder is empty, 
and as the bladder distends, these fibres increase firing activity. Most of these fibres 
respond to bladder contraction and distension, and are often referred to as tension 
receptors (de Groat and Yoshimura, 2009). Shea et al., (2000) report that a 
subpopulation of C- and Aδ-fibres in the pelvic nerve of rats are chemosensitive, 
however this is in contrast to Moss et al., (1997) who report that the pelvic nerve does 
not contain chemoreceptive bladder afferent fibres. Some C-fibre mechanoreceptors 
have been described as volume receptors that are activated by bladder distension, but 
not contraction (Morrison, 1997). 
 
Studies in mice have identified four different sub-types of mechanosensitive axons in 
the pelvic nerve innervating the bladder: muscular, muscular/urothelial, urothelial and 
serosal (Xu and Gebhart, 2008). The muscular fibres that specifically responded to 
stretch comprise the largest population of afferents travelling in the pelvic nerve. 
Other studies in the guinea pig have described four types of pelvic nerve afferents 
innervating the bladder, which include both mechanoreceptors and mechanically 
insensitive receptors (Zagorodnyuk et al., 2009). These include stretch-sensitive 
tension receptors in the detrusor, tension mechanoreceptors in the mucosa that 
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 respond to stretch and light mechanical stimuli, stretch-insensitive mucosal 
mechanoreceptors that respond to chemical stimuli, and muscle mechanoreceptors 
(Zagorodnyuk et al., 2009). Sacral afferent axons travelling in the pelvic nerve are 
widely distributed throughout the bladder including the detrusor and suburothelial 
plexus, a network of axons near, and within the urothelium (de Groat and Yoshimura, 
2009; Gabella and Davis, 1998; Xu and Gebhart, 2008).  
 
The proportion of C- and Aδ-type fibres in the hypogastric nerve are similar to those 
in the pelvic nerve (Sengupta and Gebhart, 1994a; Xu and Gebhart, 2008). In the 
mouse hypogastric nerve, three types of lumbar afferent fibres innervating the bladder 
have been identified by their responses to mechanical stimuli: muscular, 
muscular/urothelial and serosal. In contrast to axons in the pelvic nerve, here the 
serosal mechanoreceptive fibres comprise the largest subpopulation (Xu and Gebhart, 
2008). Lumbar afferent axons travelling in the hypogastric nerve are primarily 
distributed in the bladder base, innervating a smaller area of the bladder compared to 
those originating from the pelvic nerve (Xu and Gebhart, 2008).  
 
1.3.5 Distribution of afferent axons in the bladder 
The bladder is divided into two main regions; the body and the base, and is comprised 
of different layers, namely the serosa or adventitia, detrusor, lamina propria and 
urothelium (de Groat and Yoshimura, 2009) (Figure 1.5). Peptidergic afferent axons 
are widely distributed throughout the bladder and have been extensively studied using 
immunohistochemistry for CGRP in bladder sections and whole mount preparations 
(Gabella and Davis, 1998). These axons have three main targets: the detrusor, 
suburothelial plexus and vasculature. CGRP-IR axons in the detrusor are widely 
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 distributed throughout the bladder and have similar density and structure in the 
bladder base and upper body, also referred to as the bladder dome (Avelino and Cruz, 
2000; Gabella and Davis, 1998; Yokokawa et al., 1985; Yokokawa et al., 1986). 
CGRP-IR axons are present in the suburothelial plexus where they are more prevalent 
in the bladder base than the bladder dome (Andersson, 2002; Dickson et al., 2006; 
Gabella and Davis, 1998). Occasionally these axons issue collaterals that extend 
between the basal and intermediate urothelial cells (Gabella and Davis, 1998). 
Matching the co-expression patterns in bladder afferent neuron cell bodies, almost all 
CGRP-IR axons in the detrusor and suburothelial plexus contain SP-IR and TRPV1-
IR and likewise, almost all TRPV1-IR axons in the bladder contain CGRP- and SP-IR 
(Avelino et al., 2002) and are largely overlapping populations.  
 
 
 
Figure 1.5 Section through the rat bladder stained with Haematoxylin and eosin, 
showing different layers and tissues of the bladder. Luminal surface is orientated to 
the top. Ur, urothelium; LP, lamina propria; DM, detrusor muscle; S, serosal surface 
of the bladder. Scale bar represents 100 µm. Adapted from Dickson et al., 2006. 
26
  
Most blood vessels (veins, arteries and arterioles) are innervated by afferent axons 
(Furness et al., 1982). Two types of axons are commonly associated with the vascular 
tree: peri- and para-vascular axons. Peri-vascular axons functionally innervate the 
vascular tree and wrap around its branches. They are typically located in the 
adventitia of the vessel. Para-vascular axons travel along the vascular tree to reach 
their relevant target tissue or organ (Furness, 1973; Furness and Marshall, 1974). 
Similarly, in the bladder, CGRP- and SP-positive afferent axons are closely associated 
with the vasculature (Avelino et al., 2002; Avelino and Cruz, 2000; Gabella and 
Davis, 1998; Warburton and Santer, 1994; Yokokawa et al., 1985). 
 
Non-peptidergic C-fibre axons are not as prevalent in the bladder as peptidergic 
afferent axons (Studeny et al., 2005), which corresponds to the smaller proportion of 
non-peptidergic bladder afferent neurons (Bennett et al., 1996). Less is known about 
the distribution of the non-peptidergic afferent axonal population in the bladder 
because until recently it has not been possible to specifically visualise them 
(Brumovsky et al., 2012b). IB4 does not label axons in the bladder, most likely 
attributable to the binding site for IB4 not being expressed on peripheral axons. Other 
studies using P2X3 immunoreactivity have identified non-peptidergic afferent axons 
throughout the detrusor and suburothelial plexus, and shown that these axons are 
more prevalent in the bladder base (Studeny et al., 2005). However, this is not as 
robust as neuropeptide immunostaining and has not proved useful for more detailed or 
quantitative studies. 
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 1.3.6 Motor innervation of the bladder  
The parasympathetic pathway provides the major excitatory input into the bladder and 
is responsible for contraction of the detrusor and relaxation of the urethra, required for 
voiding (Fowler et al., 2008). Preganglionic autonomic neurons with axons travelling 
in the pelvic (Hancock and Peveto, 1979b; Nadelhaft and Booth, 1984) or hypogastric 
nerves (Hancock and Peveto, 1979a; Nadelhaft and McKenna, 1987) are identified by 
application of HRP to these nerves. Application of HRP to the pelvic nerve in rats 
labels approximately 550 preganglionic autonomic neurons in the SPN, mainly 
located within the IML. Almost all (98%) of these preganglionic neurons are located 
within L6/S1 spinal segments, with only a very small number located in L5 and S2 
segments (Hancock and Peveto, 1979b; Nadelhaft and Booth, 1984). Dendrites from 
these neurons extend along the lateral border of the dorsal horn, and into the 
dorsolateral funiculus. Many dendrites project medially, into the DGC (Nadelhaft and 
Booth, 1984). Axons form parasympathetic preganglionic neurons travelling in the 
pelvic nerve synapse onto parasympathetic postganglionic neurons in the pelvic 
ganglia, which is also referred to as the paracervical ganglion in females, and the 
inferior mesenteric ganglia (Keast, 2006). Parasympathetic postganglionic axons 
reach the bladder via the accessory nerves and release acetylcholine at their terminals, 
which act on muscarinic receptors to contract the bladder. Adenosine triphosphate 
(ATP), a co-transmitter is also released from parasympathetic postganglionic axon 
terminals in the bladder wall, acting on P2X3 purinergic receptors, to induce muscle 
contraction (Cervero, 1994; Fowler et al., 2008; Yoshimura, 1999; Yoshimura and de 
Groat, 1997).  
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 The sympathetic pathway is responsible for bladder relaxation and contraction of the 
urethra to allow for urine storage (Fowler et al., 2008). The majority (81%) of 
autonomic sympathetic preganglionic axons travelling in the lumbar hypogastric and 
splanchnic nerves originate in the DCG, also referred to the central autonomic area, 
and the rest in the IML of T13-L3 spinal segment. However, the majority (96%) of 
these neurons are localised to L1/2 spinal segments (Hancock and Peveto, 1979a; 
Nadelhaft and McKenna, 1987). Nadelhaft and McKenna (1987) report a strong 
sexual dimorphism with male rats containing approximately 440 preganglionic 
autonomic neurons, compared to approximately 110 in females.  Sex differences have 
been reported in postganglionic sympathetic noradrenergic neurons, which comprise 
close to one-third of neurons in the male pelvic ganglia (Keast, 1995), compared to 5-
10% in the female (Keast, 2006; Vera and Nadelhaft, 1992). These neurons innervate 
many sexually dimorphic targets (Keast, 2006). In contrast, Hancock and Peveto 
(1979a) report no difference in the number of lumbar preganglionic neurons in male 
and female rats. Axons from sympathetic preganglionic neurons synapse onto 
sympathetic postganglionic neurons in the pelvic ganglia and inferior mesenteric 
ganglion (Keast, 2006). Sympathetic postganglionic axons reach the bladder via the 
accessory nerves and release noradrenaline, acting on β-adrenergic receptors to relax 
the detrusor smooth muscle (Cervero, 1994; Fowler et al., 2008; Yoshimura, 1999; 
Yoshimura and de Groat, 1997). The noradrenergic sympathetic innervation of the 
bladder vasculature, like most vasoconstrictor axons, originates from the sympathetic 
chain (paravertebral) ganglia (Janig, 1988; Keast, 2006; Vera and Nadelhaft, 1992). 
 
In some species, intramural ganglion neurons provide efferent innervation to the 
bladder (Birder et al., 2010; Keast, 2006). These neurons are primarily associated 
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 with axon bundles, embedded in the detrusor (Alian and Gabella, 1996). In rats, they 
were originally thought to be absent (Gabella, 1990), but more recent studies have 
demonstrated their presence (Alian and Gabella, 1996; Iuchi et al., 1994; McNeill et 
al., 1992; Zvarova and Vizzard, 2005). Nevertheless, in rats they are sparse compared 
to the guinea pig and other species, including humans (Dixon et al., 1983; el-Badawi 
and Schenk, 1966; Gabella, 1990; Smet et al., 1996; Zhou and Ling, 1998). The 
majority of intramural neurons are cholinergic and few are noradrenergic (el-Badawi 
and Schenk, 1966; Iuchi et al., 1994). Afferent axons have been reported to make 
contact with these neurons (Smet et al., 1996; Zhou and Ling, 1998), but markers of 
DRG afferent neurons are not expressed by intramural ganglion neurons (Gillespie et 
al., 2006a; Zhou and Ling, 1998). 
 
Somatic motor neurons located in Onuf’s nucleus, lamina IX of the ventrolateral 
dorsal horn of the L6/S1 spinal cord, innervate the external urethral sphincter and 
pelvic floor musculature (Holstege, 2005; Holstege and Mouton, 2003). These axons 
travel in the pudendal nerve and release acetylcholine at their terminals, acting on 
nicotinic receptors to cause muscle contraction (Fowler et al., 2008; Yoshimura, 
1999), allowing for the storage of urine.  
 
1.3.7 Distribution of autonomic axons in the bladder 
In rats, the autonomic innervation of the bladder has been studied using neuropeptide 
Y (NPY) immunohistochemistry. While NPY is not a general marker of all autonomic 
postganglionic pelvic neurons, it does label the largest population including the 
majority of parasympathetic cholinergic neurons, and all sympathetic noradrenergic 
neurons (Keast, 1991; Mattiasson et al., 1985). Parasympathetic cholinergic neurons 
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 can also be labelled with nitric oxide synthase (NOS) and vasoactive intestinal 
polypeptide (VIP), but these only label a minority of the bladder-projecting 
population (Keast, 1991; Keast and de Groat, 1989). NPY-IR axons innervate all 
regions of the bladder: the detrusor, suburothelial plexus and vasculature (Lasanen et 
al., 1992; Mattiasson et al., 1985), and are more numerous than afferent axons in the 
bladder (Mattiasson et al., 1985). More recently, using a more direct marker of 
cholinergic axons (choline acetyltransferase, ChAT; vesicular acetylcholine 
transporter, VAChT), parasympathetic cholinergic axons were shown to be widely 
distributed in the bladder and are found in the suburothelial plexus, where they are 
more prevalent in the bladder base (Dickson et al., 2006; Persson et al., 1998). This 
closely matches the distribution identified earlier with NPY immunostaining (Iuchi et 
al., 1994; Mattiasson et al., 1985). 
 
In comparison with cholinergic axons, the noradrenergic sympathetic innervation of 
the detrusor is sparse with the majority of these axons confined to the bladder base. In 
rats, these axons are very rare, or non-existent in the suburothelial plexus (el-Badawi 
and Schenk, 1966; Wakabayashi et al., 1994; Wakabayashi et al., 1993; Warburton 
and Santer, 1994). In contrast to the detrusor, noradrenergic sympathetic axons 
densely innervate the bladder vasculature (el-Badawi and Schenk, 1966; Kawasaki et 
al., 1988; Llewellyn-Smith and Gnanamanickam, 2010), and comprise dense 
networks of peri- and para-vascular axons (Kawasaki et al., 1988).  
 
1.4 Bladder dysfunction arising from inflammation 
Pathological conditions of the bladder, including chronic CYP-induced cystitis, alter 
the structural, neurochemical and electrophysiological properties of bladder afferent 
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 pathways. Together, these lead to nociceptor sensitisation, altered bladder reflexes 
including increased voiding frequency and urgency, and the development of pain 
(Callsen-Cencic and Mense, 1997; Vizzard, 2001; Yoshimura and de Groat, 1999). 
Sensitisation is the increased responsiveness of neurons to their normal input or 
recruitment of a response to normally subthreshold inputs (Loesser and Treede, 2008). 
Activation and sensitisation of afferent Aδ- and C-fibres in the bladder by mechanical 
or chemical stimuli during inflammation, play an important role in initiating and 
maintaining these changes (Fowler et al., 2008). Sensitisation of afferent terminals 
involves lowering their threshold of activation and increasing their excitability in 
response to a mechanical or chemical stimulus (Costigan et al., 2009). During 
inflammation, this increases the magnitude of the afferent signal during bladder 
distension, causing the number of nerve impulses that are fired to occur at lower 
distension bladder volumes (Birder et al., 2010; de Groat and Yoshimura, 2009). The 
sensitivity of afferent terminals in the bladder is influenced by a range of 
inflammatory mediators including SP and other neuropeptides, growth factors, nitric 
oxide, bradykinin, prostaglandins, cytokines, histamine and ATP that are released by 
afferent terminals, smooth muscle cells, inflammatory cells and urothelial cells 
(Birder et al., 2010; de Groat and Yoshimura, 2009; Yoshimura and de Groat, 1997). 
These pro-inflammatory mediators further increase the sensitivity of afferent 
terminals, leading to bladder hyperactivity and the development of pain, as well as 
triggering local inflammatory responses including plasma extravasation and 
vasodilation (Birder et al., 2010; Yoshimura and de Groat, 1997). 
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 1.4.1 Inflammation-induced changes in bladder histopathology and neurotrophic 
factor expression 
Bladder biopsies from patients with interstitial cystitis show lesions, edema, 
inflammatory cell infiltrate and axonal sprouting (Christmas et al., 1990; Rosenberg et 
al., 2007; Sant and Hanno, 2001), whereas some studies report no histopathological 
abnormalities in bladder anatomy (Potts and Payne, 2012). Similar changes in bladder 
pathology are observed in rats following CYP-induced cystitis or administration of 
other chemical irritants including mustard oil, turpentine, formalin, low pH solutions 
and acrolein (Dmitrieva and McMahon, 1996; Dmitrieva et al., 1997; Rodella et al., 
1998; Sengupta and Gebhart, 1994a). These changes in bladder pathology correlate to 
increased bladder hyperactivity, which is initiated by the sensitisation of 
mechanosensitive afferent axons in the bladder (de Groat and Yoshimura, 2009). 
Acute bladder inflammation in rats induced by a short exposure to a single dose of 
CYP ranging from a few hours to a few days post-injection, cause tears in the 
urothelium, petechial haemorrhages and macrophage infiltrate (Bon et al., 1996; 
Lanteri-Minet et al., 1995; Vizzard et al., 1996). During chronic bladder inflammation 
induced by CYP, these histopathological changes are exacerbated and in addition, 
there is edema and an increase in bladder weight (Dickson et al., 2006; Vizzard, 
2000a). These changes correspond to lower micturition thresholds and increased 
voiding frequency in rats (Dickson et al., 2006) that are characteristic features of 
chronic bladder inflammation (de Groat and Yoshimura, 2009). 
 
Neurotrophic factors, in particular NGF, have been implicated in the mechanisms 
underlying the neuronal changes associated with interstitial cystitis and in the 
sensitisation of bladder afferent axons because of their role in producing nociceptor 
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 sensitisation and the development of pain (below). NGF, GDNF and neurturin are 
synthesised by the bladder and other pelvic organs (Kawakami et al., 2003; Leon et 
al., 1994; Vizzard, 2000b; Widenfalk et al., 1997; Widenfalk et al., 2000), suggesting 
that these neurotrophic factors may be involved in the maintenance of physiological 
and structural properties of bladder neurons expressing their receptors. Following 
chronic bladder inflammation, NGF, brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 and neurotrophin-4, members of the neurotrophin family (Pezet and 
McMahon, 2006a), as well as GDNF mRNA (Vizzard, 2000b) levels are increased in 
the bladder wall of rats. These neurotrophic factors have sensitising actions on 
nociceptors (Malin et al., 2006a) so provide a potential mechanism for increased 
excitability and altered neurochemical properties of bladder afferent neurons and their 
central terminals during inflammation (below, section 1.5.2). Following acute 
inflammation induced by CYP, BDNF-IR in the detrusor is increased and is observed 
in urothelial cells, when not present in control animals (Pinto et al., 2010a). In 
patients, NGF levels are increased in bladder biopsies from women with interstitial 
cystitis (Lowe et al., 1997). In addition, NGF, neurotrophin-3 and GDNF are elevated 
in the urine of patients with interstitial cystitis (Liu et al., 2009; Okragly et al., 1999). 
The increased levels of NGF in the urine corresponds to symptom severity (Liu et al., 
2009), suggesting that neurotrophic factors, especially NGF, are potential biomarkers 
of interstitial cystitis  (Ochodnicky et al., 2012).  
 
Changes in the distribution of afferent axons in the bladder occur during chronic 
inflammation with peptidergic axons containing CGRP-IR sprouting in the detrusor 
and suburothelial plexus (Dickson et al., 2006). This study reports a significant 
increase of CGRP-IR axons in the detrusor body and an overall increase throughout 
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 the detrusor. CGRP-IR suburothelial axons are increased in the body and dome of the 
bladder, an area that usually contains few CGRP-IR axons and an overall increase 
was found throughout the bladder mucosa (Dickson et al., 2006). Other studies in 
patients with interstitial cystitis have found an increase in CGRP-IR axons in the 
detrusor and suburothelial plexus (Christmas et al., 1990), and an increase of SP-IR 
suburothelial axons in the bladder (Pang et al., 1995). Parasympathetic cholinergic 
axons are also increased in the detrusor and suburothelial plexus following chronic 
bladder inflammation in rats (Dickson et al., 2006). These changes in the density of 
axons innervating the bladder occur in parallel with bladder hyperactivity associated 
with inflammation (Dickson et al., 2006). The reported increase in afferent axons in 
the detrusor and suburothelial plexus suggest an increase in the sensation of bladder 
fullness, creating symptoms such as frequency and pain (Dickson et al., 2006). In 
addition, peripheral sensitisation of nociceptor terminals occurs during inflammation. 
Inflammation and tissue damage leads to the release of inflammatory mediators such 
as CGRP and SP by axon terminals, and the release of growth factors, histamine, 
bradykinin, cytokines and ATP from mast cells, macrophages, platelets and 
endothelial cells (Basbaum et al., 2009). These pro-inflammatory agents contribute to 
the ‘inflammatory soup’, which can bind to one or more cell surface receptors on the 
nociceptor terminal (Basbaum et al., 2009), enhancing the excitability of peripheral 
terminals. The increase in the number of peptidergic axons in the suburothelial plexus 
following inflammation (above), suggest increased release of neuropeptides, further 
contributing the inflammatory soup. Together, this could enhance sensitisation and 
hyperactivity of bladder afferents (Yoshimura and de Groat, 1999). Sprouting of 
parasympathetic axons in the detrusor suggests the potential for increased release 
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 acetylcholine, acting on muscarinic receptors to produce bladder contraction (Fowler, 
2008). 
 
1.4.2 Inflammation-induced changes in excitability and neurochemical properties of 
DRG neurons 
Bladder inflammation increases the excitability of bladder afferent neurons and alters 
their neurochemical profile (Vizzard, 2001; Yoshimura and de Groat, 1999). Animal 
studies have shown that during bladder inflammation, sensitisation of 
mechanosensitive bladder afferents occurs, and activation of silent nociceptors that 
are usually unresponsive to mechanical stimuli, initiate bladder hyperactivity 
(Dmitrieva and McMahon, 1996; Habler et al., 1990; Sengupta and Gebhart, 1994b). 
Yoshimura and de Groat (1999) demonstrated in dissociated L6/S1 DRG neurons 
from rats with CYP-induced chronic inflammation, that capsaicin-sensitive bladder 
afferent neurons had a decreased threshold for activation and increased firing 
frequency. These neurons also showed spontaneous firing and altered membrane 
properties compared to control animals. The increased excitability and sensitisation of 
bladder afferent neurons during chronic inflammation is linked to bladder 
hyperactivity and pain (Yoshimura and de Groat, 1999), because they will be 
activated at lower thresholds (Costigan et al., 2009; de Groat and Yoshimura, 2009). 
Acute inflammation induced by CYP (48h) produces hyperreflexia (Maggi et al., 
1992), i.e. bladder hyperactivity characterised by increased voiding frequency and 
lower micturition thresholds (Dmitrieva et al., 1997). Hyperactivity is caused by the 
sensitisation of mechanoreceptive bladder afferents (Dmitrieva and McMahon, 1996; 
Dmitrieva et al., 1997; Sengupta and Gebhart, 1994b). Bladder hyperreflexia can be 
abolished by pre-treatment with capsaicin, a neurotoxin for C-fibres that express 
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 TRPV1 (Maggi et al., 1992). Results from this study show that altered bladder 
reflexes are mediated by capsaicin-sensitive bladder afferent neurons.  
 
More generally, mechanisms contributing to dysfunction and pain following 
inflammation include alterations in the neurochemical properties of DRG neurons, 
which can lead to synaptic facilitation, amplification of afferent signals, aberrant 
synaptic connectivity, and altered release of neurochemicals from axon terminals 
(Costigan et al., 2009; Navarro et al., 2007). Following acute and chronic bladder 
inflammation, bladder afferent neurons show altered neurochemical properties, but 
this is not uniform across lumbar and sacral DRGs. For example, the number of 
peptidergic sacral bladder afferent neurons expressing SP-, CGRP- and galanin-IR are 
increased following acute inflammation induced by mustard oil (Callsen-Cencic and 
Mense, 1997). This increase is attributable to additional neurons synthesising these 
neuropeptides following inflammation, or an increase in staining intensity in neurons 
that usually have very low expression (Callsen-Cencic and Mense, 1997). Numerous 
reports suggest that bladder hyperreflexia is partially mediated by nitric oxide in the 
spinal cord by nociceptive afferents, but nitric oxide does not have a role in regulating 
bladder activity in control animals (Kakizaki and de Groat, 1996; Vizzard et al., 
1996). Nitric oxide synthase (NOS), the enzyme that forms nitric oxide is normally 
expressed by few bladder afferent neurons, but is increased in lumbar DRGs during 
acute and chronic inflammation (Callsen-Cencic and Mense, 1997; Vizzard, 2001; 
Vizzard et al., 1996). Other studies have found that trkA- and p75-IR are increased in 
lumbar and sacral bladder afferent neurons during acute and chronic CYP-induced 
inflammation (Klinger et al., 2008; Qiao and Vizzard, 2002). In addition, SP- and 
CGRP-IR is increased in sacral bladder neurons following chronic inflammation 
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 (Vizzard, 2001). These neurochemical changes have been linked to altered bladder 
reflexes during CYP-induced inflammation as neuropeptides can be released from 
peripheral (above) and central terminals (Basbaum et al., 2009; Vizzard, 2001). 
Release of neuropeptides at the peripheral terminal contribute to the inflammatory 
soup, which can further enhance the excitability of nociceptor terminals and 
contribute to hyperactivity (section 1.4.3). SP, CGRP and other neurotransmitters can 
be released from terminals of C- and Aδ-type DRG neurons onto second order 
neurons (Basbaum et al., 2009; Vizzard, 2001). Usually silent NMDA glutamate 
receptors on the postsynaptic neuron now signal, which activate a number of 
signalling and second messenger pathways. These events increase the excitability of 
second order neurons, which facilitate nociceptive messages (Basbaum et al., 2009). 
 
1.4.3 Inflammation-induced changes in afferent fibres in the spinal cord  
Bladder inflammation increases the number of spinal neurons synaptically activated 
by stimulation of bladder afferents after CYP-induced cystitis (Vizzard et al., 1996), 
and alters neuropeptide expression in the central terminals of C-fibre afferents in 
spinal cord (Vizzard, 2001). During acute bladder inflammation, Vizzard et al., 
(1996) reported an increase in the number of neurons expressing Fos in the dorsal 
horn, DGC and SPN in lumbar and sacral spinal cord. Similar studies report an 
induction of Fos in sacral spinal cord following acetic acid-induced acute 
inflammation or by mechanical stimulation of the bladder (Birder and de Groat, 1992; 
1993). Together, these results suggest increased activation of bladder afferents 
following inflammation. In spinal cord, the neurons upregulating Fos include 
projection neurons and interneurons receiving input from bladder afferents, and 
autonomic preganglionic neurons in the SPN that are involved in bladder function 
38
 (Morgan et al., 1986; Morgan et al., 1981). Other studies have reported p75-, SP- and 
CGRP-IR in the lumbar superficial dorsal horn are increased following acute 
inflammation (Klinger et al., 2008). These results suggest that NGF in the bladder 
could mediate the altered neuropeptide expression in the spinal cord after 
inflammation. NGF acts directly on peptidergic nociceptor terminals (Basbaum et al., 
2009), which express TrkA and p75 (Pezet and McMahon, 2006a). NGF is 
retrogradely transported to the soma where it regulates gene transcription, increasing 
the expression of SP, CGRP and TRPV1. These proteins can then be transported to 
their central projections and released (Basbaum et al., 2009). 
 
Unlike acute inflammation, chronic bladder inflammation alone does not induce Fos 
in the spinal cord (Vizzard et al., 1996). However, intravesical saline distension into 
chronically inflamed bladders acting as a stimulus, induces Fos in both lumbar and 
sacral spinal cord (Vizzard, 2000a). The majority of neurons up-regulating Fos are 
located in the DGC and SPN, and a smaller number up-regulated Fos in the dorsal 
horn (Vizzard, 2000a). Chronic bladder inflammation also increases the intensity and 
the number of p75-IR (Klinger et al., 2008), SP- and CGRP-IR in terminals in the 
superficial laminae, DGC, LCP and SPN in sacral spinal cord (Vizzard, 2001).  
 
The above studies indicate that bladder inflammation impacts peptidergic afferent 
neurons and their central terminals. These changes occur in parallel with altered 
bladder reflexes and are likely to contribute to nociceptor sensitisation, altered 
bladder reflexes and pain during chronic bladder inflammation. While the majority of 
studies have focused on NGF as a possible mechanism of these effects, the GFLs 
appear to be an emerging mechanism for alterations in bladder function (section 1.6). 
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1.5 Regulation of bladder sensory function by neurotrophins 
In addition to the conduction velocity of their axons and neuropeptide content, DRG 
neurons can be classified on their potential sensitivity to neurotrophic factors. 
Peptidergic neurons express trkA and p75 and are potentially NGF-sensitive (Pezet 
and McMahon, 2006a; Woolf and Ma, 2007a). Almost all bladder afferent neurons 
containing CGRP- and SP-IR also express trkA-IR and vice versa, comprising a 
largely overlapping population of neurons (Averill et al., 1995; Bennett et al., 1996; 
Kaplan and Miller, 2000). In contrast, non-peptidergic C-type neurons express 
receptors for GDNF and neurturin (section 1.6.1).  
 
1.5.1 NGF and the neurotrophin family of neurotrophic factors 
The neurotrophin family of neurotrophic factors comprise NGF, BDNF, neurotrophin-
3 (NT-3) and NT-4/5. A fifth member, NT-6 has been identified but is present in 
teleost fish only (Albers et al., 2006; Pezet and McMahon, 2006a). All neurotrophins 
bind with low affinity to the transmembrane receptor p75 and with high affinity to a 
specific tyrosine kinase receptor; NGF to trkA, BDNF and NT-4/5 to trkB and NT-3 
to trkC (Pezet and McMahon, 2006a). The most extensively studied, particularly in 
sympathetic and DRG neurons is NGF. During development, NGF promotes the 
survival of small diameter peptidergic neurons, most of which are nociceptors, 
preventing apoptosis in neurons expressing its receptors (Barde, 1989; Lewin et al., 
1993; Petruska and Mendell, 2004). In the adult, NGF can regulate the sensitivity of 
nociceptors to thermal stimuli and produce nociceptor sensitisation and pain (Lewin 
and Mendell, 1994; Lewin et al., 1993; Shu and Mendell, 1999). 
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 1.5.2 NGF regulates bladder function 
Not only has NGF been implicated in sensitising bladder afferent terminals during 
inflammation, contributing to bladder hyperactivity and pain (Dmitrieva and 
McMahon, 1996; Vizzard, 2000b; Yoshimura et al., 2006), it also has an important 
role in regulating normal bladder sensory function. Urothelial cells, mast cells and 
detrusor muscle cells in the bladder produce NGF and are major sources of NGF in 
the bladder (Leon et al., 1994; Ochodnicky et al., 2012; Vizzard, 2000b). In rats, 
intrathecal (Yoshimura et al., 2006) and intravesical (Chuang et al., 2001; Dmitrieva 
and McMahon, 1996; Dmitrieva et al., 1997) administration of NGF produces bladder 
hyperactivity, reduces the threshold for micturition and sensitises bladder afferents. 
Other studies have demonstrated that when NGF is chronically infused directly into 
the bladder wall of rats using an osmotic pump, micturition frequency is increased 
and there is a reduction in bladder capacity (Zvara and Vizzard, 2007). These changes 
occur in parallel to an increase in CGRP-IR in lumbosacral spinal cord (Zvara and 
Vizzard, 2007). Central or peripheral NGF sequestration reduces bladder overactivity 
in animal models of bladder inflammation (Ochodnicky et al., 2012). In clinical trials, 
NGF sequestration and an NGF-neutralising antibody, tanezumab, have proven 
effective in relieving some of the symptoms of interstitial cystitis such as urinary 
urgency and bladder pain, indicating that NGF is a potential therapeutic target for the 
treatment of interstitial cystitis and other bladder disorders (Ochodnicky et al., 2012). 
The actions of NGF are thought to involve the uptake of NGF via trkA at the 
peripheral terminals of afferent axons in the bladder; NGF is then retrogradely 
transported to their cell bodies and potentially transported to their central projections, 
to induce synaptic plasticity in the spinal cord (Ochodnicky et al., 2012). 
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 Transgenic mice that over-express NGF in the urothelium show a number of 
functional abnormalities including bladder hyperactivity and reduced threshold for 
micturition (Merrill et al., 2012; Schnegelsberg et al., 2010). These mice also show 
histological changes in the bladder, including an increased mast cell infiltrate in the 
detrusor and mucosa, and hyper-innervation in the detrusor and suburothelial plexus 
by peptidergic unmyelinated and thinly myelinated afferents, and sympathetic axons 
(Girard et al., 2011; Schnegelsberg et al., 2010). Other studies have shown that 
TRPV1 knock out mice have an absence of bladder hyperactivity after receiving 
intraperitoneal injections of NGF when compared to their wild type littermates (Frias 
et al., 2012), suggesting that the TRPV1 channel is an essential mediator of NGF-
induced bladder hyperactivity and sensitisation of bladder afferents. 
 
Like NGF, BDNF has been implicated in sensory bladder function and dysfunction. 
BDNF has been identified in the urothelium and detrusor (Girard et al., 2011) and 
during inflammation, may sensitise bladder afferent terminals (Ochodnicky et al., 
2012). Other studies have found elevated BDNF levels in the urine of patients with 
interstitial cystitis (Pinto et al., 2010), and BDNF mRNA is increased in the bladder 
of rats following acute and chronic bladder inflammation induced by CYP (Oddiah et 
al., 1998; Vizzard, 2000b). In addition, NT-3 and NT-4 are synthesised by the bladder 
in rats (Kawakami et al., 2002; Vizzard, 2000b), and are increased in the bladder 
following acute and chronic inflammation (Oddiah et al., 1998; Vizzard, 2000b). NT-
3 levels are also increased in the urine of patients with interstitial cystitis (Okragly et 
al., 1999). These studies raise the possibility that multiple neurotrophic factors are 
likely to be involved in modulation of sensory bladder function. Since 20-40% of 
bladder afferent neurons are non-peptidergic and not NGF-sensitive, it is likely that 
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 members of the GFLs could contribute to normal bladder functioning and contribute 
to altered bladder reflexes and pain during inflammation (section 1.6.4). 
 
1.6 Regulation of bladder sensory function by GDNF family ligands 
1.6.1 Anatomical localisation of GFL receptors in DRG neurons 
Non-peptidergic neurons express receptors that indicate their potential to respond to 
one or more members of the GFLs (Bennett et al., 1998). The GFLs comprise GDNF, 
neurturin, artemin and persephin and signal via their preferred receptors, GFRα1-4 
respectively and the common transmembrane receptor tyrosine kinase, Ret 
(rearranged during transfection) (Airaksinen and Saarma, 2002; Bennett et al., 2000a; 
Bespalov and Saarma, 2007b; Sariola and Saarma, 2003). Currently there is no 
evidence to suggest that persephin or GFRα4 are expressed by sensory neurons. The 
majority of rat IB4-positive neurons express Ret mRNA (Priestley et al., 2002) and 
contain GFRα1 or GFRα2 (Bennett et al., 2000a; Bennett et al., 1998; Ernsberger, 
2008; Priestley et al., 2002). Conversely, Ret mRNA has been identified in small and 
large diameter DRG neurons, and almost all of these neurons bind IB4 (Bennett et al., 
2000; Bennett et al., 1998; Ernsberger, 2008; Priestley et al., 2002). Ret is also 
expressed in a subpopulation of peptidergic C-type neurons (below). However, it 
should be noted that in mice, that up to 30% of DRG neurons are both IB4 and 
CGRP-positive (Price and Flores, 2007; Robinson et al., 2004), indicating that IB4-
binding in mice is not a definitive marker for non-peptidergic neurons like it is in the 
rat. 
 
Like other family members (GFRα1 and GFRα2), GFRα3 was predicted to be 
localised in the non-peptidergic DRG population, but more recent studies show that 
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 GFRα3 is exclusively expressed in a sub-population of peptidergic, CGRP-IR neurons 
(Kalous et al., 2009; Orozco et al., 2001). Almost all GFRα3-IR neurons contain 
CGRP-, TRPV1-, trkA- and Ret-IR (Bennett et al., 1996; Elitt et al., 2006; Orozco et 
al., 2001), and GFRα3 is expressed by half of all peptidergic neurons (Bennett et al., 
2006) that are potentially NGF sensitive. Therefore, the GFRα3-IR population is 
particularly interesting as it has the potential to be regulated by two neurotrophic 
factors: NGF and artemin. However, despite these studies, there is still some 
confusion in the literature with some studies reporting GFRα3-IR is present in non-
peptidergic neurons. For example, a study by Kashiba et al., (2003) report 90% co-
expression between GFRα3- and GFRα2-IR neurons. In addition, a complete 
correlation in rats between the non-peptidergic, IB4-binding population and Ret 
(expressed by the non-peptidergic population, and the peptidergic GFRα3-positive 
population) is not expected. 
 
While most of the focus in the literature has been on the NGF-sensitive population, 
our laboratory has reported that approximately one quarter of sacral bladder afferent 
neurons contain GFRα1- or GFRα3-IR (Forrest and Keast, 2008). This study found 
that 15% of sacral bladder afferent neurons contain GFRα1-IR, close to 10% contain 
GFRα3 and very few (less than 1%) contain GFRα2-IR. Each GFR comprised 
distinct, non-overlapping sub-populations and had different central distribution 
patterns (section 1.6.2) (Forrest and Keast, 2008). These results suggest that GDNF 
and artemin may target sacral bladder afferent neurons and be involved in the 
maintenance of physiological and structural properties of bladder neurons expressing 
their receptors. 
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 Based on DRG studies that show GFRα3 is exclusively expressed in a sub-population 
of peptidergic neurons (Orozco et al., 2001), it could be predicted that GFRα3 will be 
localised in a sub-population of CGRP-IR axons in the bladder, but it is not known if 
these would target one particular region or tissue of the bladder. The distribution of 
the GFRs in the bladder has not been investigated and could identify different 
populations of axons that are potentially regulated by GDNF and artemin. 
 
1.6.2 Distribution of GFL receptors in spinal cord  
The following section describes the central projection patterns of C-type (peptidergic 
and non-peptidergic) and Aδ-type DRG neurons. Peptidergic afferent neurons give 
rise to both C- and Aδ-fibres, whereas the non-peptidergic neurons primarily give rise 
to unmyelinated C-fibres (Alvarez and Fyffe, 2000). These three populations have 
distinct central projection patterns in the dorsal horn. Central terminals of peptidergic 
neurons containing CGRP- and SP-IR are primarily localised to laminae I and II 
(outer) (Casals-Diaz et al., 2009; Gibson et al., 1984; Kalous et al., 2007; Keast et al., 
2010; Saeed and Ribeiro-da-Silva, 2012; Silverman and Kruger, 1990; Todd, 2002). 
TrkA-IR is also expressed by these terminals (Averill et al., 1995; Molliver et al., 
1995). In contrast, non-peptidergic C-fibres containing IB4, FRAP, P2X3 and Mrgprs 
terminate in lamina II, the majority in lamina II (inner) (Casals-Diaz et al., 2009; 
Cavanaugh et al., 2009; Gerke and Plenderleith, 2004; Shields et al., 2010; Silverman 
and Kruger, 1990). Ret- and GDNF-IR are also present in terminals in lamina II 
(Jongen et al., 1999). 
 
Our laboratory has recently demonstrated that afferent neurons expressing the GFRs 
have distinct central projection patterns in the dorsal horn of sacral spinal cord 
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 (Forrest and Keast, 2008) (Figure 1.6a-i). GFRα1- and GFRα2-IR fibres are found in 
lamina II, an area targeted by non-peptidergic C-fibres, whereas GFRα3-IR fibres are 
found in lamina I, an area innervated by peptidergic C-fibres (Alvarez and Fyffe, 
2000; Casals-Diaz et al., 2009; Hunt and Rossi, 1985). GFRα1-IR fibres are primarily 
localised in lamina II (outer) in sacral, thoracic and lumbar dorsal horn (Forrest and 
Keast, 2008; Kalous et al., 2007; Keast et al., 2010). In addition, GFRα1-IR fibres are 
found in the LCP and associated with preganglionic neurons and autonomic 
interneurons in sacral spinal cord. A few GFRα1-IR neurons are found in the SPN 
(Forrest and Keast, 2008). The LCP receives projections from visceral afferent fibres 
and preganglionic neurons in the SPN that innervate pelvic viscera including the 
bladder (Morgan et al., 1986; Morgan et al., 1981). The presence of GFRα1-IR in this 
tract and GFRα1-IR neurons in the SPN suggests a possible role of GDNF in visceral 
(including bladder) reflexes (Forrest and Keast, 2008). In contrast, GFRα2-IR fibres 
have a more restricted distribution and in thoracic, lumbar and sacral spinal cord, and 
are only found in lamina II (inner) (Forrest and Keast, 2008; Kalous et al., 2007; 
2009). In thoracic, lumbar and sacral cord, GFRα3-IR fibres are primarily localised to 
lamina I (Forrest and Keast, 2008; Kalous et al., 2009; Keast et al., 2010). In addition, 
in sacral cord GFRα3-IR fibres are present in the LCP and surrounding preganglionic 
neurons (Forrest and Keast, 2008). 
 
Many studies have demonstrated that DRG neurons and their central terminals show 
alterations in their neurochemical profile and connectivity following inflammation 
(Callsen-Cencic and Mense, 1997; Klinger et al., 2008; Vizzard, 2001) and injury 
(Bennett et al., 2000a; Casals-Diaz et al., 2009; Wang et al., 2008). In addition, the 
central projections of DRG neurons containing the GFRs each respond differently in 
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 animal models of chronic bladder inflammatory pain (Forrest and Keast, 2008) and 
spinal cord injury (Kalous et al., 2007; 2009). As well as indicating how GFLs may 
be involved in neuronal changes in these conditions, such studies demonstrate that the 
GFRs provide a useful tool for identifying different sub-populations of peptidergic 
and non-peptidergic C-fibres that were previously undetectable by labelling only for 
CGRP or IB4. These changes will be addressed below. 
 
 
Figure 1.6 Distribution of GFRα1-, GFRα2- and GFRα3-immunoreactive (IR) fibres 
in the rat sacral spinal cord.  Each vertical set of three images shows a transverse 
section immunostained with a GFR (a, d, g) and nitric oxide synthase (NOS, b, e, h) 
to demonstrate lamina II (inner) and sacral preganglionic neurons (arrows), and the 
merged image pairs (c, f, i). a-c: GFRα1-IR fibres are distributed in lamina II (outer) 
and associated with preganglionic neurons. d-f: GFRα2-IR fibres are found in lamina 
II (inner) and are not associated with preganglionic neurons. g-i: GFRα3-IR fibres are 
located in lamina I and a small region dorsal to preganglionic neurons. Images are 
orientated with the dorsal surface to the top, and the lateral dorsal horn to the right. 
Scale bar in (a) represents 100 µm (applies to all panels). Adapted from Forrest and 
Keast, 2008. 
GFRα1 GFRα2 GFRα3 
NOS NOS NOS 
merge merge merge 
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1.6.3 Functional effects of NGF and the GFLs 
Neurotrophic factors, in particular NGF, have important roles in pain modulation and 
transmission. NGF and the GFLs can be released from target tissues and are up-
regulated at the site of injury or inflammation (Elitt et al., 2006; Malin et al., 2006; 
Priestley et al., 2002). Recent studies have shown that NGF potentiates TRPV1 
signalling and is up-regulated in the periphery following inflammation (Malin and 
Davis, 2008). TRPV1 is activated by noxious heat, protons and capsaicin, and is 
essential for the development of inflammation-induced thermal hyperalgesia (Caterina 
et al., 2000). Thermal hyperalgesia is an increased pain sensitivity to thermal (hot or 
cold) stimuli (Loeser and Treede, 2008). Like NGF, members of the GFLs sensitise 
nociceptors in vitro (Elitt et al., 2006; Malin et al., 2006). However, there are 
conflicting reports demonstrating that artemin can have both pro-nociceptive (Malin 
et al., 2006a) and anti-nociceptive properties (Gardell et al., 2003; Wang et al., 2008) 
in in vivo experimental models. While the majority of studies have focused on NGF, 
the GFLs are now receiving attention for their role in contributing to nociceptor 
sensitisation and the development of pain during injury and inflammation (sections 
1.6.3.1 and 1.6.3.2).  
 
1.6.3.1 In vitro studies 
In dissociated mouse DRGs, NGF sensitises nociceptors by potentiating the capsaicin-
evoked TRPV1 response (Malin et al., 2006a). This study also demonstrates that the 
GFLs can sensitise nociceptors by potentiating the TRPV1 response to capsaicin 
(Malin et al., 2006a). Of particular interest was that GDNF, neurturin and artemin all 
potentiated TRPV1 responses at concentrations 100x less than NGF demonstrating 
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 that GDNF, neurturin and artemin are 10-100x more potent than NGF in the 
potentiation of capsaicin responses in sensory neurons. Another study by Elitt et al. 
(2006) shows that artemin enhances TRPV1 responsiveness to capsaicin. This 
suggests that the signalling of artemin is likely to modulate TRPV1 expression and 
afferent sensitivity in response to noxious chemical stimuli. Together these studies 
demonstrate that members of the GFLs, in particular artemin, can sensitise 
nociceptors and are likely to be involved in the development of pain. 
 
The majority of somatic DRG neurons expressing GFRα3-IR contain TRPV1- and 
TRPA1-IR (Elitt et al., 2006; Orozco et al., 2001). TRPA1 is a member of the TRP 
family of receptors and is expressed by a subpopulation of peptidergic nociceptors. 
TRPA1 is activated by noxious cold stimuli (< 15°C) and by the cooling compounds 
menthol and icilin, and to mustard and cinnamon oil (Basbaum et al., 2009; Elitt et 
al., 2006). Malin et al, (2011) demonstrated that like NGF, the GFLs can potentiate 
the TRPV1 response to capsaicin and the TRPA1 response to mustard oil, but the 
degree to which they sensitise nociceptors is dependent on the peripheral target of the 
primary sensory neuron. This differed between afferents innervating cutaneous (skin 
or muscle) and visceral (colon) tissues (Malin et al., 2011). In skin afferents, artemin 
was most effective in potentiating the response to capsaicin, followed by NGF and 
neurturin. For muscle afferents, NGF was most effective at potentiating TRPV1 
signalling. GDNF was least effective in potentiating TRPV1 responses to capsaicin in 
both skin and muscle afferents. In comparison, in colon afferents, both artemin and 
NGF were twice as effective in potentiating the response to capsaicin than GDNF and 
neurturin. Mustard oil responses were potentiated in a similar number of neurons by 
these neurotrophic factors (Malin et al., 2011). Together these results indicate that in 
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 many circumstances, members of the GFLs are more potent than NGF in potentiating 
the response to capsaicin and mustard oil, and can produce nociceptor sensitisation. 
Furthermore, the mechanisms underlying afferent neuron sensitivity are likely to be 
different depending on their peripheral targets.  
 
1.6.3.2 In vivo studies 
NGF is well known to have pro-nociceptive effects and contributes to the 
development of pain and altered nociceptor signalling (Malin et al., 2006a; Pezet and 
McMahon, 2006a; Woolf et al., 1994). Administration of NGF in neonatal or mature 
rats leads to thermal hyperalgesia and mechanical allodynia (Lewin et al., 1993). 
Allodynia is pain in response to a normally innocuous mechanical stimulus (Loeser 
and Treede, 2008). These effects are caused by sensitisation of peripheral afferent 
fibres (Lewin et al., 1993). In mice, administration of NGF into the hindpaw produces 
thermal hyperalgesia within 30 minutes of the injection (Malin et al., 2006a). This 
study also demonstrated that members of the GFLs can contribute to the development 
of pain, providing evidence that peripheral administration of members of the GFLs 
have pro-nociceptive actions, producing hyperalgesia (Malin et al., 2006a). 
Furthermore, an increase in NGF and artemin mRNA in skin following cutaneous 
inflammation was shown. These results indicate that like NGF, artemin is regulated 
by cutaneous inflammation and is likely to contribute to sensitisation of primary 
afferents in vivo leading to hyperalgesia (Malin et al., 2006a). A number of other 
studies have provided evidence that GDNF and artemin have important roles in the 
development of pain and altered nociceptor signalling. An increase in mechanical 
sensitivity occurs in cutaneous non-peptidergic C-fibres in transgenic mice that over-
express GDNF in skin (Albers et al., 2006). Transgenic artemin over-expressing mice 
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 show increased sensitivity to hot and cold stimuli, increased TRPV1- and GFRα3-IR 
fibres in the skin and elevated TRPV1 and GFRα3 mRNA levels in DRGs (Elitt et al., 
2006). Following saphenous nerve transection, a nerve that innervates skin, a 
subpopulation of heat-sensitive C-fibre neurons develop mechanical sensitivity which 
is regulated by increased target-derived artemin (Jankowski et al., 2010). Artemin 
over-expression in tongue epithelium increases the number of trigeminal ganglion 
neurons containing, TRPV1 and TRPA1 and produces oral sensitivity to capsaicin 
and mustard oil (Elitt et al., 2008). Together, these studies show that members of the 
GFLs; particularly artemin and GDNF, can modulate gene expression in sensory 
neurons, including TRPV1 activity. These changes contribute to the regulation of 
nociceptor responsiveness and to the development of thermal and mechanical 
sensitivity.  
 
1.6.4 Chronic bladder inflammation regulates GFR expression in central afferent 
axons  
The majority of studies on neurotrophic actions on bladder function have focused on 
NGF and changes in peptidergic afferents. Few studies have investigated the effect of 
chronic bladder inflammation on GFLs and non-peptidergic afferents. Our laboratory 
(Forrest and Keast, 2008) has shown that chronic bladder inflammation differentially 
affects the central distribution of neurons expressing the GFRs. During chronic 
visceral inflammatory pain induced by CYP in rats, our laboratory demonstrated that 
the immunoreactivity of sacral non-peptidergic C-fibre afferents expressing GFRα1 
increases in the dorsal horn (Forrest and Keast, 2008). No change was observed in 
GFRα2- or GFRα3-IR afferent fibres, although it should be noted that GFRα2 is not 
expressed by bladder afferent neurons so no change was predicted in this population 
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 of neurons. We did not identify the mechanism of the change in GFRα1-IR, which 
could be due to up-regulation of GFRα1-IR protein expression, increased trafficking 
of protein along the central terminal or fibre sprouting. This up-regulation of GFRα1-
IR correlated with a previous study that showed GDNF mRNA is increased in the 
bladder during chronic visceral inflammation in rats (Vizzard, 2000b). These results 
show that each GFR responds differently to bladder inflammation and suggests that 
non-peptidergic afferents undergo change during inflammation. These may be linked 
to changes in bladder afferents or nociceptor behaviour. Currently it is not known if 
these alterations in the dorsal horn are reflected by changes in GFR expression in the 
cell bodies of bladder afferent neurons, or in projections of bladder afferent neurons 
to the lumbar cord. 
 
1.7 Neuropathic pain 
1.7.1 Overview 
Members of the GFLs also promote regeneration after nerve injury (Wang et al., 
2008) and show efficacy in rat neuropathic pain models (Bennett et al., 2000a; 
Gardell et al., 2003). Following nerve injury, structural and chemical changes occur in 
primary sensory neurons and their central projections, as well as in second order 
neurons in the dorsal horn that develop spontaneous activity (Navarro et al., 2007). 
While some of these changes in DRG neurons and their central terminals are 
associated with regenerative growth (Navarro et al., 2007), other studies have linked 
these changes to nociceptor sensitisation, and the development and maintenance of 
neuropathic pain (Costigan et al., 2009). Neuropathic pain is caused by a lesion or 
disease of the somatosensory system and is often persistent in nature (Costigan et al., 
2009; Jensen et al., 2011). In animals, neuropathic pain is measured by the 
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 development of mechanical allodynia and thermal hyperalgesia (section 1.7.2). 
Multiple mechanisms are responsible for the development and maintenance of 
neuropathic pain after nerve injury. This research primarily originates from studies of 
somatic nerves in rodents, with particular focus on peptidergic and non-peptidergic C-
fibre afferents (section 1.7.4). Although these studies are very valuable, some aspects 
are difficult to interpret in terms of structural change as nerve injury can cause axonal 
sprouting, axonal degeneration and altered peptide levels in primary afferent neurons 
and their central projections (Costigan et al., 2009).  
 
1.7.2 Experimental animal models of neuropathic pain 
Animal models of neuropathic pain have improved the understanding of the 
mechanisms underlying chemical and structural plasticity of primary afferent neurons 
and their axons following injury, and the development of neuropathic pain. 
Neuropathic pain in rats can be produced by a number of surgical manipulations 
including spinal cord injury (Densmore et al., 2010; Kalous et al., 2009), spinal nerve 
ligation (Gardell et al., 2003), dorsal root crush (Wang et al., 2008) and sciatic nerve 
injury (Bennett et al., 2000a; Bennett and Xie, 1988; Casals-Diaz et al., 2009). 
 
Injury to the sciatic nerve is a favoured animal model of neuropathic pain and is a 
large, easily accessible nerve that in the rat, contains close to 30,000 axons (Decosterd 
and Woolf, 2000b). This nerve innervates a large portion of the lower limb including 
the musculature, joints, vasculature and skin (Decosterd and Woolf, 2000; 
Schmalbruch, 1986; Swett and Woolf, 1985). The sciatic nerve is divided into three 
primary distal branches (Decosterd and Woolf, 2000b): the tibial and common 
peroneal nerve branches are the largest and comprise both motor and afferent axons, 
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 whereas the third branch, the sural nerve, comprises few motor axons, the majority 
being afferent axons (Schmalbruch, 1986).  
 
Different animal models of sciatic nerve injury have been used to investigate the 
contribution of Aδ- and C-fibres to altered reflexes and the development of 
neuropathic pain. Chronic constriction injury involves tying loose ligatures around the 
sciatic nerve, proximal to the trifurcation point (Bennett and Xie, 1988). Spared nerve 
injury involves transecting the tibial and common peroneal nerves but keeping the 
sural nerve, which contains mostly afferent axons, in tact (Casals-Diaz et al., 2009; 
Nagano et al., 2003). These two methods are incomplete injuries and produce robust 
neuropathic pain measured by the development of thermal (hot or cold) hyperalgesia 
and mechanical allodynia (Bailey and Ribeiro-da-Silva, 2006; Bennett and Xie, 1988; 
Casals-Diaz et al., 2009; Gardell et al., 2003). Crush injury of the sciatic nerve is also 
an incomplete injury model where all the axons in the sciatic nerve, proximal to the 
trifurcation point are crushed, and can potentially regenerate (Casals-Diaz et al., 
2009). After crush injury, there is an initial loss of mechanical and thermal sensitivity 
in the hindpaw, indicated by higher mechanical and heat withdrawal thresholds in the 
injured hindpaw compared to the uninjured side. Three-four weeks post-crush injury, 
the injured paw starts to develop mechanical allodynia and thermal hyperalgesia, 
suggesting partial innervation recovery (Casals-Diaz et al., 2009). Transection of the 
sciatic nerve is a complete injury model. The development of neuropathic pain cannot 
be measured following sciatic transection as all afferent and efferent axons have been 
severed (Bennett et al., 2000a; Hu and McLachlan, 2003b), therefore it is not known 
if transection causes neuropathic pain in rats. 
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 Unlike visceral pain in animals (section 1.2.3), neuropathic pain following nerve 
injury is considered to be indicated by the development of mechanical allodynia and / 
or thermal hyperalgesia in the affected paw (Decosterd and Woolf, 2000b). The 
uninjured side serves as an internal control, where sensory thresholds are typically 
unaffected (Decosterd and Woolf, 2000b). Mechanical allodynia is measured by 
testing the mechanical paw withdrawal threshold using a series of von Frey hairs with 
different bending pressures, which are applied to the plantar surface of the paws 
(Chaplan et al., 1994; Klimis et al., 2011). A reduction in paw withdrawal threshold 
on the injured side indicates the development of mechanical allodynia (Chaplan et al., 
1994). Thermal (heat) hyperalgesia is commonly measured using the Hargreaves test 
where a focal heat stimulus is applied to the plantar surface of the paw (Hargreaves et 
al., 1988). Paw withdrawal latencies are then recorded (Hargreaves et al., 1988; 
Jayamanne et al., 2006). A reduction in paw withdrawal to the thermal stimulus, i.e., 
paw withdrawal at a lower temperature than the uninjured side, indicates the 
development of thermal hyperalgesia (Hargreaves et al., 1988). Cold thermal 
hyperalgesia is measured by application of an ice probe on the plantar surface of the 
paw, and measuring withdrawal latency (Casals-Diaz et al., 2009; Lindsey et al., 
2000). In addition, cold hyperalgesia can be measured by recording the number of 
paw flicks, or licking of the paw following application of acetone (a cooling agent) to 
the footpad (Bailey and Ribeiro-da-Silva, 2006; Decosterd and Woolf, 2000b). A 
reduction of paw withdrawal latency following application of the ice probe (Casals-
Diaz et al., 2009), or increased paw flicking or licking after acetone application 
(Decosterd and Woolf, 2000b), indicate thermal (cold) hyperalgesia. These changes 
correlate with neurochemical and structural changes that occur in DRG neurons and 
their central projections following nerve injury (section 1.7.4).  
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1.7.3 Central distribution patterns of afferent axons travelling in the sciatic nerve 
In rats, primary afferent neurons that project in the sciatic nerve originate from the 
L3-5 DRG, with smaller contributions from L6 DRG neurons (Decosterd and Woolf, 
2000b). Anterograde tracing studies in rats using HRP applied to the cut sciatic nerve, 
proximal to the trifurcation point, or to the proximal cut end of one of its three 
branches (Swett and Woolf, 1985b; Woolf and Fitzgerald, 1986b), have identified the 
central projections of axons in each nerve. Application of HRP to the whole sciatic 
nerve labels axons in L2-5 spinal cord. These closely match the distribution of 
afferents travelling in the individual branches of the sciatic nerve (Swett and Woolf, 
1985b). Each branch of the sciatic nerve has distinct central projection patterns in 
lumbar cord, with all afferents projecting to the medial three quarters of the dorsal 
horn (Woolf and Fitzgerald, 1986a). The terminal field of axons travelling in the tibial 
nerve comprise the largest area of all the branches in the sciatic nerve. These axons 
project to the medial third of the L2-6 dorsal horn, from the superficial dorsal horn to 
lamina VI. From here, axons extend laterally toward lamina VII (Swett and Woolf, 
1985b; Woolf and Fitzgerald, 1986b). Axons travelling in the sural nerve terminate in 
the superficial and deeper dorsal horn of L2-5 segments (Swett and Woolf, 1985b; 
Woolf and Fitzgerald, 1986b). The axons travelling in the common peroneal nerve 
terminate in an area extending from the superficial dorsal horn to the deeper dorsal 
horn. These axons are located between those projecting in the tibial nerve (medially 
distributed) and sural nerve (more laterally distributed) (Swett and Woolf, 1985b; 
Woolf and Fitzgerald, 1986b). The central distribution of axons in each nerve are 
most numerous in L4/5 spinal cord (Swett and Woolf, 1985b; Woolf and Fitzgerald, 
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 1986b). The most lateral aspect of the dorsal horn receives projections from the 
posterior cutaneous nerve, which innervates the thigh (Swett and Woolf, 1985b). 
 
1.7.4 Injury-induced changes in DRG neurons and their central projections 
The effects of sciatic nerve injury on peptidergic C-fibre afferents has been 
extensively studied, but many of these studies have produced equivocal results in 
terms of structural change. A number of studies have reported a progressive and 
sustained reduction in both strength of immunoreactivity and density of peptidergic 
C-fibres containing CGRP or SP in the superficial dorsal horn (Cameron et al., 1991; 
Casals-Diaz et al., 2009; Hughes et al., 2007; Sommer and Myers, 1995) following 
injury to the sciatic nerve. In contrast, others have reported no change in peptidergic 
fibres (Bailey and Ribeiro-da-Silva, 2006; Cameron et al., 1997; Casals-Diaz et al., 
2009). Following spared nerve and crush injury to the sciatic nerve, after an initial 
reduction in peptidergic fibres in the dorsal horn, these recover to match levels of the 
uninjured side and control animals with 2-3 weeks after injury (Casals-Diaz et al., 
2009). After partial nerve injury, while some axons are injured or severed, most are 
intact and keep contact with their target tissue, maintaining target-derived 
neurotrophic factor support. During the first few weeks after injury, there is disruption 
in retrograde transport of target-derived neurotrophic factors. Peptidergic (CGRP- and 
SP-IR) afferents contain trkA and p75, and are potentially regulated by NGF. The 
reduction in CGRP- and SP-IR following sciatic nerve injury suggests an interruption 
in target-derived NGF, which normally maintain these axons (Eriksson et al., 1997). 
These authors suggest that after 2-3 weeks, axonal regeneration is likely to have 
advanced, restoring target-derived neurotrophic factor support, as indicated by 
recovery of peptide immunoreactivity in the spinal cord. 
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Reports on the effect of nerve injury on non-peptidergic afferents are more consistent 
than studies investigating peptidergic afferents (above). Non-peptidergic afferents 
show a greater vulnerability to decrease following sciatic nerve injury than 
peptidergic afferents (Bennett et al., 2000a; Casals-Diaz et al., 2009). In addition, 
IB4-binding afferents are slower to recover after injury than peptidergic afferents 
(Casals-Diaz et al., 2009). Chronic constriction, spared nerve and crush injury to the 
sciatic nerve causes an initial reduction of IB4-binding afferents in the dorsal horn. 
IB4-binding afferents on the injured side then begin to recover within 2-3 weeks to 
match similar levels as the contralateral dorsal horn (Bailey and Ribeiro-da-Silva, 
2006; Casals-Diaz et al., 2009). The majority of these changes in the dorsal horn 
matched projection patterns of branches in the sciatic nerve, and corresponded with 
the development of neuropathic pain (Casals-Diaz et al., 2009). 
 
The effects of sciatic nerve injury on Ret expression in DRGs and their central 
terminals have been studied but to date, also show mixed results. Following sciatic 
nerve transection, Bennett et al. (2000) report little change in the proportion of DRG 
neurons expressing Ret mRNA, whereas Nagano et al. (2003) report a reduction of 
Ret expression in DRG neurons following sciatic nerve injury. Bennett et al. (2000) 
also investigated the effect of nerve injury on different DRG subpopulations 
expressing the GFRs and found that each GFR is regulated differently by injury. This 
study found an increase in the number of DRG neurons expressing GFRα1 and 
GFRα3 mRNA, but a reduction in the number of neurons containing GFRα2 mRNA 
(Bennett et al., 2000a). This study demonstrates that nerve injury produces different 
effects in subpopulations of peptidergic and non-peptidergic afferent neurons. These 
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 changes could not be detected using CGRP/SP and IB4. Another study found GDNF 
expression levels decrease in DRG neurons following sciatic nerve transection 
(Nagano et al., 2003). Currently it is not known if changes in GFR mRNA or protein 
levels in the DRG are causally linked to changes in GFR-IR levels within terminals in 
the dorsal horn after injury.  
 
1.7.5 Functional effects of GDNF family members following nerve injury 
Anti-nociceptive and pro-regenerative effects of GDNF (Bennett et al., 1998; Nagano 
et al., 2003) and artemin (Gardell et al., 2003; Wang et al., 2008) have been reported 
in rat neuropathic pain models following sciatic nerve injury and spinal nerve ligation. 
After sciatic nerve injury, intrathecal administration of GDNF prevents the loss of IB4 
fibres in the dorsal horn (Bennett et al., 1998) and reverses thermal hyperalgesia and 
mechanical allodynia without affecting thresholds on the uninjured side (Nagano et 
al., 2003). In cultured DRG neurons from naïve rats, exogenous administration of 
GDNF stimulates growth by increasing the number of neurons that initiate neurites 
(Mills et al., 2007). However, in DRG neurons cultured from animals that had 
undergone sciatic nerve transection seven days previously, GDNF caused an even 
larger growth response (neurite initiation, extension and branching). DRG neurons 
from injured animals also responded at lower doses of GDNF compared with neurons 
from control animals (Mills et al., 2007). 
 
Gardell et al. (2003) used another neuropathic pain and injury model, spinal nerve 
ligation, to investigate the potential for systemic administration of artemin to reverse 
the onset and development of neuropathic pain. Administration of artemin at the time 
of spinal nerve ligation or at two weeks post-surgery, a time point where neuropathic 
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 pain is established, reversed the onset and development of thermal and mechanical 
hypersensitivity in the hindpaw (Gardell et al., 2003). In addition, administration of 
artemin partially or completely restored the reduction in IB4 binding, P2X3-, CGRP- 
and SP-IR, and the increase in galanin- and NPY-IR in the dorsal horn (Gardell et al., 
2003). These results indicate an anti-nociceptive effect of systemic artemin 
administration in a neuropathic pain model. These results also suggest that artemin is 
able to restore the degenerative neurochemical and neuroanatomical changes that 
occur in DRG neurons, and their central projections following injury. A related study 
by the same group, Wang et al. (2008), performed a C4-T2 dorsal root crush in rats 
that induces neuropathic pain in the forepaw. This regenerative model injures axons 
entering the dorsal root entry zone at these spinal levels. Immunolabelling of nerve 
fibres with NF200, CGRP and P2X3, markers for myelinated, and peptidergic and 
non-peptidergic C-fibres respectively, stopped at the dorsal root entry zone following 
dorsal root crush. However, following systemic artemin administration, nerve fibres 
labelled with these markers were found on the spinal cord side of the dorsal root entry 
zone, indicating that artemin promotes the regeneration of multiple classes of nerve 
fibres after injury (Wang et al., 2008). This is in agreement with previous studies 
(above) demonstrating that artemin shows efficacy in promoting regeneration after 
injury. Artemin is also able to restore the increased neuronal excitation that occurs in 
the dorsal horn following inflammation of the hindpaw induced by formalin injection 
(Wang et al., 2008). Together, these results with artemin and GDNF suggest that the 
GFLs are likely to be involved in mechanisms underlying structural plasticity and the 
development of neuropathic pain following nerve injury, also promoting regeneration 
after injury. 
 
60
 1.7.6 Spinal cord injury regulates GFR expression in central afferent axons 
Further evidence for GFLs contributing to the development of neuropathic pain comes 
from recent studies on spinal cord injury. Spinal cord injury can lead to chronic 
neuropathic pain (Siddall et al., 2003). Structural remodelling in C-fibre afferent 
neurons and their central terminals may contribute to the mechanisms underlying this. 
Most studies have focused on peptidergic and non-peptidergic primary afferent C-
fibres containing CGRP and IB4. Following spinal cord injury in rats, CGRP-IR 
fibres become more prevalent in deep laminae of the dorsal horn in spinal segments 
both rostral and caudal to injury (Christensen and Hulsebosch, 1997; Krenz et al., 
1999; Ondarza et al., 2003). IB4-positive fibres are also increased in the deep dorsal 
horn following spinal cord transection (Zinck and Downie, 2008). These results are 
interpreted as sprouting of fibres that normally terminate in superficial laminae. 
Studies from our laboratory showed that subpopulations of C-fibre afferents were 
differentially affected in an animal model of complete spinal cord injury (Kalous et 
al., 2007). This study investigated changes in peptidergic afferents expressing CGRP-
IR and non-peptidergic afferents containing GFRα1- and GFRα2-IR. Following spinal 
cord transection in rats, CGRP-IR fibres in the dorsal horn showed a transient, but 
widespread loss across multiple spinal segments approaching the site of injury. Non-
peptidergic afferents containing GFRα1-IR were unaffected by injury whereas 
GFRα2-IR afferents showed a permanent loss in patches in the superficial dorsal horn 
(Kalous et al., 2007). A subsequent study using an incomplete spinal cord injury 
model (clip-compression) where forepaw hyperalgesia develops (Densmore et al., 
2010) demonstrated again that different classes of C-fibre afferents are uniquely 
affected by injury, but these changes differ from those occurring after complete 
transection (Kalous et al., 2009). Two weeks after incomplete injury, CGRP-IR fibres 
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 are reduced in the dorsal horn whereas no change is observed in afferents expressing 
GFRα1-, GFRα2- or GFRα3-IR. However, by 12 weeks post injury, all four 
populations of afferents were reduced in the dorsal horn and indicate that a prolonged 
and potentially permanent loss occurs in these fibres (Kalous et al., 2009). Together 
these studies demonstrate that structural remodelling in dorsal horn afferents, 
including populations expressing the GFRs could contribute to the development and 
maintenance of neuropathic pain. 
 
1.7.7 Visceral nerve injury 
Understanding the mechanisms underpinning how pain arises following damage to 
different nerves is essential for developing treatments for promoting regeneration and 
relieving neuropathic pain that may develop after injury. Recent evidence suggests 
that there are differences in the mechanisms that underlie how pain arises following 
damage to somatic and visceral nerves. A recent clinical study indicates the 
prevalence of post-surgical chronic pain varies between anatomical region of the 
surgery, with the highest prevalence following surgery to the back, neck, hip and 
limbs but much lower prevalence of persistent pain following surgery to a visceral 
organ (Johansen et al., 2012). In addition, it is unclear to what extent visceral pain is 
neuropathic in origin.  
 
Only a limited number of animal studies have investigated the effect of visceral nerve 
injury. These have focused primarily on the pelvic nerve because it is a pure visceral 
nerve that innervates pelvic organs (Keast, 2006; Yoshimura, 1999). The pelvic nerve 
can be damaged during routine surgical procedures (Maas et al., 2003; Walsh and 
Donker, 1982), significantly impacting quality of life (Fowler et al., 2008). In 
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 addition, the connectivity of preganglionic axons travelling in this nerve with 
postganglionic neurons in the pelvic ganglia have been well documented (Keast, 
2006).  The central distribution of afferent axons travelling within the pelvic nerve are 
also well described (Morgan et al., 1981; Nadelhaft and Booth, 1984). 
 
1.7.7.1 Visceral nerve injury-induced changes in afferent fibres in the spinal cord 
A number of studies have demonstrated that the central projections of DRG neurons 
show alterations in their neurochemical profile and connectivity following injury to a 
visceral nerve (Anand et al., 1991; Birder et al., 1991; Chung et al., 1993). Unlike 
somatic nerve injury (section 1.7.2), it is not known if these changes correlate to 
altered pain behaviours. Pelvic nerve injury increases the number of spinal neurons 
synaptically activated following injury in rats, as demonstrated by an up-regulation of 
Fos in the lumbosacral spinal cord (Birder et al., 1991). The effect of pelvic nerve 
injury on peptidergic C-fibre afferents has been examined in a few studies. Chung et 
al., (1993) report a reduction in CGRP-IR in the dorsal horn, SPN, DGC and IML of 
lumbosacral spinal cord. Another study report no change in SP- or galanin-IR in the 
dorsal horn, but a reduction in VIP-IR (Anand et al., 1991). Together, these results 
indicate that structural remodelling occurs in the dorsal horn following injury to a 
visceral nerve, however, the mechanisms responsible and if this relates to the 
development of pain is yet to be determined. Studies on the effect of visceral nerve 
injury on non-peptidergic afferents have not been performed. However, given this 
literature review has outlined the evidence to suggest that afferent axons expressing 
each of the GFRs are regulated differently by inflammation and injury (sections 1.6.4, 
1.7.4 and 1.7.6), it could be predicted that visceral nerve injury will produce different 
outcomes on the central distribution patterns of neurons expressing each GFR. 
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 1.8 Thesis proposal 
This literature review summarises the innervation of the bladder, bladder pain and 
dysfunction caused by inflammation, and how bladder function is regulated by NGF. 
It also presented emerging evidence that the GFLs could potentially regulate bladder 
function. In addition, this review demonstrates how the GFLs can contribute to 
nociceptor sensitisation and the development of visceral inflammatory and somatic 
neuropathic pain. Recent reports suggest that the GFLs and their receptors are likely 
to be regulated differently by visceral inflammation and nerve injury. Understanding 
these how these changes arise is important to develop ways to promote regeneration 
and for the successful treatment of chronic pain states without producing adverse 
outcomes on neuronal structure. This may involve tailoring treatments to individual 
nerve populations. 
 
The general aim of this project was to identify and characterise the effects of visceral 
inflammation and nerve injury on nociceptors expressing GFRs. The specific project 
aims include: 
 
• Chapter 2 will investigate the changes that occur in somatic nociceptors 
expressing the GFRs following peripheral nerve injury. I hypothesised that 
DRG neurons and their central terminals expressing the GFRs will each 
respond differently to sciatic nerve injury. To address this hypothesis, two 
models of sciatic nerve injury were used, transection and chronic constriction. 
Complete nerve injury (sciatic transection) was compared to an incomplete 
injury model (CCI), which is a well-characterised model of neuropathic pain. 
The distribution of central terminals from DRG neurons expressing the GFRs 
64
 were analysed in lumbar cord following transection of the sciatic nerve and 
compared to the effects of chronic constriction. DRGs were also examined to 
determine if neurons expressing the GFRs change after sciatic nerve injury.  
 
• Chapter 3 will examine the effect of visceral nerve injury on the central 
projections of different classes of afferent neurons expressing the GFRs. I 
hypothesised that injury to visceral nerves innervating the bladder and other 
pelvic viscera will produce different outcomes on afferent terminals in spinal 
cord than following somatic nerve injury. To test this hypothesis, the 
hypogastric and / or pelvic nerves were transected in rats and the distribution 
of central terminals expressing the GFRs analysed in lumbar and sacral spinal 
cord, regions where afferent axons travelling in these nerves project. 
 
• Chapter 4 will characterise lumbar and sacral bladder afferent neurons 
expressing the GFRs and determine the impact of chronic bladder 
inflammation induced by CYP on different populations of bladder afferent 
neurons. The distribution of their central projections in upper lumbar spinal 
cord, a site of bladder afferent projection, was also investigated. I examined if 
upregulation of GFRα1-IR following chronic bladder inflammation reported 
by Forrest and Keast (2008) was restricted to sacral cord, or if changes in 
lumbar spinal cord also occur. Sacral and lumbar DRGs were analysed to 
investigate if alterations in spinal cord following chronic inflammation reflect 
changes in GFR expression in DRG neurons. Induction of activated 
transcription factor 3 (ATF3) was also used to potentially identify a population 
of bladder afferent neurons that are injured or undergoing structural 
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 remodelling during inflammation. Currently the distribution of GFRα3-IR 
axons within the bladder is not known. This chapter also investigated the 
distribution of GFRα3-IR axons in different regions and tissues of the bladder 
and if chronic bladder inflammation altered the structure and distribution of 
these axons. These were compared to other classes of afferent and autonomic 
axons.  
 
• Chapter 5 will define the potential targets of GFRα3-IR axons across different 
regions and tissues in the bladder. I hypothesised that GFRα3-IR axons in the 
bladder would comprise a subpopulation of peptidergic afferent axons that 
target a distinct range of tissues. To test this hypothesis, 
immunohistochemistry for GFRα3 was performed in bladder whole mount 
preparations and sections, comparing the results with other major 
subpopulations of afferent and autonomic axons. 
 
• Chapter 6 will provide an overview of the major findings presented in the 
experimental thesis chapters and discuss the limitations related to the approach 
and experimental design of these studies. This chapter will also provide a 
general discussion of the results presented within this thesis in the context of 
the current literature and implications for future directions. 
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 CHAPTER 2: GFR expression in spinal cord and DRGs  
following sciatic nerve injury 
 
2.1 Introduction 
Injured adult primary sensory neurons undergo many chemical and structural changes, 
some of which are directly linked to regenerative growth (Navarro et al., 2007), while 
others may be maladaptive in the longer term and can for example lead to neuropathic 
pain (Costigan et al., 2009). Understanding the nature of these changes is therefore 
important for developing ways to promote regeneration while preventing the 
development of pain or, conversely, for developing new analgesics without adverse 
outcomes on neuronal structure. 
 
Different classes of dorsal root ganglia (DRG) neurons can be distinguished according 
to physiological properties, degree of myelination, neurotransmitter content and 
sensitivity to particular neurotrophic factors (Ernsberger, 2008; Guo et al., 1999; 
Lawson, 2002). In this study we have focused on C-type unmyelinated DRG neurons, 
which are predominantly nociceptors and many of which express the transient 
receptor potential vanilloid 1 (TRPV1) (Woolf and Ma, 2007). These neurons can be 
divided into two groups, “peptidergic” and “non-peptidergic”, based on whether or 
not they express neuropeptides such as substance P and calcitonin gene-related 
peptide (CGRP) (Averill et al., 1995; Guo et al., 1999; Molliver et al., 1995). Many 
non-peptidergic C-type neurons bind the lectin, Bandeiraea simplicifolia Isolectin B4 
(IB4) (Kitchener et al., 1993; Silverman and Kruger, 1990) and some interesting 
features have been ascribed to these neurons in laboratory rodents e.g. higher levels of 
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 expression of the voltage-gated sodium channel, Nav1.9 (Fang et al., 2006); longer 
duration of action potentials and smaller heat-activated currents (Stucky and Lewin, 
1999). However, a limitation of using IB4 is that it labels different populations of 
DRG neurons in rats and mice - in rat, a majority of IB4-binding neurons express 
TRPV1 (Guo et al., 1999; Michael and Priestley, 1999), whereas in mouse, very few 
(<5%) IB4-labelled neurons have this property (Zwick et al., 2002). Moreover, their 
growth in vitro varies between species - in mouse the IB4-binding neurons have an 
attenuated ability to grow neurites compared with peptidergic neurons (Leclere et al., 
2007), whereas in rats both populations show similar growth (Kalous and Keast, 
2010).  
 
In adult rodents, peptidergic and non-peptidergic C-type DRG neurons also differ in 
their sensitivity to neurotrophic factors. Neurotrophic factors are important pro-
regenerative molecules (Sofroniew et al., 2001) but also sensitise nociceptors  
(Bespalov and Saarma, 2007; Pezet and McMahon, 2006). Peptidergic DRG neurons 
express TrkA and p75 neurotrophin receptors that are targeted by nerve growth factor 
(NGF) (Averill et al., 1995; Pezet and McMahon, 2006). A second group of 
neurotrophic factors that target C-type DRG neurons are members of the glial cell 
line-derived neurotrophic factor (GDNF) family (Malin et al., 2006; Sah et al., 2005). 
These comprise GDNF, neurturin and artemin, which signal using the tyrosine kinase 
RET, and specific co-receptors (respectively, GFRα1, GFRα2 and 
GFRα3)(Airaksinen and Saarma, 2002). Early reports suggested this family of ligands 
exclusively targeted non-peptidergic neurons, but this has proven incorrect as the co-
receptor for artemin, GFRα3, is primarily expressed by nociceptive peptidergic DRG 
neurons (Orozco et al., 2001). As GFRα3-immunoreactivity is expressed in 
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 approximately fifty percent of peptidergic neurons (Bennett et al., 2006; Kalous et al., 
2009), it appears NGF-sensitive neurons comprise two classes distinguished by their 
potential responsiveness to artemin. In addition, GDNF and neurturin target separate 
populations of non-peptidergic neurons. As such, C-type DRG neurons can be divided 
into four categories: peptidergic/artemin-insensitive, peptidergic/artemin-sensitive, 
non-peptidergic/GDNF-sensitive, non-peptidergic/neurturin-sensitive. 
 
A recent study of GFR-immunoreactive (IR) nerve fibres in the spinal cord has 
revealed an unexpected degree of complexity in the central targets of these four 
populations (Forrest and Keast, 2008). In L6 and S1 spinal cord segments of adult 
female rats, each GFR subtype showed a distinctive pattern of termination within the 
superficial laminae, providing strong evidence for selective activation of different 
spinal circuits. In rats and mice, L6 and S1 spinal levels are targeted by the inputs 
from the pelvic viscera and this same study showed that inflammation of the lower 
urinary tract causes an increase in intensity of GFRα1-immunofluorescence (but not 
GFRα2 or GFRα3) within the superficial laminae. This raises the further possibility 
that changes in GFR signalling may be causally linked to changes in bladder afferent 
or nociceptor behaviour.  
 
The broad aim of the current study was to investigate the impact of peripheral injury 
on the central projections of DRG neurons expressing GFRs, many of which are non-
peptidergic. A change in GFR expression or distribution of GFR-expressing nerve 
fibres could have significant impact on return of neuronal function or development of 
nociceptor sensitisation after injury. To address this, we have analysed the distribution 
of central terminations from three classes of GFR-IR neurons after unilateral sciatic 
69
 nerve injury. Complete transection of this nerve causes profound changes in GFR 
mRNA levels within lumbar dorsal root ganglia (Bennett et al., 2000), but the impact 
of injury on their protein levels and central terminals is unknown. We have compared 
two well-known injury models, complete transection of the sciatic nerve and an 
incomplete injury model, chronic constriction injury (CCI), which is commonly used 
as a model of neuropathic pain (Bennett and Xie, 1988). A significant difference in 
the outcomes of these two types of injury could reveal changes specific to and 
potentially causally related to the development of pain. DRG were also examined to 
determine the likely contributions of phenotypic change or altered expression levels 
of GFRs. 
 
2.2 Methods 
2.2.1 Surgical procedures 
All procedures were approved by the University of Sydney and Royal North Shore 
Hospital Animal Ethics Committees, as required by the Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes (National Health and Medical 
Research Council of Australia). Twenty-five adult male Sprague-Dawley rats (6-8 
weeks old) were used for these experiments - 16 for sciatic nerve transection, 6 for 
sciatic chronic constriction injury, and 3 naive controls. Animals purchased from the 
Animal Resources Centre (Murdoch, WA, Australia), were housed under a 12 h light-
dark cycle and had free access to food and water. In all experiments, the side 
contralateral to injury served as the internal control. The immunohistochemical 
properties of the lumbar spinal cord in the naïve controls did not appear to differ from 
the contralateral side of operated animals so has not been described separately. 
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 All surgical procedures were carried out under isoflurane anaesthesia (5% for 
induction and 2-3% for maintenance in O2). One group of rats underwent CCI of the 
left sciatic nerve as described previously (Bennett and Xie, 1988). Briefly, the left 
sciatic nerve was exposed at the mid-thigh level and freed from surrounding 
connective tissue. Five loose ligatures were made around the nerve, proximal to the 
sciatic trifurcation, using 6-0 chromic gut. The muscle (4-0) and then the skin (3-0) 
were closed with silk sutures. Another group of rats underwent sciatic nerve 
transection. Briefly, the left sciatic nerve was exposed at the mid-thigh level and a 
single ligature was made proximal to the trifurcation point using 6-0 chromic gut. The 
sciatic nerve was then cut just distal to the ligature using fine scissors. The muscle 
and then the skin were closed with silk sutures. 
 
2.2.2 Behavioural testing 
Animals that were to undergo CCI were allowed to acclimatise to their holding cages 
for 2-3 days before any procedures were carried out. Rats were then habituated to 
testing boxes for three days before baseline testing was performed with von Frey 
filaments (see below). The withdrawal response over three days of baseline testing 
was averaged for each rat to obtain a single value. On the next day, animals 
underwent sciatic nerve CCI (see above, section 2.2.1). On days 4 and 7 following 
CCI surgery, rats underwent behavioural testing. Only rats that developed mechanical 
allodynia by day 7 were used in this study (i.e. paw withdrawal thresholds <12 g, see 
below). On day 7 after injury, all animals were heavily anesthetised with sodium 
pentobarbitone (80 mg/kg i.p.) and perfused intra-cardially with freshly made 4% 
paraformaldehyde in 0.1M phosphate buffer (pH 7.4), prior to removal of spinal cord 
and DRGs. Spinal cords and DRGs were post-fixed overnight and then washed in 
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 0.1M phosphate-buffered saline (PBS) and stored in PBS containing 0.1% sodium 
azide until sectioning. 
 
To assess mechanical allodynia, the mechanical paw withdrawal threshold (PWT) was 
measured using a series of von Frey filaments (range 2-15 g). Rats were placed in 
elevated perspex boxes (28 cm x 15 cm x 18 cm) with wire mesh bases in which they 
had been habituated. Rats were tested on day 4 and day 7 after surgery and given 20 – 
30 min to acclimatise to the testing environment. PWT was measured using the up-
down method (Chaplan et al., 1994) beginning with the 2g filament; each von Frey 
filament was pressed perpendicularly against the plantar surface of the hindpaw and 
held in place for 1-2 s, five times at random locations of the hindpaw. A positive 
withdrawal response was noted if the paw was sharply removed in response to the 
application of the filament. If a rat showed a positive withdrawal response, the next 
lighter filament was used. Once there was a withdrawal to a filament, only four more 
filaments were tested. If no response was observed, the next heaviest filament was 
used, stopping at 15 g. The mechanical PWT was calculated using the up-down 
paradigm (Chaplan et al., 1994). If animals withdrew from all filaments, the PWT was 
assigned 0.2 g. If animals did not withdraw to any of the filaments, the PWT was 
assigned 15 g.  
 
2.2.3 Immunohistochemistry 
2.2.3.1 Single-labelling experiments 
Prior to sectioning, a small cut was made in the ventral horn of the spinal cord on the 
side contralateral to injury. Segments (L1-L6) were then blocked and embedded in an 
albumin-gelatine matrix (Llewellyn-Smith et al., 2007), prior to cryoprotection 
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 overnight in phosphate-buffered saline (PBS) containing 30% sucrose. Three spinal 
segments from the same animal (L1-L3 and L4-L6) were blocked and processed 
together. Transverse cryostat sections (40µm) were processed free floating (Kalous et 
al., 2009), using antisera raised against GFRα1 (R&D Systems; Minneapolis, MN, 
USA; Cat. No. AF5601; Batch No. BQEO24081; goat; 1:400), GFRα2 (R&D 
Systems; Cat. No. AF429; Batch No. BTM02; goat; 1:1000), GFRα3 (R&D Systems; 
Cat. No. AF2645; Batch No. VFU01; goat; 1:300) and CGRP (Millipore; North Ryde; 
NSW, Australia; Cat No. AB5920; Batch No. LV1496277; rabbit; 1:2000). Sections 
were distributed sequentially into a one in four series and processed for 
immunohistochemistry using the glucose oxidase/nickel-enhanced diaminobenzidine 
(DAB) method. Sections were blocked for 30 min in 0.1 M phosphate buffer (PB; pH 
7.4) containing 5% non-immune horse serum and then incubated for 48 h at room 
temperature on a shaker with primary antibody in PB containing 2% normal horse 
serum and 0.2% triton X-100. After washes in PB, sections were incubated overnight 
at room temperature on a shaker in biotin-conjugated donkey anti-sheep (Jackson 
ImmunoResearch Laboratories, West Grove, PA; Cat. No. 713-065-003, Batch No. 
57583, 1:1000) or donkey anti-rabbit (Jackson, Cat. No. 711-065-152, Batch No. 
73931, 1:1000). Sections were then incubated for 2 h in avidin-biotin complex, 
followed by 15 min in nickel-enhanced DAB solution (0.2% D-glucose, 0.04% 
ammonium chloride, 0.025% DAB / 100 ml 0.1M acetate buffer pH 6.0, 2% nickel 
sulfate). Black reaction product was obtained by adding glucose oxidase (0.002%), 
and the reaction was stopped using large volume washes of acetate buffer. Sections 
were mounted onto 1% gelatinised slides, dried overnight, dehydrated with increasing 
concentrations of ethanol, followed by histolene, and then coverslipped with DPX 
water-free mounting media (Crown Scientific, Mulgrave, Vic, Australia). 
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2.2.3.2 Double-labelling experiments 
Double-labelling immunofluorescence was performed on L5 DRG from a separate 
group of rats that had undergone sciatic nerve transection. DRGs and spinal cord 
tissue were cryoprotected overnight in PBS containing 30% sucrose and embedded in 
an inert mounting medium (OCT Tissue-Tek, Sakura, Torrance, CA) prior to 
sectioning.  
 
For DRG studies, ganglia from each side were placed in the same cryomould, 
sectioned (14 µm), direct mounted on 1% gelatine-subbed slides and processed 
simultaneously. Sections were distributed sequentially between sets of five slides to 
avoid double-counting. Sections were blocked with PBS containing 10% horse serum 
and 0.1 triton X-100 for 1-2 h, followed by overnight incubation at room temperature 
in combinations of primary antibodies: GFRα1 with CGRP, GFRα1-3 with NeuN 
(Millipore; Cat. No. MAB377; Batch No. 22060766; mouse; 1:10000), GFRα1 with 
NF200 (Sigma; Castle Hill, NSW, Australia; Cat. No. NO142; Batch No. 17154802; 
mouse; 1:4000), GFRα3 with CGRP and GFRα3 with NF200. Antibodies were made 
up in hypertonic PBS (0.1M phosphate, 0.3M NaCl, pH 7.2). Appropriate secondary 
antibodies were applied for 2-3 h: donkey anti-goat Cy3 (Jackson, Cat. No. 705-165-
147, Batch No. 79773 1:1000), donkey anti-rabbit AF488 (Molecular 
Probes/Invitrogen, Mulgrave, Vic, Australia; Cat. No. A21206, Batch No. 57542A, 
1:500) and donkey anti-mouse AF488 (Molecular Probes, Cat. No. A-21202, Batch 
No. 84D1-1, 1:500), the sections were washed, and then the slides were coverslipped 
with 0.5 M bicarbonate-buffered glycerol (pH 8.6).  
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 2.2.4 Fibre density and distribution measurements 
Single-labelled sections were visualised using an Olympus BX51 microscope 
(Olympus Australia, Melbourne, Australia) and images captured with a Zeiss 
AxioCam HRc camera (Munchen-Hallbergmoos, Germany) and Axiovision 4.2 
software. Image analysis was performed on 8-bit monochrome TIFF images (1300 x 
1030 pixels) using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD). 
For each antibody, spinal cord sections from the same rat were imaged using the same 
camera settings and exposure time, under a 10x objective. For quantitative studies of 
immunolabelling intensity, images were obtained from 5 randomly selected sections 
of L5 spinal cord (left and right sides). Optical density was assessed in areas of 
interest (AOI, 130 x130 µm) within the dorsal horn, as shown in Figure 2.1, where 
boxes 1-3 were used for each antibody but box 4 only for GFRα1. For each antibody, 
the optical density value from each of the five sections was averaged to obtain a 
single value for each rat. In each rat, the mean white matter optical density values for 
each antibody were subtracted.  
 
2.2.5 DRGs: neuronal counts and intensity analysis 
DRG sections were viewed under an Olympus BX51 fluorescence microscope. For 
analysis of neuronal phenotype (e.g. co-expression patterns), neuronal counts were 
obtained manually from 5 sections per ganglion, under a 40x objective. For each 
antibody, approximately 150 somata were counted from a total of five sections of 
each ganglion. Only neurons sectioned through the nucleus were counted. For 
analysis of immunofluorescence intensity, 8-bit unsaturated monochrome images 
(1600 x 1200 pixels) were obtained under a 40x objective using an RT Spot camera 
(Diagnostic Instruments, Sterling Heights, MI) and digitised using Image Pro Plus. 
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 For a given antibody, images were captured using the same settings and exposure 
times for both left and right ganglia taken from the same animal. Using Image Pro 
Plus, intensity (pixel grey level) was measured in a circular AOI (6 µm diameter) 
located in the cytoplasm of each positively stained neuron, measuring at least 70 
neurons per DRG.  
 
2.2.6 Statistics and image production 
Statistical analyses were performed using SPSS v16 for PC (Chicago, IL) or 
GraphPad Prism 5.0a (Graphpad Software Inc., La Jolla, CA). A repeated measures 
analysis of variance (ANOVA) and Tukey’s multiple comparison post hoc tests were 
used to detect changes in paw withdrawal threshold in CCI rats 4 and 7 days after 
injury, compared with baseline prior to injury. To detect an effect of injury on the 
mean intensity of GFR and CGRP immunostaining in each AOI (Figure 2.1, boxes 1-
3), we performed a 2-way ANOVA with repeated measures, with the side (injured or 
not injured) and AOI as within subject factors and correcting for violations of 
sphericity using the Greenhouse-Geisser method. Differences between sides of 
GFRα1 immunostaining intensity in the deep medial dorsal horn (Figure 2.1, box 4) 
were analysed using a paired t-test. The percentages of DRG neurons expressing each 
of the GFRs, CGRP or NeuN was estimated in L5 DRG from each side of each rat 
and the arcsine transformed data compared using a paired t-test. Differences between 
sides of GFR immunostaining intensity in DRG neurons were analysed using paired t-
tests. The proportions of neurons expressing different markers were plotted as 
untransformed data. All results were expressed as the mean ± SEM and P < 0.05 was 
regarded as statistically significant. 
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 For image production, some minor adjustments were made to brightness and contrast 
to most closely demonstrate the staining as it appeared under the microscope (Adobe 
Photoshop CS2, San Jose, CA). Coloured monochrome or merged images were 
produced by pasting monochrome images into the appropriate colour channel of a 24-
bit RGB file created in Photoshop. Red-green pairs were converted into magenta-
green pairs to make images more accessible to readers with impaired colour 
discrimination. 
 
2.3 Results 
2.3.1 Sciatic nerve injury caused a widespread increase in GFRα1-IR in the dorsal 
horn of lumbar spinal cord 
Contralateral to either type of sciatic nerve injury, GFRα1-IR nerve fibres were 
distributed primarily in lamina II (outer) in the dorsal horn of the lumbar spinal cord. 
In L1-L3 these terminals extended in a uniformly dense band across the entire dorsal 
horn (Figure 2.2a-c, m-o) but in L4-5 the terminals were less dense in the medial third 
to half of this region (Figure 2.2d, e, p, q). In L2-L5, the most medial aspect of lamina 
IV also showed some weak, diffuse GFRα1-IR, but individual nerve fibres were 
difficult to distinguish (Figure 2.2a-e, m-q). In L6, the GFRα1-IR fibres extended 
uniformly across lamina II (outer) of the dorsal horn (Figure 2.2f, r) and in some 
sections extended in a band of fibres along the lateral edge of the dorsal horn, 
terminating dorsal to the sacral preganglionic nucleus (SPN), as described previously 
(Figure 2.2f and/or 2.2r) (Forrest and Keast, 2008). Weakly stained GFRα1-IR fibres 
were present in the dorsal commissure at this spinal level. GFRα1-IR motoneurons 
were present in the ventral horn of L1-L6 (not shown).  
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 All rats in the CCI group developed mechanical allodynia ipsilateral to the injury 
(baseline 15 g; post-surgery: 4d, 12.43 ± 1.49 g, range: 6.91-15 g; 7d, 8.19 ± 1.24 g, 
range: 4.79-11.981 g; mean ± SE, n = 6; 7d measurements significantly less than 
baseline  [P < 0.005] and 4d [P < 0.05]). Ipsilateral to CCI, there was an increase in 
the area of dorsal horn innervated by GFRα1-IR fibres and in the intensity of GFRα1 
immunostaining throughout L1-6, both aspects being maximal at L5 (Figure 2.2g-k). 
The location of this upregulation varied between spinal segments. In L1, a patch of 
intensely stained GFRα1-IR fibres was present along the medial aspect of lamina IV 
(Figure 2.2g). This patch increased in width in L2 (Figure 2.2h) and by L3 was even 
larger, extending laterally towards the middle of the dorsal horn and ventrally towards 
the central canal (Figure 2.2i). At this spinal level, in most sections there was a band 
of GFRα1-IR fibres spanning lamina III, approximately midway between the medial 
and lateral aspects. In L4, GFRα1-IR fibres extended throughout most of the depth 
and width of the dorsal horn (Figure 2.2j), and in L5 only a lateral region of lamina V 
did not show dense, intensely-stained GFRα1-IR fibres (Figure 2.2k). In L4 and L5, 
GFRα1-IR fibres in the deep laminae of the dorsal horn commonly extended laterally 
to the level of the central canal, and some to the ventral horn, just dorsal to 
motoneurons. Many GFRα1-IR motoneurons showed more intense immunostaining 
on the injured side of L4 and L5 and, rarely, in L6 (not shown), as previously 
described (Hammarberg et al., 2000). In some sections of L6, a delicate plexus of 
GFRα1-IR fibres was present in the deep dorsal horn, ipsilateral to the injury (Figure 
2.2l). The intensity of immunostaining in fibres in lamina II, travelling along the 
lateral edge of the dorsal horn and dorsal to the SPN was also slightly increased in the 
ipsilateral side, in some sections. Very similar changes occurred after transection 
injury of the sciatic nerve (Figure 2.2s-x).  
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To quantify and compare the effects of each type of injury, we focused on L5 spinal 
cord, where the largest changes were evident. Optical density measurements of the 
superficial dorsal horn (3 AOI’s) were compared between sides and showed a main 
effect of injury to increase GFRα1-IR after both CCI (Figure 2.3a; P = 0.039) and 
transection (Figure 2.3d; P = 0.002). Considering the data from each region of the 
superficial dorsal horn separately, we found a significant interaction between AOI and 
injury (CCI: P = 0.007; Tx: P = 0.001) (Figure 2.3b, e). These data reflect our 
qualitative observations of the contralateral side, where lower levels of GFRα1-IR 
occurred in the medial than either the central or lateral aspects of the superficial 
dorsal horn. We also quantified optical density in an AOI within the medial aspect of 
the deep dorsal horn and found a significant increase on the ipsilateral side after each 
type of injury (Figure 2.3c, f; CCI: P  = 0.002; Tx: P <0.001; P = 0.001). 
 
We next investigated a number of mechanisms that could underlie the widespread 
increase in GFRα1-IR fibres in the dorsal horn in L5 DRG following sciatic nerve 
transection (n = 6 rats). As injury can up-regulate GFRα1 mRNA in DRG neurons 
(Bennett et al, 2000), we determined if a corresponding upregulation of protein could 
be detected by measuring the intensity of GFRα1-immunofluorescence in DRG 
sections. GFRα1-IR was observed in numerous DRG somata of all sizes, where it was 
present in the cytoplasm and the plasma membrane. We found a small but statistically 
significant increase in fluorescence intensity ipsilateral to injury (Figure 2.4a; P = 
0.0005). Qualitative assessment of the sections showed that the GFRα1 
immunostaining was brighter in both small and large neurons (Figure 2.4g-j). We then 
determined the expression of GFRα1 in neurons labelled for the neuronal nuclear 
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 marker, NeuN. The results showed that about one-third of DRG neurons were 
immunostained for GFRα1 and this proportion increased on the ipsilateral side 
(Figure 2.4b; P = 0.0086). Together, these results suggest injury increased the basal 
expression of GFRα1 with an associated increase in GFRα1-IR neurons. 
 
To determine if the chemical phenotype of neurons expressing GFRα1-IR was 
changed after injury, we conducted quantitative double-labelling studies. GFRα1 is 
normally expressed by small-medium diameter unmyelinated DRG neurons 
(including many non-peptidergic but not peptidergic nociceptors), as well as larger 
diameter myelinated DRG neurons (Bennett et al, 2000). This is consistent with our 
data from DRG contralateral to the injury as ~40% of GFRα1-IR neurons expressed 
the marker of myelinated neurons, NF200, and these comprised ~20% of all NF200 
neurons (Figure 2.4c, d, g-i). Moreover, only ~10% of GFRα1-IR neurons co-
expressed CGRP, which comprised ~10% of all CGRP neurons (Figure 2.4e, f, m-o). 
The number of presumptive myelinated GFRα1-IR neurons were increased in DRG 
ipsilateral to the injury (Figure 2.4j-l), as a larger proportion of GFRα1-IR neurons 
were immunoreactive for NF200 (Figure 2.4c; P = 0.0198) and a larger proportion of 
NF200-positive neurons showed GFRα1-IR (Figure 2.4d; P = 0.0109). We also 
investigated the possibility that injured peptidergic DRG neurons may begin to 
express GFRα1. Neurons showing immunoreactivity for both GFRα1 and CGRP 
were seen infrequently in DRG ipsilateral or contralateral to injury (Figure 2.4m-r). 
Quantitative analyses showed no effect of injury on the proportion of GFRα1-IR 
neurons stained for CGRP (Figure 2.4e) or the proportion of CGRP-positive neurons 
immunostained for GFRα1 (Figure 2.4f, p-r). Therefore, the increase in number of 
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 GFRα1-IR neurons after injury is likely to comprise primarily myelinated rather than 
unmyelinated peptidergic neurons. 
 
2.3.2 Sciatic nerve injury caused a localised decrease in GFRα2-IR in the dorsal horn 
of L3-L5 spinal cord and a loss of GFRα2-IR neurons in DRG 
Contralateral to either type of sciatic nerve injury, GFRα2-IR fibres were distributed 
primarily in lamina II (inner) of the dorsal horn (Figure 2.5a-f, m-r). In L1-3 and L6, 
these fibres showed a similar density across the dorsal horn, but in L4-5 there were 
slightly less GFRα2-IR fibres in the most medial region. In L6, a few pale fibres were 
also found in the dorsal commissure but none were associated with the SPN (Figure 
2.5f, r). GFRα2-IR was not observed in motoneurons. 
 
Following CCI, there was no effect on GFRα2 immunostaining in lamina II of the 
dorsal horn of L1-L3 (Figure 2.5g, h) but in L4-L5 many sections showed a loss of 
staining from selected regions of superficial dorsal horn (Figure 2.5i-k). In L4-5, 
some sections showed that GFRα2-IR fibres were lost from the region approximately 
in the middle of this lamina, but in many others this area of loss was broader and 
included loss from the most medial aspect. In L6 dorsal horn there was no obvious 
effect of injury on GFRα2-IR intensity or location (Figure 2.5l). GFRα2-IR was not 
observed in motoneurons. Following transection injury, in L4-5 there were broadly 
similar changes to those observed after CCI but the loss of fibres was more extensive 
after transection. In some sections of L5 almost all of the GFRα2-IR was lost, except 
for the most lateral aspect of lamina II (Figure 2.5s-x). Quantification of 
immunostaining intensity in L5 spinal cord after each type of injury revealed a main 
effect of CCI (Figure 2.6a; P = 0.039) but not transection (Figure 2.6c). The lack of 
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 statistically significant effect of transection may reflect the slightly differing locations 
of fibre loss between different sections, which may not always have coincided with 
the AOI used for quantitative analysis. There was no interaction between AOI and 
injury (Figure 2.6b, d). 
 
To address the possibility that these changes in spinal cord labelling are due to down-
regulation of GFRα2 protein in DRG neurons (as described previously for GFRα2 
mRNA (Bennett et al., 2000), we assessed the intensity of GFRα2-
immunofluorescence in L5 DRG sections after sciatic nerve transection. In ganglia of 
both sides, GFRα2-IR was observed in small-medium size DRG somata (Bennett et 
al., 2000), where immunoreactivity was particularly pronounced in the plasma 
membrane (Figure 2.6g). Immunofluorescence intensity was comparable between 
contralateral and ipsilateral sides (Figure 2.6c, g, h). Quantification of the proportion 
of NeuN-labelled neurons labelled for GFRα2-IR revealed a small but significant 
decrease ipsilateral to the injury (P = 0.004; Figure 2.6f). 
 
2.3.3 Sciatic nerve injury caused a localised increase in GFRα3-IR but no change in 
CGRP fibres in the dorsal horn of lumbar spinal cord. 
Contralateral to injury, the distribution of GFRα3-IR fibres varied considerably 
between lumbar segments (Figure 2.7a-f, m-r). In all lumbar levels, a small band of 
intensely-stained fibres was present across lamina I. In occasional sections, bundles of 
GFRα3-IR axons could be seen in the dorsal root entry zone. In lamina II (outer), no 
GFRα3-IR fibres were present in L1, but some weak-moderate intensity fibres were 
present across the entire dorsal horn of L2-3 and more intensely stained GFRα3-IR 
fibres in the medial half in L4-5. In L6, GFRα3-IR fibres of moderate intensity were 
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 present in lamina II (outer) across the entire dorsal horn and a dense band of fibres 
extended along the lateral edge of the dorsal horn to terminate in a plexus just dorsal 
to the SPN (Figure 2.7f, l), as described previously (Forrest and Keast, 2008). At this 
spinal level, GFRα3-IR fibres were also found in the dorsal commissure.  In all 
lumbar levels, a small number of single GFRα3-IR fibres were present in the deep 
dorsal horn. No GFRα3-IR was present in motoneurons. 
 
Following CCI, GFRα3-IR nerve fibres in the L3-5 dorsal horn ipsilateral to injury 
appeared more intensely stained and occupied a larger area than in the contralateral 
side (Figure 2.7i-k). In L3, this increase was restricted to the medial half of the dorsal 
horn, but extended into lamina II (inner); in some sections a small but intensely 
stained patch of dense GFRα3-IR fibres was present in lamina II, near the middle of 
the dorsal horn. In L4 and L5, this increased intensity and extension into lamina II 
(inner) extended across the width of the dorsal horn. There was no obvious effect of 
injury on L1, L2 or L6 innervation by GFRα3-IR nerve fibres. Following transection 
injury, a similar range of changes in GFRα3-IR innervation were observed. 
Quantification of immunostaining in the superficial laminae showed a main effect of 
CCI (Figure 2.8a; P = 0.013) and transection (Figure 2.8c; P < 0.0001) on GFRα3-IR 
in the superficial dorsal horn, as well as a significant interaction between AOI and 
injury following transection (Figure 2.8b, d; P <0.0001 for transection). No GFRα3-
IR motoneurons were observed after either type of injury. 
 
In the absence of injury, GFRα3 is expressed almost exclusively by a sub-population 
of peptidergic C-fibre afferents (Bennet et al., 2006; Kalous et al., 2009) Therefore we 
compared the effects of sciatic nerve injury on CGRP-IR fibres in the lumbar spinal 
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 cord of the same animals from which GFR analysis had been performed. CGRP-IR 
fibres were distributed in the lumbar spinal cord as described previously in many 
mammalian species (Gibson et al., 1984) and in subsequent studies in rodents by 
numerous other research groups. Contralateral to either type of injury, numerous 
fibres were present through laminae I and II and in deeper laminae of the dorsal horn 
(Figure 2.9a-e). In L6, many immunostained fibres were also present in the dorsal 
commissure and associated with the SPN, and bundles of axons travelled along the 
lateral aspect of the dorsal horn (Figure 2.9f, r). Some motoneurons were 
immunostained with weak to moderate intensity in all lumbar levels. Ipsilateral to 
CCI or transection, there was no obvious effect on CGRP-immunostaining (intensity 
or distribution) in any spinal level (Figure 2.9g-l, s-x). Quantification of 
immunostaining in the superficial laminae showed no significant effect of either 
injury type on CGRP in the superficial dorsal horn (Figure 2.8e-g).  
 
To address the possibility that injury triggered upregulation of GFRα3 protein in 
DRG neurons, as reported previously for GFRα3 mRNA (Bennett et al., 2000), we 
assessed the intensity of GFRα3-immunofluorescence in L5 DRG following sciatic 
nerve transection. GFRα3-IR was observed in numerous somata, primarily of small 
size (Bennett et al., 2000), where strong immunoreactivity occurred in the plasma 
membrane and cytoplasm. We found no change in fluorescence intensity ipsilateral to 
injury (Figure 2.10a, g, j, m, p). We then quantified the presence of GFRα3-IR in 
neurons labelled for NeuN and found an increased proportion of GFRα3-IR neurons 
on the ipsilateral side (P = 0.006; Figure 2.10b). Together, these results suggest that 
neurons expressing GFRα3 do not express higher levels of this receptor in their 
somata after injury but additional neurons begin to express GFRα3 after injury. 
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We next investigated the effects of sciatic nerve transection on the chemical 
phenotype of GFRα3-IR DRG neurons. Previous reports of strong localisation of 
GFRα3 to unmyelinated, peptidergic afferents (see above), compared strongly with 
our data from DRG contralateral to the injury. Here, only ~2% of the GFRα3-IR 
neurons expressed the marker of myelinated neurons, NF200, and these comprised 
<2% of all NF200 neurons (Figure 2.10c, d, g-i); ~90% GFRα3-IR neurons stained 
for CGRP, while about one-third of CGRP neurons showed GFRα3-IR (Figure 2.10e, 
f, m-o). After injury there was a higher proportion of NF200-positive (presumptive 
myelinated) GFRα3-IR neurons ipsilateral to the injury, demonstrated by a higher 
proportion of GFRα3-IR neurons immunoreactive for NF200 (Figure 2.10c; P = 
0.007) and more NF200-positive neurons showing GFRα3-IR (Figure 2.10d; P = 
0.002). However, this increase represents only a numerically small population of 
neurons (Figure 2.10j-l), so we also investigated the possibility that injury increased 
the proportion of peptidergic neurons expressing GFRα3. The results showed that this 
occurred in a small but statistically significant proportion of CGRP neurons (Figure 
2.10f, p-r; P = 0.004), again unlikely to account for the overall increase in number of 
GFRα3-IR NeuN-labelled neurons (Figure 2.10b). This suggested GFRα3 was 
upregulated in non-peptidergic, NF200-negative (unmyelinated) neurons, which was 
consistent the proportion of GFRα3-IR DRG neurons expressing CGRP being also 
decreased by injury (Figure 2.10e; P = 0.002). 
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 2.4 Discussion 
This study revealed distinct effects of peripheral nerve injury on three different 
populations of primary afferent fibres immunolabelled for receptors of the GDNF 
family of ligands. Sciatic nerve injury caused a widespread increase in nerve fibre 
labelling for GFRα1, a localised increase in GFRα3, and a loss of GFRα2 in the 
lumbar dorsal horn. Complete and incomplete injury models showed similar 
outcomes, although the loss of GFRα2 was more pronounced after complete injury. 
Together these results suggest that the functional impact of nerve injury may differ 
widely between these three groups of neurons, in the nature of their communication 
within the spinal cord and in their responses to neurotrophic factors. The changes are 
unlikely to be causally related to the development of neuropathic pain, an outcome of 
incomplete injury model (Bennett and Xie, 1988), but may impact on the site and 
degree of sensitisation induced by neurotrophic factors or related pro-regenerative 
therapies administered during this state.  
 
The changes in GFR-IR we observed in DRG broadly agree with previously reported 
changes in GFR mRNA after injury, with upregulation of GFRα1 and GFRα3 but 
down-regulation or no change in GFRα2 (Bennett and Xie, 1988; Kashiba et al., 
1998; Mills et al., 2007). Therefore, it is likely that the changes in GFRα1 and GFRα3 
we observed in spinal cord immunostaining at least in part represent increased levels 
of receptor protein in central terminals, although there may also be increased GFR 
trafficking to these central processes. We also found evidence of GFR expression in 
neuronal classes that did not appear to express these GFRs prior to injury. Whether 
this is truly a phenotypic change or simply a limitation of the sensitivity of our 
immunodetection method (e.g., if we underestimated the population of neurons 
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 expressing a particular GFR in tissues from naïve animals or contralateral to injury) 
cannot be determined in this study. We also cannot discount the possibility that some 
GFRα1 and GFRα3 neurons undergo central sprouting after injury. However, the 
pattern of distribution of the increased immunoreactivity for these two GFRs matches 
very closely the projection patterns of different branches of the sciatic nerve to the 
hindlimb (see below), which does not support the innervation of novel territories after 
injury but does allow the possibility of sprouting within its normal territory. It is very 
difficult to resolve this issue without ultrastructural studies or the availability of 
alternative markers that are not modulated by injury.  
 
The distinct patterns of central termination of each GFR-IR nerve population before 
and after injury raise a number of important issues. In the absence of injury, these 
unique patterns may indicate that each neuronal population has different spinal (and 
therefore supraspinal) connectivity, pointing to a much more diverse and complex 
range of sensory and nociceptive circuitry than previously indicated by visualising 
CGRP or IB4. A similar type of complexity has recently been demonstrated in the L6-
S1 spinal cord (Forrest and Keast, 2008), a region that has a major role in pelvic 
visceral function. These patterns of termination are of particular interest when 
compared with the topography of projections from different nerve supplies to the 
hindlimb, especially different branches of the sciatic nerve. The major spinal targets 
of sensory neurons projecting in the sciatic nerve are lumbar levels 4 and 5, where 
each branch of the nerve terminates in a different territory across the mediolateral 
aspect of the dorsal horn (LaMotte et al., 1991; Rivero-Melian, 1996; Shehab, 2009; 
Swett and Woolf, 1985; Woolf and Fitzgerald, 1986) and in different regions of the 
hindlimb (Decosterd and Woolf, 2000). Therefore, if each class of GFR-IR DRG 
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 neuron projected similarly in each sciatic nerve branch, one would predict that fibres 
of each type innervate the mediolateral extent of the dorsal horn, albeit with some 
diversity in whether they terminate in deep or superficial laminae or both (as indicated 
by their expression in myelinated and/or unmyelinated fibres). However, in naive 
animals and contralateral to injury, each GFR-IR class of fibres showed uneven 
distribution, suggesting that there is either heterogeneous expression or trafficking in 
each sciatic nerve projection field. 
 
Prior to injury, GFRα1-IR was found in small unmyelinated and larger myelinated 
neurons, yet fibres were present only in lamina II, where the most medial aspect of 
this lamina (a target of the tibial nerve) showed weaker innervation. One 
interpretation of the uneven distribution in lamina II might be that few GFRα1-IR 
sensory neurons project in the tibial nerve or that the receptor is not normally 
transported to the central projections of this nerve. Low levels of transport to central 
terminals may also explain the absence of GFRα1-IR fibres from deeper laminae, 
even though many GFRα1-IR DRG neurons were large and immunoreactive for 
NF200.  After injury, GFRα1-IR fibres were visible throughout the dorsal horn – 
across the entire mediolateral aspect (except a small region on the most lateral aspect) 
and in both deep and superficial laminae – consistent with increased expression 
within both myelinated and unmyelinated fibres that project in each branch of the 
sciatic nerve. The upregulation of GFRα1 was most pronounced in L4 and L5, but it 
also occurred from L1 to L6, consistent with the known broad projection territory of 
the sciatic nerve (LaMotte et al., 1991; Swett and Woolf, 1985; Woolf and Fitzgerald, 
1986). The small region on the most lateral aspect of the dorsal horn that did not show 
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 an increase in GFRα1-IR after injury may be the territory supplied by the uninjured 
posterior cutaneous nerve (Swett and Woolf, 1985).  
 
The increase in GFRα1-immunostaining intensity observed in the superficial laminae 
indicated an upregulation in smaller diameter and unmyelinated neurons. However, 
we were unable to identify an injury-induced expression of GFRα1 in peptidergic 
DRG neurons, suggesting that GFRα1 could have been upregulated in non-
peptidergic, unmyelinated neurons that normally express GFRα2. We could not test 
this possibility directly because commercially available GFRα1 and GFRα2 antisera 
are raised in the same host species. Moreover, effects of injury on GFRα2-IR (see 
below) are likely to confound this analysis. It is also possible that changes in GFR 
distribution in the central terminals of DRG neurons do not occur in parallel with the 
levels in their somata. We observed an increase in the proportion of large diameter, 
NF200-IR (myelinated) neurons immunostained for GFRα1 after injury. Consistent 
with this, the labelling in deeper laminae resembled the pattern of immunoreactivity 
for the vesicular glutamate transporter, vGlut1 (Persson et al., 2006), after sciatic 
nerve transection and fibres visualised by retrograde labelling using the tracer cholera 
toxin (CTb) (Shehab, 2009), which preferentially labels large diameter myelinated 
axons (Robertson and Grant, 1985). Together, these observations are consistent with 
increased activation of deep dorsal horn circuits after injury, as suggested by an 
increase in Fos activation in this region after CCI (Nishiguchi et al., 2004). The 
function of the centrally transported GFRα1 is not known but the receptor is predicted 
to be physiologically active because a pre-conditioning injury of the sciatic nerve 
leads to an enhanced growth response of DRG neurons to GDNF in vitro (Mills et al., 
2007). Moreover, intraspinal administration of GDNF reverses a number of changes 
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 caused by sciatic nerve injury, including the down-regulation of P2X3 purinoceptors, 
reduction in IB4-binding and decreased conduction velocity (Bennett et al., 2006; 
Bradbury et al., 1998; Munson and McMahon, 1997). 
 
The source of endogenous ligand for GFRα1 in the spinal cord is unclear, although 
many DRG neurons do contain GDNF protein (Holstege et al., 1998; Jongen et al., 
1999) and could potentially release it from their central terminals. Moreover, 
intraspinal administration of GDNF causes rapid upregulation of c-Fos in the 
superficial dorsal horn (Jongen et al., 2005). There have been a number of reports that 
sciatic nerve injury triggers GDNF synthesis within the DRG and Schwann cells 
proximal to injury (Cameron et al., 1997; Chao et al., 2008; Hammarberg et al., 
1996), although Nagano et al (2003) showed a decrease within DRG after CCI or 
spared nerve injury; this is supported by a report of decreased levels of GDNF in 
dorsal horn (Jongen et al., 1999), suggested to be due to reduced transport from the 
periphery. In the absence of more detailed studies, it is very difficult to reconcile this 
data in order to interpret our own results, or propose specific contexts for 
physiological activation of GFRα1 within the spinal cord after peripheral nerve injury. 
 
The potential targets of GFRα3-IR nerve fibres also varied between lumbar spinal 
segments and following injury, when immunostaining became more pronounced in 
the superficial laminae of L3-L5. In naïve animals and contralateral to injury, GFRα3-
IR was restricted to lamina I and lamina II (outer), with lamina II staining more 
pronounced in L4 and L5. Ipsilateral to injury, in these spinal segments and in both 
laminae, GFRα3-IR nerve fibres increased in staining intensity and in area, extending 
deeper into the dorsal horn; there was a smaller change apparent in the most central 
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 part of the superficial dorsal horn in L3. In L4 and L5, this pattern of staining did not 
indicate preferential upregulation of GFRα3 in particular branches of the sciatic 
nerve. However, the small patch of increased immunostaining in the central region of 
L3 may coincide with territory supplied by the superficial peroneal nerve.  
 
The upregulation of GFRα3-IR we observed in the superficial laminae was due at 
least in part to increased synthesis in a minority of myelinated (NF200-IR) and 
peptidergic fibres. We cannot discount an increased expression by GFRα1- or 
GFRα2-IR neurons but could not test this directly because all GFR antisera were 
raised in the same species. Unexpectedly, we failed to see an effect of injury on the 
intensity of GFRα3-immunofluorescence within the DRG which, given the previous 
reports of increased GFRα3 mRNA after injury (Bennett et al., 2000), may reflect a 
limitation with the immunofluorescence quantitative method or that the additional 
message is translated into protein. Alternatively, more GFRα3 protein may be 
synthesised after injury but trafficked to the central terminals rather than stored in the 
soma. The role of endogenous artemin in the normal spinal cord or following 
peripheral nerve injury is not known.  
 
Different issues were raised by our observations that GFRα2-IR was lost from 
discrete zones in the dorsal horn in L4 and L5. The areas where GFRα2-IR was lost 
within the dorsal horn after sciatic nerve injury closely match the topography of 
projections from the sciatic nerve. In particular, the residual GFRα2-IR in the most 
lateral aspect of the dorsal horn may indicate a territory not strongly supplied by 
branches of the sciatic nerve, but instead innervated by the uninjured posterior 
91
 cutaneous nerve (Swett and Woolf, 1985). This was also identified as a region where 
GFRα1-IR did not increase after injury (see above).  
 
The reduction in GFRα2-IR could be due to degeneration of GFRα2-IR axons, down-
regulation of GFRα2 protein, or a mixture of both events. We consider that overt 
degeneration is the primary response, for the following reasons. First, there is a 
greater extent of loss after sciatic nerve transection compared with incomplete injury 
(CCI). Second, our studies on DRG found no change in intensity of GFRα2-IR soma 
immunofluorescence, but did identify fewer GFRα2-IR somata following injury. 
While this could be due to lower levels of receptor expression, it could also indicate 
death of a minority of GFRα2-IR DRG neurons - although previous evidence suggest 
only limited neuronal cell death occurs within a week of injury (Hu and McLachlan, 
2003). Moreover, following peripheral nerve injury, IB4 labelling is also transiently 
decreased in the dorsal horn (Hammond et al., 2004), and this comprises loss of 
terminals, not just loss of IB4 binding (Bailey and Ribeiro-da-Silva, 2006). If the loss 
of GFRα2-IR was due to degeneration of central projections from surviving DRG 
neurons, this raises the question of why only this particular population of neurons 
changed in this way, whereas CGRP-, GFRα1- and GFRα3-IR increased or did not 
change after injury. Evidence obtained with a different injury model - spinal cord 
injury - also suggests central projections of GFRα2-IR DRG neurons are especially 
susceptible to loss or receptor down-regulation (Kalous et al., 2007; 2009). Evidence 
that IB4-binding DRG neurons are less likely than peptidergic neurons to compensate 
for loss of adjacent terminals fields in the dorsal horn by sprouting (Belyantseva and 
Lewin, 1999; Runyan et al., 2007) cannot explain our result, as the IB4-binding 
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 population includes both GFRα1- and GFRα2-IR neurons. Further studies of how 
GFRα2-IR DRG neurons respond to injury are needed to resolve this issue. 
 
Signalling by GDNF family members utilises a specific GFR and, in most cases 
described to date, the common receptor tyrosine kinase, RET (rearranged during 
transfection) (Airaksinen and Saarma, 2002). Therefore interpretation of our data 
should take into account the effect of injury on RET expression. In a recent study 
employing an epitope unmasking method (Jongen et al., 2007), RET-IR was found in 
deep and superficial laminae, abolished by dorsal rhizotomy. After sciatic nerve 
transection, RET-IR was reduced in lamina II but showed a hint of an increase in 
lamina III (although this did not reach statistical significance). Interestingly, neither 
the control nor injury groups showed RET expression that resembled the sum of the 
three types of GFR expression in our study, suggesting either that the RET-
immunolabelling underestimated the distribution of RET protein or that many 
potential sites of RET-independent signalling (Paratcha and Ledda, 2008) exist in the 
cord. The effects of injury on RET expression in DRG have been studied but have 
yielded equivocal results (Bennett et al., 2006; Mills et al., 2007; Nagano et al., 2003; 
Naveilhan et al., 1998), so require further study. 
 
The marked changes we observed in GFR levels within the spinal cord contrasted 
with the absence of effect of injury on CGRP fibres. While there are some reports of a 
decrease in CGRP fibre density or CGRP levels following peripheral injury (Cameron 
et al., 1991; Casals-Diaz et al., 2009; Kajander and Xu, 1995; Sommer and Myers, 
1995), a number of groups have found no change (Bailey and Ribeiro-da-Silva, 2006; 
Cameron et al., 1997). It is possible that changes in peptide level did occur in our 
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 experiments but were not detectable with our method of analysis. Moreover, we did 
not determine the effect of injury on number or fluorescence intensity of CGRP-IR 
DRG neurons, as described previously by other groups who identified a decrease in 
peptide level (Bennett et al., 1998; Shi et al., 2001). Irrespective, given that almost all 
of the GFRα3-IR DRG neurons express CGRP and substance P and, in turn, about 
half of the CGRP neurons show GFRα3 -IR (Bennett et al., 2006; Kalous et al., 2009), 
it is interesting that there was so little change in the spinal distribution of CGRP 
fibres, yet a noticeable increase in GFRα3-IR (albeit in discrete regions of the dorsal 
horn). Our observations in spinal cord from naïve uninjured rats and contralateral to 
injury suggest that the two populations of CGRP neurons (GFRα3-positive and -
negative) have different spinal projection sites and respond quite differently to injury. 
 
In conclusion, the profound and distinctive effects of sciatic nerve injury on different 
populations of sensory neurons identified by GFR expression raises interesting 
questions about the magnitude and specificity of neurotrophic factor signalling in 
sensory neurons after injury. This may impact on sensitisation of nociceptor neurons 
and regenerative responses. 
 
2.5 Other acknowledgements  
We are grateful to Ms Kathryn Evans for conducting pilot experiments on spinal cord 
tissues. 
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Tissue GFRa1 GFRa2 GFRa3
Spinal cord
Control
    Location Lamina II (outer) Lamina II (inner) Lamina I and II (outer)
Injured
    Location Lamina II-V (except lateral 
lamina V)
Lamina II (inner) but loss 
in medial and central 
regions
Lamina I-II (inner)
    Intensity Increase Decrease Increase
DRG
Control
    Phenotype Mainly small-medium 
nonpeptidergic and large 
myelinated neurons
Small-medium 
nonpeptidergic neurons
Small-medium 
peptidergic neurons
Injured
    Phenptype Increased proportion of 
mylinated neurons
No change Increased proportion of 
myelinated and small-
medium nonpeptidergic 
neurons
    Prevalence Increase Decrease Increase
    Intensity Increase in small-medium 
and large neurons
No change No change
2.6 Chapter 2 tables and figures
Table 2.1 Summary of changes in GDNF-family receptor (GFR) immunoreactivity in L5 spinal 
cord and dorsal root ganglia (DRG) after sciatic nerve injury
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1 2
3
4
Figure 2.1 Areas of interest (AOIs) used for image analysis of L5 spinal cord dorsal 
horn. The diagram is oriented with the dorsal surface at the top and medial to the left. 
Three AOIs (boxes 1-3) were assessed for GFRα1, GFRα2, GFRα3 and CGRP. An 
additional AOI (box 4) in the deep medial aspect of the dorsal horn was assessed for 
GFRα1. Dimensions of each AOI were 130 µm x 130 µm. CGRP, calcitonin gene-
related peptide; GFR, GDNF family receptor.
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Figure 2.2 Up-regulation of GFRα1-immunoreactivity (IR) in the dorsal horn from 
lumbar spinal cord, 7 days after chronic constriction injury (a-l) or transection (m-x) 
of the sciatic nerve. For each type of injury, images are taken from left and right sides 
of the same section, and segments of each spinal level from the same animal. GFRα1-
IR was present primarily in lamina II (outer) on the uninjured side (a-f, m-r). After 
chronic constriction injury (g-l), these superficial fibres remained, but a patch of 
GFRα1-IR fibres appeared on the medial aspect of the deep dorsal horn, extending 
beyond the central canal. Progressing caudally, these fibres extended to cover most of 
the dorsal horn (j, k), with the exception of a small area on the most lateral aspect of the 
grey matter. A smaller increase in GFRα1-IR innervation of the deep dorsal horn was 
evident in the deep dorsal horn of L6 (l). After transection injury (m-x), similar changes 
were seen in the ipsilateral dorsal horn (s-x). Sacral preganglionic nucleus (L6) is 
indicated with arrowheads (f, l, r, x). Scale bar applies to all panels and represents 
200 µm. GFR, GDNF family receptor.
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Figure 2.3 Quantitation of immunostaining intensity for GFRα1 in the L5 dorsal horn 
following sciatic nerve injury. Optical density measurements in spinal cord sections from 
chronic constriction injury (CCI) animals are shown in a-c, whereas data from transection 
injury are shown in d-f. a: Optical density measurements pooled from all superficial areas 
of interest (AOI 1-3) on each side showed a main effect of CCI (*P = 0.039, F1, 5 = 7.688), 
with an increase in GFRα1-IR ipsilateral to injury. b: Optical density measurements from 
each AOI in the superficial dorsal horn showed a significant interaction between side and 
AOI (P = 0.007, F1.184, 5.922 = 15.041). c: After CCI, there was an increase in GFRα1-IR 
ipsilateral to injury in the deep dorsal horn (** P = 0.002). d: Optical density measurements 
pooled from all superficial AOI (1-3) on each side showed a main effect of transection 
(**P = 0.002, F1, 5 = 32.702), with an increase in GFRα1-IR ipsilateral to injury. e: Optical 
density measurements from each AOI in the superficial dorsal horn showed a significant 
interaction between side and AOI (P = 0.001, F12.63, 6.317 = 31.368). f: After 
transection, there was an increase in GFRα1-IR ipsilateral to injury in the deep dorsal horn 
(*** P = 0.001). Data represent mean ± SEM (n= 6 rats per group), analysed by ANOVA. 
GFR, GDNF family receptor; IR, immunoreactivity.
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Figure 2.4 Co-localisation studies of GFRα1-immunoreactive (IR) somata in L5 
dorsal root ganglia (DRG), ipsilateral and contralateral to transection of the sciatic 
nerve. a: Mean fluorescence intensity of GFRα1-IR neurons showed a small but 
significant increase ipsilateral to injury (*** P = 0.0005). b: The proportion of NeuN 
somata exhibiting GFRα1-IR increased ipsilateral to injury (** P = 0.0086). c, d: The 
proportion of GFRα1-IR neurons expressing NF200 (* P = 0.0198) and the proportion 
of NF200 neurons showing GFRα1-IR (*P = 0.0109) were also increased after sciatic 
transection. e, f: No difference was detected in the proportion of GFRα1-IR neurons 
expressing CGRP or the proportion of CGRP neurons showing GFRα1-IR following 
injury. Comparisons of ipsi- and contralateral ganglia were made by performing a 
paired t-test on arcsine transformed data. Data have been expressed as the mean 
percentage ± SEM (n = 5 rats per group), where each measurement from each 
ganglion represented the mean of at least 150 neuronal sections, including only those 
neurons sectioned through the nucleus. g-r: Colocalisation of GFRα1-IR with NF200 
(g-l) or calcitonin gene-related peptide (CGRP, m-r) in L5 dorsal root ganglion 
sections, contra- and ipsilateral to the sciatic nerve transection, shown as image pairs 
and corresponding merged images. Contralateral to injury (g-i), GFRα1-IR was found 
in small, NF200-negative and large, NF200-positive neurons. Ipsilateral to injury (j-l), 
GFRα1-IR was brighter in both of these groups of neurons. Colocalisation of GFRα1-
IR and CGRP-IR was infrequent both contralateral (m-o) and ipsilateral (p-r) to 
injury. Arrowheads show examples of double-labelled neurons. Scale bar = 50 µm 
applies to g-r. CGRP, calcitonin gene-related peptide; GFR, GDNF family receptor.
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Figure 2.5 Decrease in GFRα2-immunoreactivity (IR) in the dorsal horn from lumbar 
spinal cord, 7 days after chronic constriction injury (a-l) or transection (m-x) of the 
sciatic nerve. For each type of injury, images are taken from left and right sides of the 
same section, and segments of each spinal level from the same animal. a-f: 
Distribution of GFRα2-IR in lamina II (inner) contralateral to a chronic constriction 
injury. g-l: Ipsilateral to injury, GFRα2-IR was decreased only in L4 and L5, showing 
areas with lower levels or absent immunostaining in the most medial and the central 
aspects of the dorsal horn. m-r: Distribution of GFRα2-IR in lamina II (inner) 
contralateral to a transection injury. s-x: Ipsilateral to injury, GFRα2-IR was decreased 
only in L4 and L5, showing substantive areas with absent immunostaining in the most 
medial and the central aspects of the dorsal horn. Scale bar applies to all panels and 
represents 200 µm. GFR, GDNF family receptor.
103
010
20
30
40
50
%
 N
eu
N
 w
. G
FR
α
2
0
25
50
75
100
125
O
pt
ic
al
 d
en
si
ty
0
25
50
75
100
125
medial central lateral
b a 
contra
ipsi
medial central lateral
c d 
g contra h ipsi
e 
**
0
25
50
75
100
125
M
ea
n 
in
te
ns
ity
f 
0
25
50
75
100
125
O
pt
ic
al
 d
en
si
ty
0
25
50
75
100
125 contra
ipsi
*
Figure 2.6
104
Figure 2.6 Quantitation of immunostaining intensity for GFRα2 in the L5 dorsal horn and 
characterisation of GFRα2-IR dorsal root ganglion neurons following sciatic nerve injury. 
a-d Show data from the dorsal horn and e-h from dorsal root ganglia. Optical density mea-
surements in spinal cord sections from chronic constriction injury (CCI) animals are shown 
in a and b, whereas data from transection injury are shown in c and d.  a: Optical density 
measurements pooled from all superficial areas of interest (AOI 1-3) on each side showed 
a main effect of CCI (*P = 0.039, F
1, 5
 = 7.777), with a decrease in GFRα2-IR ipsilateral 
to injury. b: Optical density measurements from each AOI in the superficial dorsal horn 
showed no interaction between side and AOI. c: Optical density measurements pooled from 
all superficial AOIs (1-3) on each side did not detect a significant effect of transection. d: 
Optical density measurements from each AOI in the superficial dorsal horn showed no 
significant interaction between side and AOI. Data represent mean ± SEM (n= 6 rats per 
group), analysed by ANOVA. e: The mean fluorescence intensity of GFRα2-IR neurons did 
not change following transection injury. f: The proportion of NeuN-positive neurons show-
ing GFRα2-IR was significantly decreased in ganglia ipsilateral to transection (P = 0.004). 
Comparisons of ipsi- and contralateral ganglia were made by performing a paired t-test on 
arcsine transformed data. Data have been expressed as the mean percentage ± SEM (n = 5 
rats per group), where each measurement from each ganglion represented the mean of at 
least 150 neuronal sections, including only those neurons sectioned through the nucleus. g 
and h show examples of GFRα2-IR neurons contralateral and ipsilateral to injury, demon-
strating the similar intensity of immunofluorescence. Scale bar = 50 µm and applies to both 
g and h. GFR, GDNF family receptor; IR, immunoreactivity.
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Figure 2.7 Up-regulation of GFRα3-immunoreactivity (IR) in the dorsal horn from 
lumbar spinal cord, 7 days after chronic constriction injury (a-l) or transection (m-x) 
of the sciatic nerve. For each type of injury, images are taken from left and right sides 
of the same section, and segments of each spinal level from the same animal. a-f: 
Distribution of GFRα3-IR in laminae I  and II (outer), contralateral to a chronic 
constriction injury (CCI). In L6 (f), GFRα3-IR fibres also travel towards the sacral 
preganglionic nucleus (asterisks). g-l: Ipsilateral to CCI injury, GFRα3-IR is increased 
in the superficial dorsal of L3-L5, especially the most medial and the central aspects 
of the dorsal horn. m-r: Distribution of GFRα3-IR in laminae I and  II (outer), 
contralateral to a transection injury. In L6 (r), GFRα3-IR fibres also travel towards the 
sacral preganglionic nucleus (arrowheads). s-x: Ipsilateral to transection injury, 
GFRα3-IR was increased in the superficial dorsal of L3-L5, especially the most medial 
and the central aspects of the dorsal horn. Scale bar applies to all panels and represents 
200 µm. GFR, GDNF family receptor.
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Figure 2.8 Quantitation of immunostaining intensity for GFRα3 and CGRP in the L5 
dorsal horn following sciatic nerve injury. Optical density measurements in spinal 
cord sections immunostained for GFRα3 are shown in a-d, whereas data from 
sections stained for CGRP are shown in e-h. a: Optical density measurements pooled 
from all superficial areas of interest (AOI 1-3) on each side showed a main effect of 
CCI (*P = 0.013, F
1, 5
 = 14.031), with an increase in GFRα3-IR ipsilateral to injury. 
b: Optical density measurements from each AOI in the superficial dorsal horn did not 
detect a significant interaction between side and AOI after CCI. c: Optical density 
measurements pooled from all superficial AOI (1-3) on each side showed a main 
effect of transection (***P <0.0001, F
1, 5
 = 85.214), with an increase in GFRα3-IR 
ipsilateral to injury. d: Optical density measurements from each AOI in the superficial 
dorsal horn detected a significant interaction between side and AOI (P = 0.014, F
1.359, 
6.79
3 = 9.697). e: There was no effect of CCI on optical density measurements of 
CGRP-IR when all AOIs were pooled and no interaction was detected between side 
and AOI (f). g: There was no effect of transection on optical density measurements of 
CGRP-IR when all AOIs were pooled and no interaction was detected between side 
and AOI (h). Data represent mean ± SEM (n= 6 rats per group), analysed by ANOVA. 
CGRP, calcitonin gene-related peptide; GFR, GDNF family receptor; IR, immunoreactivity.
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Figure 2.9 Calcitonin gene-related peptide (CGRP)-immunoreactivity (IR) in the dorsal horn 
from lumbar spinal cord, 7 days after chronic constriction injury (a-l) or transection (m-x) of 
the sciatic nerve. For each type of injury, images are taken from left and right sides of the same 
section, and segments of each spinal level from the same animal. Distribution of CGRP-IR in 
superficial laminae contralateral to a chronic constriction (a-f) and transection (m-r) injury. 
There was no obvious change in the area or intensity of CGRP-IR ipsilateral to chronic con-
striction (g-l) or transection (s-x) injury. In all images of L6, CGRP-IR fibres travel towards the 
sacral preganglionic nucleus (arrowheads).  Scale bar applies to all panels and represents 200 
µm.
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Figure 2.10 Co-localisation studies of GFRα3-immunoreactive (IR) somata in L5 
dorsal root ganglia (DRG), ipsilateral and contralateral to transection of the sciatic 
nerve. a: Mean fluorescence intensity of GFRα3-IR neurons showed no difference 
between ganglia ipsilateral and contralateral to injury (n = 5). b: The proportion of 
NeuN somata exhibiting GFRα3-IR increased ipsilateral to injury (** P = 0.006). c, 
d: The proportion of GFRα3-IR neurons expressing NF200 (** P = 0.007) and the 
proportion of NF200 neurons showing GFRα3-IR (*P = 0.002) was also increased 
after sciatic transection. e: Following injury there was a decrease in the proportion of 
GFRα3-IR neurons expressing CGRP (P = 0.002).  f: There was a very small but 
significant increase in the proportion of CGRP neurons showing GFRα3-IR following 
injury (P = 0.004). Comparisons of ipsi- and contralateral ganglia were made by 
performing a paired t-test on arcsine transformed data. Data have been expressed as 
the mean percentage ± SEM (n = 5 rats per group), where each measurement from 
each ganglion represented the mean of at least 150 neuronal sections, including only 
those neurons sectioned through the nucleus. g-r show colocalisation of GFRα3-IR 
with NF200 (g-l) or calcitonin gene-related peptide (CGRP, m-r) in L5 dorsal root 
ganglion sections, contra- and ipsilateral to the sciatic nerve transection, shown as 
image pairs and corresponding merged images. Both contralateral (g-i) and ipsilateral 
(j-l) to injury, GFRα3-IR neurons were rarely NF200-positive (example indicated by 
arrowheads in j-l). However on both sides, many neurons showing colocalisation of 
GFRα3-IR and CGRP-IR. Arrowheads show examples of double-labelled neurons. 
Scale bar = 50 µm applies to g-r. CGRP, calcitonin gene-related peptide; GFR, GDNF 
family receptor; IR, immunoreactivity.
113
 CHAPTER 3: GFR expression in spinal cord following 
visceral nerve injury 
 
3.1 Introduction  
Damage to a peripheral nerve can lead to chronic neuropathic and post-surgical pain 
that can be difficult to treat. Peripheral nerve damage caused by actual nerve injury, 
mechanical trauma or disease is one of the major causes of neuropathic pain (Costigan 
et al., 2009). There is accumulating evidence to suggest that the prevalence of 
persistent post-surgical pain has been underestimated in clinical populations. 
However, a recent epidemiological study indicates that there is a high prevalence of 
persistent pain after many routine surgical procedures that may be of neuropathic 
origin (Johansen et al., 2012). The prevalence of persistent post-surgical pain differs 
between the anatomical region of the surgery with the highest incidence following 
surgery in the back, neck, hip and the limbs. The prevalence of persistent pain 
following surgery to a visceral organ is much lower (Johansen et al., 2012) and it is 
unclear to what extent of the pain is neuropathic in origin. This evidence suggests 
there are differences in the mechanisms that underlie how pain arises following 
damage to a somatic and visceral nerve. 
 
Chemical and structural plasticity occurs in rodent primary sensory neurons and their 
central terminals as well as in second order neurons in the dorsal horn that develop 
spontaneous activity following peripheral nerve injury (Navarro et al., 2007). These 
changes correlate with the development and progression of neuropathic pain. This 
research primarily originates from studies of somatic nerves with particular focus on 
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 peptidergic and non-peptidergic primary afferent C-fibres containing calcitonin gene-
related peptide (CGRP) and isolectin-B4 respectively (Bailey and Ribeiro-da-Silva, 
2006; Casals-Diaz et al., 2009). The effect of injury on central terminals of afferent C-
fibres has been most extensively studied after injury to different branches of the 
sciatic nerve. In contrast, the central effects of damage to nerves that project to 
visceral targets have been poorly investigated. Following injury to the pelvic nerve, a 
visceral nerve containing axons that innervate the bladder and other pelvic organs 
(Keast, 2006), Anand et al. (1991) reported a decrease of vasoactive intestinal 
polypeptide (VIP) expression in the dorsal horn of cats while other peptidergic C-
fibre afferents were unaffected. Another group (Birder et al., 1991) show a small but 
significant up-regulation of the immediate early gene cFos in lumbosacral spinal cord 
following pelvic nerve injury in rats. Together these results suggest a limited amount 
of structural remodelling also occurs in the dorsal horn after injury to a visceral nerve 
but the mechanisms responsible, and if this relates to the development of pain are yet 
to be determined.  
 
In this study we investigated the impact of injury on two different visceral nerves: the 
pelvic and hypogastric nerves.  These nerves can be damaged during routine surgical 
procedures (Maas et al., 2003; Walsh and Donker, 1982), significantly impacting 
quality of life (Fowler et al., 2008). The pelvic and hypogastric nerves are essential 
for the micturition reflex and many other urogenital and pelvic visceral functions 
(Keast, 2006; Yoshimura, 1999). The pelvic nerve contains sacral afferent and sacral 
parasympathetic preganglionic axons (Keast, 2006). The central distribution of 
visceral primary afferent axons travelling in this nerve comprises Lissauer’s tract, the 
superficial dorsal horn, medial (MCP) and lateral collateral pathways (LCP), deep 
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 dorsal horn, lamina X and the dorsal grey commissure in sacral (L6/S1) spinal cord. 
In rodents, these central projections are most prominent in L6/S1 spinal segments but 
many axons extend three spinal segments above and below these spinal levels 
(Morgan et al., 1981). Preganglionic autonomic neurons with axons travelling in the 
pelvic nerve are localised to the sacral preganglionic nucleus (SPN) (Hancock and 
Peveto, 1979b; Morgan et al., 1981; Nadelhaft and Booth, 1984). The hypogastric 
nerve contains lumbar afferent and lumbar sympathetic preganglionic axons, as well 
as some postganglionic sympathetic axons from the inferior mesenteric ganglion 
(Keast, 2006; Yoshimura, 1999). The central distribution of visceral primary afferent 
axons travelling in the hypogastric nerve comprises Lissauer’s tract, the superficial 
dorsal horn and the MCP and LCP in upper lumbar spinal cord (Morgan et al., 1986; 
Nadelhaft and McKenna, 1987). In rodents, these central projections are most 
prominent in L1/2 spinal segments but many also extend two segments above and 
below their point of entry (Morgan et al., 1986). The majority of preganglionic 
autonomic neurons with axons running in the hypogastric nerve are located in the 
dorsal grey commissure (DGC), and the remainder are found in the intermediolateral 
cell column (IML) (Hancock and Peveto, 1979a; Nadelhaft and McKenna, 1987).  
 
Our laboratory has identified that non-peptidergic C-fibre afferents expressing the 
receptor for glial cell-line derived neurotrophic factor (GDNF), GFRα1, were 
increased in sacral dorsal horn following cyclophosphamide-induced bladder 
inflammation (Forrest and Keast, 2008). We have also demonstrated that injury to the 
sciatic nerve induces a widespread increase in GFRα1 and a reduction in non-
peptidergic C-fibre afferents expressing the neurturin receptor, GFRα2 in the dorsal 
horn ((Keast et al., 2010); Chapter 2). The receptor for artemin, GFRα3, which is 
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 exclusively expressed in a sub-population of peptidergic C-fibres, showed a localised 
increase in the dorsal horn after injury (Chapter 2). These studies suggest that each 
population of C-fibre afferents have different regenerative capabilities and that 
neurons expressing the GFRs are likely to respond differently to neurotrophic factors 
after nerve injury.  
 
Based on the results in the preceding chapter, we applied the same approach to a 
study of visceral nerve injury. We hypothesised that injury to two different visceral 
nerves will produce different outcomes on afferent terminals in spinal cord than those 
observed following sciatic nerve injury. To test this hypothesis we performed pelvic 
and / or hypogastric nerve transections in rats and studied the effect of injury on four 
distinct populations of afferent fibres identified with GFRα1, GFRα2, GFRα3 and 
CGRP (which includes the GFRα3-positive population). We also investigated if 
visceral nerve injury had an effect on GFRα1-, GFRα3- and CGRP-immunoreactive 
(IR) fibres or neurons in the SPN, an area containing preganglionic neurons that are 
injured following pelvic nerve injury. 
 
3.2 Methods 
3.2.1 Surgical procedures 
All procedures were approved by Animal Care and Ethics Committees of the 
University of Sydney and Royal North Shore Hospital, as required by the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes (National 
Health and Medical Research Council of Australia). The 17 adult male Sprague-
Dawley rats (6-8 wks) used for these experiments comprised: 8 for unilateral pelvic 
nerve transection (with 6 providing transverse sections of spinal cord and 2 providing 
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 horizontal sections), 4 for unilateral hypogastric nerve transection (transverse sections 
only), 3 for bilateral pelvic and hypogastric nerve transection (transverse sections 
only), and 2 for bilateral pelvic nerve transections (horizontal sections only). All rats 
were purchased from the Animal Resources Centre (Murdoch, WA, Australia), and 
housed under a 12 h light-dark cycle with free access to food and water.  
 
All surgical procedures were performed under isoflurane anaesthesia (3% for 
induction, 1.5-2% for maintenance in O2). For unilateral nerve cuts, the left pelvic 
ganglion was exposed following a midline abdominal incision, and the pelvic (Group 
1) or hypogastric nerve (Group 2) was transected within 2 mm of the pelvic ganglion. 
For bilateral nerve cuts, the left and right ganglia were exposed and either both pelvic 
and hypogastric nerves were transected (Group 3), or the pelvic nerves only were 
transected (Group 4). After nerve transection, the abdominal wall and skin were 
closed with silk sutures (4-0 and 3-0, respectively).  Following surgery, all rats were 
closely monitored and, for animals with both pelvic nerves transected, the bladder 
emptied manually at intervals of less than 12 h. 
 
3.2.2 Immunohistochemistry 
Seven days after surgery, rats were heavily anaesthetised with sodium pentobarbitone 
(80 mg/kg i.p.) and transcardially perfused with 350 ml 0.9% saline containing 1.25% 
sodium nitrite and 0.036% heparin, followed by freshly made 4% paraformaldehyde 
in 0.1M phosphate buffer (PB, pH 7.4). The spinal cord and pelvic ganglia were 
removed and post-fixed overnight in the same fixative at 4°C, then washed three 
times in 0.1M phosphate buffered saline (PBS, pH 7.2) and stored in PBS containing 
0.1% sodium azide until sectioning. 
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After removal, fixed spinal cords were segmented into sacral (L6/S1) and lumbar 
(L1/2) regions. Prior to transverse sectioning, a superficial cut was made in the 
ventrolateral gray matter to later identify the side contralateral to injury. Spinal cord 
segments were cryoprotected overnight in PBS containing 30% sucrose. Transverse 
sections (40 µm) were collected in a 1 in 4 series so that sections processed for the 
same substance were sampled at least 160 µm apart. For horizontal sectioning, spinal 
cords were segmented into L4-S2 spinal segments to encapsulate the full extent of the 
SPN. For tissue from unilateral injuries, the caudal edge of the S2 segment was 
trimmed on one side, to later differentiate between injured and un-injured sides. 
Horizontal sections (40 µm) were collected in a 1 in 2 series so that sections 
processed for the same substance were sampled at least 80 µm apart.  
 
All transverse and horizontal sections were processed free-floating using the glucose 
oxidase/nickel enhanced diaminobenzidine (DAB) method (Hamlin et al., 2007). 
Sections were washed in PB, followed by two 50% ethanol washes, the second 
containing 3% H202 to block endogenous peroxidase activity. Sections were then 
blocked for 30 minutes in PB containing 5% normal horse serum (NHS) before 
incubation with primary antisera for 48 hours at room temperature. For transverse 
spinal cord, sections were incubated in antisera raised against GFRα1 (R&D Systems; 
Minneapolis, MN, USA; Cat. No. AF5601; Batch No. BQEO24081; goat; 1:400), 
GFRα2 (R&D Systems; Cat. No. AF429; Batch No. BTM02; goat; 1:1000), GFRα3 
(R&D Systems; Cat. No. AF2645; Batch No. VFU01; goat; 1:300) and CGRP 
(Millipore; North Ryde; NSW, Australia; Cat No. AB5920; Batch No. LV1496277; 
rabbit; 1:2000). For horizontal spinal cord, sections were incubated in GFRα1 or 
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 GFRα3 antisera only. After three washes in PB, sections were incubated in 
appropriate biotin-conjugated donkey anti-goat (Jackson ImmunoResearch 
Laboratories; West Grove, PA, USA; Cat. No. 705-065-147; 1:1000) or donkey anti-
rabbit (Jackson ImmunoResearch Laboratories; Cat. No. 711-065-152; 1:1000) 
antisera. Following three washes in PB, sections were incubated in avidin-biotin 
complex (6 µl / ml, Vectastain Elite kit; Vector Laboratories, Burlingame, C.A) for 
two hours at room temperature followed by a 15 minute incubation in nickel 
intensified DAB solution (2% nickel sulfate, 0.2% D-glucose, 0.04% ammonium 
chloride, and 0.025% DAB in 0.1M sodium acetate buffer pH 6.0). The peroxidase 
reaction was initiated by adding 0.002% glucose oxidase to the DAB solution. The 
development of black reaction product was monitored by eye under a dissecting 
microscope and stopped with three quick acetate buffer washes before a final wash in 
PB. Sections were mounted from 0.9% saline onto 0.1% gelatinised slides, dried 
overnight and dehydrated in ascending concentrations of ethanol, cleared with 
histolene and cover slipped with DPX water-free mounting media (Crown Scientific, 
Mulgrave, VIC, Australia). All antibodies were made up in PB containing 2% NHS 
and 0.2% triton X-100, the primary solution also containing 0.1% sodium azide. 
 
3.2.3 Neuronal counts 
GFRα1-IR somata in the SPN were counted in five rostro-caudal horizontal spinal 
cord sections after unilateral (Group 1) and bilateral (Group 4) pelvic nerve 
transection. GFRα1-IR somata were counted on one side only after the bilateral 
injury, and separately on the ipsi- and contra-lateral sides after the unilateral injury. 
Counts of GFRα1-IR somata were expressed as the mean ± SEM of the total number 
of neurons from each rostro-caudal section from each rat.  
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3.2.4 Image analysis and optical density measurements 
Quantification of dorsal horn and SPN immunoreactivity revealed by each antibody 
was performed on spinal cord sections immunostained using the DAB reaction. Spinal 
cord sections from unilateral pelvic and unilateral hypogastric nerve transected 
animals were visualised using an Olympus BX51 microscope (Olympus Australia, 
Melbourne, Australia) and images were captured with a Zeiss AxioCam HRc camera 
(Munchen-Hallbergmoos, Germany) and Axiovision 4.2 software. Image analysis was 
performed on 8-bit monochrome TIFF-format files (1300 x 1030 pixels) using Image-
Pro Plus software (Media Cybernetics, Silver Spring, MD, USA). For each antibody, 
spinal cord sections from the same rat were imaged using the same camera settings 
and exposure time, under a 10x objective. Images of the ipsi- and contra-lateral sides 
were also taken from the same section. For quantitative analysis on immunostaining 
intensity, images from six randomly selected sections from lumbar and sacral regions 
were obtained from both ipsi- and contralateral sides. Optical density was assessed in 
areas of interest (AOIs, 130 x 130 µm) in the dorsal horn and in the SPN (circular 
AOI, diameter = 250 µm) as shown in Figure 3.1. AOI boxes 1 and 2 were used for 
each antibody, but AOI circle 3 for GFRα1, GFRα3 and CGRP only. The circular 
AOI was large enough to include neurons and fibres within the SPN and afferent 
fibres that terminated just dorsal to the SPN. For each antibody, the optical density 
value from each of the six sections was averaged to obtain a single value for each 
AOI in each rat. In each rat the mean white matter optical density values for each 
antibody were subtracted. Changes in optical density could reflect changes in the 
staining intensity of fibres or changes in fibre density within the AOI. 
 
121
 3.2.5 Statistics and figure production 
Statistical analyses were performed using SPSS v16 for PC (Chicago, IL) or 
GraphPad Prism 5.0a (GraphPad Software, La Jolla, CA). Differences between sides 
of GFRα1-3 and CGRP immunostaining in the medial and lateral dorsal horn and 
SPN were analysed using paired t-tests. All results are expressed as the mean ± SEM 
and P < 0.05 were regarded as statistically significant. For figure production, some 
minor adjustments were made to brightness and contrast using the levels command in 
Adobe Photoshop CS2 (san Jose, CA) to best represent the immunostaining as viewed 
directly under the microscope. 
 
3.3 Results 
To determine if unilateral lesions of the pelvic or hypogastric nerves affect the central 
axons of DRG neurons we used digital image analysis to compare areas of interest 
(AOIs) in the spinal cord contralateral and ipsilateral to the injury. GFRα1- and 
GFRα2-IR were used as markers for the terminals of non-peptidergic C-fibre afferents 
(Forrest and Keast, 2008) whereas CGRP- and GFRα3-IR were used as markers for 
the terminals of peptidergic C-fibre afferents (Forrest and Keast, 2008; Keast et al., 
2010). The distribution of all markers in the dorsal horn of the sacral (L6/S1) and 
lumbar (L1/2) spinal cord (Figures 3.2, 3.4-3.6) contralateral to both injuries was 
broadly consistent with previous reports (Forrest and Keast, 2008; Keast et al., 2010). 
However, as the experimental design was limited to a within-subject comparison of 
the contralateral and ipsilateral spinal cord, this precluded using quantitative analysis 
to detect any effect of nerve injury on the contralateral dorsal horn. Mean optical 
density measurements from three AOIs in medial and lateral superficial dorsal horn 
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 and SPN are summarised in Table 3.1 for each type of immunoreactivity, spinal cord 
region and nerve injury group studied in the experiment. 
 
3.3.1 GFRα1- and GFRα2-immunoreactivity in terminals of non-peptidergic fibres 
GFRα1-IR fibres in the spinal cord contralateral to nerve injury (Figure 3.2a, c, e, g) 
were distributed primarily in lamina II (outer) of the dorsal horn as previously 
described (Forrest and Keast, 2008; Kalous et al., 2009). Occasional GFRα1-IR fibres 
were also present in the LCP that terminated just dorsal to the SPN, which have been 
shown in the previous chapter (Chapter 2, Figure 2.1f). GFRα1-IR fibres and weakly 
stained GFRα1-IR somata were located in the SPN. Only a few weakly stained 
GFRα1-IR fibres were present in the DGC (not shown), an area that contains 
autonomic preganglionic axons and interneurons (Morgan et al., 1986). GFRα1-IR 
motor neurons were also found in the ventral horn (not shown). 
 
Optical density measurements of GFRα1-IR in the sacral spinal cord 7 days after 
unilateral pelvic nerve transection revealed a significant increase in the medial 
superficial dorsal horn whereas in the lateral dorsal horn the difference approached 
significance (P = 0.07, n = 6) (Table 3.1, Figure 3.2a, b, m). A significant increase in 
GFRα1-IR was also detected in the area of the SPN (Table 3.1, Figure 3.2a, b, m, 
3.3b, c). No effect of injury on GFRα1-IR was detected in lumbar spinal cord (Table 
3.1, Figure 3.2c, d, m), and no change was detected at either spinal level after 
unilateral hypogastric nerve transection (Table 3.1, Figure 3.2e-h, n). Consistent with 
the increase in GFRα1-IR measured quantitatively in the SPN, we observed that 
staining in this region was also intense and appeared to occupy a larger area in 
sections taken from rats that underwent joint bilateral pelvic and hypogastric nerve 
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 transections (Figure 3.2i-l). No further differences were identified by visual 
inspection of these sections. 
 
The above observations suggested that a major effect of unilateral pelvic nerve 
transection was to increase GFRα1-IR in the SPN, a region that contains autonomic 
preganglionic neurons that project in the pelvic nerve (Hancock and Peveto, 1979b; 
Morgan et al., 1981; Nadelhaft and Booth, 1984). We made further qualitative 
observations relating to this result by viewing the rostro-caudal extent of the SPN in 
horizontal spinal cord sections. Seven days after unilateral pelvic nerve transection 
GFRα1-IR fibres and somata in the SPN were more intensely stained on the ipsilateral 
side (Figure 3.3a, d, e). The somata were distributed throughout the rostro-caudal 
extent of the SPN and were commonly observed in small clusters of up to 4-6 
neurons. A higher number of GFRα1-IR somata were observed on the ipsilateral (69 
in Rat 1 and 79 in Rat 2; total from 5 sections per rat) versus contralateral (7 in Rat 
and 11 in Rat 2; total from 5 sections per rat) side (Figure 3.3h, i). GFRα1-IR fibres 
were also intensely stained in the SPN 7 days after bilateral pelvic nerve transection, 
(Figure 3.3f, g) and counts of GFRα1-IR somata in the SPN (52 in Rat 1 and 69 in Rat 
2; total from 5 sections per rat, counted from one side of the SPN only) were more 
similar to those obtained from the ipsilateral than the contralateral side after unilateral 
pelvic nerve transection. 
 
GFRα2-IR fibres in the spinal cord contralateral to nerve injury were primarily 
distributed in lamina II (inner) of the dorsal horn as previously described (Forrest and 
Keast, 2008; Kalous et al., 2007; Keast et al., 2010) (Figure 3.4 a, c, e, g). A few 
weakly stained GFRα2-IR fibres were present in the lateral spinal nucleus (LSN), and 
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 in some sections, a few weakly stained fibres were also observed in the DGC as 
described in Chapter 2 (Chapter 2, Figure 2.5a-f). GFRα2-IR fibres were absent in the 
LCP and were not associated with the SPN. GFRα2-IR somata were not observed in 
the dorsal or ventral horn at either spinal level. 
 
Optical density measurements of GFRα2-IR in the sacral spinal cord 7 days after 
unilateral pelvic nerve transection showed no effect of injury in the lateral or medial 
dorsal horn (Table 3.1, Figure 3.4a, b, m). However, in the lumbar spinal cord a small 
but significant reduction in GFRα2-IR was detected in the medial, but not the lateral 
dorsal horn (Table 3.1, Figure 3.4c, d, m). No change in GFRα2-IR was detected at 
either spinal level after unilateral hypogastric nerve transection (Table 3.1, Figure 
3.4e-h, n). No differences were identified by visual inspection in sacral or lumbar 
spinal cord after joint bilateral pelvic and hypogastric nerve transections (Fig 3.4i-l). 
 
3.3.2 CGRP- and GFRα3-immunoreactivity in terminals of peptidergic fibres 
CGRP-IR fibres in the spinal cord contralateral to nerve injury (Figure 3.5a, c, e, g) 
were primarily confined to lamina I and II and deeper laminae in the dorsal horn as 
previously described (Carlton et al., 1988; Kalous et al., 2009; Lawson et al., 1993). 
In sacral spinal cord, CGRP-IR fibres in the superficial laminae extended along the 
medial border of the dorsal horn and in some sections these fibres formed a 
continuous band following the edge of grey matter to the medial side of the opposite 
dorsal horn. Many CGRP-IR fibres were also present in the DGC (not shown), LCP 
and associated with the SPN (Figure 3.5a, e). In lumbar spinal cord, CGRP-IR fibres 
also extended along the medial border of the dorsal horn but were not as prevalent as 
those in sacral levels. At this spinal level, CGRP-IR fibres were not associated with 
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 the IML. At both spinal levels, CGRP-IR motor neurons were present in the ventral 
horn (not shown). Neuronal CGRP-IR somata were not observed in any other region.  
 
Optical density measurements of CGRP-IR in the sacral dorsal horn 7 days after 
unilateral pelvic nerve transection identified a significant but small decrease in the 
lateral but not medial superficial dorsal horn (Table 3.1, Figure 3.5a, b, m). No effect 
of unilateral pelvic nerve injury was detected in the SPN (Table 3.1, Figure 3.5m) or 
in lumbar spinal cord (Table 3.1, Figure 3.5c, d, m). Quantification of CGRP 
immunostaining in sacral and lumbar spinal cord following unilateral hypogastric 
nerve transection showed no effect of injury on CGRP-IR at either spinal level (Table 
3.1, Figure 3.5e-h, n). Following combined bilateral pelvic and hypogastric nerve 
transections, no further differences were identified by visual inspection in the 
distribution of CGRP-IR at either spinal level (Figure 3.5i-l). 
 
GFRα3-IR in spinal cord dorsal horn is almost exclusively co-localised in the 
terminals of a major subpopulation of CGRP-IR peptidergic afferent neurons (Keast 
et al., 2010; Orozco et al., 2001). GFRα3-IR fibres in the spinal cord contralateral to 
nerve injury (Figure 3.6a, c, e, g) were distributed primarily in lamina I of the dorsal 
horn, consistent with previous studies (Forrest and Keast, 2008; Kalous et al., 2009; 
Keast et al., 2010). In sacral spinal cord, GFRα3-IR fibres were also found in the LCP 
and in some sections, these fibres terminated just dorsal to the SPN whereas in other 
sections, GFRα3-IR fibres terminated in the SPN. In some sections, GFRα3-IR fibres 
in the superficial laminae extended along the medial border of the dorsal horn and 
formed a continuous band that extended to the opposite dorsal horn. In many sections 
GFRα3-IR fibres were also found in the DGC as demonstrated in Chapter 2 (Chapter 
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 2, Figure 2.7f). GFRα3-IR fibres were not observed in the LSN. In lumbar spinal 
cord, GFRα3-IR fibres had a more restricted distribution and were primarily localised 
to lamina I (Figure 3.6c, g). GFRα3-IR somata were not observed in either level of the 
spinal cord. 
 
Optical density measurements of GFRα3-IR in the sacral spinal cord 7 days after 
unilateral pelvic nerve transection showed no effect of injury in the lateral or medial 
superficial dorsal horn (Table 3.1, Figure 3.6a, b, m). However, a significant increase 
in GFRα3-IR was detected in the area of the SPN (Table 3.1, Figure 3.6a, b, m, 3.7b, 
c). No effect of injury was detected on GFRα3-IR in lumbar spinal cord (Table 3.1, 
Figure 3.6c, d, m). Quantitation of GFRα3-IR in the sacral and lumbar superficial 
dorsal horn 7 days after unilateral hypogastric nerve transection showed no effect of 
injury at either spinal level (Table 3.1, Figure 3.6e-h, n). Consistent with the increase 
in GFRα3-IR measured quantitatively in the SPN, we also observed that staining in 
this region was also intense in sections taken from rats that underwent joint bilateral 
pelvic and hypogastric nerve transections (Figure 3.6i-l) and closely resembled the 
side ipsilateral to unilateral pelvic nerve transection. 
 
GFRα3-IR in the SPN was also examined in horizontal sections taken from rats that 
underwent unilateral or bilateral pelvic nerve transections. GFRα3-IR fibres were 
more intensely stained on the side ipsilateral to unilateral pelvic nerve transection 
(Figure 3.7a, d, e). GFRα3-IR fibres also appeared more intensely stained in the SPN 
after bilateral pelvic nerve transection (Figure 3.7f, g), but this was not quantified. 
GFRα3-IR fibres in the SPN formed tight nests and bundles of fibres (Figure 3.7h, i). 
GFRα3-IR somata were not observed within these tight nests or bundles of fibres. 
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3.4 Discussion 
This study investigated the impact of visceral nerve injury on central terminals of the 
primary types of GFL and NGF-sensitive afferent fibres expressing the GFRs and 
CGRP by performing unilateral and bilateral transections on two different visceral 
nerves. The incidence of persistent post-surgical pain is much lower following 
surgery to a visceral organ when compared to the higher prevalence of persistent pain 
following surgery to the back or limbs (Johansen et al., 2012). It is unclear to what 
extent this visceral pain is of neuropathic origin. The effect of somatic nerve injury on 
C-fibre afferents in the spinal cord has been extensively studied, especially after 
injury to the sciatic nerve. Many of the changes that occur coincide with the 
development of neuropathic pain (Bailey and Ribeiro-da-Silva, 2006; Bennett and 
Xie, 1988; Casals-Diaz et al., 2009). We have demonstrated in Chapter 2 that sciatic 
nerve injury caused profound structural plasticity in central terminals of neurons 
containing the GFRs. An earlier study from our laboratory also demonstrated an up-
regulation of GFRα1-IR in sacral spinal cord following visceral inflammation (Forrest 
and Keast, 2008). We hypothesised that injury to a visceral nerve will produce 
different outcomes on the central distribution of afferent terminals compared to those 
observed after injury to a somatic nerve. 
 
To address this question, we performed unilateral and bilateral transections of the 
pelvic and hypogastric nerves and investigated the effect of injury on non-peptidergic 
fibres containing GFRα1- and GFRα2-IR, and peptidergic fibres containing CGRP- 
and GFRα3-IR, which is expressed in a subpopulation of peptidergic afferents 
(Bennett et al., 2006; Keast et al., 2010). These nerves were selected on the basis that 
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 both are purely visceral nerves containing afferent and autonomic axons that innervate 
pelvic visceral targets, including the bladder (Keast, 2006). Furthermore, both the 
connectivity of preganglionic axons travelling in these nerves with post-ganglionic 
neurons in the pelvic ganglion (Keast, 2006), and the central distribution of axons 
travelling in both nerves have been well documented (Hancock and Peveto, 1979a; b; 
Morgan et al., 1986; Morgan et al., 1981; Nadelhaft and Booth, 1984; Nadelhaft and 
McKenna, 1987). We hypothesised that pelvic nerve injury would have the largest 
effect on afferent terminals in sacral cord as the majority of these afferents terminate 
in L6/S1 spinal cord. Likewise, hypogastric nerve transection would likely have the 
largest effect on afferents in lumbar cord as most axons travelling in this nerve 
terminate in L1/2 spinal cord. In this study, we also investigated if there was an effect 
on preganglionic neurons or fibres in the area of the SPN, which are damaged by 
pelvic nerve injury. In these experiments, we applied the same approach as in Chapter 
2 following sciatic nerve injury by performing optical measurements on GFR- and 
CGRP-IR fibres in medial and lateral superficial dorsal horn and the SPN. We also 
examined optical density of immunohistochemically stained sections in lumbar (L1/2) 
cord following pelvic nerve transection, and in sacral (L6/S1) cord following 
hypogastric nerve transection to determine if structural remodelling of uninjured 
afferent fibres occur following visceral nerve injury. Afferent axons travelling in the 
pelvic and hypogastric nerve do not usually project to these spinal segments in normal 
animals. 
 
3.4.1 General pattern of GFRα1 and GFRα2 in spinal cord and effect of injury 
GFRα1 and GFRα2 antibodies were used as tools to identify two distinct sub-
populations of non-peptidergic fibres (Forrest and Keast, 2008). Previous studies have 
129
 focused on IB4, a general marker of non-peptidergic fibres (Bailey and Ribeiro-da-
Silva, 2006; Casals-Diaz et al., 2009), but recent studies from our laboratory 
demonstrate that GFRα1 and GFRα2 comprise separate populations and their central 
terminals respond differently to injury and inflammation (Forrest and Keast, 2008; 
Kalous et al., 2009; Keast et al., 2010). In addition, GFRα1-IR fibres and neurons are 
associated with the SPN (Forrest and Keast, 2008). Consistent with these reports, in 
this study contralateral to either injury, GFRα1-IR fibres were primarily localised to 
lamina II (outer) and GFRα2-IR fibres were primarily localised to lamina II (inner).  
 
After unilateral pelvic nerve transection, GFRα1-IR showed a localised increase in the 
medial dorsal horn of sacral spinal cord. This increase in immunostaining indicates an 
up-regulation in small-medium diameter unmyelinated afferent neurons with higher 
levels of GFRα1 protein being trafficked to central terminals or additional small-
medium unmyelinated neurons synthesising GFRα1. No change was detected in 
GFRα1-IR fibres in sacral or lumbar cord following hypogastric nerve transection 
indicating that lumbar visceral afferents expressing GFRα1-IR are regulated 
differently by injury. This small effect of visceral nerve injury on afferent fibres 
expressing GFRα1 is in contrast to the widespread increase in GFRα1-IR that occurs 
in lumbar and sacral cord following sciatic nerve injury ((Keast et al., 2010); Chapter 
2). This was attributed to an increased number of DRG neurons synthesising GFRα1-
IR following injury and an increase in GFRα1 protein as detected by measuring the 
intensity of GFRα1 immunoreactivity in DRG neurons. Because of the smaller 
response after visceral nerve injury, we did not perform follow-up experiments to 
investigate if changes in GFRα1-IR fibres in spinal cord reflect changes in primary 
afferent neurons containing GFRα1-IR or any other GFR. The widespread effect of 
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 sciatic nerve injury on GFRα1-IR in the dorsal is likely to be related to the large 
number of afferent axons travelling in the sciatic nerve and their widespread 
terminations in the spinal cord (Swett and Woolf, 1985). The sciatic nerve in rats 
contains approximately 30,000 axons, almost three quarters of which are sensory 
(Schmalbruch, 1986). In comparison, the pelvic and hypogastric nerves are smaller 
nerves, comprising fewer afferent axons (Morgan et al., 1986; Morgan et al., 1981). In 
cats, the number of axons travelling in the pelvic nerve varies between studies with 
some reporting that the pelvic nerve contains 1000 preganglionic axons (Nadelhaft et 
al., 1986; Nadelhaft et al., 1980), whereas Morgan et al. (1981) and Hulsebosch and 
Coggeshall (1982) report a total of approximately 5000 and 20,000 axons 
respectively, including both afferent and preganglionic axons. In guinea pigs, the 
hypogastric nerve comprises approximately 2000 axons with males having more than 
double the number of preganglionic axons than females (McLachlan, 1985). In cats, 
the number is much higher, with an estimate of 21,000 axons in the hypogastric nerve 
(Baron et al., 1985; Hulsebosch and Coggeshall, 1982). In rats, the pelvic nerve is 
reported to contain approximately 2,000 axons, three quarters of which are sensory 
(Hancock and Peveto, 1979b; Nadelhaft and Booth, 1984), whereas the hypogastric 
nerve comprises approximately 500 axons (Nadelhaft and McKenna, 1987). These 
earlier studies in rats on the number of axons in the pelvic and hypogastric nerves are 
likely to be underestimated as Gabella (1999) estimated that close to 8,000 axons 
reach the rat bladder alone. However, the smaller effect of visceral nerve injury on the 
central terminals examined in the current study compared to those observed following 
sciatic nerve injury ((Keast et al., 2010); Chapter 2) correlates with the smaller 
number of axons in the pelvic and hypogastric nerves that project to the spinal cord. 
Together these results suggest that GDNF signalling through GFRα1 may be altered 
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 in visceral afferent nerves after injury. It is also interesting to notice that the effect of 
transecting a visceral nerve did not produce such a widespread effect on GFRα1-IR 
fibres in the dorsal horn as chronic bladder inflammation observed by Forrest and 
Keast, 2008. Forrest and Keast (2008) report that the intensity of GFRα1-IR was 
increased in both the medial and lateral sacral dorsal horn following 
cyclophosphamide-induced bladder inflammation. These results indicate that 
prolonged inflammation, rather than direct injury to a visceral nerve is a stronger 
stimulus required to drive structural reorganisation or alterations in protein levels of 
GFRα1-IR in visceral afferent fibres.  
 
These observations raise the question of how and when GFRα1 could be activated in 
the spinal cord. The source of endogenous GDNF is not clear in the spinal cord, 
however many DRG neurons contain GDNF protein (Holstege et al., 1998; Jongen et 
al., 1999) and mRNA (Kashiba et al., 2003), that could potentially be released from 
their central terminals. In naïve animals, GFRα1-IR fibres from the LCP terminate in 
the region of the SPN, and with the exception of the small number of neurons in the 
SPN that express the receptor for GDNF (Forrest and Keast, 2008), the neurotrophic 
factors that are required for the support and maintenance of parasympathetic 
preganglionic neurons are unknown. These GFRα1-IR neurons have also been shown 
to contain NOS-IR (Forrest and Keast, 2008), a marker of parasympathetic 
preganglionic autonomic neurons (Vizzard et al., 1995). Other studies have 
demonstrated neurons in the thoracic IML express both Ret and GFRα1 mRNA 
(Schober et al., 1999), and a number of growth factor receptors including those for the 
neurotrophins are located on many sympathetic preganglionic neurons (Schober and 
Unsicker, 2001). GDNF is a pro-survival factor for injured sympathetic preganglionic 
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 neurons in the thoracic IML, which is mediated by GFRα1 (Schober et al., 1999). 
Following pelvic nerve transection, GFRα1-IR was increased in the SPN. This is 
likely to comprise an up-regulation of terminals, which appeared to have a larger 
terminal field, and an increase in the number of neurons containing GFRα1-IR. It is 
possible that injured GFRα1-IR fibres travelling in the LCP are up-regulating GFRα1 
or are sprouting in the region of the SPN. These axons could potentially release 
GDNF to stimulate regeneration of injured parasympathetic preganglionic neurons, or 
provide a mechanism for increased excitability of pelvic visceral pathways following 
injury. 
 
All parasympathetic preganglionic neurons innervating the pelvic ganglia are located 
in the SPN (Morgan et al., 1981) and would be axotomised by pelvic nerve 
transection. GFRα1-IR neurons were increased throughout the rostro-caudal extent of 
the SPN following pelvic nerve transection and a similar number were observed in 
this region after bilateral pelvic nerve transection. It is likely these neurons are up-
regulating GFRα1-IR following transection of their preganglionic axons. From our 
earlier study (Forrest and Keast, 2008), it is likely these additional GFRα1-IR neurons 
will also contain NOS-IR. A similar study was carried out by Vizzard et al., (1995), 
who demonstrated that NOS-IR neurons in the SPN are increased following excision 
of the pelvic ganglion; this would have removed pre- and post-ganglionic efferent 
input and lumbar and sacral afferent axons to the pelvic viscera. These were sacral 
preganglionic NOS-IR neurons rather than autonomic interneurons (Vizzard et al., 
1995). In the current study we also observed similar changes to GFRα1-IR in the SPN 
following bilateral hypogastric and pelvic nerve transection but no effect of unilateral 
hypogastric nerve injury. This suggests that changes in immunostaining following 
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 bilateral transections were likely to be attributed to axons travelling in the pelvic 
nerve, which is consistent with the lack of afferent axons travelling in the pelvic nerve 
projecting to lumbar cord and the location of sacral preganglionic neurons. 
 
In the current study, only a subpopulation of sacral preganglionic neurons upregulated 
GFRα1-IR after pelvic nerve transection. A recent study by Peddie and Keast (2011) 
demonstrated an induction of immediate early gene c-Jun and activated transcription 
factor 3 (ATF-3) in sacral preganglionic neurons ipsilateral to unilateral pelvic nerve 
injury. A decrease in choline acetyltransferase (ChAT), a marker of cholinergic 
preganglionic autonomic neurons was also found. These changes occurred in a 
subpopulation of preganglionic neurons suggesting that different subpopulations have 
different potentials for regeneration and susceptibility to injury. Since GFRα1-IR 
neurons in the SPN are likely to contain NOS-IR (see above), and nearly all NOS-IR 
preganglionic neurons are ChAT-positive (Dun et al., 1993), it would be interesting to 
ascertain if the up-regulated GFRα1-IR neurons in the current study are likely to 
down-regulate ChAT, or up-regulate c-Jun or ATF-3. However, the total number of 
GFRα1-IR neurons in the SPN after pelvic nerve transection are much lower than the 
number of neurons that down-regulate ChAT or up-regulate c-Jun or ATF-3 as 
reported by Peddie and Keast (2011). 
 
Following pelvic nerve transection, there was a small, localised reduction in GFRα2-
IR in the medial dorsal horn of lumbar cord. Visceral nerve transection (pelvic or 
hypogastric) had no other effect on GFRα2-IR fibres in any other spinal region 
examined. Afferent axons travelling in the pelvic nerve do not normally terminate in 
L1/2 segments, suggesting that a small amount of structural remodelling occurs in 
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 uninjured GFRα2-IR fibres. Structural reorganisation and sprouting has been reported 
to occur in uninjured preganglionic neurons following visceral nerve injury. De Groat 
and Kawatani (1989) demonstrated that following pelvic nerve injury, uninjured 
preganglionic axons travelling in the hypogastric nerve grow collateral branches to re-
innervate the parasympathetic postganglionic neurons that would normally be 
innervated by pelvic axons. Similar studies have also been performed after 
hypogastric nerve transection, demonstrating that injured sympathetic preganglionic 
neurons are re-innervated by uninjured parasympathetic preganglionic axons (Kihara 
et al., 1996). These arrangements are not observed in uninjured animals and are likely 
to serve as compensatory mechanisms for loss of functional connectivity. Similar 
studies showing structural reorganisation in uninjured afferent fibres in different 
spinal segments have not been performed. 
 
Following sciatic nerve injury, a decrease in GFRα2-IR occurs in lumbar cord, which 
is caused by a reduction of primary afferent neurons expressing GFRα2-IR (Keast et 
al., 2010). This contrasts with the lack of effect of either visceral nerve injury on 
GFRα2-IR fibres in lumbar or sacral spinal cord. This would indicate that visceral 
nerve injury has no effect on this sub-population of non-peptidergic afferent fibres or 
that GFRα2 is regulated differently by injury. Alternatively, few neurons innervating 
pelvic visceral organs may express GFRα2-IR. This has been demonstrated in sacral 
bladder-projecting neurons in the female rat, with less than 1% containing GFRα2-IR 
(Forrest and Keast, 2008). Results from the current study strongly correlate with the 
absence of GFRα2-IR in bladder afferent neurons. Other studies have demonstrated 
the presence of GFRα2-IR axons in the mouse bladder and vas deferens 
(Wanigasekara et al., 2004) but these were primarily autonomic axons. Neurturin 
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 mRNA is expressed in the bladder, penis, vas deferens and seminal vesicle of rats 
(Laurikainen et al., 2000) and GFRα2-IR is also expressed in penis-projecting 
autonomic neurons in the pelvic ganglia (Laurikainen et al., 2000). Despite these 
studies, it is not yet known if GFRα2 is expressed in other pelvic visceral afferents.  
 
3.4.2 General pattern of CGRP and GFRα3 in spinal cord and effect of injury 
CGRP is a marker of peptidergic C-fibres (Averill et al., 1995; Guo et al., 1999) and 
GFRα3-IR is expressed exclusively in a sub-population of these afferents (Bennett et 
al., 2006; Kalous et al., 2009). Approximately one third to half of all CGRP-IR 
neurons contain GFRα3-IR (Kalous et al., 2009) so that two different populations of 
CGRP-IR axons have been identified, GFRα3-positive and GFRα3-negative. 
Consistent with these reports, contralateral to either visceral nerve injury, GFRα3-IR 
fibres have a more restricted distribution pattern in the spinal cord when compared to 
CGRP-IR fibres. Recent studies from our laboratory have demonstrated that both 
peptidergic populations respond very differently to somatic nerve injury ((Keast et al., 
2010), Chapter 2) and spinal cord compression injury (Kalous et al., 2009). After 
unilateral pelvic nerve injury, we detected a reduction of CGRP-IR only in the lateral 
dorsal horn in sacral spinal cord. The reduction in CGRP-immunostaining indicates a 
decrease in smaller diameter and unmyelinated neurons, a degeneration of CGRP-IR 
axons, or a mixture of both events. The location of the decreased CGRP-IR matches 
the projection patterns of sacral afferent axons entering the dorsal horn that travel in 
the pelvic nerve (Morgan et al., 1981). The localised reduction in CGRP-IR suggests 
there was a selective degeneration of a sub-population of CGRP-IR axons and/or 
neurons that are more susceptible to injury than the rest of the population. Our study 
indicates this degeneration occurs in the CGRP-positive GFRα3-negative population, 
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 as pelvic nerve injury had no effect on GFRα3-IR fibres. Together these results 
suggest that artemin and NGF may contribute differently to plasticity and 
degeneration of afferent fibres following different injury conditions. It is also 
interesting that pelvic nerve injury increased non-peptidergic fibres labelled with 
GFRα1-IR in the SPN but had no effect on peptidergics labelled with CGRP. 
 
Small-medium diameter unmyelinated DRG neurons contain GFRα3-IR which 
primarily project to lamina I and to a lesser extent, to lamina II (Keast et al., 2010). In 
sacral spinal cord GFRα3-IR fibres are also present in the LCP, which terminate in, or 
just dorsal to the SPN. After unilateral pelvic nerve injury, GFRα3-IR was up-
regulated in the SPN. GFRα3-IR fibres terminating in this region surround 
preganglionic autonomic neurons (Forrest and Keast, 2008), and after pelvic nerve 
transection, these neurons are axotomised. One interpretation could be that GFRα3-IR 
axons travelling in the LCP are sprouting collaterals in the area of the SPN. Similar 
observations were made for GFRα3-IR in the SPN following bilateral pelvic and 
hypogastric nerve transections, whereas no effect of hypogastric nerve transection 
was detected. These results suggest that changes in immunoreactivity in the SPN are 
caused by pelvic nerve contributions only.  
 
3.4.3 Expression of RET 
GDNF family ligands require a specific GFR and the common tyrosine kinase, RET 
(rearranged during transfection) for signalling (Airaksinen and Saarma, 2002). Our 
results need to take into account the presence of RET and the effect of visceral nerve 
injury on its expression. Many studies have demonstrated RET-immunostaining in 
lamina II, where non-peptidergic C-fibre afferents are located (Casals-Diaz et al., 
137
 2009; Cavanaugh et al., 2009), and in neurons throughout the dorsal and ventral horn 
(Bennett et al., 1998; Jongen et al., 2007). Neurons in the thoracic IML have also 
been shown to express both RET and GFRα1 mRNA (Schober et al., 1999) 
suggesting that GDNF is required for the survival and differentiation of IML neurons. 
It is currently unknown if RET expression in spinal cord is altered following visceral 
nerve injury, but we cannot predict if it would closely match the pattern of GFR-
immunostaining after injury. The changes in GFR expression in the dorsal horn 
following sciatic nerve injury (Chapter 2) did not match reports in the literature of 
changes in RET-IR after the same type of injury. Therefore it is possible that RET-
immunolabelling underestimates the distribution of RET protein in spinal cord. 
 
3.4.4 Other effects of visceral nerve injury 
In the current study we found no effect of hypogastric nerve transection on the central 
projections of all populations of non-peptidergic and peptidergic afferent fibres 
examined. The simplest explanation of this is that the central terminals of lumbar 
visceral GFR- and CGRP-IR neurons are not affected by transection of their 
peripheral axons. It is also possible that lumbar visceral afferents expressing CGRP 
and the GFRs are regulated differently by injury than sacral visceral afferents. We 
have not ruled out that phenotypic change occurs in lumbar primary afferent neurons 
or changes in their protein levels occur, but if they do, they do not occur in parallel 
with their central terminals. It is also possible that injury does cause small changes of 
protein levels in lumbar visceral axons that express GFR- and CGRP-IR but were not 
detected by our method of analysis.  
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 In sacral cord, preganglionic neurons innervating the pelvic ganglia are located in the 
SPN in L6/S1 spinal segments (Hancock and Peveto, 1979b; Morgan et al., 1981) and 
by cutting the pelvic nerve, axotomised neurons will only be found in this region. At 
this spinal level, there is also substantial sensory innervation of sacral preganglionic 
neurons with GFRα1-, GFRα3- and CGRP-IR fibres travelling in the LCP terminating 
just dorsal to, or in the SPN. In lumbar cord, the circuitry is quite different. The 
majority (>80%) of sympathetic preganglionic neurons innervating the pelvic ganglia 
are located in the DGC in L1/2 spinal segments (Hancock and Peveto, 1979b), 
therefore after cutting the hypogastric nerve, axotomised axons and neurons were 
likely to be found in this region, whereas fewer sympathetic preganglionic axons are 
found in the IML (Hancock and Peveto, 1979b). In comparison to sacral cord, sensory 
fibres labelled with CGRP and the GFRs are absent or very sparse in both lumbar 
autonomic regions. After axotomy of lumbar afferent and sympathetic preganglionic 
axons we found no noticeable up-regulation of any of these markers in the lumbar 
IML. However, we cannot rule out that a change did occur in sympathetic 
preganglionic neurons or sensory fibres innervating these neurons, but it is likely this 
occurred in other populations not expressing CGRP or the GFRs. 
 
3.4.5 Conclusions 
We have demonstrated that injury to visceral nerves produce different effects on the 
central distribution of afferent fibres containing the GFRs and CGRP when compared 
to a somatic nerve injury. We have also shown that injury to different visceral nerves 
produce different outcomes on the protein levels of peptidergic and non-peptidergic 
afferent fibres travelling within these nerves. These alterations could reflect different 
mechanisms of altered nociceptive responses following damage to a visceral or 
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 somatic nerve, or their regenerative capabilities after injury. Our results also suggest 
that GDNF could be a potential regenerative molecule for injured sacral preganglionic 
neurons.  
 
3.5 Chapter 3 tables and figures 
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Pelvic nerve transection Hypogastric nerve transection
Immunoreactivity
(spinal level)
location of area of 
interest
contralateral ipsilateral P value2 contralateral ipsilateral P value2, 4
GFRa1 sacral lateral dorsal horn 57.2 ± 6.9 61.7 ± 5.5 0.073 48.5 ± 2.6 46.8 ± 2.5 0.73
medial dorsal horn 50.3 ± 7.5 56.7 ± 6.9 0.04 42.3 ± 1.8 46.3 ± 0.9 0.23
SPN5 28.7 ± 5.7 36.2 ± 4.5 0.01 21.3 ± 1.4 22.2 ± 1.7 0.77
lumbar lateral dorsal horn 57.3 ± 3.0 59.7 ± 1.9 0.364 49.5 ± 2.1 52.2 ± 3.4 0.25
medial dorsal horn 53.9 ± 3.5 54.6 ± 2.4 0.75 51.1 ± 2.8 49.5 ± 2.5 0.45
GFRa2 sacral lateral dorsal horn 64.3 ± 1.6 64.3 ± 1.9 0.973 49.8 ± 4.1 45.7 ± 6.7 0.50
medial dorsal horn 63.6 ± 1.7 64.3 ± 2.4 0.74 51.6 ± 3.3 49.4 ± 4.3 0.38
lumbar lateral dorsal horn 66.1 ± 2.7 63.5 ± 1.6 0.384 65.3 ± 2.9 63.7 ± 2.8 0.64
medial dorsal horn 59.9 ± 2.3 57.3 ± 2.4 0.02 60.3 ± 1.8 58.3 ± 3.1 0.45
CGRP sacral lateral dorsal horn 39.7 ± 5.3 31.6 ± 5.9 0.013 29.9 ± 3.5 32.1 ± 3.6 0.56
medial dorsal dorn 30.9 ± 3.1 29.0 ± 3.5 0.26 27.8 ± 2.2 30.4 ± 3.5 0.28
SPN 16.8 ± 1.3 12.9 ± 2.3 0.12 15.9 ± 2.1 17.7 ± 1.3 0.28
lumbar lateral dorsal horn 38.5 ± 4.4 31.8 ± 2.2 0.304 32.9 ± 2.8 34.7 ± 3.0 0.38
medial dorsal horn 22.0 ± 1.9 20.7 ± 1.2 0.58 24.3 ± 2.2 23.4 ± 1.7 0.21
GFRa3 sacral lateral dorsal horn 58.7 ± 5.5 60.9 ± 4.3 0.293 33.9 ± 2.8 36.6 ± 1.8 0.37
medial dorsal horn 52.6 ± 3.4 56.6 ± 3.3 0.13 24.6 ± 2.5 25.7 ± 1.7 0.47
SPN 24.9 ± 1.4 29.8 ± 2.1 0.02 17.5 ± 0.8 18.3 ± 1.2 0.12
lumbar lateral dorsal horn 43.3 ± 1.4 42.5 ± 0.9 0.694 47.9 ± 5.4 44.9 ± 4.5 0.63
medial dorsal horn 31.4 ± 1.4 32.6 ± 0.9 0.27 34.8 ± 4.2 32.9 ± 4.1 0.49
Table 3.1 Optical density (± SEM) of GDNF-family receptor (GFR)-alpha immunoreactivity in sacral (L6/S1) and lumbar (L1/2) spinal cord segments 
following unilateral visceral nerve transection1
1: For each rat a single estimate of the optical density expressed in arbitrary units was obtained by averaging measurements from six sections per rat. 
2: Ipsilateral vs contralateral (P values obtained from Paired t-test). 3, 4: n = 6 or 4, respectively. 5: SPN, sacral preganglionic nucleus.
Figure 3.1 Areas of interest (AOIs) used for densitometric image analysis of GFRα1, 
GFRα2, GFRα3- and CGRP-immunoreactivity (IR) in the superficial dorsal horn in 
lumbar and sacral spinal cord and sacral preganglionic nucleus (SPN) overlaid on a 
micrograph showing CGRP-IR. AOIs 1 and 2 had dimensions 130 x 130 μm and were 
aligned with the medial and lateral margins of the superficial dorsal horn. Two AOIs 
(boxes 1 and 2) were assessed for GFRα1, GFRα2, GFRα3 and CGRP in the sacral 
and lumbar superficial dorsal horn. An additional AOI (circle 3, diameter 250 μm) in 
the SPN was assessed for GFRα1, GFRα3 and CGRP. Image also shows location of 
the dorsal grey commissure (DGC), lateral collateral pathway (LCP) and the lateral 
spinal nucleus as indicated by the asterisks. Scale bar represents 200 μm. CGRP, 
calcitonin gene-related peptide; GFR, GDNF family receptor.
1
2
3
SPN
DGC
LCP *
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Figure 3.2 Distribution of GFRα1-immunoreactivity (IR) in sacral and lumbar spinal 
cord following visceral nerve transection. For each type of injury, images were taken 
from left and right sides of the same section, and segments of each spinal level from 
the same animal. a-l: Images of GFRα1-IR in transverse sections through sacral 
(L6/S1) and lumbar (L1/2) dorsal horn 7 days after unilateral pelvic nerve transection 
(a-d), unilateral hypogastric nerve transection (e-h) or bilateral pelvic and hypogastric 
nerve transection (i-l). GFRα1 optical density measurements in spinal cord sections 
from unilateral pelvic nerve transected animals are shown in m, whereas data from 
unilateral hypogastric nerve transected animals are shown in n. m: No effect of injury 
was detected in the sacral lateral dorsal horn whereas a significant increase of GFRα1-
IR was observed in the medial dorsal horn and SPN ipsilateral to injury. No effect of 
injury on GFRα1-IR was detected in lumbar spinal cord. n: Hypogastric nerve 
transection had no effect on GFRα1-IR in sacral or lumbar spinal cord. Data 
represents the mean ± SEM (n = 6 rats for sacral data for unilateral pelvic nerve 
transection and n = 4 rats for lumbar unilateral pelvic nerve transection and unilateral 
hypogastric nerve injury), analysed by a paired t-test. SPN (L6/S1) is indicated with 
arrowheads (a, b, e, f, i, j). Scale bar in panel A = 200 μm (applies to all). GFR, 
GDNF family receptor.
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h i
d contra e ipsi f g
a contra ipsi
b contra c ipsi
Figure 3.3 Distribution of GFRα1-immunoreactivity (IR) in the sacral preganglionic 
nucleus (SPN) following unilateral and bilateral pelvic nerve transection. For each 
type of injury, images were taken from left and right sides of the same section. a: 
Horizontal image through the SPN following unilateral pelvic nerve transection. b, c: 
GFRα1-IR in the SPN on the contralateral (b) and ipsilateral (c) side following 
unilateral pelvic nerve transection. d, e: Higher magnification through the SPN in a 
horizontal section demonstrating GFRα1-IR following unilateral pelvic nerve 
transection. f, g: GFRα1-IR in the SPN following bilateral pelvic nerve transection. h, 
i: GFRα1-IR somata in the SPN on the ipsilateral side to unilateral pelvic nerve 
transection. Scale bar in A = 100 µm; 50 µm in B (applies b, c); 50 µm in D (applies 
d-g); 50 µm in H (applies h, i). GFR, GDNF family receptor. 
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Figure 3.4 Distribution of GFRα2-immunoreactivity (IR) in sacral and lumbar spinal 
cord following visceral nerve transection. For each type of injury, images were taken 
from left and right sides of the same section, and segments of each spinal level from 
the same animal. a-l: Images of GFRα2-IR in transverse sections through the sacral 
(L6/S1) and lumbar (L1/2) dorsal horn 7 days after unilateral pelvic nerve transection 
(a-d), unilateral hypogastric nerve transection (e-h) or bilateral pelvic and hypogastric 
nerve transection (i-l). GFRα2 optical density measurements in spinal cord sections 
from unilateral pelvic nerve transected animals are shown in m, whereas data from 
unilateral hypogastric nerve transected animals are shown in n. m: Injury had no 
effect on GFRα2-IR in sacral dorsal horn. A decrease in GFRα2-IR was observed in 
the medial, but not lateral dorsal horn in lumbar spinal cord following pelvic nerve 
transection. n: Hypogastric nerve transection had no effect on GFRα2-IR in sacral or 
lumbar dorsal horn. Data represents the mean ± SEM (n = 6 rats for sacral data 
unilateral pelvic nerve transection and n= 4 rats for lumbar unilateral pelvic nerve 
transection and unilateral hypogastric nerve transection), analysed by a paired t-test. 
Scale bar in panel A = 200 μm (applies to all). GFR, GDNF family receptor.
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Figure 3.5 Distribution of CGRP-immunoreactivity (IR) in sacral and lumbar spinal 
cord following visceral nerve transection. For each type of injury, images were taken 
from left and right sides of the same section, and segments of each spinal level from 
the same animal. a-l: Images of CGRP-IR in transverse sections through the sacral 
(L6/S1) and lumbar (L1/2) dorsal horn 7 days after unilateral pelvic nerve transection 
(a-d), unilateral hypogastric nerve transection (e-h) or bilateral pelvic and hypogastric 
nerve transection (i-l). CGRP optical density measurements in spinal cord sections 
from unilateral pelvic nerve transected animals are shown in m, whereas data from 
unilateral hypogastric nerve transected animals are shown in n. m: A decrease of 
CGRP-IR was observed in the sacral lateral but not medial dorsal horn or SPN 
following pelvic nerve transection. No effect of injury on CGRP-IR was detected in 
lumbar cord. n: Hypogastric nerve transection had no effect on CGRP-IR in sacral or 
lumbar spinal cord. Data represents the mean ± SEM (n = 6 rats for sacral data for 
unilateral pelvic nerve transection and n = 4 rats for lumbar unilateral pelvic nerve 
transection and unilateral hypogastric nerve injury), analysed by a paired t-test. SPN 
(L6/S1) is indicated with arrowheads (a, b, e, f, i, j). Scale bar in panel A = 200 μm 
(applies to all). GFR, GDNF family receptor.
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Figure 3.6 Distribution of GFRα3-immunoreactivity (IR) in sacral and lumbar spinal 
cord following visceral nerve transection. For each type of injury, images were taken 
from left and right sides of the same section, and segments of each spinal level from 
the same animal. a-l: Images of GFRα3-IR in transverse sections through the sacral 
(L6/S1) and lumbar (L1/2) dorsal horn 7 days after unilateral pelvic nerve transection 
(a-d), unilateral hypogastric nerve transection (e-h) or bilateral pelvic and hypogastric 
nerve transection (i-l).  GFRα3-IR optical density measurements in spinal cord 
sections from unilateral pelvic nerve transected animals are shown in m, whereas data 
from unilateral hypogastric nerve transected animals are shown in n. m: No effect of 
injury on GFRα3-IR was observed in the sacral dorsal horn whereas GFRα3-IR was 
increased in the SPN. No effect of injury on GFRα3-IR was detected in lumbar spinal 
cord. n: Hypogastric nerve transection had no effect on GFRα3-IR in sacral or lumbar 
spinal cord. Data represents the mean ± SEM (n = 6 rats for sacral data for unilateral 
pelvic nerve transection and n = 4 rats for lumbar unilateral pelvic nerve transection 
and unilateral hypogastric nerve injury), analysed by a paired t-test. SPN (L6) is 
indicated with arrowheads (a, b, e, f, i, j). Scale bar in panel A = 200 μm (applies to 
all). GFR, GDNF family receptor.
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Figure 3.7 Distribution of GFRα3-immunoreactivity (IR) in the sacral preganglionic 
nucleus (SPN) following unilateral and bilateral pelvic nerve transection. For each 
type of injury, images were taken from left and right sides of the same section. a: 
Horizontal image through the SPN following unilateral pelvic nerve transection. b, c: 
GFRα3-IR in the SPN on the contralateral (b) and ipsilateral (c) side following 
unilateral pelvic nerve transection. d, e: Higher magnification through the SPN in a 
horizontal section demonstrating GFRα3-IR following unilateral pelvic nerve 
transection. f, g: GFRα3-IR in the SPN following bilateral pelvic nerve transection. h, 
i: GFRα3-IR axons formed dense clusters in the SPN. Scale bar in A = 100 μm; 50 
μm in B (applies b, c); 50 μm in D (applies d-g); 50 μm in H (applies h, i). GFR, 
GDNF family receptor.
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CHAPTER 4: Characterisation of bladder afferent neurons 
 
4.1 Introduction 
Visceral pain is one of the most frequent types of pain seen in the clinical setting. It is 
poorly localised, associated with referred pain, and is resistant to many analgesics that 
alleviate somatic pain (Cervero and Laird, 1999; Cervero and Laird, 2004; 
Giambererdino, 1999). Animal models of acute and chronic bladder inflammatory 
pain show alterations in structural, neurochemical and electrophysiological properties 
of bladder afferent pathways (Callsen-Cencic and Mense, 1997; Qiao and Vizzard, 
2002; Vizzard, 2001; Yoshimura and de Groat, 1999). These changes can contribute 
to increased pain sensation and nociceptor sensitisation. 
 
Bladder inflammatory pain in rodents induced by administration of cyclophosphamide 
(CYP) initiates alterations in neuropeptide expression in sacral spinal cord, bladder 
afferent neurons and their terminals in the bladder contributing to hyperreflexia and 
pain. Numerous reports suggest nitric oxide (NO) synthase (NOS) plays an important 
role in visceral afferent pathways. During acute and chronic inflammation, NOS and 
calcitonin gene-related peptide (CGRP), a marker of peptidergic neurons and C-
fibres, are upregulated in bladder afferent neurons (Callsen-Cencic and Mense, 1997; 
Vizzard et al., 1996). Up-regulation of NOS also occurs in the sacral preganglionic 
nucleus (SPN) (Vizzard et al., 1996), an area containing autonomic preganglionic 
neurons that innervate the bladder, reproductive organs and lower bowel (Morgan et 
al., 1981). Other studies have demonstrated an increase of the immediate early Fos in 
lumbar and sacral spinal cord following acute CYP treatment (Vizzard, 2000a; 
Vizzard et al., 1996), demonstrating altered spinal signalling during inflammation. In 
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addition, CGRP-immunoreactive (IR) axons undergo sprouting in the bladder during 
chronic bladder inflammation (Dickson et al., 2006). These changes correspond to 
altered reflex behaviours including increased voiding frequency and a reduction in 
micturition threshold characteristic of bladder inflammation (McMahon et al., 1995). 
Despite these studies, sub-populations of bladder afferent neurons and terminals that 
may be susceptible to injury or physically remodel during inflammation are not 
known. 
 
Lumbar (L1/2) and sacral (L6/S1) dorsal root ganglia (DRG) contain the majority of 
afferent neurons innervating the urinary bladder (Keast and de Groat, 1989). Bladder 
afferent neurons comprise small-diameter (<23 µm) C-type and medium-diameter 
(23-32 µm) Aδ-type neurons (Lawson et al., 1984; Robinson and Gebhart, 2008). 
These neurons have axons projecting to the lumbar and sacral superficial dorsal horn, 
and also project to the bladder via the lumbar splanchnic, hypogastric nerves and 
sacral pelvic nerves respectively (Yoshimura, 1999). Bladder afferent neurons can be 
broadly characterised on the basis of their neuropeptide and estrogen receptor (ER) 
content, and responsiveness to neurotrophic factors. The majority of bladder afferent 
neurons are peptidergic and contain CGRP (Bennett et al., 1996; Bennett et al., 2003; 
Callsen-Cencic and Mense, 1997), and express receptors for nerve growth factor 
(NGF). Most of these neurons are nociceptors and also express substance P (SP) and 
transient receptor potential vanilloid 1 (TRPV1) (Bennett et al., 1996; Kiasalari et al., 
2010).  
 
Approximately 20-40% of bladder afferent neurons do not contain CGRP or other 
neuropeptides (Bennett et al., 2003; Keast and De Groat, 1992; Vizzard, 2001) and 
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are referred to as the non-peptidergic population. Many non-peptidergic DRG neurons 
are regulated by the glial cell line-derived neurotrophic factor (GDNF) family of 
ligands (GFL) and express receptors for GDNF (GFRα1) and neurturin (GFRα2)  
(Bennett et al., 1998; Forrest and Keast, 2008). However, the receptor for artemin, 
GFRα3, a member of the GFLs is expressed in a sub-population of peptidergic 
nociceptors (Orozco et al., 2001). Studies in DRG neurons have demonstrated that 
members of the GFLs have pro-nociceptive effects where GDNF and artemin have 
been shown to contribute to nociceptor sensitisation and hyperalgesia (Elitt et al., 
2006; Malin et al., 2006). A more recent study demonstrated that the GFLs have the 
ability to potentiate the response to capsaicin and mustard oil that is specific to 
different afferents innervating the skin, muscle and colon (Malin et al., 2011). 
Artemin is also likely to contribute to the development and maintenance of colorectal 
hypersensitivity (Tanaka et al., 2011). GDNF levels in the bladder are also increased 
during bladder inflammation (Vizzard, 2000b). Together these results indicate that 
GDNF and artemin may be involved in the sensitisation and plasticity of pelvic 
visceral pathways.  
 
Many sacral bladder afferent neurons contain GFRα1 and GFRα3 (Forrest and Keast, 
2008) and this study also demonstrated that each GFR had distinct central projection 
patterns in sacral spinal cord, suggesting that each GFR has a different function and 
supraspinal connectivity. Following chronic bladder inflammation, the intensity of 
GFRα1 immunolabelling increased in the dorsal horn (Forrest and Keast, 2008), 
suggesting structural remodelling (e.g., sprouting), increased receptor expression or 
increased trafficking of receptor to central terminals. Together these results indicate 
these neurotrophic factors may be involved in the maintenance of physiological and 
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structural properties of bladder neurons expressing their receptors and mediate 
plasticity of sacral visceral afferent neurons following inflammation. The effect of 
inflammation on bladder afferent neurons containing the GFRs has not been directly 
examined and is unknown. 
 
The majority of bladder afferent neurons contain ER (Bennett et al., 2003), and 
studies from our laboratory have shown that estradiol acts directly on DRG neurons to 
reduce TRPV1 activation by capsaicin (Xu et al., 2008). This study suggests that 
pelvic pain may be influenced by modulation of ERs in DRG neurons. Hormonal 
status can influence the development and severity of a number of pelvic visceral pain 
conditions including interstitial cystitis (Cheng and Keast, 2009; Robbins et al., 2010; 
Sanoja and Cervero, 2008; Warren et al., 2011). Bladder activity is also influenced by 
changes in estrogen exposure (Dmitrieva and Berkley, 2005; Sato et al., 1989). It is 
not known if GFR-IR bladder afferent neurons are likely to be targeted by circulating 
estrogens. In this study, we utilised two different ERα antibodies, the first purchased 
from Affinity, has been used by our laboratory (Bennett et al., 2003). The second 
from Millipore, has been reported to label a different population of neurons (Kiasalari 
et al., 2010). In this study, the two different ERα antibodies were named according to 
their manufacturer; ERα (Affinity) and ERα (Millipore). 
 
In this study our first aim was to characterise bladder afferent neurons in the context 
of two molecular families known to modulate nociceptor behaviour: neurotrophic 
factors and estrogens. The distributions of the GFRs were also investigated in upper 
lumbar spinal cord (a site of bladder afferent projection), using an anatomical marker 
of the superficial laminae to allow visualisation of potentially distinct distribution 
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patterns. Our second aim was to further characterise the impact of bladder 
inflammation on various populations of bladder afferent neurons. First, we 
determined if upregulation of GFRα1 following chronic bladder inflammation was 
localised to sacral spinal cord or if changes in lumbar cord also occur. In parallel, 
sacral and lumbar DRGs were analysed to determine if changes in spinal cord 
following chronic inflammation reflect alterations in GFR expression in DRG 
neurons. We also determined if chronic bladder inflammation alters the structure and 
distribution of axons containing GFRα3-IR in the bladder, and how these compare to 
other classes of sensory and autonomic axons. We did not include other GFRs in this 
aspect of the study because an early pilot study found that GFRα1 antibodies failed to 
detect axons in the bladder and few GFRα2-IR axons were expected, as less than 1% 
of bladder afferent neurons contain GFRα2-IR (Forrest and Keast, 2008).  
 
In the final part of this study, activated transcription factor 3 (ATF-3) expression was 
studied in bladder afferent neurons. ATF-3 can be induced in a variety of tissues 
following nerve injury, application of noxious chemical stimuli and cellular stress 
(Hai and Hartman, 2001; Hai et al., 1999; Peddie and Keast, 2011; Tsujino et al., 
2000). The majority of studies consider ATF-3 to be a marker of injured neurons, 
commonly studied after axotomy (Dominguez et al., 2010; Hunt et al., 2012; 
Shortland et al., 2006). Other studies have demonstrated that ATF-3 can also be up-
regulated in models of joint inflammation (Christianson et al., 2010) and partial 
urethral obstruction (Xu et al., 2010). We therefore investigated if acute bladder 
inflammation induces ATF-3 expression in sacral and lumbar DRGs and, if so, if this 
occurred in a particular chemical class. If so, this could identify a population of 
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bladder afferent neurons that are injured and subsequently undergoing structural 
remodelling following the transient urothelial cell loss associated with inflammation.  
 
4.2 Methods 
4.2.1 Animals 
All procedures were approved by Animal Care and Ethics Committees of the 
University of Sydney and Royal North Shore Hospital, as required by the Australian 
Code of Practice for the Care and Use of Animals for Scientific Purposes (National 
Health and Medical Research Council of Australia). Forty-two adult female Sprague 
Dawley rats (6-10 weeks) were used for these experiments. These comprised: 24 for 
retrograde tracer injections into the bladder (4 for chronic CYP treatment, 3 for acute 
CYP treatment, 17 for control); 16 for bladder wholemounts (8 for chronic CYP 
treatment, 8 for controls) and 2 naïve rats for double labelled immunohistochemistry 
in the spinal cord. All rats were purchased from the Animal Resources Centre 
(Murdoch, WA, Australia), and housed under a 12 h light-dark cycle with free access 
to food and water. 
 
4.2.2 Retrograde tracer injections and animal treatments 
To identify bladder-projecting afferent neurons in sacral and lumbar DRG, the 
retrograde tracer Fluorogold (FG, 4% in sterile saline; Fluorochrome, Englewood, 
CO) or Fast Blue (FB, 5% in sterile saline, Polyloy, Gross Umstadt, FRG) was 
injected (total <10 µl) into approximately 8 sites in the urinary bladder base (Figure 
4.1a) using an insulin syringe with a 30G needle under isoflurane anaesthetic (3% for 
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induction, 1.5-2% for maintenance in O2) as previously described (Forrest and Keast, 
2008).  
 
Animals for retrograde tracing studies only were perfused 7 days after surgery (Group 
1). Animals undergoing chronic bladder inflammation (Group 2) were allowed to 
recover for 3-4 days following retrograde tracer injections before being briefly re-
anaesthetised with isoflurane (3% for induction) and treated with CYP or saline 
(SAL) (see below). Animals for the acute bladder inflammation study (Group 3) were 
allowed to recover from retrograde tracer surgery for 7 days before treatment with 
CYP or SAL (see below). 
 
To administer CYP, animals were briefly anaesthetised with isoflurane (as above). 
The chronic treated group (Group 2) were injected with CYP (75 mg/kg in sterile 
saline i.p) or SAL (1 ml/kg i.p) every third day for ten days, and perfused on day ten 
of treatment. The acute treated group (Group 3) received a single dose of CYP (75 
mg/kg in sterile saline i.p.) or SAL (1 ml/kg i.p.) and were perfused 24 hours later.  
 
4.2.3 Tissue fixation and dissection 
Rats were heavily anaesthetised with sodium pentobarbitone (80 mg/kg i.p) and 
transcardially perfused with 0.9% saline containing 1.25% sodium nitrite and 0.036% 
heparin, followed by freshly made 4% paraformaldehyde in 0.1M phosphate buffer 
(PB, pH 7.4). Spinal cords, DRGs and bladders were removed and post-fixed 
overnight in the same fixative at 4°C, then washed in 0.1M phosphate buffered saline 
(PBS, pH 7.2) and stored in PBS containing 0.1% sodium azide until sectioning. 
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Bladders from SAL and chronic CYP-treated animals were quickly blot dried and 
weighed as an indicator of inflammation, before being placed back into PBS azide. 
 
4.2.4 Immunohistochemistry 
4.2.4.1 Double-labelled spinal cord 
For spinal cord sections, L1/2 spinal segments from chronic CYP and SAL treated 
animals were cut into 40 µm transverse sections on a cryostat in a 1 in 4 series so that 
sections processed for the same substance were sampled at least 160 µm apart and 
processed simultaneously for free-floating immunohistochemistry. Sections were 
washed in PBS and blocked for two hours in PBS containing 10% normal horse 
serum (NHS) and 0.5% triton X-100. After washing, sections were incubated for 48 
hours in NOS with CGRP, GFRα1, GFRα2 or GFRα3 antisera (Table 4.1). After 
washing off unbound primary antibodies, sections were incubated in appropriate host-
specific secondaries (Table 4.1) for four hours. Antibodies were made in PBS 
containing 2% NHS and 0.5% Triton X-100, the primary containing 0.1% sodium 
azide. Sections were mounted onto 0.1% gelatinised slides and coverslipped with 
buffered glycerol pH 8.6. All incubations were performed at room temperature on a 
shaker. 
 
4.2.4.2 Dorsal root ganglia 
Sacral (L6) and lumbar (L1) DRGs were cryoprotected overnight in PBS containing 
30% sucrose and cut on a cryostat into 14 µm sections. Sections were collected onto 
0.1% gelatinised slides and distributed between slides so that sections stained for the 
same substance were sampled at least 60 µm apart. Sacral and lumbar DRGs from 
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CYP and SAL treated animals were placed in the same cryomould so that for each 
CYP-treated DRG, there was the matched sacral or lumbar control DRG on the same 
slide. Sections were air-dried, washed in PBS and blocked for 1-2 hours in PBS 
containing 10% NHS and 0.1% triton X-100. DRG sections were incubated overnight 
in combinations of antisera (Table 4.1), washed and incubated for 2-3 hours in 
appropriate host-specific secondaries (Table 4.1). Antibodies were diluted with 0.1M 
hypertonic PBS pH 7.2 and all incubations were performed in a humid chamber, in 
the dark at room temperature. Slides were coverslipped with buffered glycerol. 
 
4.2.4.3 Bladder sections 
The base of the bladder was dissected and cryoprotected overnight in PBS containing 
30% sucrose and cut horizontally into rings on a cryostat into 14 µm sections. Bladder 
base sections from SAL and CYP treated animals were placed in the same cryomould 
and processed simultaneously using the same method as described for DRG 
immunohistochemistry. Bladder sections were incubated overnight in ED-1 antisera 
(Table 4.1) with the host-specific fluorescent secondary antibody. The bladder base 
was selected as peptidergic afferent axons in the detrusor and suburothelial plexus are 
prevalent in this region (Gabella and Davis, 1998). In addition, peptidergic axons 
undergo sprouting in the bladder base following chronic bladder inflammation 
(Dickson et al., 2006). 
 
4.2.5 Preparation of bladder wholemounts 
In a separate group of naïve rats and chronic CYP-treated animals, the bladder was 
removed for wholemount preparation. Rats were heavily anaesthetised with sodium 
pentobarbitone (80 mg/kg i.p.) and perfused transcardially with 350 ml prewash 
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(0.9% saline containing 1.25% sodium nitrite and 0.036% heparin). The bladder was 
removed and placed in a Petri dish containing prewash. The bladder was bisected 
longitudinally on the dorsal side, i.e. between the ureters. The bladder was then 
pinned out flat on a Sylgard-lined Petri dish with the urothelial surface facing 
upwards and stretched out making a circle. The prewash was replaced with freshly 
made 4% paraformaldehyde in PB and post-fixed overnight at 4°C. The following 
day, the pins were removed and bladders washed in PB. The border of the bladder 
where the pins were inserted was trimmed and the bladder cut into three longitudinal 
strips (Figure 4.1b) before being processed for immunohistochemistry or stored at 
4°C in PBS containing 0.05% thimerosol (PBS / thimerosol). 
 
4.2.6 Immunostaining wholemount preparations 
A similar single-labelled immunohistochemistry protocol was used as described 
previously (Llewellyn-Smith and Gnanamanickam, 2010). All washes were of a large 
volume (~50 ml) for at least 30 minutes and all incubations were performed on a 
shaker at room temperature. Bladder strips were washed in PB, then 50% ethanol 
followed by another wash in 50% ethanol containing 3% H202. Strips were then 
blocked for 30 minutes in PB containing 10% NHS before incubation with primary 
antisera for 5 days at room temperature. Primary antibodies were made in PB / 
thimerosol containing 10% NHS and 0.2% triton X-100. Large well plates containing 
1-2 ml of antibody solution were used for each bladder strip to ensure the antibody 
had good access to all surfaces of the wholemount and to prevent folding of the 
bladder strip. Antibodies used were: CGRP, GFRα3, NOS and NF200 (refer to Table 
4.1). After three washes in PB, bladder strips were incubated in appropriate biotin-
conjugated secondaries made in PB / thimerosol for 5 days at room temperature. 
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Following three washes in PB, bladder strips were incubated in avidin-biotin complex 
for 5 days at room temperature (6 µl / ml; Vectastain Elite kit; Vector Laboratories; 
Burlingame C.A). Bladder strips were then washed twice in PB followed by an 0.1M 
acetate buffer (pH 6.0) wash before a 20 minute incubation in DAB solution (0.2% D-
glucose, 0.04% ammonium chloride, 0.025% diaminobenzidine / 100 ml 0.1M acetate 
buffer pH 6.0, 2% nickel sulfate). A black reaction product was produced by adding 
glucose oxidase (0.002%) and the reaction stopped by three quick washes with acetate 
buffer. Bladder strips were washed twice in PB before being mounted onto 0.1% 
gelatinised slides and air-dried overnight. Strips were washed twice in dH20 for 15 
minutes before being dehydrated in ascending concentrations of ethanol (two 15 
minute incubations in 30%, 50%, 70%, 90%, 95% and 100% ethanol) and cleared in 
histolene (two 15 minute incubations). Bladder strips were coverslipped with DPX 
water-free mounting media (Crown Scientific, Mulgrave, VIC, Australia). 
 
4.2.7 Spinal cord: Distribution and fibre density  
Spinal cord sections were viewed under an Olympus BX51 fluorescence microscope 
(Olympus Australia, Melbourne, Australia) and images captured with an RT SPOT 
camera (Diagnostic Instruments, Sterling Heights, MI) and digitised using Image Pro 
Plus (Media Cybernetics, Silver Spring, MD). Image analysis was performed on 8-bit 
unsaturated monochrome images (1600 x 1200 pixels). For each antibody, spinal cord 
sections were imaged using the same camera settings and exposure time for SAL and 
CYP treated animals, under a 10x objective. Pixel intensity was assessed in the areas 
of interest (AOIs, medial and lateral dorsal horn, 130 x 130 µm; Figure 4.2). For each 
antibody the pixel intensity was averaged to obtain a single value for each AOI in 
each rat. For quantitation of GFR intensity, images were obtained from six randomly 
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selected sections of L1/2 spinal cord from each animal. Control and CYP treated 
values were expressed as the mean ± SEM and compared via an un-paired t-test and 
results where P < 0.05, were regarded as statistically significant.  
 
4.2.8 DRGs: neuronal counts  
DRGs were viewed under the same Olympus BX51 fluorescence microscope and 
camera as above. To characterise bladder-projecting neurons, a minimum of 120 
nucleated profiles of FG-labelled neurons were counted from a total of five sections 
from each ganglion using a 40x objective. These neurons were classified on the basis 
of their expression with each of the GFRs, TRPV1, CGRP, ERα (both antibodies), 
NF200 and NOS. The percentage of FG neurons expressing each marker with a co-
marker in sacral and lumbar DRGs were averaged for each rat, and expressed as a 
percentage of all FG neurons. The arcsine transformed data from sacral and lumbar 
DRGs was compared using a paired t-test. The number of FG-labelled neurons 
containing CGRP, NOS and the GFRs following chronic CYP treatment in sacral and 
lumbar DRGs were compared by performing Tukey’s multiple comparison post-hoc 
test on arcsine transformed data. This was used to detect an effect of CYP treatment 
on the proportion of FG-labelled neurons expressing each of these markers and their 
co-expression, and a comparison between sacral and lumbar DRGs. The number of 
FG-labelled neurons containing ATF-3, NOS, CGRP, GFRα1 and GFRα3 in control 
and acute CYP-treated animals were compared in sacral and lumbar DRGs using a 
paired t-test on arcsine transformed data. All results are expressed as the mean ± SEM 
and P ≤ 0.05 were regarded as statistically significant. 
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4.2.9 Counts of axon terminals 
Axon terminals in bladder wholemounts were counted on a Zeiss Axio Imager.M1 
microscope (Munchen-Hallbergmoos, Germany). In this study, an axon terminal was 
defined as the point where a single axon ended in the suburothelial plexus or detrusor. 
This was determined for GFRα3 and CGRP in the suburothelial plexus and for CGRP 
only in the detrusor. For CGRP- and GFRα3-IR terminal counts in the suburothelial 
plexus in control and CYP-treated animals, the total number of endings per 500 µm2 
were counted in the bladder base. Bladder strips were subdivided under low 
magnification into three: base, middle and dome (Figure 4.1c). Under the 20x 
objective, a graticule was positioned at the top end of the lower third segment, 
representing the bladder base. The graticule was used as the grid and moved across 
the bladder base to make a row. The number of terminals in each area were counted 
across the bladder in rows and averaged for each rat. Two rows were counted, missing 
the second row to avoid potentially double counting terminals. The grey squares 
illustrate the AOIs in which axon terminals were counted (Figure 4.1c). The number 
of CGRP- and GFRα3-IR terminals in the suburothelial plexus in each rat were 
converted to mm2. The number of GFRα3- and CGRP-IR terminals in the 
suburothelial plexus from control and CYP treated animals were compared using a 
paired t-test and results where P < 0.05, were regarded as statistically significant. The 
same method of counting was used for CGRP-IR axons in the detrusor; this was only 
performed in control rats.  
 
4.2.10 Counts and size measurement of intramural neurons 
The number of NOS- and NF200-IR somata in the detrusor were manually counted 
under a 20x objective in bladder wholemounts preparations using the same Zeiss 
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microscope as above. The area of bladder wholemount stained for NOS and NF200 
was calculated using ImageJ 1.45b software (from http://fiji.sc/wiki/index.php/Fiji) 
and the total number of somata were averaged for each rat and expressed as the mean 
± SEM / cm2. The number of NOS- and NF200-IR somata from control and CYP 
treated animals were compared using a paired t-test and results where P < 0.05, were 
regarded as statistically significant. 
 
To measure the size of NOS- and NF200-IR somata, images of neurons were captured 
from wholemount preparations when viewed under a 40x objective. The diameter 
along the longest axis was measured using ImageJ 1.45b software. The size of each 
soma was averaged for each rat and cell diameters expressed as the mean ± SEM. 
 
4.2.11 Figure production 
All immunofluorescent sections were visualised under an Olympus BX51 fluorescent 
microscope (above) and 8-bit monochrome images gathered using an RT Spot camera 
(Diagnostic Instruments, Sterling Heights, MI, USA). All bladder wholemounts were 
visualised under a Zeiss Axio Imager.M1 microscope and 8-bit monochrome images 
captured using an AxioCam MRm camera (Munchen-Hallbergmoos, Germany) and 
Axiovision 4.2 software. For figure production, no adjustments were made to grey-
scale images except for minor adjustments to brightness and contrast with the levels 
command in Adobe Photoshop CS2 (San Jose, CA) to best represent the staining as 
viewed directly under the microscope. Colourised merged images were produced by 
pasting grey-scale images into the appropriate colour channel of a 24-bit RGB file in 
Photoshop.  
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4.3 Results 
4.3.1 Distribution of TRPV1, CGRP and the GFRs in sacral and lumbar bladder-
projecting neurons 
To determine which chemical class(es) of bladder-projecting afferent neurons 
contained the GFRs, we first quantified the number of sacral and lumbar FG-labelled 
neurons expressing the GFRs with TRPV1, a marker of polymodal nociceptor 
neurons that is expressed by the majority of bladder afferent neurons (Bennett et al., 
2003). We also performed co-expression studies on GFRα3 with CGRP, a marker of 
peptidergic nociceptors (Orozco et al., 2001) that is expressed by 60-80% of bladder 
afferent neurons (Bennett et al., 1996; Bennett et al., 2003; Callsen-Cencic and 
Mense, 1997). Almost all CGRP-IR neurons contain TRPV1 (Kiasalari et al., 2010) 
and are a largely over-lapping population. Reports also show that GFRα3-IR is 
expressed in a sub-population of CGRP-IR neurons (Orozco et al., 2001). On this 
basis, we investigated GFRα3 expression in TRPV1- and CGRP-IR neurons. From 
the literature we hypothesised that GFRα1- and GFRα2-IR neurons will be expressed 
in non-peptidergic neurons (Bennett et al., 1998; Keast et al., 2010).  
 
Assessment of FG-labelled neurons in sacral DRG revealed 70.6 ± 3.1% contained 
TRPV1-IR and 54.2 ± 2.5% contained CGRP-IR (n = 4, Figure 4.3a-f, x). Consistent 
with previous reports (Forrest and Keast, 2008; Keast et al., 2010), GFRα1-IR was 
observed in numerous DRG neurons of all sizes, where it was present in the plasma 
membrane and cytoplasm (Figure 4.3h). Small-medium sized DRG neurons were 
found to express GFRα2-IR, with strong immunoreactivity in the plasma membrane 
(Figure 4.3k). GFRα3-IR was observed in numerous DRG neurons of small-medium 
size with strong immunoreactivity in the plasma membrane and cytoplasm (Figure 
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4.3n). Bladder afferent neurons comprise small-diameter (<23 µm) C-type and 
medium-diameter (23-32 µm) Aδ-type neurons. Large diameter neurons (>32 µm) 
containing Aα- and Aβ- fibres do not project to the bladder (Lawson et al., 1984; 
Robinson and Gebhart, 2008). Quantification of FG-labelled neurons revealed that 
20.4 ± 1.4% contained GFRα1-IR, <2% contained GFRα2-IR and 34.3 ± 3.0% 
contained GFRα3-IR (n = 4, Figure 4.3g-o, x). These proportions were similar to our 
previous publication in rat DRG (Forrest and Keast, 2008). Quantification of FG-
labelled neurons in lumbar DRG found similar proportions of the above markers as 
sacral DRG (n = 4; Figure 4.3x). Consistent with previous publications (Bennett et al., 
2003), we found a higher proportion of lumbar bladder afferent neurons containing 
CGRP-IR than sacral DRGs (54.2 ± 2.5% sacral vs. 67.7 ± 1.8% lumbar, n = 4, P < 
0.001, Figure 4.3x). 
 
We then investigated the co-expression of GFRα1-, GFRα3- and CGRP-IR neurons 
containing TRPV1-IR in sacral and lumbar bladder afferent neurons. Co-expression 
studies were not performed with GFRα2 as it was expressed in a very small number 
of bladder neurons. Quantification revealed that approximately one third of sacral and 
lumbar FG-labelled neurons immunostained with GFRα1-IR contained TRPV1-IR, 
and these comprised ~10% of all TRPV1-IR neurons (Figure 4.3y, z). Almost all 
GFRα3- and CGRP-IR neurons contained TRPV1-IR (Figure 4.3p-s, y). 
Approximately half of all TRPV1-IR neurons contained GFRα3-IR and the majority 
contained CGRP-IR (Figure 4.3z). FG-labelled neurons labelled with GFRα3 and 
CGRP revealed that in sacral DRGs, ~95% of GFRα3-IR neurons contained CGRP-
IR, and these comprised ~70% of all CGRP-IR neurons. In lumbar DRGs, ~95% of 
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GFRα3-IR neurons contained CGRP-IR, and these comprised ~60% of all CGRP-IR 
neurons (n = 4, Figure 4.3t-w, data not shown). 
 
4.3.2 Distribution of NF200-IR in sacral and lumbar afferent bladder-projecting 
neurons 
We next investigated if small myelinated, non-peptidergic neurons labelled with 
NF200 contained the GFRs. Previous studies have reported that just over half of all 
bladder afferent neurons express NF200-IR (Hayashi et al., 2009) but its distribution 
in different chemical classes is unknown. GFRα1 mRNA is expressed in small-
medium diameter unmyelinated, non-peptidergic neurons and many larger diameter 
myelinated DRG neurons (Bennett et al., 2000). Therefore, we hypothesised that 
GFRα1 was likely to be expressed in small, myelinated (non-peptidergic) neurons, 
labelled with NF200. NF200-IR neurons were also categorised according to their 
expression with the neuronal markers CGRP, NOS and both ERα antisera (as above). 
NOS has been reported to play an important role in visceral afferent pathways and is 
expressed in some bladder afferent neurons (Callsen-Cencic and Mense, 1997; 
Vizzard et al., 1995). We did not perform co-expression studies on the number of 
NF200-IR bladder afferent neurons containing GFRα3-IR. A high level of co-
expression was not expected as almost all GFRα3-IR neurons were found in the 
peptidergic population and contain CGRP-IR (above). 
 
NF200 labelled many DRG neurons with varying intensity. This labelling appeared to 
be localised to the endoplasmic reticulum (and possibly the Golgi apparatus). Many 
NF200-IR axons were also observed running through the DRG. Consistent with 
previous reports (Hayashi et al., 2009), we found just over half of all sacral and 
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lumbar bladder-projecting neurons contained NF200-IR (54.8 ± 1.6% sacral; 57.3 ± 
1.4% lumbar, n = 3). Qualitative assessment of sections showed many NOS-IR 
somata in each section, localised to medium sized neurons that labelled with varying 
intensity. Assessment of FG-labelled neurons revealed that in sacral DRGs, 45.9 ± 
1.5% contained NOS-IR and 46.6 ± 3.1% contained NOS in lumbar DRGs (n = 3). 
This is a much higher basal expression of NOS than previously reported (Callsen-
Cencic and Mense, 1997; Vizzard et al., 1995; 1996) and may reflect differences in 
antisera or differences in the labelling intensity that was regarded as positive 
immunoreactivity. Assessment of FG-labelled neurons in sacral and lumbar DRG 
showed a similar proportion contained CGRP and GFRα1 as reported above. 
Approximately one third of sacral and lumbar bladder afferent neurons contained ERα 
(Affinity), whereas less than 20% contained ERα (Millipore), see below for detailed 
characterisation of ER-IR neurons (section 4.3.3). 
 
To determine which chemical class of bladder afferent neurons contained NF200-IR, 
DRG sections were co-stained for NOS, CGRP, GFRα1 and both ERα’s.  
Quantification revealed that just over half of all sacral and lumbar NOS-IR neurons 
contained NF200-IR, and these comprised almost half of all NF200-IR neurons 
(Figure 4.4a-f). In sacral and lumbar DRGs, ~40% of CGRP-IR neurons contained 
NF200-IR and in lumbar DRGs, a higher proportion of NF200-IR neurons contained 
CGRP-IR than sacral DRGs (32.1 ± 2.0% sacral vs. 48.3 ± 4.4% lumbar (P = 0.02, n 
= 3). Approximately 80% of GFRα1-IR neurons in sacral and lumbar DRGs 
contained NF200-IR, and these comprised ~40% of all NF200-IR neurons (Figure 
4.4a, b, g-j). A higher proportion of ERα (Affinity)-IR neurons contained NF200-IR 
in sacral DRGs compared to lumbar DRGs (49.4 ± 4.1% sacral vs. 34.1 ± 2.1% 
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lumbar; n = 5, P = 0.05), and similarly, a higher proportion of NF200-IR neurons 
contained ERα (Affinity)-IR in sacral DRGs (25.8 ± 2.0% sacral vs. 17.4 ± 1.0% 
lumbar; n = 5, P = 0.03). Although ERα (Millipore) labelled a smaller proportion of 
neurons, similar patterns of co-expression were observed with this antibody as ERα 
(Affinity). A higher proportion of ERα (Millipore)-IR neurons contained NF200-IR in 
sacral DRGs compared to lumbar DRGs (50.0 ± 4.3% sacral vs. 8.9 ± 1.5% lumbar; n 
= 5, P = 0.02). A higher proportion of NF200-IR neurons also contained ERα 
(Millipore)-IR in sacral DRGs compared to lumbar neurons (17.6 ± 1.1% sacral vs. 
2.0 ± 0.5% lumbar; n = 5, P < 0.01, Figure 4.4a, b). 
 
4.3.3 Distribution of ERα in sacral and lumbar bladder-projecting neurons 
ERα-IR is primarily localised to the nuclear compartment of neurons as the majority 
of these receptors are localised in the nucleus with, or without circulating estrogens 
present (Hager et al., 2000). Like previous studies from our laboratory (Bennett et al., 
2003), we found that DRG sections immunostained with either ERα antibody labelled 
the nucleus of a subpopulation of neurons. In some ERα (Affinity)-positive neurons 
there was weak cytoplasmic staining. In all ERα-immunostained sections, neurons 
with a nucleus that was brighter than the cytoplasm were regarded as 
immunoreactive-positive. Assessment of FG-labelled neurons revealed that 29.6 ± 
3.9% contained ERα (Affinity) in sacral DRG and 39.4 ± 1.2% contained ERα 
(Affinity) in lumbar DRGs (n = 5, Figure 4.5a, b). We found a similar proportion of 
sacral and lumbar FG-labelled neurons containing GFRα1-, GFRα3-, CGRP- and 
TRPV1-IR as reported above (Figure 4.5a, b). We also found that ~60% of sacral and 
lumbar FG-labelled neurons were immunoreactive for NF200 (n = 5, Figure 4.5a, b,).  
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ERα (Affinity)-IR neurons were then categorised according to their co-expression 
with GFRα1, GFRα3, CGRP, TRPV1 and NF200. Approximately 40% of GFRα1-IR 
FG-labelled neurons in sacral and lumbar DRGs contained ERα (Affinity)-IR, and 
these comprised ~30% of all ERα (Affinity)-IR neurons (Figure 4.5c-h). Assessment 
of FG-labelled neurons revealed that few sacral GFRα3-IR neurons contained ERα 
(Affinity)-IR, compared to ~20% in lumbar DRG (n = 5, P = 0.01). This was also 
similar to the higher proportion of lumbar ERα (Affinity)-IR neurons containing 
GFRα3-IR (5.8 ± 2.3% sacral vs. 27.3 ± 3.6 lumbar; n = 5, P < 0.001, Figure 4.5c, d). 
Between 20-30% of all CGRP- and TRPV1-IR neurons contained ERα (Affinity)-IR 
in sacral and lumbar DRGs (Figure 4.4c, d). Approximately 30% of ERα (Affinity)-
IR neurons contained CGRP-IR (Figure 4.45i-l) and half contained TRPV1-IR 
(Figure 4.5d). Assessment of FG-labelled neurons revealed that ~25% of sacral 
NF200-IR neurons contained ERα (Affinity)-IR, compared to ~15% in lumbar DRGs 
(P = 0.03, n = 5).  This was also similar to the higher percentage of ERα (Affinity)-IR 
neurons containing NF200-IR in sacral DRGs compared to lumbar DRGs (P = 0.05, n 
= 5). 
 
ERα (Millipore) produced a similar pattern of immunoreactivity in the nucleus of 
DRG neurons as ERα (Affinity), however, this antibody labelled fewer bladder 
afferent neurons (17.9 ± 1.8% sacral vs. 13.5 ± 1.5% lumbar, n = 5, data not shown). 
In sacral DRG, co-expression studies revealed that ~25% of GFRα1-IR neurons 
contained ERα (Millipore)-IR, and these comprised half of all ERα (Millipore)-IR 
neurons. Less than 2% of GFRα3- and CGRP-IR neurons contained ERα (Millipore)-
IR, and these comprised <3% of all ERα (Millipore)-IR neurons. Approximately 20% 
of TRPV1-IR neurons contained ERα (Millipore)-IR, and these comprised half of all 
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ERα (Millipore)-IR neurons. Less than 10% of NF200-IR neurons contained ERα 
(Millipore)-IR, and these contained approximately one third of all ERα (Millipore)-IR 
neurons (n = 5, data not shown). In lumbar FG-labelled neurons, co-expression 
studies revealed that ~5% of GFRα1-IR neurons contained ERα (Millipore)-IR, and 
these comprised ~10 of all ERα2-IR neurons. Like sacral DRG, <2% of GFRα3- and 
CGRP-IR neurons contained ERα (Millipore)-IR. Less than 3% of ERα (Millipore)-
IR neurons contained GFRα3-IR and ~10% contained CGRP-IR. Approximately 15% 
of TRPV1 neurons contained ERα (Millipore)-IR, and these comprised ~70% of all 
ERα (Millipore)-IR neurons. Less than 5% of NF200-IR neurons contained ERα 
(Millipore)-IR, and these comprised ~20% of all ERα (Millipore)-IR neurons (n = 5). 
These studies revealed that not only does the ERα (Millipore) antibody label fewer 
bladder-projecting neurons, but also that it is rarely expressed in the peptidergic 
population. 
 
4.3.4 Effect of chronic cyclophosphamide on CGRP, NOS and GFR expression in 
sacral and lumbar bladder afferent neurons 
Animal studies of chronic bladder inflammation show alterations in structural, 
neurochemical and electrophysiological properties of bladder afferent pathways 
(Callsen-Cencic and Mense, 1997; Vizzard, 2001; Yoshimura, 1999). These changes 
are thought to be responsible for nociceptor sensitisation and bladder hyperactivity. 
Numerous reports suggest that NOS plays an important role in visceral afferent 
pathways. NOS is expressed in bladder afferent pathways and is up-regulated in 
spinal cord and bladder afferent neurons during inflammation (Callsen-Cencic and 
Mense, 1997; Vizzard et al., 1995; 1996), suggesting a role of nitric oxide in altered 
bladder reflexes and nociceptive responses. In this study, we investigated which 
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chemical class(es) of bladder neurons contain NOS-IR and how these are altered 
following chronic bladder inflammation. 
 
We used bladder weight, qualitative assessment of macroscopic bladder appearance 
and the presence of an inflammatory cell infiltrate in bladder sections as indicators of 
bladder inflammation. Following chronic CYP treatment, bladder weight was 
significantly increased compared to control animals (139.3 ± 7.0 mg control vs. 234.5 
± 15.3 mg CYP, P = 0.001). On macroscopic appearance, bladders from chronically 
inflamed animals looked red and contained many petechial haemorrhages, particularly 
in the base and middle of the bladder. To confirm bladder inflammation 
histologically, bladder sections from chronically inflamed and control rats were 
processed simultaneously with ED-1, a marker of inflammatory cell infiltrate 
(Vizzard, 2001). ED-1 is expressed by most tissue macrophages and monocytes and 
in control bladders, relatively few of these cells were observed in the detrusor (Figure 
4.6a) and mucosa (Figure 4.6b). Following chronic CYP treatment, there was an 
infiltration of inflammatory cells expressing ED-1 throughout the bladder (Figure 
4.6c) but this was most prominent in the mucosa (Figure 4.6d). 
 
Quantification of FG-labelled neurons in sacral and lumbar DRG revealed a similar 
proportion of neurons containing CGRP, NOS and the GFRs as reported above. We 
found a higher proportion of FG-labelled neurons contained CGRP- (42.9 ± 2.0% 
sacral vs. 76.2 ± 1.3% lumbar, n = 4, P < 0.001), NOS- (24.3 ± 5.0% sacral vs. 40.9 ± 
2.4% lumbar, n = 4, P < 0.01) and GFRα3-IR (27.0 ± 1.6 sacral vs. 51.0 ± 3.0% 
lumbar, n = 4, P < 0.01) in lumbar DRGs. Chronic CYP treatment did not alter the 
proportion of sacral and lumbar bladder afferent neurons expressing any of these 
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markers (GFRα1, GFRα3, CGRP, NOS) compared to control animals (Figure 4.7a, d). 
These studies suggest that changes in GFRα1-IR in the dorsal horn following chronic 
bladder inflammation (Forrest and Keast, 2008) may reflect structural remodelling 
(e.g. sprouting) or increased trafficking of receptor from the cell body to central 
terminals in the spinal cord. 
 
We next investigated the possibility that CYP treatment altered the phenotype of 
neurons containing NOS-IR. For example, if one subpopulation of NOS-IR neurons 
were down-regulated and another subpopulation were up-regulated, this could be 
detected by an overall change in co-expression pattern. Assessment of sacral FG-
labelled neurons revealed that almost half of all CGRP-IR neurons contained NOS-
IR, and these comprised ~40% of NOS-IR neurons (Figure 4.7b, c, g-j). 
Approximately one third of all GFRα1- and GFRα3-IR neurons contained NOS-IR, 
and these comprised one third of all NOS-IR neurons (Figure 4.7b, c, k-r). Co-
expression of these markers was not affected by chronic CYP treatment (Figure 4.7b, 
c). Assessment of lumbar FG-labelled neurons revealed that ~60% of CGRP-IR 
neurons contained NOS-IR, and these comprised almost all NOS-IR neurons. 
Approximately 20% of GFRα1-IR neurons contained NOS-IR, and these comprised 
~10% of all NOS-IR neurons. Approximately 60% of GFRα3-IR neurons contained 
NOS-IR, and these comprised ~80% of all NOS-IR neurons. Like sacral DRGs, 
chronic inflammation had no effect on co-expression of these markers (Figure 4.7e, f). 
These results suggest that chronic CYP does not cause a net change or alter the 
expression of NOS- or GFR-IR in bladder afferent neurons. 
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We also determined if there was a difference in co-expression between NOS and the 
GFRs in sacral and lumbar bladder afferent neurons. Quantitative assessment of co-
expression in control animals between sacral and lumbar FG-labelled neurons 
revealed that a higher proportion of lumbar GFRα3-IR neurons contained NOS-IR 
than sacral DRGs (24.9 ± 5.9% sacral vs. 65.5 ± 6.5% lumbar, P <0.001, n = 4). A 
higher proportion of lumbar NOS-IR neurons contained CGRP- (37.1 ± 6.4% sacral 
vs. 94.9 ± 2.3% lumbar, P < 0.001, n = 4) and GFRα3-IR (24.4 ± 10.3% sacral vs. 
79.4 ± 6.4% lumbar, P < 0.001, n = 4). 
 
4.3.5 GFR-IR fibres showed distinct patterns of distribution within lumbar spinal 
cord 
GFRα1, GFRα2 and GFRα3 fibres each had a distinct distribution within lumbar 
spinal cord. This was demonstrated by double-labelling with NOS to provide a 
reference point for lamina II (inner) and to demonstrate the location of preganglionic 
neurons in the intermediolateral cell column (IML) as described previously (Vizzard 
et al., 1995; 1996). In lumbar spinal cord, CGRP-IR fibres were primarily located in 
lamina I and II (outer), as described previously (Gibson et al., 1984; Kalous et al., 
2007; Keast et al., 2010). Like sacral spinal cord, immunostaining with CGRP and 
NOS distinguish the superficial laminae, specifically the inner and outer portions of 
lamina II (Figure 4.8a-f). In lumbar spinal cord, GFRα1-IR fibres were found in 
lamina II (outer)(Figure 4.8g-l) and GFRα2-IR fibres were primarily located in lamina 
II (inner) (Figure 4.8m-r). GFRα3-IR fibres had a more restricted distribution in 
lumbar cord and were primarily located in lamina I (Figure 4.8s-x). Refer to chapters 
2 and 3 for a more comprehensive description of each GFR in lumbar spinal cord. 
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4.3.6 Chronic cyclophosphamide did not alter GFR expression in lumbar spinal cord 
Our laboratory has reported that the intensity of GFRα1-IR in sacral dorsal horn 
increased following chronic CYP treatment, whereas no change occurred in GFRα2- 
or GFRα3-IR fibres (Forrest and Keast, 2008). To determine if CYP treatment also 
affects GFRα1-IR in the upper lumbar spinal cord, another target of bladder afferents, 
we assessed GFRα1-IR in lumbar medial and lateral superficial dorsal horn following 
CYP. In contrast to sacral spinal cord from our previous study (Forrest and Keast, 
2008), optical density measurements of GFRα1-IR in lumbar dorsal horn showed no 
effect of chronic CYP treatment in sections that were immunostained in parallel with 
sections from control animals (87.0 ± 5.6 SAL med. AOI vs. 86.3 ± 4.2 CYP med. 
AOI; 83.5 ± 2.7 SAL lat. AOI vs. 82.6 ± 2.6 CYP lat. AOI; n = 3). Chronic CYP had 
no effect on GFRα2-IR (109.6 ± 7.0 SAL med. AOI vs. 106.4 CYP med. AOI; 110.0 
± 5.8 SAL lat. AOI vs. 102.1 ± 1.6 CYP lat. AOI; n = 3) or GFRα3-IR (40.4 ± 0.6 
SAL med. AOI vs. 36.3 ± 0.6 CYP med. AOI; 35.2 ± 0.12 SAL lat. AOI vs. 32.7 ± 
1.2 CYP lat. AOI; n = 3) in lumbar dorsal horn. Together these results demonstrate 
that chronic bladder inflammation caused specific alterations in GFRα1-IR in sacral 
spinal cord and this appears to be a localised effect. 
 
4.3.7 Peripheral innervation of the bladder 
In this chapter we have characterised bladder-projecting afferent neurons containing 
the GFRs and have described their distribution in lumbar spinal cord. We next 
investigated the peripheral terminals of GFRα3 in the bladder. We also investigated if 
chronic bladder inflammation alters the distribution of these terminals and compared 
these changes to other sensory and autonomic axons in the bladder. We did not 
investigate the distribution of GFRα1- and GFRα2-IR axons in the bladder as an early 
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pilot experiment showed that GFRα1 antibodies failed to detect axons in the bladder 
and few afferent axons were likely to contain GFRα2-IR. For this study, we utilised 
bladder wholemount preparations to allow us to compare staining between tissues and 
different regions of the bladder. 
 
4.3.7.1 NOS  
NOS immunohistochemistry was predicted to label cholinergic postganglionic axons 
(most of which are parasympathetic) as well as a minority of lumbar and sacral 
sensory axons in different regions of the bladder. NOS-IR axons were prevalent in the 
detrusor and had a similar distribution throughout the bladder (Figure 4.9a-c). All 
NOS-IR axons were varicose and travelled as single axons or in axon bundles that 
traversed the bladder. Specialised NOS-IR endings were common throughout the 
whole thickness of the detrusor (Figure 4.9d-f), originating from single axons that 
issued multiple side branches consisting of many terminating axons running in 
parallel. The number of side branches varied (Figure 4.9d-f). 
 
NOS-IR axons were also associated with the vasculature in the detrusor (Figure 4.9g, 
h) and lamina propria (Figure 4.9i). The majority of NOS-IR axons were para-
vascular, with relatively few peri-vascular axons. Some NOS-IR endings were 
observed in the suburothelial plexus originating from para-vascular axons branching 
off the vascular tree. Para-vascular axons travel along branches of the vascular tree to 
reach the relevant organ or tissue. Peri-vascular axons functionally innervate the 
vascular tree and wrap around its branches, typically located in the adventitia of the 
vessel (Haberberger et al., 1997; Henrich et al., 2003; Warburton and Santer, 1994). 
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NOS-IR neurons were observed in the detrusor and were evenly distributed 
throughout the bladder. These were closely associated with axon bundles or attached 
to single axons. Both single and clusters of up to six NOS-IR neurons were found 
throughout the detrusor (Figure 4.9j-l) and measured 14.6 ± 0.9 µm in diameter (n = 4 
animals). The length of their dendrites varied (Figure 4.9j-l). Quantitative analysis 
revealed that the number of NOS-IR neurons in the detrusor were increased following 
chronic bladder inflammation from 8 ± 1 / cm2 (n = 5) in controls to 28 ± 8 / cm2 (n = 
4) in CYP treated animals, which was close to reaching statistical significance (P = 
0.06). This was likely to be an up-regulation of NOS-IR in pre-existing neurons rather 
than an increased number of intramural neurons in the detrusor following CYP. 
Although the increase of NOS-IR neurons was close to reaching statistical 
significance, there was variation in the CYP group as well as the total number of 
neurons counted in the bladder sample.   
 
NOS-IR axons were also present under the urothelium and were more prevalent in the 
bladder base rather than the middle and dome of the bladder (Figure 4.9m-o). These 
axons are referred to as the suburothelial plexus (Gabella and Davis, 1998). Almost 
all NOS-IR axons in the suburothelial plexus were varicose. NOS-IR closed axonal 
loops originating from the middle of axons were also observed in the suburothelial 
plexus, where a single axon branched into two and appeared to re-join, forming a loop 
in the middle of an axon (Figure 4.9p). Closed axonal loops at axon terminals were 
not observed, as have been described in sensory axons by Gabella and Davis (1998). 
NOS-IR terminals were observed in the suburothelial plexus and consisted of 
terminals that did not branch, or branched into two before terminating (Figure 4.9q, r), 
and those originating from para-vascular axons that had branched off mucosal 
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vasculature. NOS also labelled urothelial cells throughout the bladder with varying 
intensity (Figure 4.9i, m-o, q, r). 
 
4.3.7.2 CGRP and GFRα3 
CGRP was used to identify peptidergic afferent axons in the bladder (Gabella and 
Davis, 1998). We have demonstrated that almost half of all peptidergic bladder 
afferent neurons contained GFRα3-IR, and all GFRα3-IR bladder-projecting neurons 
contained CGRP-IR. Therefore we hypothesised that CGRP-IR axons in the bladder 
would be more prevalent than GFRα3-IR axons. We found a similar pattern of CGRP-
IR axons throughout the bladder as previously described (Gabella and Davis, 1998) 
that had three main targets: the detrusor, suburothelial plexus and vasculature. CGRP-
IR axons in the detrusor travelled as single, varicose axons or in bundles of axons that 
traversed the bladder (Figure 4.10a-c). CGRP-IR terminals were common and 
occurred throughout the whole thickness of the detrusor. To assess the prevalence of 
CGRP-IR axon terminals in the detrusor, the number of endings were counted in the 
bladder base in wholemount preparations. Quantification revealed 139 ± 12 CGRP-IR 
terminals / mm2 (n = 4) in the detrusor of the bladder base. As previously described 
(Gabella and Davis, 1998), numerous CGRP-IR axons were present in the 
suburothelial plexus and progressively tapered toward the bladder dome (Figure 
4.10g-i). Many CGRP-IR axons also travelled in para-vascular axons throughout the 
detrusor (not shown; discussed in detail in Chapter 5).  
 
GFRα3-IR axons were prevalent in the detrusor, and like CGRP-IR axons, were 
distributed evenly throughout the bladder where they had a similar density in the 
bladder base and dome (Figure 4.10d-f). GFRα3-IR axons occurred throughout the 
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whole thickness of the detrusor, less than half of which were varicose and travelled 
singularly or in bundles. Numerous GFRα3-IR terminals were observed throughout 
the detrusor and were evenly distributed throughout the bladder. However, the 
prevalence of these terminals could not be quantified as their intensity varied. 
Because many of these axons were quite poorly stained, their true prevalence was 
likely to be underestimated. Numerous GFRα3-IR axons were associated with the 
vascular tree and consisted of both para- and peri-vascular axons (not shown; 
discussed in detail in Chapter 5). GFRα3-IR axons in the detrusor and associated with 
the vasculature were more prevalent than CGRP-IR axons in these regions. GFRα3-IR 
axons were also associated with the suburothelial plexus (Figure 4.10j-l) but were not 
as prevalent as CGRP-IR axons. Numerous GFRα3-IR cells were also observed in the 
detrusor and suburothelial plexus. These were small cells with elongated processes 
that were potentially non-neuronal cells. The distribution and co-expression of 
GFRα3 with CGRP and other neuronal and non-neuronal markers are described in 
detail in the following chapter. 
 
CGRP-IR axons sprout in the detrusor and suburothelial plexus following chronic 
bladder inflammation (Dickson et al., 2006). These changes are thought to contribute 
to bladder hyper-reflexia and pain during inflammation. To determine if chronic 
inflammation altered the distribution of CGRP- and GFRα3-IR axons, we performed a 
semi-quantitative analysis comparing the number of terminals in the suburothelial 
plexus in the bladder base from control and chronic CYP treated animals. Qualitative 
assessment of control and CYP-treated animals revealed no obvious effect of CYP on 
CGRP- (Figure 4.10m-o) or GFRα3-IR (Figure 4.10p-r) axons in the suburothelial 
plexus. Quantification revealed that inflammation had no effect on the number of 
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GFRα3-IR (31 ± 1 control vs. 30 ± 2 CYP) or CGRP-IR (70 ± 4 control vs. 80 ± 6 
CYP) axon endings / mm2 in the suburothelial plexus. This is consistent with above 
results that demonstrated chronic bladder inflammation had no effect on the 
proportion of bladder afferent neurons containing GFRα3- or CGRP-IR (section 
4.3.4).  
 
4.3.7.3 NF200 
NF200 was used to identify myelinated sensory axons (Robertson et al., 1991; 
Scherrer et al., 2010) in the bladder. NF200-IR axons were found throughout the 
detrusor and distributed evenly throughout the bladder (Figure 4.11a-c). The majority 
of these axons travelled in axon bundles rather than single axons. NF200-IR axons 
were non-varicose and terminals were difficult to observe. For this reason, NF200-IR 
terminals could not be quantified in control or CYP-treated animals. Few NF200-IR 
axons were associated with the vasculature, which consisted of para-vascular axons 
only. NF200-IR somata were observed in the detrusor and had short processes and 
measured 15.18 ± 0.56 µm in diameter (n = 4 rats). These neurons were found 
individually or in small clusters of up to 4 somata (Figure 4.11d-f). Chronic CYP 
treatment had no effect on the number of NF200-IR somata (22 ± 8 / cm2 control (n = 
5) vs. 16 ± 4 / cm2 CYP (n = 4); P = 0.3). The presence of NF200-IR intramural 
neurons led to further characterisation of NF200-IR axons in the following chapter. 
NF200-IR axons were not associated with the suburothelial plexus. 
 
4.3.8 Acute bladder inflammation induces ATF-3 activation and increases NOS 
expression in sacral bladder afferent neurons 
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To confirm acute bladder inflammation, bladder sections from acute CYP-treated 
animals and controls were processed for ED-1. Qualitative assessment of bladder 
sections revealed a pronounced ED-1 infiltration in the detrusor and mucosa of acute 
CYP-treated animals (not shown). Qualitative assessment also revealed that the 
inflammatory cell infiltrate was not as dense as in chronic CYP-treated animals. 
 
Assessment of FG-labelled neurons following acute CYP treatment revealed a small, 
but significant induction of ATF-3 in sacral bladder neurons (Figure 4.12a; P = 0.03; 
n = 3) and an increase in the number of neurons expressing NOS-IR (Figure 4.12b; P 
= 0.01; n = 3) compared to control animals. Quantification of FG-labelled neurons in 
sacral DRG revealed a similar proportion of neurons containing CGRP-, GFRα1- and 
GFRα3-IR as reported above, and these were unaffected by acute CYP (Figure 
4.12b). In contrast to sacral bladder afferent neurons, acute inflammation had no 
effect on the expression of ATF-3, NOS-, CGRP-, GFRα1- or GFRα3-IR in lumbar 
FG-labelled neurons (Figure 4.12c, d). Co-expression studies in sections 
immunolabelled with NOS and ATF-3 revealed that ~80% of ATF-3 nuclei were 
found in NOS-IR neurons (Figure 4.12e-h). 
 
4.4 Discussion  
This study characterised bladder afferent neurons in the context of receptors for two 
families of molecules known to modulate nociceptor behaviour: GFLs and estrogens. 
Figure 4.13 provides a co-expression summary of bladder-projecting neurons. Forrest 
and Keast (2008) have shown that many bladder afferent neurons express two of the 
GFRs (GFRα1 and GFRα3), and each GFR has a distinct distribution pattern in sacral 
spinal cord, suggesting that each has a different function. We hypothesised that 
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bladder afferent neurons containing the GFRs are likely to be found in different 
functional neuronal sub-populations. GFRα1-IR in sacral spinal cord increases 
following chronic bladder inflammation (Forrest and Keast, 2008), and in the current 
study, we investigated if this also occurred in lumbar spinal cord (the target of 
afferents projecting from the bladder in the hypogastric nerve). We also investigated 
if changes in GFR expression in bladder afferent neurons occur in parallel with their 
central projections. We also determined if GFRα3-IR axons were distributed in 
different regions and tissues in the bladder and if chronic inflammation altered their 
structure or distribution. These were compared to other major populations of bladder 
autonomic and sensory axons. Our final aim was to investigate which sub-
population(s) of bladder afferent neurons are potentially susceptible to physical injury 
and physically remodel during acute inflammation.  
 
4.4.1 DRG studies 
We have demonstrated that bladder afferent neurons in lumbar DRG have a similar 
GFR expression as sacral DRGs, indicating that both GDNF and artemin may target 
bladder afferent neurons. Therefore, these neurotrophic factors may play a role in the 
normal physiological signalling and functioning of these neurons. Consistent with 
Vizzard (2001), we found a slightly higher expression of CGRP-IR in lumbar bladder 
afferent neurons and all GFRα3-IR neurons were found in a sub-population of CGRP-
IR neurons, in agreement with Orozco et al., (2001). Previous studies in DRG neurons 
innervating the skin have shown that almost all GFRα3-IR (Elitt et al., 2006; Malin et 
al., 2006) and CGRP-IR (Averill et al., 1995) neurons express TRPV1-IR. In 
dissociated mouse DRG neurons, NGF, GDNF and artemin potentiate TRPV1 
signalling and contribute to nociceptor sensitisation and pain (Malin et al., 2006). On 
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this basis, we investigated TRPV1 expression in bladder afferent neurons containing 
the GFRs and CGRP. Consistent with previous reports (above), almost all GFRα3- 
and CGRP-IR neurons contained TRPV1-IR, and comprise largely overlapping 
populations of neurons. In contrast, only one third of GFRα1-IR neurons contained 
TRPV1-IR. TRPV1 is a marker of polymodal nociceptors (Avelino et al., 2002) but 
bladder neurons expressing TRPV1-IR are not exclusively involved in nociception 
and are likely to play a role in normal micturition reflexes. For example, intravesical 
injection of capsaicin into the bladder decreases the micturition threshold and induces 
bladder contraction (Dmitrieva et al., 1997; Maggi, 1992). However, some bladder 
neurons can have a nociceptive function under inflammatory conditions (Bjorling et 
al., 2003; Nazif et al., 2007). TRPV1-IR axons are present in the suburothelial plexus 
and contain CGRP-IR (Avelino et al., 2002). Results from the current study suggest 
that GFRα3-IR suburothelial axons will also contain CGRP- and TRPV1-IR. The role 
of artemin in the inflamed bladder is not known but our results indicate that artemin 
could potentially sensitise suburothelial axons, contribute to hypersensitivity and 
changes in bladder reflex patterns. 
 
Other studies have performed retrograde tracing studies incorporating GFR 
localisation to determine their expression in afferent neurons innervating the pancreas 
(Fasanella et al., 2008), penis (Laurikainen et al., 2000), tongue (Elitt et al., 2008), 
and facial skin (Takeda et al., 2010). Takeda et al. (2010) demonstrated almost 90% 
of trigeminal neurons innervating the facial skin in rats contain GFRα1-IR, a much 
higher proportion than bladder afferent neurons containing GFRα1 in the current 
study. Elitt et al. (2008) report that 25% of tongue afferent neurons in the trigeminal 
ganglia contain GFRα3-IR and just under half of all penis-projecting afferent neurons 
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contain GFRα3-IR (Laurikainen et al., 2000), proportions that more closely resemble 
the bladder. In comparison, Fasanella et al. (2008) report that a much higher 
proportion (75%) of pancreas afferent neurons contain GFRα3-IR, most of which 
contain TRPV1- and CGRP-IR. These results demonstrate that the GFLs are likely to 
be involved in the maintenance of physiological and structural properties of these 
neurons expressing their receptors but this is not uniform across different organs and 
skin. Despite these studies, the effects of the GFLs on lumbar and sacral DRGs have 
been poorly investigated. Our results show that GDNF and artemin target different 
functional groups of bladder afferent neurons in lumbar and sacral DRGs, potentially 
regulating different components of bladder function. Some studies in DRG neurons 
have also demonstrated that the GFLs have pro-nociceptive effects. At other spinal 
levels, GDNF and artemin have been shown to contribute to nociceptor sensitisation 
and hyperalgesia (Elitt et al., 2006; Malin et al., 2006). A more recent study 
demonstrated that the GFLs have the ability to potentiate the response to capsaicin 
and mustard oil that is specific to different afferents innervating the skin, muscle and 
colon (Malin et al., 2011). Artemin is also likely to contribute to the development and 
maintenance of colorectal hypersensitivity (Tanaka et al., 2011). GDNF levels in the 
bladder are also increased during bladder inflammation (Vizzard, 2000b). Together 
these results indicate that GDNF and artemin may be involved in the sensitisation and 
plasticity of pelvic visceral pathways. 
 
4.4.1.1 NF200 
Consistent with previous studies (Hayashi et al., 2009; Russo et al., 2013), we found 
over half of all bladder afferent neurons contained NF200-IR. We predict that these 
are the A-delta mechanosensitive neurons with thinly myelinated axons (Scherrer et 
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al., 2010). These neurons are likely to respond to innocuous stimuli such as bladder 
distension. Given the prevalence of NF200-IR in bladder afferent neurons and that 
few single myelinated axons and endings are found in the bladder, as shown in this 
study and by Gabella (1999), suggests that NF200 only labels pre-terminal axons in 
the detrusor. 
 
This is the first study to demonstrate that NF200-IR bladder afferent neurons 
comprise different chemical classes that show similar co-expression patterns in 
lumbar and sacral DRGs. Our results indicate that the majority of GFRα1-IR bladder 
afferent neurons are mechanoreceptive neurons, and that about half of all NOS, 
CGRP and ERα-IR bladder neurons are mechanosensitive. In turn, these bladder 
mechanosensitive neurons have the potential to be regulated by GDNF, NGF and 
estrogens. Our results are consistent with Lawson et al., (1993) who demonstrate that 
NF200-IR is found in approximately one third of all CGRP-IR neurons in lumbar 
DRG, mostly focusing on L5. This is likely to comprise the GFRα3 negative 
population as less than 1% of NF200-IR neurons in lumbar DRGs contain GFRα3-IR 
(Chapter 2). Based on this result, we did not specifically investigate NF200 and 
GFRα3 co-expression in bladder afferent neurons. 
 
4.4.1.2 Estrogens 
Estrogens can modulate nociceptor behaviour and in this study, we characterised 
bladder afferent neurons with two ERα antibodies, the first, ERα (Affinity), has been 
used by our laboratory (Bennett et al., 2003). In sacral bladder neurons, ERα 
(Affinity) was located in the GDNF- and NGF-sensitive, GFRα3-negative peptidergic 
populations. At this level, half of all ERα (Affinity) neurons had NF200-IR and based 
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on our results, it is likely that the GFRα1- and NF200-IR neurons containing ERα 
(Affinity)-IR are largely overlapping populations as the majority of GFRα1-IR 
bladder afferent neurons contained NF200-IR. In contrast, in lumbar bladder afferent 
neurons, ERα (Affinity) was located in both GDNF-, NGF- and artemin-sensitive 
populations. At this level, ERα (Affinity) was also found in a smaller proportion of 
NF200-IR bladder neurons. These studies suggest that lumbar ERα (Affinity) bladder 
afferent neurons have the potential to be influenced by three neurotrophic factors: 
artemin, NGF and GDNF, whereas sacral ERα (Affinity) bladder neurons have the 
potential to be influenced by two, NGF and GDNF. These populations are in turn 
likely to be targets of circulating estrogens. Bennett et al., (2003) provided evidence 
to suggest that there are a number of estrogen-sensitive sub-populations within 
bladder afferent neurons, a significant proportion of which are peptidergic. Many of 
these were also likely to contain GFRα3-IR. The current study is in agreement with 
this report. 
 
We also performed co-expression studies on a second ERα antibody, ERα (Millipore), 
which was used by Kiasalari et al. (2010) and reported to label a different population 
of neurons. Kiasalari et al. (2010) demonstrated that sacral DRG neurons showing 
very intense levels of TRPV1-IR did not contain CGRP or other markers of C-fibre 
nociceptors. Instead, almost all of these neurons contained Ret-IR, approximately half 
contained GFRα1-IR and the majority contained GFRα2-IR. In addition, almost all of 
these TRPV1-IR neurons contained the ERα (Millipore). On this basis we expected to 
find that many of ERα (Millipore)-IR bladder afferent neurons would contain GFRα1-
IR and label few peptidergic neurons. In contrast to our ERα (Affinity) antibody, ERα 
(Millipore) only labelled half as many bladder afferent neurons, half of which 
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contained GFRα1-IR. Approximately one third contained NF200-IR, which are likely 
to be an overlapping population with those containing GFRα1-IR. This antibody 
failed to label CGRP- and GFRα3-IR populations of bladder neurons. It is interesting 
that in our hands, these ERα antibodies did not label a similar number of bladder 
afferent neurons. A possible explanation for this discrepancy is that Kiasalari et al. 
(2010) used male Wistar rats, suggesting a possible sex and strain difference, and also 
used tyramide signal amplification for their ERα (Millipore) immunohistochemistry. 
It is likely that this method revealed additional ERα (Millipore) staining that was not 
observed using our standard direct immunofluorescence method. 
 
Estrogens have complex actions on bladder afferent neurons and can directly 
modulate two signalling pathways involved in neural plasticity, p38 and extracellular 
signal-related (ERK) mitogen-activated protein (MAP) kinase within these neurons 
(Cheng and Keast, 2009). Another study from our laboratory (Xu et al., 2008) has 
shown that estradiol acts directly on DRG neurons to reduce TRPV1 activation by 
capsaicin and suggested that pelvic pain could be influenced by modulation of 
estrogen receptors in DRG neurons. Results from the current study also indicate the 
ERs could potentially modulate bladder nociceptor activity. In our study, we found 
that many bladder afferent neurons contained ERα suggesting that circulating 
estrogens are likely to influence their activity. Estrogen has been shown to do this by 
regulating neuropeptide and neurotrophin receptor expression in DRG neurons 
(Lanlua et al., 2001; Liuzzi et al., 1999). Whether estrogen has a similar effect on 
neurons containing the GFRs remains to be investigated. 
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4.4.2 Chronic bladder inflammation 
4.4.2.1 DRGs and spinal cord 
The next part of our study investigated chronic CYP-induced changes in bladder 
afferent neurons and their central and peripheral terminals. We first investigated the 
expression of NOS in bladder afferent neurons in control animals as NOS has been 
reported to be up-regulated in bladder afferent neurons following chronic bladder 
inflammation (Vizzard et al., 1996). We found a higher basal expression of NOS-IR 
in lumbar and sacral bladder-projecting neurons in control animals than previously 
reported (Callsen-Cencic and Mense, 1997; Vizzard et al., 1996; Vizzard et al., 1994). 
We have also demonstrated a non-uniform topographical distribution of NOS at 
different DRG levels with lower basal expression in sacral DRGs, consistent with 
previous studies (Vizzard et al., 1996). These results suggest a more prominent role of 
nitric oxide in rostral lumbar afferent pathways. It is possible that the higher levels of 
basal NOS expression we observed is attributable to the difference in NOS antibodies 
used in each of these studies, or that the earlier studies did not regard the faintly NOS-
IR neurons as positive. Another explanation could be that our immunohistochemical 
methods are more sensitive than these earlier studies. 
 
In the current study NOS-IR bladder afferent neurons in lumbar and sacral DRGs 
were found to have a different neurochemical profile. Almost all NOS-IR neurons in 
lumbar DRGs were peptidergic, containing both CGRP- and GFRα3-IR and are likely 
to be NGF- and artemin-sensitive. In comparison, about one third of NOS-IR neurons 
in sacral DRGs were peptidergic, and a higher proportion were non-peptidergic, 
containing GFRα1-IR. As almost all GFRα3-IR neurons at either spinal level contain 
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CGRP-IR, it is interesting that most peptidergic NOS-IR neurons are GFRα3-positive, 
and have the potential to be influenced by both NGF and artemin. 
 
Inconsistent with previous reports (Vizzard et al., 1996), we did not find an increase 
in the number of bladder afferent neurons expressing NOS-IR following chronic 
bladder inflammation. It is possible that a change did occur but was not detected by 
our method of analysis. For example, future analysis of immunofluorescence intensity 
could be performed on NOS-IR neurons. Although we did not observe an obvious 
change in intensity while viewing the sections, detailed quantitation may reveal an 
effect of CYP. An increase in intensity could indicate a higher level of protein in the 
soma, which could then be transported to their central terminals. Another explanation 
could be simply that there is a difference in the sensitivity of antibodies used between 
the different studies or there was a difference in the visual threshold for determining if 
a neuron was NOS-positive. 
 
We also investigated if a change in phenotype occurs in NOS-IR bladder afferent 
neurons following CYP-induced inflammation by assessing co-expression patterns 
with CGRP, GFRα1 and GFRα3. For example, if NOS is down-regulated in one 
population but is increased in another, the total number of bladder afferent neurons 
containing NOS may not be altered but a change in its neurochemical profile may be 
detected. In our study, the proportion of bladder neurons expressing CGRP was 
unaffected by chronic CYP, inconsistent with a previous report (Vizzard, 2001) 
demonstrating an up-regulation of CGRP-IR in bladder neurons during chronic 
inflammation. Chronic bladder inflammation also had no effect on the number of 
sacral and lumbar bladder neurons containing the GFRs. We also found that a 
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phenotypic change did not occur in NOS-IR neurons when co-expression studies were 
performed with CGRP and the GFRs. Further investigation on the intensity of the 
immunofluorescence signal (as discussed above for NOS) of CGRP-, GFRα1- and 
GFRα3-IR bladder afferent neurons following chronic inflammation may be 
informative for the future. 
 
Forrest and Keast (2008) reported an increase of GFRα1-IR in sacral cord following 
chronic bladder inflammation, suggesting a role of GDNF in sacral visceral pathways 
during inflammation and could be a potential mechanism for altered neurochemical 
properties of bladder afferent neurons. This was consistent with reports that show 
GDNF levels are increased in the bladder wall following inflammation (Vizzard, 
2000b) and GDNF levels are increased in the urine of patients with interstitial cystitis 
(Okragly et al., 1999). In contrast to sacral spinal cord reported by Forrest and Keast 
(2008), in the current study, bladder inflammation had no effect on GFRα1 in lumbar 
cord. These results suggest that the up-regulation of GFRα1-IR reported by Forrest 
and Keast (2008) is a localised effect due to structural remodelling of central 
terminals or increased protein synthesis in the DRG. Based on our above DRG study, 
the increased GFRα1-IR in sacral cord is not likely to be caused by additional neurons 
in the DRG synthesising GFRα1. Another possible explanation could be that changes 
in primary afferent neurons and their central terminals do not occur in parallel. 
Further studies would need to be done to investigate this. Together these results 
indicate that GDNF is likely to mediate plasticity of sacral visceral afferents 
following inflammation but is unlikely to affect lumbar visceral afferents. 
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4.4.3 Peripheral innervation of the bladder 
The next part of our study investigated if GFRα3-IR axons target different regions 
and tissues in the bladder and if they are altered by chronic CYP-induced bladder 
inflammation. We also compared these to other markers of sensory and autonomic 
axons by using wholemount preparations to visualise the innervation across different 
regions and tissues of the bladder.  
 
4.4.3.1 NOS  
Varicose NOS-IR axons in the bladder were found throughout the whole thickness of 
the detrusor and had a similar structure and density in the bladder base and dome. In 
bladder wholemount preparations, we identified two different types of NOS-IR 
endings: 1) specialised and 2) those originating from para-vascular axons. NOS-IR 
specialised endings were observed throughout the whole thickness of the bladder 
whereas those originating from para-vascular axons were mainly observed in the 
suburothelial plexus. It would be interesting to investigate the physiological 
differences in neurotransmission at these physically different sites. At present we do 
not know if these endings are sensory or cholinergic, or if one type of ending is 
sensory or cholinergic. Further investigation is needed to determine this, which could 
be done be performing fluorescent immunohistochemistry in bladder wholemount 
preparations and co-staining NOS with CGRP (sensory marker), VAChT (cholinergic 
marker), or NPY that labels that largest population of cholinergic and noradrenergic 
autonomic axons in the rat bladder (Keast and de Groat, 1989). 
 
Intramural NOS-IR neurons were found throughout the detrusor, closely associated 
with single axons or bundles of axons. Intramural neurons were originally regarded as 
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absent in rats (Gabella, 1990), however more recent studies demonstrate they are 
present (Alian and Gabella, 1996; Iuchi et al., 1994; Zvarova and Vizzard, 2005) but 
sparse compared to other species (Gabella, 1990; Smet et al., 1996; Zhou and Ling, 
1998). Intramural neurons are found embedded in the detrusor and are thought to also 
provide efferent innervation to the detrusor (Birder et al., 2010; Keast, 2006). NOS-IR 
neurons were found singularly or in small clusters and are likely to be autonomic 
ganglion neurons, as afferent neurons are not found in intramural ganglia (Gillespie et 
al., 2006b). Cholinergic intramural neurons have been described in the rat bladder and 
comprise the majority of neurons in intramural ganglia (Alian and Gabella, 1996; el-
Badawi and Schenk, 1966; Iuchi et al., 1994). For this reason, it is thought that their 
role has been to relay activity in cholinergic nerves to the detrusor to facilitate bladder 
contraction and micturition. Following chronic CYP treatment, we found a trend 
towards an increase in the number of NOS-IR intramural neurons. Further 
investigation is required to confirm if these NOS-IR intramural neurons are 
cholinergic by co-staining for VAChT (above) but in the major pelvic ganglion no 
NOS-positive neurons are noradrenergic (Keast, 2006). Along with the up-regulation 
of NOS-IR intramural neurons, ED-1 bladder infiltrate and the macroscopic 
appearance of inflamed bladders, we were confident that the CYP protocol used in 
this study was successful in inducing chronic inflammation despite not replicating the 
NOS and CGRP up-regulation in DRG neurons (above). 
 
NOS-IR axons were found in the suburothelial plexus, which were most prevalent in 
the bladder base, consistent with previous studies (Dickson et al., 2006). NOS-IR 
closed axonal loops were also observed in the suburothelial plexus. This is the first 
time NOS-IR closed axonal loops have been reported. Although the function of these 
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loops is not clear, they were not observed in the detrusor and appeared to be a unique 
feature of the suburothelial plexus. Closed axonal loops on terminal axons have been 
described previously with peptidergic sensory axons immunostained with CGRP in 
the rat where a terminal axon branches forming a loop at the end of the axon. These 
were proposed to have a role in synaptic transmission (Gabella, 1999). We did not 
determine if the NOS-IR closed axonal loops were sensory or cholinergic but this 
could be done with dual labelled immunofluorescence (see above). 
 
In the current study, NOS labelled urothelial cells with varying intensity.  
Gillespie et al., (2005) reported that basal, intermediate and superficial urothelial cells 
in the guinea pig bladder express neuronal NOS (nNOS). nNOS expression was not 
uniform across the three types of urothelial cells or across different regions in the 
bladder indicating different functions or signalling within these neurons (Gillespie et 
al., 2005). Other studies in rats have demonstrated that NO is released from urothelial 
cells (Birder et al., 1998) and urothelial cells in cultures or bladder sections express 
inducible and endothelial NOS, but not nNOS (Birder et al., 2002; Persson et al., 
1999). The NOS antibody used in the current study identifies nNOS and does not 
show cross-reactivity with inducible or endothelial NOS (antibody data sheet). This is 
the first study to show nNOS-IR in rat urothelial cells but this should be verified using 
Western blotting or RNA analysis methods. 
 
4.4.3.2 CGRP and GFRα3 
We found that CGRP-IR axons in the bladder had a similar structure and distribution 
as previously described (Gabella, 1999) although we report a smaller proportion of 
bladder-projecting neurons contain CGRP-IR than previous studies (Bennett et al., 
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1996; Bennett et al., 2003; Callsen-Cencic and Mense, 1997). In this chapter we have 
also demonstrated that almost half of all CGRP-IR bladder-projecting neurons 
contained GFRα3-IR, and almost all GFRα3-IR neurons contained CGRP-IR. We 
hypothesised that CGRP-IR axons in the bladder would be more prevalent than those 
containing GFRα3-IR but we did not know if GFRα3-IR axons would target the same 
bladder regions or tissues as CGRP-IR axons. 
 
CGRP-IR axons had three main targets in the bladder: detrusor, suburothelial plexus 
and the vasculature. We found GFRα3-IR axons also targeted these three regions but 
were more prevalent than CGRP-IR axons in the detrusor and associated with the 
vasculature. Numerous GFRα3-IR cells with elongated processes were also present in 
both the detrusor and suburothelial plexus, which appeared to be non-neuronal cells. 
Further investigation is required to determine the nature of this immunostaining and 
the proportion of axons containing both CGRP- and GFRα3-IR. This will be 
examined in detail in the following chapter. 
 
Sprouting of CGRP-IR axons in the bladder has been reported to occur following 
chronic CYP treatment in rats, corresponding to altered bladder reflexes (Dickson et 
al., 2006). This study assessed fibre density in the suburothelial plexus and detrusor as 
a way of measuring innervation changes following CYP treatment. We anticipated 
that wholemount bladder preparations would be effective in performing quantitative 
analysis on axon density in the suburothelial plexus and detrusor, but this proved not 
to be that case due to the nature of the tissue sample. Bladder wholemounts were thick 
preparations and when imaging suburothelial axons, many out of focus axons and 
large axon bundles in the detrusor were also captured in the image. These axons and 
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bundles could not be removed from the image without losing the fine, in focus 
suburothelial axons. Likewise, when imaging axons in the detrusor, out of focus 
suburothelial axons could not be removed without losing the fine, in focus axons in 
the detrusor. Therefore, we were restricted to counting the number of axon endings in 
control and CYP-treated animals, which was a potential limitation of the current 
study. 
 
In contrast to the study by Dickson et al. (2006), we found that chronic bladder 
inflammation had no effect on the number of CGRP- or GFRα3-IR endings in the 
suburothelial plexus. However this finding is consistent with our above results 
demonstrating that chronic CYP had no effect on CGRP or GFRα3 expression in 
bladder-projecting neurons or their central terminals. Given that approximately half of 
CGRP-IR neurons contain GFRα3-IR, together these results suggest that the up-
regulation of CGRP-IR suburothelial axons reported by Dickson et al., (2006) are 
likely to occur in the CGRP-positive GFRα3-negative population. However, it was 
surprising that we did not detect even a small change in the number of CGRP-IR 
suburothelial endings given the large increase reported by Dickson et al, (2006). It is 
likely that our method of analysis hindered our ability to detect a change following 
CYP and that analysis of tissue sections is a more suitable approach. 
 
4.4.3.3 NF200 
In the detrusor, the majority of NF200-IR axons travelled in large diameter axon 
bundles and few single axons were observed. This suggests that NF200 only labels 
pre-terminal axons in the bladder. These axons are likely to originate from the lumbar 
and sacral DRG, as shown above. Few studies have investigated the distribution of 
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NF200-IR axons in the bladder (Liu et al., 2010; Schnegelsberg et al., 2010) but our 
results are consistent with Gabella (1999) who demonstrated that the majority of 
myelinated axons in the bladder travel in large diameter axon bundles and rarely as 
single axons. We also identified NF200-IR intramural neurons throughout the 
detrusor, closely associated with individual axons or bundles of axons. Based on the 
literature, these are likely to be cholinergic intramural neurons and will be discussed 
in more detail in the following chapter. We found that the number of intramural 
neurons containing NF200-IR were not affected by CYP-treatment. 
 
4.4.4 Confirmation of bladder inflammation 
Despite the lack of effect of chronic inflammation in our study, we have provided 
strong evidence to show that chronic CYP treatment did produce bladder 
inflammation. We used the standard chronic CYP model of inflammation with the 
same sex and rat strain used as previous studies (Forrest and Keast, 2008; Yoshimura 
and de Groat, 1999) and demonstrated increased cellular infiltrate in the bladder as 
well as an increase in bladder weight, both indicative of bladder inflammation. 
Secondly, we also found that there was a trend for NOS-IR intramural neurons to 
increase following chronic CYP treatment. It is possible that by using a different 
method of analysis such as intensity analysis on NOS- and CGRP-IR bladder afferent 
neurons, we may have been able to detect an effect following inflammation. 
 
4.4.5 Acute bladder inflammation 
In the current study, we investigated GFR (GFRα1 and GFRα3), CGRP and NOS 
expression in bladder afferent neurons following acute bladder inflammation induced 
by a single dose of CYP. ATF-3 was also used to identify populations of bladder 
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afferent neurons that were injured and undergoing structural remodelling during acute 
bladder inflammation. Here we report that acute bladder inflammation increased the 
number of sacral bladder afferent neurons containing NOS-IR but had no effect on 
CGRP- or GFR-IR neurons at either lumber or sacral levels. We cannot rule out that 
the GFRs and CGRP do not have a role in acute inflammation-induced plasticity in 
lumbar and sacral DRGs, but we could not detect any altered regulation of their levels 
in bladder afferent neurons using our immunofluorescence method. 
 
It is interesting that in our study, chronic CYP had no effect on the number of bladder 
afferent neurons containing NOS-IR (above), but we found a very rapid up-regulation 
of NOS during acute inflammation. Up-regulation of NOS has been reported to occur 
rapidly for example, Vizzard (1996) and Callsen-Cencic and Mense (1997) show 
NOS is increased in bladder afferent neurons following CYP administration two hours 
prior to animal sacrifice and 48 hours after the bladder was exposed to mustard oil 
respectively. Our results raise the possibility that NOS could have additional 
functions in bladder primary afferent pathways during acute bladder inflammation, 
potentially contributing to altered bladder reflexes. Kakizaki and de Groat (1996) 
demonstrated that intrathecally administering the NO inhibitor, L-NAME, had no 
effect on bladder activity as recorded during anaesthetised cystometry. Following 
acetic acid-induced acute bladder inflammation that induced bladder hyperreflexia, 
administration of L-NAME reduced bladder hyperactivity. These results demonstrate 
that NO in the spinal cord does not play a role in regulating bladder activity during 
normal conditions but during inflammation, bladder hyperactivity is partly mediated 
by NO in the spinal cord by nociceptive afferents activated by acute bladder 
inflammation. Our results are also consistent with Lagos and Ballejo (2004) who 
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provide evidence demonstrating that bladder hyperreflexia induced by CYP is 
associated with an increase of calcium-dependent NOS activity in spinal cord.  
 
Animal studies of bladder inflammatory pain show changes in neurochemical and 
structural properties of bladder afferent pathways, leading to alterations in bladder 
reflexes and pain. For example, CGRP and NOS have been reported to be up-
regulated in bladder afferent neurons following acute mustard oil-induced 
inflammation and chronic CYP-induced bladder inflammation (Callsen-Cencic and 
Mense, 1997; Vizzard et al., 1996). These studies suggest a role of NO in altered 
bladder reflexes and nociceptive signalling during acute inflammation (Kakizaki and 
de Groat, 1996; Lagos and Ballejo, 2004). These studies indicate that a certain 
subpopulation of bladder afferent neurons are either susceptible to injury, or injured 
during inflammation.  
 
Using ATF-3 as a marker of injured neurons (Peddie and Keast, 2011), we found 
acute CYP treatment caused a small induction of ATF-3 in sacral bladder neurons, the 
majority being in the NOS-positive population. This is the first study to demonstrate 
that ATF-3 can be up-regulated by acute bladder inflammation. A possible 
explanation for the ATF-3 induction is that at this time point, destruction of the 
urothelium occurs, allowing toxic substances in urine to make contact with 
suburothelial axons. These axons could potentially be sensitised and contribute to 
altered reflex behaviours during inflammation and contribute to the neurochemical 
changes that occur in DRGs during inflammation. Our study is consistent with 
previous reports indicating that concurrent nerve damage is required to drive the 
induction of ATF-3 (Braz and Basbaum, 2010), and bladder inflammation is a 
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sufficient stimulus to cause this. Reports of ATF-3 induction in lumbar DRGs by 
mono-iodoacetate-induced osteoarthritis (Ivanavicius et al., 2007; Thakur et al., 
2012), a model of joint in inflammation, also produces concurrent axonal damage 
required to drive ATF-3 induction. Other studies have used ATF-3 to investigate 
which class of neurons are likely to be activated by injection of noxious irritants into 
the hindpaw of mice, and have shown that these neurons are likely to contribute to 
altered behavioural responses (Braz and Basbaum, 2010). Our results suggest that a 
small subpopulation of NOS-IR sacral bladder afferent neurons may be particularly 
susceptible to injury or are physically remodelling following acute inflammation. 
These findings also support the role of NOS in altered bladder reflexes. Although at 
present the functional significance of ATF-3 in unclear, it is likely that its functions 
under normal conditions are different from those under inflammation, nerve injury 
and other pathological conditions. 
 
4.4.6 Conclusions 
This study has revealed additional markers for anatomically and functionally separate 
populations of afferent C-fibre neurons and their central terminals that could be used 
as tools to track changes in different peptidergic and non-peptidergic C-fibre 
populations after inflammation or injury. Furthermore, GDNF and artemin target 
different functional groups of bladder-projecting neurons, potentially regulating 
different components of bladder function and modulating different aspects of bladder 
activity and pain during inflammation. Our results indicate that sacral ER bladder 
neurons have the potential to be regulated by NGF and GDNF, whereas lumbar ER 
neurons have the potential to be influenced by NGF, GDNF and artemin. Chronic 
bladder inflammation had no effect on bladder-projecting neurons expressing the 
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GFRs. Each GFR had distinct central distributions in lumbar cord and in contrast to 
sacral spinal cord, chronic inflammation had no effect on their central terminals. This 
suggests that GDNF may mediate plasticity of sacral visceral afferents following 
chronic inflammation but is unlikely to affect lumbar visceral afferents. GFRα3-IR 
axons were widespread throughout the bladder but further investigation is required to 
determine the nature of this staining. These axons were also unaffected by chronic 
bladder inflammation. Our study has also identified a sub-population of NOS-IR 
neurons that are likely to be undergoing structural remodelling during acute 
inflammation. Together, these results contribute to the increased understanding of the 
neurons that are known to be involved in pain modulation and hyperreflexia during 
inflammation. 
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Antibodies Host Supplier / catalogue number Dilution
Primaries
ATF-3 Rabbit Santa Cruz Biotechnology (Scoresby, VIC, 
Australia); sc-188
1:500
CD86 (ED-1) Mouse Millipore (Kilsyth, VIC, Australia); 
MAB1435
1:1000
CGRP Goat Millipore; 1720-9007 1:2000
CGRP Rabbit Sigma-Aldrich (Castle Hill, NSW, 
Australia); C8198
1:5000
ERa Rabbit Affinity Bioreagents (Scoresby, VIC, 
Australia); PA1-308
1:350
ERa Rabbit Millipore; C1355 1:5000
GFRa1 Goat R&D Systems (Minneapolis, MN); AF560 1:400
GFRa2 Goat R&D Systems; AF429 1:300
GFRa3 Goat R&D Systems; AF2645 1:300
NF200 Mouse Sigma-Aldrich; N0142 1:4000
NOS Rabbit Zymed Laboratories (now Invitrogen, 
Mulgrave, Vic, Australia); 61-7000
1:500
TRPV1 Guinea pig Millipore; AB5566 1:5000
TRPV1 Rabbit Neuromics (Burwood East, VIC, 
Australia); RA10110
1:8000
Secondaries
anti-goat Cy3 Donkey Jackson Laboratories; 705-165-147 1:1000
anti-guinea pig FITC Donkey Jackson Laboratories; 706-095-148 1:100
anti-mouse AF488 Donkey Molecular Probes (now Invitrogen); 
A-21202
1:1000
anti-mouse Cy3 Donkey Jackson Laboratories; 715-165-150 1:2000
anti-rabbit AF488 Donkey Invitrogen; A21206 1:2000
anti-rabbit Biotin Donkey Jackson Laboratories; 711-065-152 1:1000
anti-sheep AF488 Donkey Invitrogen; A-11015 1:1000
anti-sheep Biotin Donkey Jackson Laboratories; 713-065-003 1:1000
4.5 Chapter 4 tables and figures
Table 4.1
List of primary and secondary antibodies used
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Figure 4.1 Bladder section and diagram of bladder wholemount 
preparations and areas of interest (AOIs). a: Section through the 
bladder base showing a Fluorogold injection site (arrow) in the 
bladder wall. Urothelial surface is orientated to the top. Many 
urothelial cells have taken up the tracer dye. b: The bladder was 
cut into three longitudinal strips of approximately equal size for 
wholemount preparation. c: AOIs (shaded boxes) were assessed 
for GFRα3- and CGRP-IR terminals in the suburothelial plexus 
and for CGRP-IR terminals in the detrusor. Dimensions for each 
AOI were 500 x 500 μm. Scale bar represents 200 μm.
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Figure 4.2 Areas of interest (AOIs) used for densitometric image analysis of GFRα1, 
GFRα2- and GFRα3-immunoreactivity (IR) in the superficial dorsal horn in lumbar 
spinal cord in control or chronic cyclophosphamide treated animals. Two AOIs (boxes 
1 and 2) were assessed for GFRα1, GFRα2 and GFRα3. Each box had dimensions of 
130 x 130 μm and was aligned with the medial and lateral margins of the superficial 
dorsal horn. GFR, GDNF family receptor.
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Figure 4.3 Distribution of TRPV1-, CGRP- and GFRα-immunoreactivity (IR) in 
sacral and lumbar bladder afferent neurons. a-f: Numerous Fluorogold (FG)-labelled 
neurons expressed TRPV1- (a-c) and CGRP-IR (d-f). g-i: Many FG-labelled neurons 
contained GFRα1-IR. j-l: Few FG-labelled neurons contained GFRα2-IR. m-o: Many 
FG-labelled neurons contained GFRα3-IR. p-w: Co-expression of GFRα3 with 
TRPV1 (p-s) and CGRP (t-w) in bladder-projecting neurons. x: The proportion of 
sacral and lumbar bladder afferent neurons containing TRPV1-, CGRP- and GFR-IR. 
A higher proportion of lumbar FG-labelled neurons contain CGRP-IR than sacral 
DRGs (***P < 0.001). y: The proportion of GFRα1-, GFRα3- and CGRP-IR bladder 
afferent neurons co-expressing TRPV1-IR. z: The proportion of TRPV1-IR bladder 
afferent neurons co-expressing GFRα1-, GFRα3- and CGRP-IR. Images a-w are 
shown as monochrome image pairs and the corresponding merged colourised image. 
Data on graphs represents the mean ± SEM (n = 4), analysed by a paired t-test on 
arcsine transformed data. Scale bar = 50 μm in panel A (applies to all). TRPV1, 
transient receptor potential vanilloid 1; CGRP, calcitonin gene-related peptide; GFR, 
GDNF family receptor.
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Figure 4.4 Distribution of NF200-immunoreactivity (IR) in sacral and lumbar 
bladder afferent neurons. a: The proportion of NOS-, CGRP-, GFRα1-, ERα-IR 
sacral and lumbar bladder-projecting neurons containing NF200-IR. A higher 
proportion of sacral ERα-IR (*P = 0.05 Affinity, *P = 0.02 Millipore) neurons 
contain NF200-IR than lumbar DRGs. b: The proportion of NF200-IR sacral 
and lumbar bladder afferent neurons containing each marker. A higher 
proportion of lumbar NF200-IR neurons contain CGRP-IR than sacral DRGs 
(*P = 0.02). A higher proportion of NF200-IR bladder afferent neurons 
contain both ERα’s compared to lumbar DRGs (*P = 0.03 for ERα (Affinity), 
**P < 0.01 for ERα (Millipore). c-j: Co-expression of NF200 with NOS (c-f) 
and GFRα1 (g-j) in bladder-projecting neurons. Data represents the mean ± 
SEM (n = 5), analysed by a paired t-test on arcsine transformed data. Images 
are shown as monochrome image pairs and the merged image. Scale bar in C = 
50 μm (applies to all). NF200, neurofilament 200; NOS, nitric oxide synthase; 
CGRP, calcitonin gene-related peptide; GFR, GDNF family receptor; ER, 
estrogen receptor.
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Figure 4.5 Distribution of ERα (affinity) and GFRs in sacral and lumbar bladder 
afferent neurons. a, b: The proportion of sacral (a) and lumbar (b) bladder-projecting 
neurons containing ERα (Affinity), GFRα1-, GFRα3-, CGRP-, TRPV1- and NF200-
immunoreactivity (IR). c: The proportion of GFRα1-, GFRα3-, CGRP-, TRPV1- and 
NF200-IR sacral and lumbar bladder afferent neurons containing ERα (Affinity)-IR. 
A higher proportion of GFRα3-IR neurons contained ERα (Affinity)-IR in lumbar 
vs. sacral DRGs (*P = 0.01). A higher proportion of NF200-IR neurons contained 
ERα (Affinity)-IR in sacral vs. lumbar DRGS (*P = 0.03). d: The proportion of ERα 
(Affinity)-IR sacral and bladder FG-labelled neurons containing each marker. A higher 
proportion of ERα (Affinity)-IR neurons contained GFRα3-IR in lumbar vs. sacral 
DRGs (***P < 0.001). A higher proportion of sacral ERα-IR (*P = 0.05) neurons 
contain NF200-IR than lumbar DRGs. e-h: Co-expression of ERα (Affinity)- and 
GFRα1-IR in a fluorogold (FG)-labelled neuron. i-l: Co-expression of ERα (Affin-
ity)- and CGRP-IR in a FG-labelled neuron. Data represents the mean ± SEM (n = 5), 
analysed by a paired t-test on arcsine transformed data. Images are shown as mono-
chrome image pairs and the merged colourised image. Scale bar in E = 50 μm (applies 
to all). ER, estrogen receptor; GFR, GDNF family receptor; CGRP, calcitonin gene-
related peptide; TRPV1, transient receptor potential vanilloid 1; NF200, neurofilament 
200.
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Figure 4.6 Distribution of ED-1 in control and chronically inflamed bladders. a, b: Few ED-1 
immunoreactive cells were observed in the detrusor (a) and mucosa (b) in control animals. c, 
d: ED-1 infiltrate throughout the bladder following chronic cyclophosphamide treatment. This 
infiltrate was most pronounced in the mucosa (d). Scale bar = 100 μm in A (applies a, c); 50 
μm in B (applies b, d).
c CYP
a SAL b SAL
d CYP
213
% sacral bladder neurons
0
20
40
60
80
CG
RP
GF
Ra
1
GF
Ra
3
NO
S
GF
Ra
2
a % marker with NOS
0
20
40
60
80
100
% marker with NOS
0
20
40
60
80
100
% NOS with marker
0
20
40
60
80
100
% NOS with marker
0
20
40
60
80
100
CYP
control
c
CGRP GFRa1 GFRa3
Figure 4.7
g CGRP h NOS i FG j merge
k GFRa1 l NOS m FG n merge
o GFRa3 p NOS q FG r merge
f
CGRP GFRa1 GFRa3
e
CGRP GFRa1 GFRa3
b
CGRP GFRa1 GFRa3
% lumbar bladder neurons
0
20
40
60
80
CG
RP
GF
Ra
1
GF
Ra
3
NO
S
GF
Ra
2
d
214
Figure 4.7 Co-localisation of CGRP and the GFRs with NOS following chronic 
bladder inflammation. a: Chronic cyclophosphamide (CYP) treatment had no effect 
on the number of sacral fluorogold (FG)-labelled neurons containing CGRP, NOS or 
the GFRs. b, c: Chronic CYP had no effect on the number of CGRP-, GFRα1- and 
GFRα3-immunoreactive (IR) neurons containing NOS-IR (b), or the number of NOS-
IR neurons containing each marker (c). d: The proportion of lumbar bladder afferent 
neurons containing CGRP, NOS and the GFRs were not affected by chronic CYP 
treatment. e, f: Chronic CYP had no effect on the number CGRP-, GFRα1 and 
GFRα3-IR neurons containing NOS (e), or the number of NOS-IR neurons containing 
each marker (f). g-r: Co-expression of NOS with CGRP (g-j), GFRα1 (k-n) and 
GFRα3 (o-r) in FG-labelled neurons. Data represents the mean ± SEM (n = 4), 
analysed by Tukey’s multiple comparison post-hoc test on arcsine transformed data. 
Images are shown as monochrome image pairs and the merged image. Scale bar in G 
= 50 μm (applies to all). CGRP, calcitonin gene-related peptide; GFR, GDNF family 
receptor; NOS, nitric oxide synthase.
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Figure 4.8 Distribution of GFRα1-, GFRα2- and GFRα3-immunorective (IR) fibres 
in lumbar spinal cord. Each horizontal set of three micrographs shows 
immunoreactivity for a GFR and NOS to demonstrate lamination of the superficial 
dorsal horn and the intermediolateral cell nucleus (IML), and merged images. a-f: 
CGRP-IR fibres in lumbar spinal cord were distributed in lamina I and II (outer) and 
in deeper dorsal horn. NOS-IR fibres were located in lamina II (inner) and associated 
with the IML. g-l: GFRα1-IR fibres were distributed in lamina II (outer). m-r: GFRα2-IR 
fibres were distributed in lamina II (inner) and were associated with the IML, closely 
associated with NOS-IR in the area. s-x: GFRα3-IR fibres were primarily located in lamina I 
of lumbar dorsal horn. All images are orientated with dorsal surface at the top and medial cord 
to the right. Images are shown as monochrome image pairs and the merged image. Scale bar = 
200 μm in A (applies a-c, g-i, m-o, s-u); 100 μm in D (applies d-f, j-l, p-r, v-x). CGRP, 
calcitonin gene-related peptide; GFR, GDNF family receptor; NOS, nitric oxide synthase.
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Figure 4.9 Bladder wholemount preparations demonstrating NOS-immunoreactivity 
(IR) in the bladder. a-c: NOS-IR axons showed a uniform distribution throughout the 
bladder (a: base; b: middle; c: dome). d-f: Many specialised NOS-IR nerve endings 
were observed throughout the bladder. g-i: NOS-IR axons were associated with the 
vasculature in the detrusor (g, h) and mucosa (i). j-l: NOS-IR somata were distributed 
evenly throughout the bladder. NOS-IR somata were found individually or in small 
clusters. The length of their dendrites varied widely between neurons. m-o: NOS-IR 
axons were found in the suburothelial plexus and became progressively less dense 
towards the bladder dome (m: base; n: middle; o: dome). p: A few NOS-IR closed 
axonal loops were found in the suburothelial plexus. q, r: NOS-IR axon terminals 
were also observed in the suburothelial plexus. Arrowheads indicate specialised axons 
in the detrusor (d-f), NOS-IR axons associated with the vascular tree in the detrusor 
(g, h) and mucosa (i); NOS-IR neuron with short dendrites (k) and a closed axonal 
loop (p). Arrows indicate NOS-IR neurons with long dendrites (j, l). Scale bar = 500 
μm in A (applies a-c); 100 μm in D (applies d-f); 50 μm in G (applies g-i); 50 μm in J 
(applies j-l); 50 μm in M (applies m-r). NOS, nitric oxide synthase.
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Figure 4.10 Bladder wholemount preparations demonstrating CGRP- and GFRα3-
immunoreactivity (IR) in the bladder in control and chronic bladder inflammation animals. 
a-f: Bladder wholemounts showed a uniform distribution of CGRP- (a-c) and GFRα3-IR 
(d-f) axons throughout the bladder (a, d: base; b, e: middle; c, f: dome). g-l: CGRP- (g-
i) and GFRα3-IR (j-l) axons in the suburothelial plexus became progressively less dense 
towards the bladder dome (g, j: base; h, k: middle; i, l: dome). m-r: Chronic cyclophospha-
mide (CYP) treatment had no obvious effect on CGRP- (m-o) or GFRα3-IR (p-r) axons 
in the suburothelial plexus (m, p: base; n, q: middle; o, r: dome). Scale bar = 500 μm in A 
(applies a-f); 50 μm in G (applies g-r). CGRP, calcitonin gene-related peptide; GFR, GDNF 
family receptor.
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Figure 4.11 Bladder wholemount preparations demonstrating NF200-immunoreactivity 
(IR) in the bladder. a-c: Many NF200-IR axons were found evenly distributed throughout 
the bladder (a: base; b: middle; c: dome). d-f: NF200-IR somata were found throughout 
the detrusor associated with single axons or bundles of axons. Most had short feet-like 
processes and were found individually or in small clusters. Scale bar = 500 μm in A (ap-
plies a-c); 50 μm in D (applies d-f). NF200, neurofilament 200.
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Figure 4.12 Acute bladder inflammation induced ATF-3 and 
increased NOS-IR in sacral bladder afferent neurons. a: Acute 
cyclophosphamide (CYP) treatment induced a small, but significant 
induction of ATF-3 in sacral bladder afferent neurons (*P = 0.03). 
b: Acute CYP treatment increased the number of sacral FG-labelled 
neurons containing NOS-immunoreactivity (IR) (*P = 0.01), but did 
not affect the number of CGRP-, GFRα1- or GFRα3-IR neurons. c, 
d: The proportion of lumbar bladder afferent neurons 
containing ATF-3 (c), NOS-, CGRP-, GFRα1- or GFRα3-IR (d) 
were not affected by acute CYP treatment. e-h: Almost all ATF-3-
IR nuclei were found in NOS-IR neurons. Data represents the mean 
± SEM (n = 3), analysed by a paired t-test on arcsine transformed 
data. Images are shown as monochrome image pairs and the merged 
image. Scale bar in E = 30 μm (applies to all). ATF-3, activated 
transcription factor 3; NOS, nitric oxide synthase; CGRP, calcitonin 
gene-related peptide; GFR, GDNF family receptor; FG, fluorogold.
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Figure 4.13 Summary diagram illustrating the percentage of co-expression in 
bladder-projecting neurons expressing immunoreactivity for each marker used in 
the current study. Individual lines represent the overall percentage of bladder-
projecting neurons expressing each marker, and the overlap between line represents 
co-expression with other markers. 
224
CHAPTER 5: Peripheral innervation of the bladder 
 
5.1 Introduction  
Artemin, a member of the glial cell line-derived neurotrophic factor (GDNF) family 
of ligands, is upregulated within sensory nerves and their peripheral target tissues 
following injury or inflammation (Elitt et al., 2006; Malin et al., 2006). As 
demonstrated for nerve growth factor (NGF) and GDNF, artemin can regulate the 
sensitivity of nociceptors to thermal stimuli, and combined with NGF, can induce 
prolonged nociceptor sensitisation and pain (Elitt et al., 2006). The receptor for 
artemin, GFRα3, is found in approximately half of all peptidergic dorsal root ganglion 
(DRG) neurons (Bennett et al., 2006; Kalous et al., 2009; Keast et al., 2010), therefore 
these neurons have two potential neurotrophic influences: NGF and artemin. Recently 
our laboratory reported that GFRα3-immunoreactivity (IR) occurs in approximately 
30% of bladder afferent neurons (Forrest and Keast, 2008) and almost all of these 
contain calcitonin gene-related peptide (CGRP)-IR (Chapter 4).  
 
Chronic bladder inflammation induces many structural, neurochemical and 
electrophysiological changes in bladder afferent pathways (Callsen-Cencic and 
Mense, 1997; Vizzard, 2001; Yoshimura and de Groat, 1999). These changes are 
thought to be responsible for nociceptor sensitisation and visceral hyperactivity. 
Numerous reports have linked NGF in contributing to the mechanisms of these 
changes (Chuang et al., 2001; Dmitrieva et al., 1997; Yoshimura et al., 2006). NGF 
and GDNF levels are also increased in the bladder wall and in the urine of patients 
with interstitial cystitis (Okragly et al., 1999; Vizzard, 2000b). However, despite its 
implication in somatic sensitisation, the role of artemin in sensory bladder signalling 
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is poorly understood. GFRα3-IR axons are widely distributed in the bladder (Chapter 
4), but it is not known if these axons comprise a subpopulation of peptidergic afferent 
axons that target a distinct range of tissues in the bladder.  
 
The peripheral innervation of the bladder by peptidergic afferent axons has been 
extensively studied using immunohistochemistry for CGRP (Gabella and Davis, 
1998; Yokokawa et al., 1986). These axons are found throughout the detrusor and the 
suburothelial plexus. Afferent axons innervating the bladder originate from lumbar 
and sacral spinal DRG and travel in the hypogastric, splanchnic and pelvic nerves 
(Yoshimura, 1999). They are essential for the voiding reflex. The majority of afferent 
nerve fibers innervating the bladder have thinly myelinated (A-delta) or unmyelinated 
(C) axons and are involved in mechanoreception, chemoreception and pain (Birder et 
al., 2010; Fowler et al., 2008).  
 
The aim of this study was to explore the potential for artemin to target sensory axons 
in different regions and tissues of the bladder. We hypothesised that the majority of 
GFRα3-IR in the bladder would be expressed in a subpopulation of peptidergic 
afferent axons. GFRα3-IR may also occur in noradrenergic axons as reports in other 
tissues suggest that GFRα3 is expressed in many noradrenergic axons and many 
smooth muscle cells of the vasculature express artemin (Honma et al., 2002; 
McIlvried et al., 2010). To map GFRα3 expression in the bladder wall, 
immunohistochemistry was performed in bladder wholemount preparations and 
sections. Wholemounts provide an opportunity to visualise the innervation across all 
regions of the bladder, while sections from the bladder base were used for the 
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majority of co-expression studies because suburothelial and noradrenergic axons in 
the detrusor are most prevalent in this region. 
 
5.2 Methods 
5.2.1 Animals  
All procedures were approved by the University of Sydney and Royal North Shore 
Hospital Animal Ethics Committees, as required by the Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes (National Health and Medical 
Research Council of Australia). Twenty-six adult female Sprague Dawley rats (6-10 
weeks) were used for these experiments. These comprised 10 for DAB-processed 
bladder wholemount preparations, 2 for fluorescent-stained bladder wholemount 
preparations, 9 for bladder sections, 3 for retrograde tracer injections and 2 for 
accessory nerve transection.  
 
5.2.2 Retrograde tracer injections 
To identify bladder-projecting post-ganglionic neurons in pelvic ganglia (PG), the 
retrograde tracer Fluorogold (FG, 4% in sterile saline; Fluorochrome, Englewood, 
CO) was injected (total <10 µl) into approximately 8 sites in the urinary bladder base 
using an insulin syringe with a 30G needle under isoflurane anaesthesia (3% for 
induction and 1.5-2% for maintenance in O2) as previously described (Forrest and 
Keast, 2008). Seven days after surgery, rats were perfused and PG harvested for 
immunohistochemistry (as described below). 
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5.2.3 Accessory nerve transection 
For unilateral denervation of the bladder, unilateral accessory nerve transections were 
performed. The accessory nerves originate from the ventral aspect of the PG and 
contain afferent and autonomic axons that supply the bladder and some of the 
reproductive tract (Keast et al., 1989). Rats were anaesthetised with isoflurane (3% 
for induction and 1.5-2% for maintenance) and a midline incision made in the lower 
abdomen. The accessory nerves on one side of the bladder were identified and cut 
using micro-scissors. The abdominal wall and skin were closed with silk sutures (4-0 
and 3-0, respectively). Bladder tissue was harvested from these rats 7 days post 
surgery. 
  
5.2.4 Tissue fixation and dissection 
Rats were heavily anaesthetised with sodium pentobarbitone (80 mg/kg i.p.) and 
transcardially perfused with 0.9% saline containing 1.25% sodium nitrite and 0.036% 
heparin, followed by freshly made 4% paraformaldehyde in 0.1M phosphate buffer 
(PB, pH 7.4). The bladder and PG were removed and post-fixed overnight in the same 
fixative at 4°C, then washed three times in 0.1M phosphate buffered saline (PBS, pH 
7.2) and stored in PBS containing 0.1% sodium azide until sectioning. 
 
5.2.5 Immunohistochemistry 
The base of the bladder was dissected and cryoprotected overnight in PBS containing 
30% sucrose and cut horizontally into rings on a cryostat into 14 µm sections. 
Sections were collected onto 0.1% gelatinised slides and distributed between slides so 
that sections stained for the same substance were sampled at least 60 µm apart. 
Sections were then air dried, washed in PBS and blocked for 1-2 hours in PBS 
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containing 10% NHS and 0.1% triton X-100. Bladder sections were incubated 
overnight in combinations of antisera (Table 5.1), washed and incubated for 2-3 hours 
in appropriate host-specific secondaries (Table 5.1). Antibodies were diluted in 0.1M 
hypertonic PBS pH 7.2 and incubations performed in a dark humid chamber, at room 
temperature. Sections were then washed, counter-stained with 4',6-diamidino-2-
phenylindole (DAPI) and coverslipped with Vectashield mounting medium (Vector 
Laboratories, Burlingame, C.A).  
 
Bladders from rats that had undergone accessory nerve injury were bisected 
longitudinally to separate injured and non-injured sides. The bladder base was cut 
horizontally into half rings, processed as above and stained for GFRα3 with PGP, 
GFAP or S100. PG from FG-injected rats were processed as above and incubated in 
NF200 with TH or NOS primary antisera. The bladder base was selected because 
suburothelial and noradrenergic axons are most prevalent in this region. 
  
5.2.6 Preparation of bladder wholemounts 
In a separate group of naïve rats, the bladder was removed for wholemount 
preparation. Rats were heavily anaesthetised with sodium pentobarbitone (80 mg/kg 
i.p.) and perfused transcardially with 350 ml prewash (0.9% saline containing 1.25% 
sodium nitrite and 0.036% heparin). The bladder was removed and placed in a Petri 
dish containing prewash. The bladder was bisected longitudinally on the dorsal side, 
i.e., between the ureters. The bladder was then pinned out flat on a Sylgard-lined Petri 
dish with the urothelial surface facing upwards and stretched out making a circle. The 
prewash was then replaced with freshly made 4% paraformaldehyde in PB and post-
fixed overnight at 4°C. The following day, the pins were removed and bladders 
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washed in PB. The border of the bladder where the pins were inserted was trimmed 
and the bladders cut into three longitudinal strips (Figure 5.1a) before being processed 
for immunohistochemistry or stored at 4°C in PBS containing 0.05% thimerosol (PBS 
/ thimerosol). 
 
5.2.7 Immunostaining wholemount preparations - DAB protocol 
A similar single labelled immunohistochemistry protocol was used as described by 
Llewwllyn-Smith and Gnanamanickam (2010). All washes were of a large volume 
(~50 ml) in specimen or glass containers of at least 30 minutes. All incubations were 
performed on a shaker at room temperature. Bladder strips were washed in PB, then 
50% ethanol followed by another wash in 50% ethanol containing 3% H202. Strips 
were then blocked for 30 minutes in PB containing 10% normal horse serum (NHS) 
before incubation with primary antisera for 5 days at room temperature. Primary 
antibodies were made up in PB / thimerosol containing 10% NHS and 0.2% triton X-
100. Large well plates containing 1-2 ml of antibody solution were used for each 
bladder strip to ensure the antibody had good access to all surfaces of the wholemount 
and to prevent folding of the bladder strip.  
 
Five antibodies were used for single labelling: NPY, GFRα3, CGRP, TH and NF200 
(refer to Table 5.1). After three washes in PB, bladder strips were incubated in 
appropriate biotin-conjugated secondaries made in PB / thimerosol for 5 days at room 
temperature. Following three washes in PB, bladder strips were incubated in avidin-
biotin complex for 5 days at room temperature (6 µl / ml, Vectastain Elite kit (Vector 
Laboratories, Burlingame C.A). Bladder strips were then washed twice in PB 
followed by an 0.1M acetate buffer pH 6.0 wash before a 20 minute incubation in 
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DAB solution (0.2% D-glucose, 0.04% ammonium chloride, 0.025% 
diaminobenzidine / 100 ml 0.1M acetate buffer pH 6.0, 2% nickel sulfate). A black 
reaction product was produced by adding glucose oxidase (0.002%) and the reaction 
stopped by three quick washes with acetate buffer. Bladder strips were washed twice 
in PB before being mounted onto 0.1% gelatinised slides and air-dried overnight. 
Strips were then washed twice in H20 for 15 minutes before being dehydrated in 
ascending concentrations of ethanol (two 15 minute incubations in 30%, 50%, 70%, 
90%, 95% and 100% ethanol) and cleared in histolene (two 15 minute incubations). 
Bladder strips were coverslipped with DPX water-free mounting media (Crown 
Scientific, Mulgrave, VIC, Australia) and allowed to dry overnight then sealed with 
nail polish.  
 
5.2.8 Immunostaining wholemount preparations – fluorescence protocol 
Tissue preparation was the same as described above except PBS was used instead of 
PB. Bladder strips were washed three times in PBS before being blocked in PBS 
containing 10% NHS and 0.5% triton X-100 overnight. After three PBS washes, strips 
were incubated for 5 days in primary antisera made up in PBS containing 0.5% 
thimerosol (PBS / thimerosol pH7.2), 10% NHS and 0.5% triton X-100. Primary 
antisera used included GFRα3 with CGRP, TH or GFAP, and CGRP with TH. 
Following three PBS washes, bladder strips were incubated in appropriate secondary 
antibodies made up in PBS / thimerosol containing 2% NHS and 0.5% triton X-100 
for 5 days. Wholemounts were then washed in PBS and mounted onto 0.1% 
gelatinised slides and coverslipped with Vectashield and sealed with nail polish.  
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5.2.9 Neuronal counts and size measurement 
PG sections were viewed under an Olympus BX51 Fluorescence microscope. To 
assess NF200-IR in bladder-projecting neurons, FG-labelled neurons were classified 
as NF200-, TH- or NOS-IR positive or negative and expressed as a percentage of all 
FG neurons. Under a 40x objective, a minimum of 250 FG neurons were counted 
from a total of four sections through each ganglion for each rat. We included only 
those neurons that were sectioned through the nucleus to prevent double counting. 
 
The number of NPY- and NF200-IR somata in the detrusor were manually counted 
under a 20x objective in bladder wholemount preparations using an Olympus BX51 
microscope (Olympus Australia, Melbourne, Australia). The area of the bladder 
wholemount stained for each substance was calculated using ImageJA 1.45b software 
(from http://fiji.sc/wiki/index.php/Fiji) and the total number of somata were averaged 
for each rat and expressed as the mean ± SEM / cm2. 
 
To measure the size of neuronal cell bodies, images of neurons were captured from 
wholemounts immunostained using the DAB protocol. All preparations were viewed 
under a 40x objective. The diameter along the longest axis was measured using Image 
Pro Plus. The size of each cell body was averaged for each rat and cell diameters 
expressed as the mean ± SEM.  
 
5.2.10 Counts of axon terminals 
The number of axon terminals in DAB bladder wholemounts were counted on the 
same Olympus BX51 microscope. This was determined for GFRα3 and CGRP in the 
suburothelial plexus and for CGRP and TH in the detrusor. For CGRP- and GFRα3-
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IR terminal counts in the suburothelial plexus, the total number of endings per 500 
µm2 were counted in the bladder base. Bladder strips were subdivided under low 
magnification into three: base, middle and dome (Figure 5.1a). Under the 20x 
objective, a graticule was positioned at the top end of the lower third segment, 
representing the bladder base. The graticule was used as the grid and moved across 
the bladder base to make a row. The number of terminals in each area were counted 
across the bladder in rows and averaged for each rat. Two rows were counted, missing 
the second row to avoid potentially double counting terminals. The grey squares 
illustrate the areas of interest (AOI) in which axon terminals were counted (Figure 
5.1b). The number of CGRP- and GFRα3-IR terminals in the suburothelial plexus in 
control rats were converted to mm2. The same method of counting was used for 
CGRP- and TH-IR axons in the detrusor. For TH-IR, terminals were categorised into 
three groups: non-specialised terminals, specialised terminals and those originating 
from blood vessels. Non-specialised terminals were defined as terminals that did not 
branch, or branched once before ending; specialised terminals originated from a 
single axon that issued multiple branches before terminating; and those originating off 
blood vessels were from para-vascular axons that branched off the vascular tree and 
terminated. The total number of TH-IR terminals in each category were pooled and 
averaged for each rat. 
 
5.2.11 Image analysis and figure production 
Tissues were visualised using an Olympus BX51 microscope (Olympus Australia, 
Melbourne, Australia) and images of DAB-stained sections were captured with a 
Zeiss AxioCam MRm camera (Munchen-Hallbergmoos, Germany) and Axiovision 
4.2 software. Fluorescent bladder sections were viewed under an Olympus BX51 
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Fluorescence microscope and 8-bit monochrome images gathered using an RT Spot 
camera (Diagnostic Instruments, Sterling Heights, MI, USA) and digitised using 
Image Pro Plus. For figure production, no adjustments were made to grey-scale 
images except for minor adjustments to brightness and contrast with the levels 
command in Adobe Photoshop CS2 (San Jose, CA) to best represent the staining as 
viewed directly under the microscope.  Colourised merged images were produced by 
pasting grey-scale images into the appropriate colour channel of a 24-bit RGB file 
created in Photoshop.  
 
Bladder sections and fluorescent bladder wholemounts were also visualised under a 
Leica LCS SP5 II confocal microscope using LAS AF software (Version 2.3.6 build 
5381), which was used to acquire images and z-stacks. Excitation wavelengths of 405 
nm, 488 nm and 561 nm were used. DAPI (λex = 405 nm) was detected at 420 - 470 
nm. AF488 (λex = 488 nm) was detected at 500 – 570 nm. Cy3 (λex = 561 nm) was 
detected at 590 – 670 nm. All images and z-stacks were acquired using sequential 
scanning and captured at size 2048 x 2048 pixels with a line average of two to reduce 
noise. 1 µm step size were used for z-stacks of the vasculature and axon bundles and 
0.5 µm step size was used for z-stacks of somata and single axons to investigate co-
expression. Z-stacks were re-constructed in Photoshop by using the scripts option to 
load Tif files into an image stack. Images were then converted into smart objects and 
displayed as the maximum projection. Z-stacks of axon bundles in the detrusor ranged 
from a thickness of approximately 20-80 µm and comprised 20-80 images (1 µm step 
size) that were collapsed to form a 2D maximum projection of the z-stack. Z-stacks of 
the vasculature ranged from a thickness of approximately 30-50 µm and comprised 
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30-50 collapsed images (1 µm step size); those in the suburothelial plexus were 
approximately 15 µm thick comprising ~30 collapsed images (0.5 µm step size). 
  
5.3 Results 
5.3.1 Distribution of autonomic axons in the bladder 
Before commencing this study, we familiarised ourselves with the structure and 
distribution of axons across different tissues and regions of the bladder using NPY in 
wholemount preparations. NPY labels the largest population of autonomic axons in 
the bladder, comprising sympathetic and parasympathetic post-ganglionic axons 
(Mattiasson et al., 1985; Wanigasekara et al., 2003). This allowed us to visualise 
axons in the detrusor and those associated with the vasculature and suburothelial 
plexus. 
 
The bladder was densely targeted by NPY-IR axons that innervated the whole 
thickness of the detrusor. NPY-IR axons travelled as single axons or in large diameter 
axon bundles that traversed the detrusor, having a similar structure and density in the 
bladder base and dome (Figure 5.2a-c). In this study, large diameter axon bundles 
typically ranged 30 – 80 µm in diameter comprising numerous axons, and does not 
refer to the diameter of individual axons. All NPY-IR axons were varicose and 
travelled singularly or in bundles (Figure 5.2d-f). NPY-IR terminals in the detrusor 
were very common and terminated with a varicosity. These terminals were found 
throughout the whole thickness of the detrusor. NPY-IR somata were also observed in 
the detrusor, evenly distributed throughout the bladder. Quantitative analysis revealed 
that 14 ± 7 / cm2 (n = 4) NPY-IR somata were found throughout the bladder and 
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measured 15.99 ± 0.59 µm in diameter. These somata were found singularly or in 
clusters, associated with axon bundles or attached to single axons (Figure 5.2g-i).  
 
Arterioles and venules could not be confidently distinguished so are described 
together simply as vasculature. Two classes of axons are associated with the vascular 
tree, para- and peri-vascular axons. Para-vascular axons travel along the vascular tree 
to reach the relevant tissue or organ. Peri-vascular axons functionally innervate the 
vascular tree and wrap around its branches, typically located in the adventitia of the 
vessel (Haberberger et al., 1997; Henrich et al., 2003). The majority of these axons 
are sympathetic vasoconstrictors. NPY-IR axons were associated with the vasculature 
in mucosal tissue and traversing the detrusor. These consisted of both para- and peri-
vascular axons that densely innervated all branches of the vascular tree (Figure 5.2j-l). 
Peri-vascular axons formed a dense meshwork on primary and secondary branches 
but were less dense on distal branches.  
 
NPY-IR axons were also associated with the suburothelial plexus. These were more 
prevalent in the bladder base and became progressively less dense towards the bladder 
dome (Figure 5.2m-o). All NPY-IR axons in the suburothelial plexus were varicose, 
the majority originating from para-vascular axons that have branched off mucosal 
vasculature (Figure 5.2p-r). 
 
5.3.2 Distribution of GFRα3-IR in relation to peptidergic afferent distribution 
We have previously demonstrated that approximately 30% of bladder-projecting 
afferent neurons contain GFRα3-IR and almost all of these were found in the 
peptidergic CGRP-IR population (Chapter 4). To determine the likely targets of 
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artemin in the bladder, we assessed the distribution of GFRα3-IR relative to a well 
established marker of peptidergic afferent fibres, CGRP (Gabella and Davis, 1998). 
Like CGRP, GFRα3-IR was abundant in the bladder (Figure 5.3a-c) and had three 
main targets: the detrusor, suburothelial plexus and vasculature. This observation is 
consistent with the distribution of these axons in the bladder reported in Chapter 4. 
Each of these will be described in more detail below.  
 
5.3.2.1 Detrusor 
CGRP-IR axons in the detrusor travelled as single, varicose axons or in axon bundles 
that traversed the bladder. CGRP-IR axon terminals were common and occurred 
throughout the whole thickness of the detrusor. To assess the prevalence of CGRP-IR 
axon terminals in the detrusor, the number of endings were counted in the bladder 
base in wholemount preparations. Quantification revealed 139 ± 12 CGRP-IR 
terminals / mm2 (n=4) in the detrusor base. Many CGRP-IR axons also travelled in 
para-vascular axons throughout the detrusor. These observations were consistent to 
those reported in Chapter 4. 
 
GFRα3-IR axons were prevalent in the detrusor, and like CGRP-IR axons (Figure 
5.3d-f), were distributed evenly throughout the bladder where they had similar density 
and structure in the bladder base and dome (Figure 5.3g-i). These travelled as single 
axons or in bundles of multiple axons that ran parallel to muscle bundles. GFRα3-IR 
axons innervated the whole thickness of the detrusor but were preferentially located 
on the serosal aspect of the bladder (Figure 5.3b). In comparison to CGRP-IR axons, 
which were mostly varicose (Figure 5.4a-c), less than half of all GFRα3-IR axons 
were varicose (Figure 5.4e, f). Both CGRP-IR and GFRα3-IR terminals were 
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observed throughout the detrusor where single axons terminated or branched into two 
before terminating (Figure 5.4d, g, h). CGRP-IR and GFRα3-IR specialised endings 
were not observed in the detrusor. Intensely stained GFRα3-IR cells embedded in the 
detrusor were also common throughout the bladder (Figure 5.4i-m). The majority of 
these were elongated cells with long processes preferentially located close to the 
serosal surface of the bladder and always closely associated with axons or bundles of 
axons. These GFRα3-IR cells appeared to be potentially non-neuronal cells. Neither 
neuronal nor non-neuronal CGRP-IR cells were observed in the detrusor. These 
observations were consistent to those reported in Chapter 4. 
 
Co-expression studies were then performed to directly determine if GFRα3-IR was 
expressed in peptidergic afferent axons in the detrusor. Double labelling in bladder 
sections and wholemounts revealed that most GFRα3-IR did not contain CGRP-IR. 
GFRα3-IR was much more prevalent throughout the detrusor than CGRP, although 
the intensity of GFRα3-IR varied. Co-expression studies also revealed that in the 
detrusor, many but not all CGRP-IR axons in large and small diameter axon bundles 
contained GFRα3-IR (Figure 5.5a-c). Furthermore, most, but not all, single CGRP-IR 
axons contained GFRα3-IR (Figure 5.5d-f).  
 
Like CGRP, GFRα3-IR terminals were common in the detrusor and were distributed 
evenly throughout the bladder. However, the prevalence of GFRα3-IR terminals could 
not be quantified in the detrusor as their intensity varied and therefore, their true 
prevalence was likely to be underestimated. Most CGRP-IR endings in the detrusor 
contained GFRα3-IR but often GFRα3-IR was faint (Figure 5.5g-i). GFRα3-IR cells 
with elongated processes in the detrusor did not contain CGRP-IR (Figure 5.5k-n).  
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 5.3.2.2 Suburothelial plexus 
As previously described (Gabella and Davis, 1998), CGRP-IR axons were present 
under the urothelium and were more prevalent in the bladder base than the middle and 
dome of the bladder (Figure 5.6a-c). These axons formed a dense network and are 
referred to as the suburothelial plexus. GFRα3-IR was also prevalent in the 
suburothelial plexus and was most dense in the bladder base, progressively tapering 
towards the bladder dome (Figure 5.6d-f). Two types of CGRP-IR closed axonal 
loops were observed in the suburothelial plexus. Here, a single axon branched into 
two and appeared to re-join, forming a loop in the middle of an axon (Figure 5.6g), or 
where a terminal axon branched and formed a loop (Figure 5.6h, i). Both types of 
closed axonal loops were also observed in GFRα3-IR axons in the suburothelial 
plexus (Figure 5.6j, k). Like CGRP, these were not observed in the detrusor and were 
a unique feature of suburothelial axons. Many potential GFRα3-IR non-neuronal cells 
were also common throughout the suburothelial plexus. These were small cells with 
processes that branched to closely appose GFRα3-IR axons (Figure 5.6j-l). They had 
a similar appearance to those observed in the detrusor. Many terminal CGRP-IR 
axons in the suburothelium were varicose and endings were commonly observed 
(Figure 5.6m-o). GFRα3-IR varicose endings were observed in the suburothelial 
plexus but were not as common as CGRP-IR endings (GFRα3: 31 ± 1 / mm2 vs. 
CGRP: 70 ± 4 / mm2).  Like CGRP, these also terminated with a varicosity (Figure 
5.6p-r). 
 
Few CGRP- and GFRα3-IR axons were in close apposition to urothelial cells and 
intra-urothelial axons were rare. This was demonstrated by co-staining CGRP with 
239
CYTO-20 (Figure 5.7a-d), which labels superficial urothelial cells or CYTO-17 
(Figure 5.7e-h), which labels intermediate and basal urothelial cells. 
 
CGRP-IR axons in the suburothelial plexus were more prevalent than GFRα3-IR 
axons (Figure 5.8a-c). Double labelling revealed that the majority of GFRα3-IR axons 
(Figure 5.8d-f) and closed axonal loops (Figure 5.8g-i) in the suburothelial plexus 
contained CGRP-IR, but most CGRP-IR axon terminals did not contain GFRα3-IR 
(Figure 5.8d-i). Single labelled GFRα3-IR axons were observed but these were rare. 
The small GFRα3-IR cells in the suburothelial plexus did not contain CGRP-IR but 
occasionally CGRP-IR axons were in close proximity to these GFRα3-IR cells. 
 
5.3.2.3 Vasculature 
Both CGRP- and GFRα3-IR axons were associated with the vasculature in mucosal 
tissue and traversing the detrusor. The majority of CGRP-IR nerves associated with 
the vasculature were small bundles of para-vascular axons. These were found on 
primary, secondary and tertiary branches of the vascular tree (Figure 5.9a-c). CGRP-
IR para-vascular axons were rarely found on quaternary branches and did not extend 
to the most distal aspects of the vascular tree. The primary branch of the vascular tree 
also contained CGRP-IR peri-vascular axons (Figure 5.9b) that branched to form a 
meshwork around the vessel. CGRP-IR peri-vascular axons were relatively sparse on 
all other branches of the vascular tree (Figure 5.9b-c). Numerous GFRα3-IR axons 
were also associated with the vascular tree and consisted of both para- and peri-
vascular axons (Figure 5.9d-f). GFRα3-IR para-vascular axons travelled in small 
bundles and were found on all branches of the vascular tree. Peri-vascular GFRα3-IR 
axons consisted of a few axons intertwined that frequently branched to form a dense 
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meshwork on primary and secondary branches. GFRα3-IR peri-vascular axons were 
also present, but less prevalent on proximal aspects of tertiary branches of the 
vascular tree. GFRα3-IR peri-vascular axons did not extend to distal tertiary or 
quaternary vascular branches. 
 
Double labelling in bladder sections and wholemounts revealed that GFRα3-IR axons 
were more prevalent than CGRP-IR axons, suggesting that some GFRα3-IR axons 
associated with the vasculature may not be peptidergic afferents and could potentially 
be non-afferent axons. Co-expression studies were then performed to determine the 
proportion of GFRα3-IR axons associated with the vasculature that were peptidergic 
afferents by co-labelling with CGRP. Double labelling revealed that GFRα3-IR para-
vascular axons were more prevalent than CGRP-IR para-vascular axons, many of 
which contained CGRP-IR (Figure 5.9g-l). Both CGRP- and GFRα3-IR para-vascular 
axons commonly branched off the vascular tree and did not extend to the most distal 
aspects of the vascular tree (Figure 5.9m-o). GFRα3-IR peri-vascular axons were 
more prevalent than CGRP-IR peri-vascular axons and extended for a greater distance 
along the vascular tree, being present on secondary and tertiary branches. On all 
vascular branches, potentially non-neuronal small, elongated GFRα3-IR cells were 
observed closely associated with axons.  
 
5.3.3 GFRα3-IR noradrenergic axons 
5.3.3.1 Vasculature 
As described above, double staining in bladder sections and wholemounts revealed 
that in the vasculature, GFRα3-IR axons were more prevalent than CGRP-IR axons. 
Furthermore, the majority of peri-vascular GFRα3-IR axons did not contain CGRP-IR 
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and were therefore unlikely to be afferent axons. Taken together, we considered that 
GFRα3-IR could be expressed in sympathetic vasoconstrictor axons that have been 
well documented (Gibbins, 1992) and can be visualised using TH. The following 
section summarises the expression of GFRα3-IR relative to the two primary 
populations of sympathetic axons in the bladder, vasoconstrictor axons and axons 
innervating the detrusor of the bladder base. 
 
TH-IR axons densely innervated all branches of the vascular tree that traversed the 
detrusor and mucosa (Figure 5.10a-c). These are the most prevalent type of axon 
associated with the vasculature and consist of both para- and peri-vascular axons. 
Both para- and peri-vascular TH-IR axons did not extend to the most distal aspects of 
the vascular tree. TH-IR para-vascular axons travelled in small axon bundles that 
commonly branched on the primary and secondary branches of the vascular tree, but 
were less common on tertiary and quaternary branches of the vascular tree. TH-IR 
peri-vascular axons formed a dense meshwork that was most dense on the primary 
and secondary branches of the vascular tree, and more sparse on the distal branches.  
 
To directly compare the nature of this staining with afferent axons innervating the 
vasculature, we co-stained bladder wholemounts with CGRP. Both TH-IR para- and 
peri-vascular axons were more prevalent than peptidergic afferent axons associated 
with the vascular tree. Double labelling revealed that both CGRP- and TH-IR para-
vascular axons had a similar distribution and density on the proximal aspect of the 
primary branch of the vascular tree. Like CGRP-IR para-vascular axons, TH-IR para-
vascular axons were less prevalent on the tertiary branches of the vascular tree 
compared to the primary and secondary branches. However, they were still more 
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prevalent than CGRP-IR para-vascular axons (Figure 5.10d-i). TH-IR para-vascular 
axons extended much further along the vascular tree than CGRP-IR para-vascular 
axons where many distal portions of the vascular tree were devoid of CGRP-IR axons 
(Figure 5.10j-l). Double labelling also revealed that both CGRP- and TH-IR peri-
vascular axons had a similar distribution pattern on the proximal aspect of primary 
branches of the vasculature tree. However, at the distal aspect of the primary branch, 
CGRP-IR peri-vascular axons became less prevalent and were far outnumbered by 
TH-IR peri-vascular axons (Figure 5.10g-i). On all further branches of the vascular 
tree, CGRP-IR peri-vascular axons were sparse compared to TH-IR peri-vascular 
axons. Co-expression of TH- and CGRP-IR did not occur in para- or peri-vascular 
axons.  
 
To directly determine if GFRα3 was expressed in noradrenergic vasoconstrictor 
axons, bladder wholemounts and sections were double-labelled for TH and GFRα3. 
Double labelling revealed that throughout the bladder, there was a strong co-existence 
of TH- and GFRα3-IR axons in para- and peri-vascular axons (Figure 5.11a-c). These 
axons containing GFRα3- and TH-IR had a very similar density and distribution 
pattern on all branches of the vascular tree (Figure 5.11d-f), forming a dense 
meshwork around the primary and secondary branches but not extending to the distal 
portions of the tertiary branch or quaternary branches of the vascular tree.  Double 
labelling revealed that many TH-IR para-vascular axons contained GFRα3-IR and 
were closely associated, travelling in the same axon bundle. Most, but not all TH-IR 
peri-vascular axons contained GFRα3-IR but the intensity of GFRα3-IR varied 
(Figure 5.11g-i).  
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In summary, afferent axons had a similar density as noradrenergic axons in the para- 
and peri-vascular innervation of the primary branch of the vascular tree but afferent 
peri-vascular axons were relatively sparse on all other branches. Afferent peri-
vascular axons did not contain GFRα3-IR but many para-vascular afferent axons did. 
GFRα3-IR was expressed by many noradrenergic vasoconstrictor peri-vascular axons 
on all branches of the vascular tree and, conversely, many noradrenergic para-
vascular axons contained GFRα3-IR. Noradrenergic GFRα3-IR para- and peri-
vascular axons extend further along the vascular tree than afferent axons.  
 
5.3.3.2 Detrusor 
In addition to the vasculature, sympathetic axons also innervate the detrusor 
(Wakabayashi et al., 1994; Wakabayashi et al., 1993); therefore, we investigated if 
GFRα3-IR was expressed in this population of noradrenergic axons. As reported 
previously, in contrast to the dense noradrenergic innervation of the vasculature, TH-
IR axons were very sparse in the detrusor and primarily confined to the bladder base.  
 
The majority of TH-IR axons in the detrusor were varicose and travelled as single 
axons or in bundles consisting of multiple axons (Figure 5.12a-c). Quantification 
revealed 40 ± 7 TH-IR axon terminals / mm2 (n = 4) in the detrusor and these 
consisted of 3 types: non-specialised (Figure 5.12d), specialised (Figure 5.12e) and 
those originating from para-vascular axons that have branched off the vascular tree 
(Figure 5.12f). Non-specialised TH-IR axon terminals were either unbranched or 
branched into two, both branches terminating with a varicosity. Specialised axon 
terminals originated from one axon that issued multiple branches before terminating. 
Both non-specialised and specialised endings were observed throughout the whole 
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thickness of the detrusor. In comparison, endings originating from para-vascular 
axons branching off the vascular tree were most frequently observed in the mucosa 
where they branched from distal branches of vascular trees. TH-IR axons were not 
associated with the suburothelial plexus and TH-IR cell bodies were rarely identified 
in the detrusor. 
 
Double labelling revealed that GFRα3-IR was much more prevalent throughout the 
detrusor than TH-IR axons. Occasionally TH-IR axons were in close proximity to 
GFRα3-IR axons but their immunoreactivity rarely co-localised (Figure 5.12g-i). TH-
IR axons travelled with bundles of GFRα3-IR axons but these did not show GFRa3-
IR (Figure 5.12j-l). As previously reported (Brumovsky et al., 2012a), within the 
detrusor, TH- and CGRP-IR axons comprised completely separate populations 
(Figure 5.12m-o).  
 
5.3.4 GFRa3-IR associated with other neuronal markers 
At the outset of the study, we predicted that the majority of GFRα3-IR in the bladder 
would be expressed in a sub-population of peptidergic afferent axons as almost half of 
the peptidergic bladder afferent neurons are GFRa3-IR and, conversely, all GFRα3-IR 
bladder-projecting afferent neurons contain CGRP-IR (Chapter 4). On this basis we 
also expected CGRP-IR axons in the bladder to be more prevalent than those 
containing GFRα3-IR. Partial co-expression of GFRα3-IR was also expected in 
noradrenergic axons, as reports suggest that GFRα3 is expressed in many 
noradrenergic axons and many smooth muscle cells of the vasculature express artemin 
(Honma et al., 2002; McIlvried et al., 2010). While many peptidergic afferent and 
noradrenergic vasoconstrictor axons contained GFRα3-IR, these two populations 
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together could not account for all of the GFRa3-IR observed. Furthermore, many 
small GFRα3-IR cells were also observed throughout the bladder. Therefore, we 
investigated the possibility that GFRa3-IR was present in other types of axons not 
labelled by CGRP or TH antisera (e.g., non-peptidergic afferent or parasympathetic 
autonomic axons) by using a broader range of neuronal markers. We also tested a 
number of glial markers. Alternatively, it is possible that CGRP-negative GFRa3-
positive structures are terminals of peptidergic afferent nerves that do not transport 
peptide to their peripheral terminals.  
 
5.3.4.1 PGP 
PGP (Protein gene product 9.5) was used as a broad spectrum neuronal marker to 
determine if all GFRα3-IR structures were likely to be neuronal. As expected, PGP-IR 
axons innervated the whole thickness of the detrusor and axons associated with the 
vasculature. However, PGP labelled relatively few single axons in the detrusor 
compared to what would be seen with NPY and PGP-IR axons in the suburothelial 
plexus were rare. This raised the possibility that in the bladder, PGP labels pre-
terminal axons and not the whole axon population. For this reason, PGP-IR was only 
used to assess GFRα3-IR in the detrusor and vasculature. PGP also produced bright 
immunostaining in all urothelial cells (shown below in Figure 5.20a, d), but in no 
other non-neuronal structure. 
 
PGP-IR was prevalent in the bladder and labelled axon bundles throughout the 
detrusor and a small number of single axons. Many large diameter PGP-IR axon 
bundles were found on the serosal surface of the bladder and smaller diameter bundles 
deeper in the detrusor. Large diameter axon bundles labelled with PGP did not 
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contain, or had very little GFRα3-IR (Figure 5.13a-c). In contrast, most small 
diameter PGP-IR axon bundles and single axons in the detrusor contained GFRα3-IR 
(Figure 5.13d-g). Double labelling also revealed that GFRα3-IR was more prevalent 
in the detrusor than PGP and most GFRα3-IR did not contain PGP-IR. PGP-IR 
somata were occasionally observed in the detrusor, some of which contained GFRα3-
IR (Figure 5.13h-k). However, only a minority of GFRα3-IR cells in the detrusor 
contained PGP-IR and were proposed to be non-neuronal cells (e.g., glia). Bladder 
sections were counter-stained with DAPI to confirm the presence of a nucleus within 
GFRα3-IR cells and to visualise their relationship to axon bundles. DAPI was 
visualised under a UV filter, which produced some auto-fluorescence in the internal 
elastic lamina of blood vessels (Figure 5.13n). 
 
In contrast to the detrusor, the majority of GFRα3-IR axons associated with the 
vasculature contained PGP-IR (Figure 5.13l-o), and from our earlier study is likely to 
comprise noradrenergic vasoconstrictor and peptidergic afferent para-vascular axons. 
Few GFRα3-IR cells associated with the vasculature contained PGP-IR (Figure 5.13l-
o), suggesting that they were likely to be non-neuronal cells. Together these 
observations suggest that a substantial proportion of GFRα3-IR structures in the 
detrusor, including the small cells with elongated processes in both the detrusor and 
vasculature, were likely to be non-neuronal.  
 
5.3.4.2 SYN 
SYN (synaptophysin) is a synaptic vesicle protein and was used to potentially show 
more effective labelling of single axons in the bladder, as PGP did not label the 
complete axonal population. We would expect that SYN labels both cholinergic and 
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noradrenergic autonomic axons in the bladder. However, few peptidergic afferent 
axons were likely to be detected with SYN as the majority of this population lack 
SYN-IR and other synaptic vesicular proteins (Morris et al., 2005). Few non-
peptidergic afferent axons were also likely to be detected with SYN as SYN-IR is 
only expressed in a sub-population of non-peptidergic terminals (Brock et al., 2004; 
Sun et al., 2006). Because noradrenergic axons are so sparse in the detrusor and 
absent from the sub-urothelial layer, we did not specifically investigate the potential 
for SYN and TH co-expression in these tissues. 
 
SYN-IR axons densely innervated the detrusor and vasculature but were less 
prevalent in the suburothelial plexus. All SYN-IR axons were varicose and travelled 
as single axons or in axon bundles that were distributed throughout the whole 
thickness of the detrusor. Co-staining bladder sections with SYN and VAChT, a 
marker of autonomic cholinergic axons, revealed that the majority of SYN-IR axons 
in the bladder contained VAChT-IR, and that almost all VAChT-IR axons contained 
SYN-IR (Figure 5.14a-c). As stated above, few peptidergic afferent axons were likely 
to contain SYN and double labelling with CGRP revealed that SYN-IR axons in the 
detrusor were much more prevalent than CGRP-IR axons (Figure 5.14d-f). 
Furthermore, few SYN-IR axons in the detrusor (Figure 5.14g-i) or vasculature 
(Figure 5.14j-l) contained CGRP-IR; CGRP-IR axons in the suburothelial plexus also 
did not contain SYN-IR. These results confirm that the majority of SYN-IR axons in 
the bladder were likely to be cholinergic autonomic axons. 
 
In the detrusor, GFRα3-IR axons rarely contained SYN-IR (Figure 5.14m-p), 
suggesting that very few GFRα3-IR axons were likely to be autonomic, although 
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some SYN-IR and GFRα3-IR axons travelled in the same bundle (Figure 5.14m-p). In 
contrast, many GFRα3-IR axons associated with the vasculature contained SYN-IR 
(Figure 5.14q-t), consistent with our earlier observation that most GFRα3-IR 
associated with the vasculature is autonomic. As demonstrated above, few SYN-IR 
axons were associated with the suburothelial plexus and all GFRα3-IR axons in this 
region were SYN-IR negative (Figure 5.14u-x) and therefore unlikely to be 
autonomic. Together these results suggest that few GFRα3-IR axons in the detrusor 
are autonomic but many associated with the vasculature are. 
 
5.3.4.3 NF200 
NF200-IR is found in medium-large diameter, myelinated DRG neurons (Robertson 
et al., 1991; Scherrer et al., 2010), so we used NF200 to identify axons of myelinated 
sensory neurons in the bladder. In Chapter 4 we showed that approximately 60% of 
bladder afferent neurons express NF200-IR. GFRα3-IR is expressed by approximately 
30% of bladder-projecting neurons (Chapter 4) but these are small-medium sized 
neurons so we predicted that GFRα3 would not be expressed in NF200-IR axons in 
the bladder.  
 
We used wholemounts to describe the distribution of NF200-IR axons in different 
tissues and regions in the bladder. NF200-IR axons were prevalent in the detrusor and 
had a similar distribution throughout the bladder (Figure 5.15a-c). The majority of 
NF200-IR axons travelled in large diameter axon bundles (Figure 5.15d-e) that 
traversed the detrusor but relatively few single axons were NF200-positive. NF200-IR 
axons were non-varicose and their terminals were sparse and difficult to visualise. 
NF200-IR axon terminals were occasionally observed after an axon branch point 
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(Figure 5.15f). Few NF200-IR axons were associated with the vasculature; these 
consisted of para-vascular axons that were observed on primary and secondary 
branches of the vascular tree (Figure 5.15g-i). NF200-IR para-vascular axons rarely 
branched and were rarely observed past the secondary branch of the vascular tree. 
These observations were consistent to those reported in Chapter 4. 
 
NF200-IR intra-mural neurons were observed in the bladder (22 ± 4 / cm2, n= 4), 
closely associated with single axons or bundles (Figure 5.15j-l). NF200-IR neurons 
measured 15.18 ± 0.56 µm in diameter and were evenly distributed throughout the 
bladder. Many of these somata had short processes and were found individually or in 
small clusters containing 3-4 neurons (Figure 5.15j-l).  
 
In the detrusor, NF200-IR axons were relatively sparse in comparison to GFRα3-IR. 
Double labelling of bladder sections revealed that almost all large diameter NF200-IR 
axon bundles that were common on the serosal surface of the bladder did not contain 
GFRα3-IR (Figure 5.15m-o). In comparison, many small diameter NF200-IR axon 
bundles and single axons contained GFRα3-IR (Figure 5.15p-r). 
 
The presence of NF200-IR somata in the detrusor raised the possibility that NF200-IR 
may be expressed in autonomic axons originating from PG. To investigate this 
possibility, we examined the distribution of NF200-IR in the PG. NF200-IR neurons 
were very prevalent in the PG and labelled neurons with varying intensity. 
Immunolabelling appeared to be localised in the endoplasmic reticulum (and possibly 
the Golgi apparatus). Numerous intensely stained NF200-IR axons were also 
observed passing through the ganglia. We then investigated if NF200-IR was 
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expressed in bladder-projecting neurons and, if so, if this was restricted to 
noradrenergic (TH-IR) or a major group of cholinergic (nitric oxide synthase positive 
[NOS-IR]) populations. Assessment of retrogradely labelled neurons revealed that 
22.4 ± 0.8% contained NOS-IR, <2% contained TH-IR and 82.08 ± 1.91% contained 
NF200-IR. Double labelling revealed that 92.04 ± 3.38% of NOS-IR neurons 
contained NF200-IR, and these comprised 25.04 ± 0.52% of all NOS-IR neurons 
(Figure 5.16a-h). Although a very small percentage of FG neurons in the female rat 
PG contained TH-IR, these all contained NF200-IR (Figure 5.16i-p). This is the first 
time NF200-IR has been demonstrated in the PG and suggests that NF200 is 
expressed by both afferent and autonomic post-ganglionic axons in the bladder, the 
majority of which were cholinergic. 
 
5.3.5 GFRα3-IR with non-neuronal markers 
The above observations demonstrate that a large proportion of GFRα3-IR in the 
detrusor, including the small GFRα3-IR cells, cannot be labelled with any of the 
above neuronal markers. This suggested that much of the GFRα3-IR in the bladder 
was non-neuronal. Therefore, we conducted further studies to determine if GFRα3-IR 
was expressed in myofibroblasts, interstitial cells or glia. 
 
5.3.5.1 Vimentin 
Myofibroblasts and interstitial cells can be identified with vimentin (Vim) (Davidson 
and McCloskey, 2005; McCloskey, 2010). Vim-IR cells and their processes were 
numerous throughout the bladder and were found in the detrusor, vasculature and a 
dense band beneath the urothelium (Figure 5.17a-d). In the detrusor, most Vim-IR 
cells did not express GFRα3-IR and few GFRα3-IR cells expressed Vim-IR (Figure 
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5.17e-l). GFRα3-IR cells associated with the vasculature did not contain Vim-IR 
(Figure 5.17m-p). GFRα3-IR structures associated with the suburothelial plexus were 
located on the superficial aspect of the band of Vim-IR cells beneath the urothelium 
and but did not co-express Vim (Figure 5.17q-t). 
 
5.3.5.2 Smooth muscle actin 
Smooth muscle actin (SMA) is a cytoskeletal protein in smooth muscle cells that also 
labels myofibroblasts in the detrusor, vasculature and a thin band beneath urothelial 
cells (Figure 5.18a-d). Individual myofibroblasts and muscle bundles can be identified 
in the detrusor with SMA (Figure 5.18e). Many GFRα3-IR axons and axon bundles 
were observed traversing the edge of muscle bundles or travelling between 
myofibroblasts within a muscle bundle (Figure 5.18e-h). Co-expression between 
GFRα3- and SMA-IR was not observed in the detrusor. All vessels in the mucosa and 
detrusor were associated with SMA-IR and, like the detrusor, co-expression with 
GFRα3-IR was not observed (Figure 5.18i-l). GFRα3-IR axons associated with the 
suburothelial plexus were located on the superficial aspect of the band of SMA-IR 
myofibroblasts beneath the urothelium and did not show co-expression (Figure 
5.18m-p).  
 
5.3.5.3 GFAP 
The above observations with Vim and SMA indicate that very little GFRα3-IR was 
expressed in myofibroblasts or interstitial cells, so we examined the possibility that 
GFRα3-IR was expressed in glia. GFAP (glial fibrillary acidic protein) was used to 
identify Schwann cells and their individual processes associated with axons in the 
bladder. GFAP-IR was located throughout the bladder; in the detrusor, preferentially 
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towards the serosal aspect and associated with the vasculature and mucosa (Figure 
5.19a, h). All GFAP-IR was closely associated with individual axons and bundles of 
axons. To first confirm that GFAP did not label neuronal structures, double labelling 
was performed on bladder sections with SYN (Figure 5.19a-c). Double labelling 
demonstrated that GFAP-IR processes were in very close proximity to axons (Figure 
5.19d-g), usually adjacent to the axon so that the two wrap around each other, 
consistent with previous studies (Gabella, 1995).  However, we found no evidence of 
co-expression between SYN and GFAP. 
 
Double labelling of bladder sections and wholemounts revealed that GFRα3-IR was 
more prevalent in the bladder than GFAP-IR (Figure 5.19h-j). As observed with many 
of the above neuronal markers, large diameter axonal bundles on the serosal surface 
were closely associated with GFAP-IR, which contained relatively few, or no GFRα3-
IR axons.  Of particular relevance for this set of experiments, GFRα3-IR cells were 
more prevalent in the bladder than GFAP-IR cells, but there was only partial co-
expression between the two markers in the detrusor. Here, GFAP- and GFRα3-IR 
were closely associated with smaller diameter axon bundles. Many of the numerous 
GFAP-IR cells with processes observed throughout all levels of the detrusor did not 
contain GFRα3-IR (Figure 5.19k-n). Likewise, in the detrusor, some GFRα3-IR cells 
contained GFAP-IR (Figure 5.19o-r), but the majority did not (Figure 5.19s-v). Many 
GFAP-IR cells were associated with the vasculature and most GFRα3-IR cells 
associated with the vasculature contained GFAP-IR (Figure 5.19w-z).  
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5.3.5.4 S100 
S100 was also used as a glial marker to identify Schwann cells in the bladder. S100 
had a similar distribution in the bladder to GFAP-IR, except that it was not present 
beneath the urothelium. Like GFAP-IR glial cells, GFRα3-IR cells were more 
prevalent than S100-IR cells. Double labelling revealed that many S100-IR cells in 
the detrusor expressed GFRα3-IR (Figure 5.19aa-dd) but the majority of GFRα3-IR 
cells did not contain S100-IR (Figure 5.19ee-gg). Many S100-IR processes and small 
diameter axon bundles containing S100-IR glial cells were closely associated with 
GFRα3-IR. As seen with the above neuronal markers, large diameter axon bundles on 
the serosal surface of the bladder containing S100-IR did not contain GFRα3-IR. 
While a significant proportion of GFRα3-IR cells in the bladder could be labelled 
with GFAP- or S100-IR, the above results indicate that most GFRα3-IR cells could 
not be labelled with any of the non-neuronal markers used. 
 
5.3.6 Effect of unilateral dennervation of the bladder 
To further address the issue of non-neuronal sources of GFRα3-IR in the bladder, a 
unilateral accessory nerve transection was performed to denervate half the bladder. 
Bladder sections from injured and uninjured sides were processed simultaneously and 
co-stained for GFRα3 with PGP, GFAP and S100 to compare neuronal and non-
neuronal staining. After denervation, throughout the detrusor there was a significant 
reduction in the number of PGP-IR axons and in many areas, an absence of axons. 
This loss was most obvious for single axons and, to a lesser degree, axon bundles 
throughout the detrusor. There were also a few small areas on the uninjured side that 
had a reduced number of PGP-IR axons (Figure 5.20a, d).  
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GFRα3-IR was also greatly reduced on the denervated side of the bladder (Figure 
5.20a-f), which was most obvious for individual GFRα3-IR axons. In the detrusor, 
there were areas of reduced density of both PGP- and GFRα3-IR axons and small 
areas that were devoid of both PGP- and GFRα3-IR axons. In most areas, it was a 
reduction in the number of GFRα3-IR axons and to a lesser extent, a reduction in 
axon bundles in the detrusor. After unilateral accessory nerve transection, there was 
incomplete denervation of the injured side, with some PGP- and GFRα3-IR axons 
remaining. Many large diameter axon bundles on the serosal surface remained intact 
on the injured side. Some GFRα3-IR associated with axon bundles remaining on the 
injured side contained PGP-IR (Figure 5.20g-j) but most were PGP-negative. 
Furthermore, some axon bundles with weak GFRα3-IR remaining on the serosal 
surface of the injured side did not contain PGP-IR. There was also a reduction in the 
density of PGP- and GFRα3-IR axons associated with the vasculature (Figure 5.20k-
n) and GFRα3-IR cells were rarely observed on the injured side. 
 
As demonstrated above, GFAP-IR processes and small diameter axon bundles 
containing GFAP-IR cells were closely associated with GFRα3-IR in the detrusor, 
whereas large diameter axon bundles on the serosal surface, closely associated with 
GFAP-IR, contained few, or no GFRα3-IR axons. After injury, GFAP-IR was greatly 
reduced on the denervated side of the bladder, which was most obvious for individual 
GFAP-IR processes and GFAP-IR associated with small diameter axon bundles. In 
the detrusor, there were areas of reduced density of both GFRα3- and GFAP-IR 
structures and small areas that were devoid of both GFRα3- and GFAP-IR. 
Denervation produced an incomplete loss of GFAP-IR on the injured side with some 
GFAP-IR structures remaining. Most GFAP-IR associated with large diameter axon 
255
bundles on the serosal surface of the bladder were unaffected (Figure 5.21a-h) by 
injury. Most of this remaining GFAP-IR associated with axon bundles on the injured 
side contained weak GFRα3-IR. GFAP-IR cells were reduced on the injured side of 
the bladder. There were also a few areas on the uninjured side that had a reduction in 
the number of GFAP-IR structures. 
 
Unilateral denervation of the bladder had a similar effect on S100-IR in the detrusor 
as GFAP-IR. After denervation, throughout the detrusor there was a reduction in 
density of S100-IR structures that was most obvious with individual S100-IR 
processes and S100-IR associated with small diameter axon bundles. There were also 
areas in the detrusor that were devoid of both S100- and GFRα3-IR structures. As 
with the above markers, this was not a complete loss with most S100-IR associated 
with large diameter axon bundles remaining unaffected by denervation. Most 
remaining S100-IR associated with large diameter axon bundles contained weak, or 
no GFRα3-IR. Most S100-IR associated with smaller diameter axon bundles 
remaining on the injured side contained weak GFRα3-IR. There was also a reduction 
in the number of S100-IR cells on the injured side. Some areas in the detrusor on the 
uninjured side also had a reduced number of S100-IR structures. Unilateral 
dennervation revealed a dramatic reduction of GFRα3-, PGP-, GFAP- and S100-IR 
on the injured side and suggests that a significant portion of GFRα3-IR in the bladder 
was likely to be both neuronal and glial. 
 
5.4 Discussion 
This study investigated the potential for artemin to target peptidergic afferent and 
noradrenergic axons in different regions and tissues of the bladder by mapping 
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GFRα3 expression. We have demonstrated in Chapter 4 that GFRα3-IR is expressed 
in approximately 30% of bladder-projecting afferent neurons and almost all of these 
were found in the peptidergic CGRP-IR population. Conversely, almost half of the 
peptidergic bladder afferent neurons contained GFRα3-IR. We hypothesised that the 
majority of GFRα3-IR in the detrusor and suburothelial tissue would be expressed in 
a subpopulation of peptidergic afferent axons. Smooth muscle cells of the vasculature 
can express artemin and many noradrenergic axons are reported to express GFRα3-IR 
(Honma et al., 2002). On this basis, we investigated GFRα3 expression in 
noradrenergic axons that can be identified using TH. 
 
To address these possibilities, we used bladder sections and wholemounts to visualise 
the structure and distribution of axons across different tissues and regions of the 
bladder. We followed a similar wholemount protocol as described by Llewellyn-
Smith and Gnanamanickam (2010) that used extended incubation times to allow for 
antibody penetration through the whole thickness of the tissue. Wholemount 
preparations have been for used many different tissue types (Furness et al., 1982; 
Gabella and Davis, 1998; Gibbins, 1983; Gnanamanickam and Llewellyn-Smith, 
2011; Klinger et al., 2007; Llewellyn-Smith and Gnanamanickam, 2010; Sharrad et 
al., 2013) and provide an excellent opportunity to visualise the innervation across all 
regions of the tissue. However, there are some limitations in using wholemounts such 
as increased background fluorescence. For most co-expression studies, we used 
bladder sections and focused on the bladder base because axons in the suburothelial 
plexus and sympathetic axons innervating the detrusor are primarily located in this 
region.  
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5.4.1 Afferent innervation of the bladder 
Bladder afferent axons originate from lumbar and sacral DRG, and project to the 
bladder via the lumbar splanchnic, hypogastric nerves and sacral pelvic nerves 
(Yoshimura, 1999). Many are sensitive to bladder distension and essential for the 
voiding reflex while others are chemosensitive. Peptidergic afferent axons are 
commonly visualised with CGRP. Previous studies have demonstrated that CGRP-IR 
is expressed in 60-80% of bladder afferent neurons (Bennett et al., 1996; Bennett et 
al., 2003) and their axons are widely distributed in the bladder (Gabella and Davis, 
1998). Although we report a smaller proportion of bladder afferent neurons 
containing CGRP-IR (Chapter 4) than these studies, we found a similar pattern and 
density of CGRP-IR axons in the bladder as previously described by Gabella and 
Davis, 1998.  
 
The first part of this study explored the potential for artemin to target peptidergic 
afferent axons in different regions and tissues of the bladder. CGRP-IR axons were 
evenly distributed throughout the detrusor but were far less prevalent than autonomic 
axons labelled with NPY. As previously reported (Gabella and Davis, 1998), CGRP-
IR axons had three main targets in the bladder: detrusor, suburothelial plexus and the 
vasculature. We demonstrated that GFRα3-IR axons were prevalent throughout the 
bladder and had similar targets as CGRP-IR axons, consistent with findings in 
Chapter 4. We also found that in the detrusor, most neuronal GFRα3 contained 
CGRP-IR and many, but not all CGRP-IR axon bundles and single axons contained 
GFRα3-IR. These most likely originate from neurons in lumbar and sacral DRG 
containing both markers i.e. bladder-projecting afferent neurons containing both 
CGRP- and GFRα3-IR. Almost all CGRP-IR afferent neurons express trkA and are 
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responsive to NGF (Averill et al., 1995; Bennett et al., 1996; Molliver et al., 1995). 
GFRα3 is localised to a subpopulation of CGRP-IR neurons so this group of 
peptidergic neurons has the potential to be regulated by both NGF and artemin.  
 
5.4.2 Suburothelial plexus  
GFRα3-IR axons in the suburothelial plexus had a similar distribution to suburothelial 
axons containing CGRP-IR; however, these axons were not as prevalent as those 
containing CGRP-IR. We also found that the majority of GFRα3-IR axons and closed 
axonal loops contained CGRP-IR. Both types of loops were not observed in the 
detrusor and were a unique feature of the suburothelial plexus. In our study, closed 
axonal loops were not observed with autonomic axons immunostained with NPY and 
appear to be a unique feature of peptidergic afferent axons, which may be involved in 
synaptic transmission on these axon terminals. However, NOS-IR closed axonal loops 
originating from the middle of axons were described in Chapter 4. NOS 
immunohistochemistry was predicted to label cholinergic parasympathetic 
postganglionic axons, and lumbar and sacral sensory axons.  It is likely these NOS-IR 
closed axonal loops are sensory as autonomic closed axonal loops labelled with NPY 
were not observed in the bladder. Chapter 4 demonstrated that approximately one 
third of CGRP- and GFRα3-IR bladder afferent neurons contain NOS-IR in sacral 
DRGs, compared to ~60% in lumbar DRGs. However, further investigation is 
required to determine if CGRP- and GFRα3-IR closed axonal loops contain NOS-IR. 
 
Many sensory and sympathetic axons require artemin to direct growth and synapse 
formation with their target organs during development. As demonstrated for NGF and 
GDNF, artemin may also contribute to nociceptor sensitisation and hyperalgesia (Elitt 
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et al., 2006; Malin et al., 2006). A recent study has shown that artemin has the ability 
to potentiate the response to capsaicin that is specific to different afferents innervating 
skin, muscle and the colon (Malin et al., 2011). Many afferent axons innervating the 
bladder are capsaicin sensitive (Avelino and Cruz, 2000; Maggi, 1990; Sharkey et al., 
1983) and intravesical injection of capsaicin or NGF induces bladder hyper-reflexia 
and decreases the micturition threshold (Dmitrieva et al., 1997; Maggi, 1992; 
Yoshimura et al., 2006). TRPV1-IR axons are abundant in the suburothelial plexus, 
almost all of which contain CGRP- and SP-IR. The majority CGRP- and SP-IR 
suburothelial axons also co-express TRPV1-IR (Avelino et al., 2002). We have 
demonstrated in Chapter 4 that GFRα3-IR bladder-projecting neurons contain both 
CGRP- and TRPV1-IR and all CGRP-IR neurons contain TRPV1-IR. As almost all 
GFRα3-IR suburothelial axons contain CGRP-IR, it is also likely they will express 
TRPV1-IR. The role of artemin in the inflamed bladder is not known but results from 
this study suggest that artemin could potentially sensitise suburothelial axons and 
contribute to altered reflex behaviours during inflammation. Animal studies of 
bladder inflammatory pain show alterations in structural, neurochemical and 
electrophysiological properties of bladder afferent pathways, leading to changes in 
reflex behaviours, urgency and pain (Callsen-Cencic and Mense, 1997; Vizzard, 
2001; Yoshimura and de Groat, 1999). While most of the attention on possible 
mechanisms underlying these changes has been on NGF, results from this study and 
others (Forrest and Keast, 2008) raise the possibility that artemin may be involved in 
the sensitisation and plasticity of pelvic visceral pathways. 
 
CGRP-IR suburothelial axons undergo sprouting following chronic bladder 
inflammation induced by cyclophosphamide (CYP) treatment in rats, that also 
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corresponds to altered reflex behaviours (Dickson et al., 2006). However, we do not 
know if this is the GFRα3-positive or negative population. Our laboratory has 
demonstrated that the central terminals of neurons expressing the GDNF receptor, 
GFRα1, in sacral spinal cord are increased following chronic CYP treatment. No 
change was observed in the central terminals of neurons containing GFRα3 (Forrest 
and Keast, 2008) and in Chapter 4, we demonstrate that chronic CYP had no effect on 
GFRα3-IR in lumbar and sacral bladder projecting neurons or GFRα3-IR axons in the 
bladder. Together these results indicate that the up-regulation of CGRP-IR in 
suburothelial axons in the bladder following chronic inflammation reported by 
Dickson et al. (2006), are likely to be CGRP-positive GFRα3-negative axons. 
 
5.4.3 Vasculature  
In the present study, numerous GFRα3-IR axons were associated with the vasculature. 
Our study suggests that GFRα3-IR paravascular axons are likely to be peptidergic 
sensory axons but GFRα3-IR peri-vascular axons are primary sympathetic. All 
CGRP-IR axons associated with the rat bladder vasculature are peptidergic sensory 
(Gabella and Davis, 1998; Warburton and Santer, 1994). We found a similar 
distribution of sensory axons associated with the bladder vasculature as previously 
described (Gabella and Davis, 1998; Yokokawa et al., 1986). CGRP-IR perivascular 
axons formed a dense meshwork around the proximal aspect of the primary branch of 
the vasculature but there was a reduced density of these axons as the diameter of the 
vascular lumen decreased, consistent with the distribution of sensory axons in the 
cerebral artery of rats (Tsai et al., 1988). There are known species differences with 
CGRP-IR vascular axons associated with other regions, and while these studies have 
been useful, they may not necessarily be translated directly into the rat. For example, 
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in the guinea pig, CGRP-IR peri-vascular axons comprise both autonomic and 
sensory subpopulations (Anderson et al., 1997; Morris et al., 1998). 
 
In this study we have provided evidence that GFRα3 is expressed by many 
noradrenergic vasoconstrictor peri-vascular axons in the bladder. Kawasaki et al. 
(1988) has demonstrated that stimulation of perivascular noradrenergic axons 
produces vasoconstriction in mesenteric vascular beds of rats. Our findings with TH-
IR and CGRP-IR axons associated with the vasculature are also consistent with 
reports in other organs (Haberberger et al., 1997) demonstrating that sympathetic 
vasoconstrictor axons extend for a much greater distance along the vascular tree than 
vasodilator axons. 
 
Artemin promotes the survival of sympathetic neurons (Baloh et al., 1998) and is 
required for sympathetic axons to reach their target organs during development 
(Honma et al., 2002), which do so by following the course of blood vessels. 
Sympathetic neurons that innervate the vasculature have also been found to express 
GFRα3 and RET (Damon et al., 2007). Our observation that GFRa3 is expressed by 
both sensory and sympathetic axons innervating blood vessels raises the possibility 
that vascular-derived artemin (Honma et al., 2002) is an important guidance factor for 
both sympathetic and peptidergic sensory axons. In this study, we found no evidence 
of GFRα3-IR being expressed by vascular smooth muscle cells although GFRα3 
mRNA and protein have been reported to be expressed by smooth muscle cells in 
neonatal arteries (Damon et al., 2007). It is possible that artemin is down-regulated in 
these cells postnatally once sympathetic axons have already reached their target or 
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that we failed to detect GFRα3-IR in these cells by our immunohistochemical 
techniques. 
 
5.4.4 Efferent innervation of the bladder 
The urinary bladder has two main functions: elimination and storage of urine. Both 
processes involve complex neuronal control in peripheral ganglia, spinal cord and 
supraspinal centres. During voiding there is initial relaxation of the pelvic floor 
muscles and the urethra, followed by subsequent contraction of the detrusor and 
opening of the bladder neck to expel urine. During storage, the bladder outlet is 
closed and bladder contraction is inhibited to allow for bladder filling (Fowler et al., 
2008; Yoshimura and de Groat, 1999). Autonomic sympathetic and parasympathetic 
nerves, and somatic motor nerves control these functions. In this study, NPY was 
used to label that largest population of autonomic axons in the bladder, comprising 
sympathetic noradrenergic and parasympathetic cholinergic post-ganglionic axons 
(Keast and de Groat, 1989). Sympathetic axon terminals release noradrenaline, acting 
on β-adrenergic receptors to relax the detrusor smooth muscle. Parasympathetic axon 
terminals release acetylcholine, acting on muscarinic receptors in the detrusor, 
resulting in bladder contraction. Adenosine triphosphate (ATP) is also released from 
parasympathetic terminals in the bladder wall, acting on purinergic receptors resulting 
in muscle contraction (Cervero, 1994; Fowler et al., 2008; Yoshimura and de Groat, 
1997). 
 
Varicose NPY-IR axons were found throughout the whole thickness of the detrusor 
and had a similar structure and density in the bladder base and dome. These axons 
were also associated with the suburothelial plexus and vasculature. Consistent with 
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previous reports (Iuchi et al., 1994), intramural neurons containing NPY-IR were also 
observed throughout the detrusor, closely associated with single axons or bundles of 
axons. Most of these neurons are considered non-adrenergic, cholinergic neurons and 
decrease in number with postnatal age (Iuchi et al., 1994).  
 
The efferent innervation of the bladder originates in the pelvic ganglia (Keast and de 
Groat, 1989), with a smaller source from the inferior mesenteric ganglia; however, in 
some species autonomic neurons are also embedded in or on the serosal surface of the 
detrusor. These are referred to as intramural or intravesical neurons (Birder et al., 
2010; Keast, 2006) and are thought to also provide efferent innervation to the 
detrusor. In rats they were originally regarded as absent (Gabella, 1990) but more 
recent studies have demonstrated that they are present (Alian and Gabella, 1996; Iuchi 
et al., 1994; Zvarova and Vizzard, 2005), but are sparse compared to other species 
(Dixon et al., 1983; el-Badawi and Schenk, 1966; Gabella, 1990; Smet et al., 1996; 
Zhou and Ling, 1998). Intramural neurons are located along axon bundles throughout 
the detrusor and appear singularly or in clusters. They are more prevalent at the entry 
point of the ureter, an area that also corresponds to the entry point of main blood 
vessels supplying the bladder compared to the bladder dome. Intramural neurons have 
also been found to be more prevalent on the ventral wall than the dorsal surface 
(Alian and Gabella, 1996; Gabella, 1990) however we did not find this was the case in 
our study. 
 
The majority of intramural neurons are cholinergic and few are adrenergic (el-Badawi 
and Schenk, 1966; Iuchi et al., 1994) therefore, their role has been thought to relay 
activity in cholinergic nerves to the detrusor to facilitate micturition. Other studies 
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have also proposed that intramural neurons and ganglia can interact with smooth 
muscle cells via interstitial cells (Gillespie et al., 2006b). Afferent axon terminals are 
also reported to make contact with intramural ganglia (Smet et al., 1996; Zhou and 
Ling, 1998) but CGRP and other markers of afferent neurons are not expressed by 
intramural neurons (Gillespie et al., 2006b; Zhou and Ling, 1998). Consistent with 
these studies, we did not observe any CGRP-IR intramural neurons in our study. 
 
5.4.5 Detrusor – other neuronal markers  
We found a similar pattern of TH-IR axons in the detrusor as previously described 
(Warburton and Santer, 1994) which were very sparse compared to the dense 
innervation of the vasculature. In bladder wholemounts, we identified three different 
types of TH-IR endings: non-specialised, specialised and those originating from para-
vascular axons that have branched off the vascular tree. As described above, 
sympathetic axons release noradrenaline, relaxing the detrusor to allow for urine 
storage. Both specialised and non-specialised endings were observed throughout the 
whole thickness of the bladder. It is possible that specialised TH-IR endings that issue 
multiple branches before terminating spread over a large area of the detrusor provide 
a coordinated release of noradrenaline over a widespread area to inhibit bladder 
contraction. It is also possible that non-specialised TH-IR endings, which are 
unbranched or branch in two, have a more localised effect. TH-IR endings originating 
from para-vascular axons were more commonly found in the mucosa where they 
branched off distal branches of vascular trees. These para-vascular axons were likely 
to have followed the vascular tree to reach their target. It would be interesting to 
understand more about the physiological differences in neurotransmission at each of 
these physically distinctive sites.  
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 In our study, most GFRα3-IR axons did not contain the neuronal marker PGP. Very 
few single axons in the detrusor were immunolabelled with PGP and suburothelial 
axons were rare, which suggested that our antibody only labelled pre-terminal axons. 
This is inconsistent with other reports that demonstrate many PGP-IR axons in the 
suburothelial plexus in rats (Klinger et al., 2007; Zvarova and Vizzard, 2005), mice 
(Schnegelsberg et al., 2010), guinea pig (Gillespie et al., 2006b; Grol et al., 2008) and 
human bladder (Jen et al., 1995), and suggests a difference in sensitivity of the 
antibodies. Only a minority of GFRα3-IR cells in the detrusor and associated with the 
vasculature contained PGP-IR, suggesting they were likely to be non-neuronal cells. 
This is discussed further below. 
 
SYN was used in the current study to potentially show more effective labelling of 
single axons. We found a similar distribution of SYN-IR axons in the bladder as 
previously described (Gabella and Davis, 1998) and confirmed reports that SYN 
labels few afferent axons (Brock et al., 2004; Morris et al., 2005; Sun et al., 2006), 
and mostly comprised cholinergic autonomic axons. In the detrusor, GFRα3-IR 
showed rare co-expression with SYN-IR indicating that few GFRα3-IR axons were 
likely to be autonomic. In contrast to the detrusor, the majority of GFRα3-IR axons 
associated with the vasculature contained SYN-IR and were likely noradrenergic 
vasoconstrictor axons. 
 
This is the first study providing a detailed report of the distribution and structure of 
NF200-IR axons in the bladder and NF200-IR neurons in the PG. In the detrusor 
NF200-IR axons mostly travelled in large diameter axon bundles. It is likely that 
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NF200 only labels pre-terminal axons or the myelin sheath but does not extend the 
whole distance of the axon, possibly accounting for the low number of NF200-IR 
single axons and terminals observed in the detrusor. This is consistent with Gabella 
(1999) who demonstrated that myelinated axons primarily occurred in large diameter 
axon bundles rather than single axons. Double-labelling experiments confirmed our 
hypothesis that few GFRα3-IR sensory axons were likely to be myelinated as very 
few contained NF200-IR. 
 
NF200-IR intramural neurons were found throughout the detrusor, closely associated 
with single axons or axon bundles. These were found as single neurons or small 
clusters of neurons and were likely to be autonomic ganglion neurons as afferent 
neurons are not located in intramural ganglia. NF200-IR intramural neurons have 
been reported in the cat, almost all of which were found to be intramural 
parasympathetic ganglion neurons and contained choline acetyltransferase (Ruan et 
al., 2006). NF200-IR intramural neurons have also been reported in the guinea pig, 
many of which have VAChT-IR terminals surrounding these neurons, suggesting they 
receive cholinergic input (Coelho et al., 2012). Together, this suggested that NF200-
IR might be expressed in autonomic axons originating from the PG. Here we report 
that NF200-IR neurons were prevalent in the PG and the majority (over 80%) of 
bladder projecting autonomic neurons contained NF200-IR, the majority of which 
were cholinergic. Other studies have reported NF200-IR in sympathetic and enteric 
ganglia (Chiocchetti et al., 2009; Trojanowski et al., 1986) and together with this 
study, suggest that NF200 is a marker of both myelinated afferent and cholinergic 
post-ganglionic autonomic axons in the bladder. We did not determine which NF200-
IR axons in the bladder were afferent and those that were autonomic, or if the two 
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populations targeted different bladder regions. This could be investigated by co-
staining bladder sections or wholemounts with NF200 and SYN or CGRP. 
 
5.4.6 Non-neuronal markers 
We discovered a large non-neuronal source of GFRα3 in the bladder, which we 
believe is largely due to its expression in glia associated with all regions of the 
bladder. One limitation of the current study was that GFAP and S100 used to identify 
Schwann cells do not label the entire the glial population or label exactly the same 
populations of glia. Glial cells labelled with these two markers were elongated cells 
with processes, similar in size and structure to GFRα3-IR cells. While we 
demonstrated that a significant proportion of GFRα3-IR cells in the bladder could be 
labelled with GFAP or S100, the majority of GFRα3-IR cells were not labelled with 
these markers. However, the GFRα3-positive but GFAP- and S100-negative cells had 
the same structure, therefore we propose that they are also glial cells. In this study, all 
GFAP- and S100-IR processes were closely associated with individual axons and 
bundles of axons. An extensive study of the relationship between axons and glia in the 
rat bladder has been carried out by Gabella (1999) and demonstrated the close 
apposition of axons and glia in the detrusor. Glial cells follow the length of the axon 
down to the terminal so that the total number of glial cells are more numerous than 
the number of axons in the bladder. Elsewhere in the body there is bidirectional 
communication between glial cells and neurons such that glial cells are required for 
axon conduction, synaptic transmission and information processing (Fields and 
Stevens-Graham, 2002). The expression of GFRα3-IR in glial cells suggest complex 
glial-neuronal interactions that could potentially influence axonal excitability and 
synaptic transmission in the bladder. We also investigated the possibility that GFRα3-
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IR was expressed in myofibroblasts or interstitial cells that can be labelled with Vim 
and SMA. These cell types are found in the suburothelial plexus and detrusor, 
functioning in pace making activities and relaying information from urothelial cells to 
the detrusor (Davidson and McCloskey, 2005; Lagou et al., 2006). In the detrusor, 
only a few GFRα3-IR cells contained Vim-IR and we did not find evidence of GFRα3 
being expressed in smooth muscle cells of the vasculature. Together, these results 
support our observations that GFRα3-IR cells in the bladder are likely to be glial. 
 
5.4.7 Unilateral bladder denervation 
In this study we have provided evidence that the majority of GFRα3-IR structures in 
the bladder comprise both neuronal and glial components. This was further 
demonstrated by unilateral denervation of the bladder by transecting the accessory 
nerve, which will cause axons and their supporting glial cells to degenerate. After 
denervation, we found a large reduction of GFRα3-IR axons on the injured side of the 
bladder and GFRα3-IR cells were rarely observed. A similar reduction was observed 
with PGP-IR axons and both glial markers, supporting previous reports that 
degeneration occurs following nerve transection (Alm and Ekstrom, 1981; Berggren 
and Uvelius, 1996; Gabella and Davis, 1998). On the injured side of the bladder there 
was incomplete loss of all GFRα3-, PGP-, GFAP- and S100-IR structures and we also 
found partial loss on the uninjured side. Together, this indicates that some of the 
bladder innervation originates from the contralateral side (Gabella and Davis, 1998). 
  
5.4.8 Source of artemin in the bladder   
NGF, GDNF and neurturin are synthesised by the bladder and other pelvic organs 
(Kawakami et al., 2003; Leon et al., 1994; Vizzard, 2000; Widenfalk et al., 1997; 
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Widenfalk et al., 2000), suggesting that these neurotrophic factors may be involved in 
the maintenance of physiological and structural properties of bladder neurons 
expressing their receptors. Schwann cells can also produce GDNF, providing 
neurotrophic support for injured axons (Springer et al., 1994; Trupp et al., 1997; 
Zhang et al., 2009). Both NGF and GDNF levels in the bladder are increased 
following bladder inflammation and spinal cord injury (Vizzard, 2000b) suggesting a 
potential mechanism of increased excitability and altered neurochemical properties of 
bladder afferent neurons. However, the source of artemin in the bladder and other 
pelvic organs has not been investigated.  
 
Signalling by artemin requires GFRα3 and the common receptor tyrosine kinase, RET 
(rearranged during transfection) (Airaksinen and Saarma, 2002). Our results need to 
take into account the presence and distribution of RET in the bladder. Almost all 
GFRα3-IR DRG neurons co-express RET-IR (Orozco et al., 2001), and GFRα3-IR 
axons in the bladder should also contain RET-IR. It would also be valuable to 
determine if the non-neuronal GFRα3-IR cells reported here contain RET-IR. One 
study (Yang et al., 2006) using immunohistochemistry reported the presence of 
GFRα3- and RET-IR axons in the rat bladder, however the signal was reported to be 
weak and the data was not shown. These authors also reported occasional RET-IR 
intramural neurons in the bladder. If any RET-positive but GFRα3-negative structures 
were present in the bladder, it is likely these would contain GFRα1- or GFRα2-IR. 
We did not investigate the distribution of GFRα1- and GFRα2-IR axons in the bladder 
as an early pilot experiment showed that GFRα1 antibodies failed to detect axons in 
the bladder and few axons were likely to contain GFRα2-IR. We also did not 
investigate RET localisation in different cellular structures within the bladder, due to 
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lack of specific antibodies. Another way to investigate RET expression in the bladder 
would be to use in situ hybridization techniques (Bennett et al., 1998; Luo et al., 
2009) or reporter mice (Enomoto et al., 2001).  
 
5.4.9 Conclusions 
This study has demonstrated that GFRα3 has three main targets in the bladder: the 
detrusor, suburothelial plexus and vasculature. GFRα3 labels very specific 
populations of axons and non-neuronal cells in the periphery, targeting distinct 
populations of peptidergic afferent axons, sympathetic noradrenergic vasoconstrictor 
axons and glia. We have also provided evidence that NF200-IR is found in bladder-
projecting cholinergic post-ganglionic neurons and labels both afferent and autonomic 
axons in the detrusor. Two populations of cholinergic intramural ganglion neurons 
containing NPY and NF200 have also been identified in the rat bladder. 
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Antibodies Host Supplier / catalogue number Dilution
Primaries
Calcitonin gene-related 
peptide (CGRP)
Rabbit Sigma-Aldrich (Castle Hill, NSW, 
Australia); C8198
1:5000
Cytokeratin-17 
(CYTO-17)
Mouse DakoCytomation (Vancouver, BC, 
Canada); M7046
1:5000
Cytokeratin-20 
(CYTO-20)
Mouse DakoCytomation; M7019 1:1000
Glial fibrillary acidic 
protein (GFAP)
Rabbit DakoCytomation; Z0334 1:1000
Glial cell line-derived 
neurotrophic factor family 
receptor (GFRa3)
Goat R&D Systems (Minneapolis, MN); 
AF2645
1:300
Neurofilament 200 (NF200) Mouse Sigma-Aldrich; N0142 1:4000
Neuropeptide Y (NPY) Rabbit DiaSorin (North Ryde, NSW, Australia); 
22940
1:3000
Nitric oxide synthase (NOS) Rabbit Zymed Laboratories (now Invitrogen, 
Mulgrave, Vic, Australia); 61-7000
1:500
Protein gene product 9.5 
(PGP)
Rabbit Millipore (Kilsyth, Vic, Australia); 
AB5925
1:400
S100 Mouse Millipore; MAB079 1:500
Smooth muscle actin-a 
(SMA)
Mouse Sigma-Aldrich; A5228 1:5000
Synaptophysin (SYN) Mouse DakoCytomation; M0776 1:300
Tyrosine hydroxylase (TH) Rabbit Millipore; AB152 1:1000
Vimentin (Vim) Mouse Sigma-Aldrich; V6630 1:10,000
Secondaries
anti-goat Cy3 Donkey Jackson ImmunoResearch Laboratories 
(West Grove, PA); 705-165-147
1:1000
anti-guinea pig Cy3 Donkey Jackson Laboratories; 706-165-148 1:5000
anti-mouse AF488 Donkey Molecular Probes (now Invitrogen); 
A-21202
1:1000
anti-mouse Biotin Donkey Vector Laboratories (Burlingame, CA); 
BA-2000
1:1000
anti-mouse Cy3 Donkey Jackson Laboratories; 715-165-150 1:2000
anti-rabbit AF488 Donkey Invitrogen; A21206 1:2000
anti-rabbit Biotin Donkey Jackson Laboratories; 711-065-152 1:1000
anti-rabbit Cy3 Donkey Jackson Laboratories; 711-165-152 1:1500
anti-sheep AF488 Donkey Invitrogen; A-11015 1:1000
anti-sheep Biotin Donkey Jackson Laboratories; 713-065-003 1:1000
5.5 Chapter 5 tables and figures
Table 5.1
List of primary and secondary antibodies used
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Figure 5.1 Diagram of bladder wholemount preparations. a. The bladder was cut into 
three longitudinal strips of approximately equal size. b. Areas of interest (AOI; 
shaded boxes) were assessed for GFRα3- and CGRP-IR terminals in the suburothelial 
plexus and for CGRP- and TH-IR terminals in the detrusor. Dimensions of each box 
were 500 x 500 μm.
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Figure 5.2
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Figure 5.2 DAB bladder wholemount preparations demonstrating NPY-IR 
distribution in the bladder. a-c: Bladder wholemounts show a uniform distribution of 
NPY-IR axons throughout the bladder (a: base; b: middle; c: dome). d-f: All NPY-IR 
axons were varicose and travelled singularly in dense bands commonly observed on 
the serosal surface, or in axon bundles. g-i: NPY-IR neurons, commonly in clusters 
were found in the detrusor. j-l: Numerous para- and peri-vascular NPY-IR axons were 
associated with all branches of the vasculature tree. m-o: NPY-IR axons were found 
in the suburothelial plexus and became progressively less dense towards the bladder 
dome (m: base; n: middle; o: dome). p-r: The majority NPY-IR axons in the 
suburothelial plexus originated from para-vascular axons that branched from the 
mucosal vascular tree. Numbered arrowheads in (j-l) indicate primary, secondary, 
tertiary and quaternary vessel branches, and in (p-r) para-vascular axons branching off 
the vascular tree. Dashed box in (q) is magnified in (r). Scale bar = 200 μm in (a) also 
applies to (b, c, j, k, p, q); 100 μm in (d) also applies to (e, f, r); 50 μm in (g) also 
applies to (h, i, l-o).
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Figure 5.3 Distribution of CGRP- and GFRα3-IR in the detrusor. a-c: Confocal micrograph of a 
fluorescently labelled section through the bladder base, immunostained with CGRP, GFRα3 and 
the merged image pair. d-i: Immunostained bladder wholemounts processed with DAB show a 
uniform distribution of CGRP-IR (d-f) and GFRα3-IR (g-i) in the detrusor throughout the bladder 
(d, g: base; e, h: middle; f, i: dome). The urothelium is orientated at the top in panels a-c. Scale 
bar = 100 μm in (a) also applies to (b, c); 500 μm in (d) also applies to (e-i).
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Figure 5.4 CGRP- and GFRα3-IR axons near the serosal surface of the detrusor in wholemount 
preparations. a-b: CGRP-IR varicose axons in the detrusor. c: Higher magnification of CGRP-IR 
axons showing varicosities. d: Many CGRP-IR terminals were observed in the detrusor. e-f: Ex-
amples of varicose GFRα3-IR axons. g, h: Varicosities were also observed on GFRα3-IR 
terminals. i-m: Numerous small, intensely stained GFRα3-IR cells were observed in the 
detrusor. Arrowheads show CGRP-IR varicosities (c) and terminals (d), varicosities on GFRα3-IR 
axons (e, f) and endings (g, h) and GFRα3-IR cells (i, l, m). Dashed boxes in (i) are 
magnified in (j) and (k). Scale bar = 100 μm in (a) also applies to (b, d); 50 μm in (c) also applies 
to (e-h, i); 10 μm in (j) also applies to (k); 20 μm in (l); 10 μm in (m).
i j k l m 
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Figure 5.5 Co-expression of CGRP- and GFRα3-IR in the detrusor. a-c: Confocal z-stack (34 μm 
thick, 1 μm step size) through the detrusor showing that many CGRP-IR axon bundles contained 
GFRα3-IR, but some single axons labelled for CGRP-IR were GFRα3-negative (arrowheads). 
d-f: Confocal image in the detrusor showing co-expression between CGRP- and GFRα3-IR 
axons. g-i: Confocal image of double-labelled CGRP- and GFRα3-IR axon terminals. k-n: 
Confocal image in the detrusor showing numerous small, elongated GFRα3-IR cells with 
elongated processes. Arrowheads indicate CGRP-IR only axons (a-c), double labelled CGRP- and 
GFRα3-IR axons (d-f) and terminals (g-i), GFRα3-IR cells (k-n). Scale bar = 100 μm in (a) also 
applies to (b, c); 30 μm in (d) also applies to (e, f); 50 μm in (g) also applies to (h, i); 20 μm in (k) 
also applies to (l, n).
a CGRP b GFRa3 c merge
d CGRP e GFRa3 f merge
g CGRP h GFRa3 i merge
k CGRP l GFRa3 m DAPI n merge
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Figure 5.6
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Figure 5.6 Bladder wholemounts showing distribution of CGRP- and GFRα3-IR in 
the suburothelial plexus. a-f: CGRP- (a-c) and GFRα3-IR (d-f) axons in the 
suburothelial plexus become progressively less dense towards the bladder dome (a, d: 
base; b, e: middle; c, f: dome). g-i: CGRP-IR axons formed closed axonal loops 
originating in the middle of axons (g) or on axon terminals (h, i). j, k: GFRα3-IR 
axons also formed closed axonal loops at the end of terminating axons (j) or in the 
middle of axons (k). j-l: Numerous GFRα3-IR cells were observed in the 
suburothelial plexus. m-r: CGRP-IR (m-o) and GFRα3-IR (p-r) terminals in the 
suburothelial plexus. Arrowheads indicate CGRP- (g-i) and GFRα3-IR (j, k) closed 
axonal loops and CGRP- (m-o) and GFRα3-IR (p-r) terminals. Arrows (j-l) indicate 
GFRα3-IR cells. Scale bar = 100 μm in (a) also applies to (b-f); 50 μm in (g) also 
applies to (h-l); 50 μm in (m) also applies to (n-r).
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Figure 5.7 Distribution of CGRP-IR axons relative to the urothelium. a-h: Confocal images 
showing CGRP-IR axons in the suburothelial plexus in relation to superficial urothelial cells 
labelled with CYTO-20 (a-d) and intermediate and basal urothelial cells labelled with CYTO-17 
(e-h). The urothelium is orientated to the top in all panels. Scale bar = 30 μm in (a) and applies to 
all images.
a CGRP b CYTO-20 c DAPI d merge
e CGRP f CYTO-17 g DAPI h merge
281
Figure 5.8 Co-expression of CGRP- and GFRα3-IR in the suburothelial plexus. a-c: Confocal z-
stack (15 μm thick, 0.5 μm step size) showing the majority of GFRα3-IR axons contained CGRP-
IR but relatively few peptidergic sensory axons contained GFRα3-IR. d-i: Confocal images 
demonstrating that most GFRα3-IR terminals (d-f) and closed axonal loops (g-i) contained 
CGRP-IR, but most CGRP-IR terminals do not contain GFRα3-IR. Arrows indicate single-
labelled CGRP-IR axons (a-c) and terminals (d-i), arrowheads indicate double-labelled GFRα3- 
and CGRP-IR axon (a-c), terminal (d-f) and closed axonal loop (g-i). Scale bar = 100 μm in (a) 
also applies to (b, c); 100 μm in (d) also applies to (e, f); 30 μm in (g) also applies to (h, i).
a CGRP b GFRa3 c merge
d CGRP e GFRa3 f merge
g CGRP h GFRa3 i merge
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Figure 5.9
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Figure 5.9 CGRP- and GFRα3-IR axons associated with the vasculature. a-c: Many 
CGRP-IR para-vascular axons were found on the primary, secondary (a, b) and 
tertiary (c) branches of the vascular tree. Peri-vascular axons were also found on the 
primary branch but were sparse on subsequent branches. d-f: Para- and peri-vascular 
GFRα3-IR axons were associated with all branches of the vascular tree. g-i: Many 
para-vascular CGRP- and GFRα3-IR axons were associated with the primary and 
secondary branch of the vascular tree. GFRα3-IR peri-vascular axons were more 
prevalent than CGRP-IR peri-vascular axons on these branches. j-l: CGRP- and 
GFRα3-IR para-vascular axons were associated with secondary and tertiary vessel 
branches. Many GFRα3-IR peri-vascular axons were present in these branches. m-o: 
Both CGRP- and GFRα3-IR para-vascular axons did not extend to the most distal 
aspects of the vascular tree. Numbered arrowheads indicate primary, secondary and 
tertiary branches. The majority of these axons are sympathetic vasoconstrictors. 
Images (g-o) are confocal z-stacks (g-i: 45 μm thick; j-l: 28 μm thick; m-o: 30 μm 
thick; all with 1 μm step size) of vessels through the detrusor in wholemount 
preparations. Scale bar = 200 μm in (a) also applies to (d); 100 μm in (b) also applies 
to (c, e, f); 100 μm in (g) also applies to (h, i); 100 μm (j) also applies (k, l); 100 μm 
in (m) also applies to (n, o).
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Figure 5.10
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Figure 5.10 Comparison of peptidergic sensory and noradrenergic vascular 
innervation in the detrusor. a-c: TH-IR axons densely innervated all branches of the 
vascular tree that traversed the bladder (a: base; b: middle; c: dome). d-f: Many TH-
IR axons and relatively few CGRP-IR axons are associated with distal portions of 
primary vessel branches. g-i: Higher magnification of the branch point in a-c that 
demonstrates relatively few of CGRP-IR peri-vascular axons. j-l: Low magnification 
of distal portions of secondary and tertiary branches of the vascular tree containing 
few CGRP-IR para-vascular axons. Numbered arrowheads in (d-f) indicate distal 
primary, secondary and tertiary vascular branches, in (g-i) distal primary and 
secondary branches and in (j-l) distal secondary and tertiary branches of the vascular 
tree. Panels (d-l) are confocal z-stacks (d-f: 50 μm thick; g-i: 31 μm thick. j-l: 36 μm 
thick; all with 1 μm step size) through the detrusor in a bladder wholemount 
preparation. Scale bar = 500 μm in (a) also applies to (b, c); 200 μm in (d) also applies 
to (e, f); 50 μm in (g) also applies to (h, i); 200 μm in (j) also applies to (k, l).
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Figure 5.11 Many noradrenergic vasoconstrictor axons contain GFRα3-IR. a-c: Confocal 
image of a blood vessel in the detrusor in a bladder section. Many TH-IR axons associated with 
the vasculature contained GFRα3-IR (arrowheads). d-f: Numerous TH- and GFRα3-IR para- 
and peri-vascular axons densely innervated the primary and secondary branches of the vascular 
tree. g-i: Many TH-IR para- and peri-vascular axons contained GFRα3-IR. Panels (a-c) show 
a confocal image in the detrusor of a bladder section, whereas (d-i) comprise confocal z-stacks 
(d-f: 30 μm thick; g-i: 32 μm thick; all with 1 μm step size) through the detrusor in a 
wholemount preparation. Numbered arrowheads in (d-f) indicate primary and secondary 
branches of the vascular tree. Scale bar = 20 μm in (a) also applies to (b, c); 50 μm in (d) also 
applies (e, f); 40 μm in (g) also applies to (h, i). 
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Figure 5.12
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Figure 5.12 Non-vascular noradrenergic innervation of the detrusor. a-c: TH-IR 
axons and bundles in the detrusor of the bladder base in a wholemount preparation. 
TH-IR axons were prevalent on the vascular tree (arrowhead, panel A). d-f: Three 
types of TH-IR terminals were found in the detrusor: non-specialised (d), specialised 
(e) and those originating from para-vascular axons that branch off the vascular tree 
(f). g-i: TH- and GFRα3-IR were rarely co-expressed in axons in the detrusor. j-l: 
Few TH-IR axons travelled in large diameter axon bundles expressing GFRα3-IR but 
were not co-expressed. m-o: TH- and CGRP-IR axons often travelled in the same 
axon bundle but were never co-expressed. Arrowheads indicate a branch of the 
vascular tree (a) and TH-IR terminals (d-f). Arrows indicate a branch point from a 
single specialised TH-IR axon (e) and TH-IR para-vascular axons on a distal portion 
of the vascular tree (f). Images (g-o) are confocal z-stacks (g-i: μm thick; j-l: 20 μm 
thick; m-o: 77 μm thick; all with 1 μm step size) through the detrusor. Scale bar = 100 
μm in (a) also applies to (b, c); 100 μm in (d) also applies to (e, f); 10 μm in (g) also 
applies to (h, i); 50 μm in (j) also applies to (k, l); 100 μm in (m) also applies (n, o).
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Figure 5.13 Comparison of PGP- and GFRα3-IR in the bladder. a-c: Large diameter bundles of 
PGP-IR axons, commonly observed on the serosal surface of the bladder, did not contain GFRα3-
IR. d-g: Many small diameter bundles of PGP-IR axons in the detrusor contained GFRα3-IR. 
h-k: Few GFRα3-IR cells in the detrusor contained PGP-IR. l-o: Most GFRα3-IR axons 
associated with the vasculature contained PGP-IR but most GFRα3-IR cells associated with the 
vasculature did not contain PGP-IR and are unlikely to be neuronal. Arrowheads illustrate single-
labelled large diameter bundles of PGP-IR axons (a-c), a small diameter bundle of PGP-IR axons 
containing GFRα3-IR (d-g), double-labelled cells (h-k) and a double-labelled PGP- and GFRα3-
IR axon associated with a blood vessel (l-o). Arrow indicates a double-labelled GFRα3-IR cell 
(l-o). The serosal surface of the bladder is orientated to the bottom in panels a-c. All panels are 
confocal images in the detrusor from bladder sections. Scale bar = 50 μm in (a) also applies to 
(b, c); 10 μm in (d) also applies to (e-g); 10 μm in (h) also applies to (i-k); 20 μm in (l) also 
applies to (m-o).
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Figure 5.14 Distribution of SYN-IR axons in the bladder. a-c: Almost all SYN-IR 
axons contained VAChT-IR and almost all VAChT-IR axons contained SYN-IR in 
the detrusor. d-f: Confocal image showing the distribution of SYN- and CGRP-IR 
axons in the detrusor. g-i: Both CGRP- and SYN-IR axons were varicose and many 
travelled next to each other, but co-expression of the two markers was rare. j-l: Many 
SYN-IR axons were associated with the vasculature and like the detrusor, did not co-
express CGRP. m-p: Confocal image from a bladder section showing that few 
GFRα3-IR axons in the detrusor contained SYN-IR. q-t: Many GFRα3-IR axons 
associated with the vasculature contained SYN-IR. u-x: GFRα3-IR axons in the 
suburothelial plexus did not contain SYN-IR. Arrowheads indicate axons co-
expressing SYN- and VAChT-IR in the detrusor (a-c); single-labelled SYN-IR axons 
that do not co-express CGRP-IR in the detrusor (g-i) and associated with the 
vasculature (j-l); double-labelled GFRα3-IR axon in the detrusor (m-p); double-
labelled GFRα3-IR axons associated with the vasculature (q-t) and a single-labelled 
GFRα3-IR axon in the suburothelial plexus (u-x). Arrows indicate single-labelled 
CGRP-IR axons in the detrusor (g-i), associated with the vasculature (j-l) and SYN- 
and GFRα3-IR axons travelling in the same bundle (m-p). The urothelial surface is 
orientated to the top in panels (d-f) and (u-x). All panels are single confocal images 
from bladder sections. Scale bar = 10 μm in (a) also applies to (b, c); 200 μm in (d) 
also applies to (e, f); 10 μm in (g) also applies (h, i); 10 μm in (j) also applies (k, l); 
20 μm in (m) also applies (n-p); 10 μm in (q) also applies (r-t); 10 μm in (u) also 
applies (v-x).
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Figure 5.15 Distribution of NF200-IR axons in the bladder. a-c: Many NF200-IR axons were 
found in the detrusor and were distributed evenly throughout the bladder (a: base; b: middle; 
c: dome). d-e: The majority of NF200-IR axons travelled in large diameter axon bundles. f: 
NF200-IR terminals were occasionally observed in the detrusor (arrowhead). g-i: Few NF200-
IR axons were associated with the vasculature, these were para-vascular and only observed on 
primary (g, h) and secondary (i) vascular branches. j-l: NF200-IR neurons were observed in the 
detrusor. Many had short processes and were found individually or in small clusters. m-o: Large 
diameter NF200-IR axon bundles on the serosal surface did not contain GFRα3-IR. p-r: Some 
small diameter NF200-IR axons bundles and single axons in the detrusor contained GFRα3-IR. 
Arrowheads in (g, h) indicate NF200-IR para-vascular axons on primary vessel branches and 
in (i) NF200-IR para-vascular axons on a secondary vessel branch; in (m-o) a single-labelled 
NF200-IR axon bundle; and a double-labelled axon (p-r). All panels are confocal images from 
bladder sections. The serosal surface of the bladder is orientated to the bottom in panels a-c. 
Scale bar = 200 μm in (a) also applies to (b, c); 100 μm in (d) also applies to (e); 20 μm in (f); 
200 μm in (g); 100 μm in (h); 200 μm in (i), 50 μm in (j) also applies to (k, l); 20 μm in (m) also 
applies to (n, o); 10 μm in (p) also applies (q, r).
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Figure 5.16 Distribution of NF200-IR in the pelvic ganglia (PG). a-d: Distribution of NF200-, 
NOS-IR and retrogradely-labelled (FluoroGold; FG) neurons in the PG. e-h: Co-expression of 
NF200- and NOS-IR in FG-labelled neurons. i-l: Distribution of NF200-, TH-IR and FG-labelled 
neurons in the PG. m-p: Co-expression of NF200- and TH-IR in FG-labelled neurons. All panels 
are fluorescent images and arrowheads indicate double- (e-h) and single-labelled (m-p) NF200-
IR neurons. Scale bar = 200 μm in (a) also applies to (b-d, i-l); 50 μm in (e) also applies to (f-h, 
m-p).
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Figure 5.17 Distribution of vimentin- (Vim) and GFRα3-IR in the bladder. a-d: Confocal image 
of a section through the bladder base immunostained for Vim, GFRα3, and the merged image. 
e-l: Little co-expression occurred between Vim-IR  and GFRα3-IR in cells in the detrusor. m-p:. 
GFRα3-IR cells associated with the vasculature did not contain Vim-IR. q-t: GFRα3- and Vim-
IR in the mucosa were not co-expressed. Arrowhead indicates double-labelled cell (e-h); closed 
arrows indicate single-labelled GFRα3-IR cell (3-t); open arrows indicate single-labelled Vim-IR 
cells (i-l, q-t). All panels are confocal images in bladder sections. The urothelial surface is 
orientated to the top in panels a-d, q-t. Scale bar = 200 μm in (a) also applies to (b-d); 10 μm in 
(e) also applies to (f-l); 10 μm in (m) also applies to (n-p); 20 μm in (q) also applies to (r-t).
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Figure 5.18 Distribution of smooth muscle actin- (SMA) and GFRα3-IR in the bladder. a-d: 
Confocal image of a section through the bladder base comparing the distribution of SMA-, 
GFRα3-IR and the merged image. e-h: Co-expression of SMA- with GFRα3-IR was not observed 
in the detrusor. GFRα3-IR axons traversed multiple muscle bundles. i-l: SMA- and GFRα3-IR 
associated with the vasculature were not co-expressed. m-p: GFRα3-IR in the suburothelial 
plexus was located superficially to the band of SMA-IR myofibroblasts in the mucosa. Arrow-
heads indicate single-labelled GFRα3-IR axons. All panels are confocal images in bladder 
sections. The serosal surface of the bladder is orientated to the bottom in panels a-d and the 
urothelial surface is orientated to the top in panels m-p. Scale bars = 200 μm in (a) also applies 
to (b-d); 30 μm in (e) also applies to (f-h); 20 μm in (i) also applies to (j-l); 20 μm in (m) also 
applies to (n-p).
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Figure 5.19 Comparison of GFAP- and S100-IR with GFRα3-IR distribution in the 
bladder. a-c: Confocal image of a section through the bladder base comparing GFAP-, 
SYN-IR in the bladder and the merged image. d-g: GFAP-IR was closely associated 
with axons in the detrusor. h-j:  Confocal image comparing GFAP- and GFRα3-IR 
distribution in the bladder. k-n: Many, but not all GFAP-IR cells in the detrusor 
contained GFRα3-IR. o-r: Example of a GFAP- and GFRα3-IR glial cell in the 
detrusor. s-v: The majority of GFRα3-IR cells with elongated processes did not 
contain GFAP-IR. w-z: Many GFRα3-IR cells associated with the vasculature 
contained GFAP-IR. aa-dd: Many S100-IR cells in the detrusor contained GFRα3-IR. 
ee-gg: Most GFRα3-IR cells did not contain S100-IR. Arrowheads indicate single-
labelled GFAP-IR cell (k-n), single-labelled GFRα3-IR cell (o-r), double-labelled 
GFAP-IR cell (s-z), double-labelled S100-IR cell (aa-dd) and a single-labelled 
GFRα3-IR cell (ee-gg). The vessel in panels w-z is indicated with the letter ‘v’. All 
panels are confocal images from bladder sections (a-j, w-gg) and wholemount 
preparations (k-v). Scale bar = 200 μm in (a) also applies (b, c); 20 μm in (d) also 
applies (e-g); 200 μm in (h) also applies to (i, j); 20 μm in (k) also applies to (l-n); 20 
μm in (o) also applies to (p-r); 20 μm in (s) also applies to (t-v); 10 μm in (w) also 
applies to (x-z); 20 μm in (aa) also applies (bb-dd); 10 μm in (ee) also applies to (ff, 
gg).
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Figure 5.20 Effect of unilateral denervation of the bladder on PGP- and GFRα3-IR in the 
detrusor. a-f: GFRα3- and PGP-IR was reduced on the ipsilateral side following unilateral 
denervation of the bladder. g-j: Most remaining PGP-IR was closely associated with GFRα3-IR. 
k-n: Both PGP- and GFRα3-IR axons associated with the vasculature were reduced following 
injury. All panels are confocal images in bladder sections and in all panels, the serosal surface of 
the bladder is orientated to the bottom. Scale bar = 200 μm in (a) also applies to (b-f); 30 μm in 
(g) also applies to (h-n).
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Figure 5.21 Effect of unilateral denervation on GFAP-, S100- and GFRα3-IR in the detrusor. a-f: 
GFAP- and GFRα3-IR was reduced following denervation. g-l: Denervation had a similar effect 
on S100-IR in the detrusor. All panels are confocal images in bladder sections and in all panels, 
the serosal surface of the bladder is orientated to the bottom. Scale bar represents 50 μm in (a) also 
applies to (b-d); 30 μm in (e) also applies (f-h); 20 μm in (i) also applies (j-l); 20 μm in (m) also 
applies (n-p).
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CHAPTER 6: General discussion 
 
6.1 Overview 
Members of the glial cell line-derived neurotrophic factor (GDNF) family of ligands 
(GFL) show efficacy in rat neuropathic pain models and promote regeneration after 
injury (Bennett et al., 1998; Gardell et al., 2003). However, there is accumulating 
evidence to suggest that the GFLs can contribute to nociceptor sensitisation and 
influence a number of pain states (Elitt et al., 2006; Malin et al., 2006). This differs 
between neurons innervating somatic and visceral targets (Malin et al., 2011). 
Receptors for the GFLs (GFR) are expressed in adult dorsal root ganglion (DRG) 
neurons and each have distinct central distribution patterns (Forrest and Keast, 2008), 
suggesting different functions. Changes in GFR expression in DRG neurons and the 
dorsal horn have been reported following chronic visceral inflammatory pain (Forrest 
and Keast, 2008) and spinal cord injury (Kalous et al., 2007; 2009). These findings 
indicate that altered GFR signalling may contribute to the mechanisms that underlie 
visceral inflammatory, and somatic neuropathic pain. A greater understanding of how 
these changes arise is important to promote regeneration and the successful treatment 
of chronic pain states without producing adverse outcomes on neuronal function. This 
may involve tailoring treatments to individual neuronal populations. Using 
immunohistochemical techniques, this thesis investigated the effects of visceral 
inflammation and nerve injury on DRG neurons expressing the GFRs. The major 
outcome of this study was that the three populations of DRG neurons expressing the 
GFRs are expressed by different functional classes of neurons. These populations 
show distinct responses to nerve injury and inflammation. This has important 
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implications for regeneration after injury and how pain arises from somatic and 
visceral origin. Results from this thesis indicate the GFLs and their receptors 
represent a promising new target for therapies aimed at regeneration and the 
development of pain. 
 
Investigation into the effects of somatic (sciatic, Chapter 2) and visceral (Chapter 3) 
nerve injury on DRG neurons and their central terminals expressing the GFRs 
revealed that nerve injury had profound effects on GFR expression. These changes are 
summarised in Table 6.1. Each population of GFR-expressing neurons responded 
differently to somatic and visceral nerve injury. In addition, injury to somatic and 
visceral nerves produced different outcomes on the central distributions of neurons 
expressing the GFRs. These results suggest that DRG neurons are likely to respond 
differently to neurotrophic factors than predicted from their expression of receptors in 
the uninjured state. In addition, each ligand may contribute differently to plasticity 
following somatic and visceral nerve injury. This may impact their regenerative 
capabilities following injury and have significant implications for the effects of 
exogenous GFL administration following nerve injury. 
 
Chapter 4 characterised lumbar and sacral bladder afferent neurons expressing the 
GFRs and investigated the impact of chronic bladder inflammation induced by 
cyclophosphamide (CYP), summarised in Figure 4.13. This study demonstrated that 
GDNF and artemin have the potential to target different functional groups of bladder 
afferent neurons, potentially regulating different aspects of bladder activity. Chronic 
bladder inflammation had no effect on immunohistochemical properties of bladder 
afferent neurons expressing the GFRs. Each GFR has distinct distribution patterns in 
303
lumbar cord, which were unaffected by inflammation. This was in contrast to the 
increase in fluorescent intensity of GFRα1-imunoreactive (IR) fibres in sacral cord 
following chronic inflammation, reported by Forrest and Keast (2008). By using the 
induction of activated transcription factor 3 (ATF-3), this study revealed a 
subpopulation of sacral bladder neurons containing nitric oxide synthase that are 
potentially undergoing structural remodelling during acute inflammation. Results 
from this study contribute to the increased understanding of neurons that are known to 
be involved in pain modulation and hyperreflexia during inflammation. Chapter 4 also 
investigated if CYP-induced inflammation altered the structure or distribution of 
GFRα3-IR axons in the bladder, and compared these to other classes of afferent and 
autonomic axons. Chronic inflammation had no effect on the structure of these axons. 
Chapter 5 further explored potential targets of GFRα3-IR axons in different tissues 
and regions of the bladder. GFRα3-IR axons were found widely distributed 
throughout the bladder and labelled specific populations of peptidergic axons, 
sympathetic vasoconstrictor axons and glial cells (Table 6.2). These results raise the 
possibility that GDNF and artemin have the potential to regulate different aspects of 
bladder function and may contribute to pain or hyperreflexia following inflammation. 
 
A greater understanding of the characteristics of DRG neurons expressing the GFRs 
and how they respond to nerve injury or inflammation would aid in the development 
of therapeutic targets aiming to restore the nociceptor back to its normal function. 
This would also have important implications for regeneration or the mechanisms 
underlying plasticity after injury or inflammation. Together, results from this thesis 
suggest that the GFRs are promising new targets of therapies aimed at promoting 
regeneration or the development of pain.  
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Table 6.1 Summary of changes in GDNF-family receptor (GFR) immunoreactivity in 
spinal cord and dorsal root ganglia after nerve injury and bladder inflammation 
 
Condition 
 
 
GFRα1 
 
GFRα2 
 
GFRα3 
  
Spinal cord 
 
Control    
     Location 
 
Lamina II (outer) Lamina II (inner) Lamina I and II (outer) 
Sciatic nerve injury    
     Location Lamina II-V (except lateral 
lamina V) 
Lamina II (inner) but 
loss in medial and 
central regions 
Lamina I-II (inner) 
     Intensity 
 
Increase Decrease Increase  
Pelvic nerve injury         
     Location No change dorsal horn, 
increase in SPN 
No change No change 
     Intensity Increase in sacral medial 
dorsal horn and SPN 
Decrease in lumbar 
medial dorsal horn 
 
Increase in SPN 
Hypogastric nerve 
injury 
   
     Location No change No change No change 
     Location No change No change No change 
    
Chronic bladder 
inflammation 
   
     Location No change No change No change 
     Intensity Increase in sacral dorsal 
horn only* 
No change No change 
  
Dorsal root ganglia 
 
Control    
     Phenotype Mainly small-medium 
nonpeptidergic and large 
myelinated neurons 
Small-medium 
nonpeptidergic neurons 
Small-medium 
peptidergic neurons 
Sciatic nerve injury    
     Phenotype Increased proportion of 
myelinated neurons 
No change Increased proportion of 
myelinated and small-
medium nonpeptidergic 
neurons 
     Prevalence Increase Decrease Increase 
     Intensity Increase in small-medium 
and large neurons 
No change No change 
Chronic bladder 
inflammation 
   
     Phenotype No change No change No change 
     Prevalence No change No change No change 
    
Acute bladder 
inflammation 
   
     Prevalence No change - No change 
 
* Reported by Forrest and Keast, 2008. 
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Table 6.2 Summary of GFRα3 immunoreactive axons in the bladder 
 
 
Location 
 
Neuronal 
 
 
Non-neuronal 
 
Suburothelial plexus 
 
Mostly peptidergic sensory 
axons 
 
 
Small, elongated cells with 
processes 
Mostly Schwann cells* 
Vimentin- and SMA-negative* 
 
Detrusor Most neuronal GFRα3 is 
peptidergic sensory 
Small, elongated cells with 
processes 
Many Schwann cells contain 
GFRα3 
Mostly Vimentin- and SMA-
negative 
 
Vasculature Para-vascular axons, many are 
peptidergic sensory 
Peri-vascular axons, most are 
sympathetic noradrenergic 
vasoconstrictor 
Small, elongated cells with 
processes 
Many Schwann cells contain 
GFRα3 
Vimentin- and SMA-negative 
 
 
* Glial fibrillary protein and S100 were used to label Schwann cells; Vimentin labels 
myofibroblasts and interstitial cells; Smooth muscle actin (SMA) is a cytoskeletal 
protein in smooth muscle cells and labels myofibroblasts in the detrusor and 
vasculature, and a thin band beneath urothelial cells. 
 
6.2 Technical limitations 
Sample size is one of the most critical issues in designing a research study as it 
impacts all aspects of result interpretation. The sample size needs to be large enough 
so that sufficient power is obtained from statistical testing to generate an accurate 
answer to the null hypothesis. One limitation of this thesis was the small group sizes 
and an inconsistent number of animals used in each experimental group in some of 
the studies, for example, in Chapters 3-5. Previous published studies from our 
laboratory using similar methodology partially guided the decisions regarding animal 
numbers. However, the probability of type 2 errors is likely to be high when small 
group sizes are used, where false negative results are reported. This occurs when an 
important biological difference exists between groups but does not reach statistical 
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significance due to the effect not being captured by the small sample. This leads to the 
null hypothesis being incorrectly accepted. In this thesis, where small group sizes 
were used, it should be noted that positive outcomes are more meaningful than 
negative ones as the biological effect is likely to be large, and therefore captured by 
our analyses. 
 
Another aspect of the experimental design that needs to be addressed is the way in 
which analyses of immunostaining in spinal cord and DRG neurons were performed 
in Chapters 2-4. Ideally these would have been performed by the observer blinded to 
experimental group. However, early pilot experiments on GFR-immunoreactivity in 
spinal cord following sciatic nerve transection revealed very obvious changes to the 
normal staining distribution pattern that it was impossible to perform blinded optical 
density measurements. Having predefined areas of interest for spinal cord analyses 
addressed this limitation. For consistency, this approach was adopted when analysing 
CGRP and GFR expression in spinal cord following visceral nerve injury (Chapter 3). 
DRG counts following sciatic nerve injury and inflammation were also made un-
blinded by the observer. However, for consistency, approximately 150 somata were 
counted from a total of five sections from each ganglion in every experiment. 
Similarly, predefined areas of interest were used when counting axon terminals in the 
bladder in control and CYP-treated animals (Chapter 4). By adopting these methods, 
we hoped to reduce sampling bias by the observer while keeping counts and analyses 
as random as possible within experimental groups. 
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It is appropriate to acknowledge the limitation of only using immunohistochemical 
methods in this thesis to detect protein in different populations of primary afferent 
neurons and their terminals, and the impact of nerve injury and inflammation on these 
populations. Follow-up confirmatory mRNA studies would enhance a number of key 
findings in this thesis and address some un-answered questions. For example, 
investigating CGRP and GFR mRNA expression in DRGs and spinal cord following 
sciatic nerve injury, and investigating GFR, CGRP and NOS mRNA expression in 
DRG neurons following bladder inflammation. It is possible that mRNA methods 
would be more sensitive at detecting an effect of injury on neurons expressing these 
markers. It would also be informative to confirm nNOS expression in urothelial cells 
with follow-up mRNA studies. Other follow-up studies would include investigating a 
potential neuronal source of neurturin and artemin; if artemin is synthesised by the 
bladder; and if neurturin and artemin mRNA is up-regulated in the bladder following 
CYP. In addition, from the immunohistochemical data presented in this thesis, we can 
only make assumptions about the function of GFR-expressing neurons and their 
terminals but these could be investigated with functional studies as indicated in the 
individual chapter discussions. 
 
6.3 Each GFR-expressing population has different regenerative capabilities 
This thesis examined the impact of somatic and visceral nerve injury on different 
classes of peptidergic and non-peptidergic DRG neurons. This thesis first established 
that two somatic nerve injury models, which differed in severity, had profound effects 
on GFR expression in DRG neurons and their central projections (Chapter 2). Results 
from Chapter 3 revealed that each population of primary afferent fibres containing the 
GFRs responded differently to visceral nerve injury. The changes in GFR expression 
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in spinal cord following somatic and visceral nerve injury have the potential to impact 
pro-regenerative therapies administered during these states. A number of studies have 
demonstrated that GDNF, neurturin and artemin promote growth in DRG neurons. In 
cultured DRG neurons from naïve rats, exogenous administration of GDNF, neurturin 
and artemin stimulate growth by increasing the number of neurons that initiate 
neurites (Bennett et al., 2006; Mills et al., 2007; Paveliev et al., 2004). In DRG 
neurons from animals that were pre-conditioned with sciatic nerve injury, exogenous 
GDNF administration further enhances growth by increasing the percentage of 
neurons that initiate neurites, and increases neurite outgrowth. This effect was found 
to occur at lower doses of GDNF (Mills et al., 2007). Following sciatic nerve injury, 
intrathecal administration of GDNF prevents the loss of IB4-binding fibres in the 
dorsal horn of rats (Bennett et al., 1998), and reverses thermal hyperalgesia and 
mechanical allodynia without affecting thresholds on the uninjured side (Nagano et 
al., 2003). Related studies have been performed with artemin that show similar pro-
regenerative effects. Following spinal nerve ligation, a model of neuropathic pain, 
Gardell et al., (2003) demonstrate that administration of artemin is able to restore the 
degenerative neurochemical and neuroanatomical changes that occur in DRG 
neurons, and their central projections following injury. Artemin administration also 
reversed the onset and development of thermal and mechanical hypersensitivity in the 
hindpaw that develops after spinal nerve ligation (Gardell et al., 2003). Artemin has 
also been shown to have regenerative properties following a C4-T2 dorsal root crush 
injury. This is a regenerative injury model that injures multiple classes of axons 
(peptidergic, non-peptidergic, and myelinated) entering the dorsal root entry zone 
(Wang et al., 2008). Following systemic artemin treatment, these axons were found 
on the spinal cord side of the dorsal root entry zone, indicating that artemin promotes 
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the regeneration of multiple classes of nerve fibres after injury (Wang et al., 2008). 
Together these studies provide evidence that GDNF and artemin are likely to have 
important implications for regeneration following nerve injury. These neurotrophic 
factors are able to restore the neurochemical and neuroanatomical changes that occur 
in DRG neurons and their central projections following injury. 
 
Results in Chapters 2 and 3 demonstrate an upregulation of GFRα1- and GFRα3-IR in 
DRGs and their central terminals after somatic and visceral nerve injury. It could be 
predicted that experimental regenerative therapies using GDNF and artemin could be 
broader than expected based on GFRα1 and GFRα3 expression in naïve animals. 
While this could positively impact regeneration after injury (Bennett et al., 2000a; 
Wang et al., 2008), it could also have adverse outcomes on nociceptor sensitisation 
(Elitt et al., 2006; Malin et al., 2006). Like NGF, GDNF, neurturin and artemin can 
sensitise nociceptors by potentiating the TRPV1 response to capsaicin (Malin et al., 
2006). Of particular interest, GDNF, neurturin and artemin are 10-100x more potent 
than NGF in the potentiation of capsaicin responses in DRG neurons (Malin et al., 
2006). Elitt et al., (2006) show that artemin enhances TRPV1 responsiveness to 
capsaicin. This study suggests that signalling of artemin is likely to modulate TRPV1 
expression and afferent sensitivity in response to noxious chemical stimuli. 
Importantly, these studies indicate that the GFLs can sensitise nociceptors and are 
likely to be involved in the development of pain. Further studies would be required to 
explore the difference in the pro-regenerative and pro-nociceptive actions of the 
GFLs. While the vast majority of studies involving the GFLs have been performed in 
somatic systems, much less is known about their potential to impact pro-regenerative 
therapies following visceral nerve injury. 
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 In contrast to GDNF and artemin, experimental nerve regenerative therapies using 
neurturin are likely to have a smaller impact on regeneration than predicted from 
GFRα2 expression in the uninjured state. This is due to reduced GFRα2 expression in 
DRG neurons and their central terminals following injury (Chapters 2 and 3). A 
recent report by Wang et al., (2013) used transgenic mice that over-express neurturin 
in keratinocytes to demonstrate that neurturin can regulate gene transcription in 
cutaneous afferents as well as thermal, chemical and mechanical sensitivity. An 
earlier study provided evidence that administration of neurturin enhances erectile 
function after cavernous nerve injury (Bella et al., 2007). Despite these studies, it is 
not known if neurturin will show similar efficacy as GDNF or artemin in neuropathic 
pain models. Based on the reduced GFRα2-IR following nerve injury in the current 
study (Chapters 2 and 3), it could be predicted that neurturin is unlikely to be as 
efficacious as GDNF and artemin in nerve injury models. 
  
6.4 Nerve injury produces unique effects on GFR expression in DRG neurons 
and their central projections 
The observation that GFRα1- and GFRα3-positive afferents had a tendency to 
increase following somatic nerve injury whereas GFRα2 decreased (Chapter 2) raises 
the question of why only this population of afferents responded this way. Previous 
studies from our laboratory also found that GFRα2-IR was reduced in the superficial 
dorsal horn after complete (Kalous et al., 2007) and incomplete (clip-compression) 
(Kalous et al., 2009) spinal cord injury. In addition, a recent study by Wang et al., 
(2011) demonstrate that GFRα2-IR afferents rapidly decrease in vivo and in vitro after 
sciatic nerve transection. This study demonstrates that approximately one third of 
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adult DRG neurons die within four days of culture, which can be prevented by 
exogenous administration of NGF, GDNF and artemin, but not by neurturin. The lack 
of effect of neurturin correlated with a rapid down-regulation, and almost complete 
loss of GFRα2-IR in dissociated neurons (Wang et al., 2011). This study also shows 
that cutaneous GFRα2-positive neurons in vivo switch phenotype after sciatic nerve 
injury. This experiment was conducted by labelling cutaneous afferents in vivo prior 
to sciatic nerve injury by injecting fluorescently-tagged IB4 (IB4-488) subcutaneously 
into the hindpaw of mice. IB4-488 is retrogradely transported by afferents in the 
saphenous nerve to cutaneous neurons in L2-3 DRG, which label both GFRα1- and 
GFRα2-positive populations. Following sciatic nerve injury, GFRα2-IR is down-
regulated in IB4-488 labelled cutaneous neurons, and instead, these neurons start 
expressing GFRα3- and TRPV1-IR (Wang et al., 2011). This study provides further 
evidence that the GFRα2-positive population of afferents show a susceptibility to 
degenerate following in vitro and in vivo injury. Together, these observations are 
consistent with a number of other reports indicating that non-peptidergic, IB4-binding 
afferents are particularly susceptible to degeneration after injury compared to 
peptidergic afferents (Bailey and Ribeiro-da-Silva, 2006; Casals-Diaz et al., 2009; 
Leclere et al., 2007). These changes are likely to be caused by altered target-derived 
neurotrophic factor levels at the site of injury (below). However, the IB4-binding 
population includes both GFRα1 and GFRα2 subpopulations (Bennett et al., 2000a). 
Therefore, the above studies cannot explain the results in this thesis demonstrating a 
significant increase in GFRα1-IR in DRG neurons and their central projections 
following somatic and visceral nerve injury (Chapters 2 and 3).  
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Sciatic nerve injury triggers GDNF and artemin synthesis in Schwann cells proximal 
to injury (Baloh et al., 1998; Trupp et al., 1995), which helps support the regeneration 
of injured axons (Navarro et al., 2007). This increase in GDNF and artemin synthesis 
corresponds to an increased number of DRG neurons expressing GFRα1 and GFRα3 
mRNA after sciatic nerve injury (Bennett et al., 2000a). The expression of neurturin 
at the site of injury has not been examined, however, the number of neurons 
containing GFRα2 mRNA (Bennett et al., 2000a) and protein (Chapter 2) are reduced 
following sciatic nerve injury. This raises two possibilities; firstly if neurturin is 
down-regulated at the site of nerve injury, indicating a loss or absence of target-
derived neurturin, it can potentially cause a degeneration of GFRα2-positive axons 
and neurons. In contrast, a potential up-regulation of neurturin (similarly to GDNF 
and artemin) at the site of injury may be insufficient to prevent the axotomy-induced 
down-regulation of GFRα2-IR in DRG neurons and their terminals. Given the rapid 
down-regulation of GFRα2-positive afferents reported by Wang et al., (2011), even if 
neurturin is increased at the injury site, it may be too late to rescue degenerating 
GFRα2-IR axons. Further studies are required to reconcile this and to investigate the 
difference in regenerative capabilities between the two populations of non-peptidergic 
afferents (GFRα1 and GFRα2). 
 
6.5 Each GFL may impact nociceptor sensitisation differently after somatic or 
visceral nerve injury 
This thesis established that injury to somatic and visceral nerves produce different 
outcomes on nociceptors and central terminals expressing the GFRs (Chapters 2 and 
3). These results indicate that the functional impact of nerve injury is likely to differ 
between these groups of GFR-expressing neurons and their responses to neurotrophic 
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factors. The changes in GFR expression in DRG neurons and their central projections 
observed after injury are unlikely to be causally related to the development of 
neuropathic pain. However, they may impact the site and degree of sensitisation 
induced by neurotrophic factors. This is also likely to differ between somatic and 
visceral nociceptors (Malin et al., 2011). There is emerging evidence indicating that 
like NGF, the GFLs can contribute to nociceptor sensitisation by potentiating the 
TRPV1 response to capsaicin (Elitt et al., 2006; Malin et al., 2006). The degree to 
which they sensitise nociceptors is dependent on the peripheral targets of the primary 
sensory neuron, which varies between afferents innervating skin, muscle or viscera 
(Malin et al., 2011). NGF, via trkA receptors, potentiates TRPV1 function through the 
phosphorylation of TRPV1 by protein kinase A and C (Bhave et al., 2003; Bhave et 
al., 2002; Shu and Mendell, 2001), and by tyrosine kinase c-Src (Zhang et al., 2005). 
While these studies provide compelling evidence that the GFLs act on somatic and 
visceral nociceptors to regulate pain, the mechanisms of how these effects are 
produced at the cellular level have not been identified. However, these results indicate 
that the TRPV1 channel is an essential mediator of GFL-induced sensitisation, as 
demonstrated for NGF (Frias et al., 2012).  
 
Damage to a somatic nerve caused by mechanical trauma, is one of the major causes 
of neuropathic pain (Costigan et al., 2009). It is not known if damage to a visceral 
nerve causes pain in rodents but persistent pain has been reported in patients 
following surgery to visceral organs (Johansen et al., 2012). However, the prevalence 
of persistent pain following surgery to a visceral organ is much lower than 
experienced following surgery to a somatic structure (Johansen et al., 2012). This 
evidence suggests that different mechanisms are responsible for how pain arises from 
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visceral or somatic nerves, and the two classes of nerves may have different 
regenerative capabilities after injury. Together with results from this thesis (Chapters 
2 and 3) and functional studies with the GFLs (above), it could be proposed that both 
of these components may be mediated, or partially mediated by neurotrophic factors. 
The GFRs are differentially expressed in visceral and somatic DRG neurons 
(Chapters 2 and 4; (Forrest and Keast, 2008; Kalous et al., 2007; 2009)) with a higher 
proportion of somatic afferents being non-peptidergic, expressing receptors for GDNF 
and neurturin. This thesis also provides evidence that each neuronal population 
expressing the GFRs respond differently to somatic and visceral nerve injury. In 
addition, the above study by Malin et al. (2011) found that the degree to which the 
GFLs sensitise nociceptors is highly specific depending on the peripheral target, 
which is not uniform across somatic and visceral afferents. Once nociceptors become 
sensitised, their threshold for activation is reduced and they develop spontaneous 
activity, becoming hyperexcitable (Yoshimura and de Groat, 1999). These features 
maintain neuropathic pain and produce a reduction in thermal and mechanical pain 
thresholds (Costigan et al., 2009). Together, results from this thesis suggest that many 
neurons innervating somatic structures have the potential to be regulated by NGF, 
GDNF, neurturin and artemin. However, it should be noted that thesis did not 
specifically identify somatic afferents. In comparison, few neurons innervating the 
bladder (and possibly other viscera) are likely to be regulated by neurturin (Chapter 
4). Therefore, it is possible that each GFL provides a different contribution to 
nociceptor sensitisation and the development of pain originating from somatic or 
visceral origin (above). Furthermore, both GDNF and artemin are potent regenerative 
molecules (Gardell et al., 2003; Nagano et al., 2003). The difference in GFR 
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expression between visceral and somatic DRGs will limit the number of neurons 
likely to regulated, and influenced by their ligands. 
 
6.6 Regulation of bladder sensory function by the GFLs and neurotrophins 
NGF can regulate bladder function (Chuang et al., 2001; Ochodnicky et al., 2012; 
Yoshimura et al., 2006; Zvara and Vizzard, 2007) and there is emerging evidence to 
suggest that members of the GFLs could also regulate bladder function (Forrest and 
Keast, 2008; Vizzard, 2000b). Detrusor muscle cells, urothelial and mast cells 
produce NGF and are major sources of NGF in the bladder (Leon et al., 1994; 
Ochodnicky et al., 2012; Vizzard, 2000b). Intrathecal (Yoshimura et al., 2006) and 
intravesical (Chuang et al., 2001) administration of NGF in rats produce bladder 
hyperactivity, reduces the threshold for micturition and sensitises bladder afferents. 
Increased micturition frequency and a reduction of bladder capacity is also reported 
when NGF is chronically infused directly into the bladder wall of rats using an 
osmotic pump (Zvara and Vizzard, 2007). Central or peripheral NGF sequestration 
reduced bladder overactivity in animal models of bladder inflammation (Ochodnicky 
et al., 2012). In clinical trials, NGF sequestration and administration of an NGF-
neutralising antibody, tanezumab, have proven efficacious in relieving many 
symptoms of interstitial cystitis (Ochodnicky et al., 2012). These reports indicate that 
NGF can regulate bladder function and is a potential therapeutic target for the 
treatment of interstitial cystitis. Our laboratory reported that approximately one 
quarter of bladder afferent neurons contain GFRα1- and GFRα3-IR (Forrest and 
Keast, 2008). These results raise the possibility that GDNF and artemin may target 
sacral bladder afferent neurons and be involved in the maintenance of physiological 
and structural properties of bladder neurons expressing their receptors. This thesis has 
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demonstrated that GDNF and artemin have the potential to target different functional 
groups of bladder afferent neurons (Chapter 4), potentially regulating different 
components of bladder function. After chronic bladder inflammation induced by 
CYP, GFRα1 intensity is increased in the sacral dorsal horn (Forrest and Keast, 2008) 
and GDNF mRNA in up-regulated in the bladder (Vizzard, 2000b). These results 
indicate that inflammation-induced synthesis of GDNF by the bladder could stimulate 
expression of its receptor, GFRα1. This could provide a potential mechanism to 
stimulate structural remodeling or increased excitability of pelvic visceral afferent 
neurons that has been reported to occur following chronic inflammation (Yoshimura 
and de Groat, 1999). Results from this thesis also suggest that GDNF could modify 
activity of sacral, but not lumbar (Chapter 4) bladder afferents, possibly contributing 
to bladder hyperactivity. It is currently unknown if neurturin or artemin levels are also 
increased in the bladder at this time. 
 
While the majority of studies have focused on the role of NGF in regulating bladder 
function (above), and to a lesser extend, GDNF (Vizzard, 2000b); the role of artemin 
in the inflamed bladder is not known. This thesis suggests that artemin is likely to 
significantly contribute to regulating bladder function. A significant proportion of 
bladder afferent neurons express GFRα3-IR, which are potentially targeted by artemin 
(Chapter 4). GFRα3 axons are widely distributed within the bladder and target very 
specific axonal and non-neuronal populations (Chapter 5). However, further 
investigation is required to determine the co-expression of Ret in axons containing 
GFRα3-IR. In dissociated neurons, artemin and NGF potentiate the response to 
capsaicin (Malin et al., 2011) and the majority of bladder afferent neurons are 
capsaicin sensitive (Avelino and Cruz, 2000; Maggi, 1990; Sharkey et al., 1983), 
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expressing TRPV1 (Chapter 4). Intravesical injection of capsaicin or NGF induces 
bladder hyperreflexia and decreases the micturition threshold (Dmitrieva et al., 1997; 
Maggi, 1992; Yoshimura et al., 2006). Results in Chapter 4 demonstrated that 
GFRα3-IR bladder-projecting neurons contain both CGRP- and TRPV1-IR, and all 
CGRP-IR neurons contain TRPV1-IR. As almost all GFRα3-IR suburothelial axons 
contain CGRP-IR, it is likely they will express TRPV1-IR. Together these results 
suggest that artemin could potentially sensitise suburothelial axons and contribute to 
altered reflex behaviours during inflammation (Chapters 4 and 5) but functional 
studies are required to investigate this.  
 
The presence of GFRα3-IR axons in the suburothelial plexus (Chapter 5) also 
suggests they are particularly vulnerable to damage during CYP-induced 
inflammation. Suburothelial axons, are easily exposed to toxic substances in urine 
when urothelial barrier function is lost (Dickson et al., 2006). This could in turn 
contribute to peripheral sensitisation and bladder hyperactivity (Birder et al., 2010). In 
support of this conclusion, a recent study in mice has shown that enhanced GFRα3 
signalling in visceral afferents is likely to contribute to colorectal hypersensitivity 
(Tanaka et al., 2011). This study investigated the role of GFRα3 signalling in 
colorectal hypersensitivity produced by intracolonic administration of 2,4,6-
trinitrobenzene sulfonic acid (TNBS). TNBS induces long-lasting colorectal 
inflammatory hypersensitivity (Tanaka et al., 2011). Colonic hypersensitivity was 
quantified in wild type and GFRα3 knock out mice by measuring visceromotor 
responses to colorectal distension before, and after treatment with TNBS. TNBS 
significantly increased visceromotor responses in wild type mice with a 
corresponding increase in the number of retrogradely-labelled colorectal afferent 
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neurons containing GFRα3-IR. In contrast, TNBS-induced colorectal hypersensitivity 
was suppressed in GFRα3 knock out mice (Tanaka et al., 2011). This study suggests a 
role of GFRα3 signalling in modulating the excitability of colorectal afferents that 
contribute to hypersensitivity following inflammation. It also raises the possibility 
that artemin may contribute to sensitisation of colorectal afferents following 
inflammation (Tanaka et al., 2011). 
 
This thesis has provided further evidence that the bladder is not innervated by 
GFRα2-expressing afferent neurons and is unlikely to be influenced by neurturin. 
This was consistent with the lack of effect chronic bladder inflammation had on 
GFRα2 expression in DRGs and the dorsal horn (Chapter 4), and the very small effect 
visceral nerve injury had on this population (Chapter 3). Kiasalari et al. (2010) 
identified a population of highly expressing TRPV1-IR neurons that are also not 
expressed by bladder afferent neurons. These neurons express GFRα2-IR and are 
activated by innocuous and moderately noxious thermal stimuli (Kiasalari et al., 
2010). It is likely the GFRα2-IR, highly expressing TRPV1 neurons innervate 
cutaneous, rather than visceral targets (Kiasalari et al., 2010). This could be important 
in the context where detecting cutaneous thermal stimuli serves an important 
discriminating sensory function. It would be interesting to ascertain if GFRα2-
expressing afferent neurons innervate other visceral organs. 
 
6.7 GDNF and artemin are potential biomarkers for interstitial cystitis 
A number of studies have implicated NGF in sensitising bladder afferents during 
inflammation, contributing to bladder hyperactivity and pain (Chuang et al., 2001; 
Yoshimura et al., 2006; Zvara and Vizzard, 2007). Increased levels of NGF in the 
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urine of patients with interstitial cystitis correspond to symptom severity (Okragly et 
al., 1999) and in rats, NGF sequestration relieves many symptoms of the disease (Hu 
et al., 2005). In light of these studies, NGF has been proposed as a potential 
biomarker for interstitial cystitis (Liu et al., 2009) but it is not known if the effects are 
mediated by the artemin-sensitive or artemin-insensitive population. Biomarkers are 
used as diagnostic tools as indicators of disease state, its severity and progression, and 
response to treatment (Bhide et al., 2013; Seth et al., 2013). However, using NGF 
alone as a biomarker for interstitial cystitis is potentially problematic and likely to be 
inconclusive. This is because NGF is also elevated in the urine of patients with 
overactive bladder syndrome and bladder outlet obstruction (Kuo et al., 2010; Liu and 
Kuo, 2008). Results presented in this thesis (Chapters 4 and 5) suggest that similar 
studies be carried out for GDNF and artemin, as have been with NGF (above). While 
it is not known if artemin is increased in the bladder wall or in the urine of patients 
with interstitial cystitis, results from Chapter 4 indicate that both GDNF and artemin 
are likely to regulate different components of bladder activity and pain during 
inflammation. In addition, GDNF is increased in the bladder wall of rats following 
CYP-induced inflammation (Vizzard, 2000b) and in urine from patients with 
interstitial cystitis (Okragly et al., 1999). While further studies are required, it is 
possible that GDNF and artemin could be used as additional biomarkers that are 
specific for interstitial cystitis. In support of this assumption, a recent study by 
Antunes-Lopes et al., (2013) provided evidence that urinary GDNF levels are not 
elevated in patients with overactive bladder syndrome but in contrast, both urinary 
NGF and brain-derived neurotrophic factor (BDNF) levels were (Antunes-Lopes et 
al., 2013). Therefore, it is possible that altered GDNF (and artemin) levels in the urine 
320
of patients with interstitial cystitis, could distinguish it from overactive bladder 
syndrome, and potentially other painful visceral conditions. 
 
6.8 Potential functions of GFR-expressing neurons 
This thesis has demonstrated that each GFR is expressed in distinct neuronal 
populations (Chapter 2 and 4) that respond differently to nerve injury (Chapters 2 and 
3) and bladder inflammation (Chapter 4) (Forrest and Keast, 2008). These results 
raise the question of what is the function of each GFR-expressing subpopulation of 
neurons. This may have broader implications when comparing GFR-positive somatic 
and visceral neurons. The Mas-related G-protein-coupled receptor D (MrgprD) labels 
a population of non-peptidergic cutaneous polymodal nociceptors that are essential 
for the full expression of mechanical nociception (Cavanaugh et al., 2009; Rau et al., 
2009; Zylka et al., 2005). MrgprD-positive neurons selectively contribute to 
mechanical (but not heat or cold) pain behaviours (Braz and Basbaum, 2010; 
Cavanaugh et al., 2009; Zhang et al., 2013). However, a recent study reported that 
MrgprD neurons also respond to extreme heat and cold stimuli (Pogorzala et al., 
2013). MrgprD neurons are unmyelinated (NF200-negative), bind IB4, and contain 
Ret- and P2X3-IR (Zylka et al., 2003; Zylka et al., 2005). Central projections of 
MrgprD-IR neurons are located in lamina II, the majority found in lamina II outer 
(Zylka et al., 2005). Currently there is not enough evidence to definitively predict 
whether MrgprD mechanoreceptive neurons will comprise the GFRα1 or GFRα2 
population. However, based on the distribution of MrgprD terminals in the dorsal 
horn, it is more likely they will comprise the GFRα1-positive population, as GFRα1-
IR fibres terminate in lamina II outer (Chapter 2, 3 and 4). GFRα1-IR is expressed in 
DRG neurons of all sizes (Chapter 2 and 4), and Chapter 2 demonstrated that 
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approximately half of all cutaneous GFRα1-positive neurons did not contain NF200-
IR. This result suggests this population of GFRα1 neurons are smaller-diameter C-
type neurons that could potentially contain MrgprD-IR and be mechanoreceptive C-
type nociceptors. Together, these results indicate that cutaneous GFRα1-IR neurons 
are likely to comprise both C-type (GFRα1-positive, NF200-negative) and Aδ-type 
mechanoreceptors (GFRα1-positive, NF200-positive). This is consistent with a 
number of earlier studies (Albers et al., 2006; Bennett et al., 1998; Molliver et al., 
1997; Silverman and Kruger, 1990). The GFRα1 population of afferent 
mechanoreceptive neurons are potentially regulated by GDNF. This population of 
neurons are likely to be significant not only in the context of normal cutaneous 
mechanosensation, but may have broader implications for altered behavioural 
mechanosensitivity following nerve injury. Intrathecal administration of GDNF 
reverses altered mechanical responses (mechanical allodynia) following spinal nerve 
ligation and sciatic nerve injury in rats (Nagano et al., 2003)(above). Functional 
studies are required to investigate the role of GDNF-sensitive neurons in cutaneous 
mechanoreception and nerve injury. 
 
In contrast to cutaneous afferent neurons, almost all GFRα1-IR bladder afferent 
neurons contain NF200-IR (Chapter 4). These neurons are therefore unlikely to 
contain MrgprD and be C-type mechanoreceptors. GFRα1-positive bladder afferent 
neurons are likely to comprise low threshold Aδ-mechanoreceptors (Chapter 4; 
(Scherrer et al., 2010)) that respond to innocuous stimuli such as changes in bladder 
distension and detrusor contraction during voiding (Chapter 4). This population of 
GFRα1-IR low threshold visceral mechanoreceptors (Aδ-) can potentially sensitise 
during inflammation, which involves lowering their threshold of activation and 
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increasing their excitability in response to a mechanical stimulus. During 
inflammation, this increases the magnitude of the afferent signal during bladder 
distension, causing the number of nerve impulses that are fired to occur at lower 
distension volumes (Birder et al., 2010). Together, this causes bladder hyperactivity 
and decreased bladder threshold for micturition (Birder et al., 2010). 
 
GFRα3-IR neurons are polymodal nociceptors, almost all of which contain TRPV1-
IR (Chapter 4) and TRPA1-IR (Elitt et al., 2006). In addition, almost all TRPA1-IR 
neurons contain GFRα3-IR (Elitt et al., 2006). TRPA1 plays a critical role in the 
development and maintenance of mechanical and cold nociception during persistent 
inflammatory conditions (da Costa et al., 2010; McGaraughty et al., 2010). The 
TRPV1 channel is thermosensitive and contributes to nociceptive signalling, as mice 
that lack TRPV1 show attenuated responses to noxious heat, but normal responses to 
mechanical stimuli (Caterina et al., 2000). Genetically modified mice that over-
express artemin in the skin show increased GFRα3 and TRPA1 expression in DRG 
neurons, which correlates to increased behavioural response to thermal (heat and 
cold) sensitivity (Elitt et al., 2006). These results indicate there is an almost exclusive 
population of peptidergic nociceptors that express GFRα3- and TRPA1-IR that are 
temperature-sensitive, regulating the response to heat and cold stimuli. This 
population of GFRα3/TRPA1 afferents are likely to have important roles in cutaneous 
temperature (heat and cold) discrimination and thermal nociception.  
 
Another cold receptor that belongs to the TRP family, TRPM8, activated by cold 
temperatures (<28°C) and cooling compounds (McKemy et al., 2002; Woolf and Ma, 
2007a), is expressed in DRG neurons. A study by Hayashi et al., (2009) report that 
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TRPM8-IR is expressed by the majority (80%) of rat bladder afferent neurons. The 
majority of these neurons contain CGRP- and NF200-IR i.e. peptidergic and thinly 
myelinated (Aδ). In contrast, a second group of TRMP8-IR neurons have been 
described that do not project to the bladder, and are likely to comprise cutaneous 
afferents. This population of TRMP8-IR DRG neurons contain NF200-IR but few 
express CGRP-, TRPV1 or TRPA1-IR i.e. most are non-peptidergic, myelinated 
neurons (Blackshaw et al., 2010; Hayashi et al., 2009). Together this data suggests 
that neurons (bladder and non-bladder) containing TRPM8 are likely to comprise Aδ-
type neurons that are unlikely to contain the GFRs. Firstly, few TRPM8-positive 
neurons bind IB4 (Hayashi et al., 2009). TRPM8-IR neurons are therefore unlikely to 
contain GFRα1- or GFRα2-IR, as these neurons are found in the non-peptidergic, 
IB4-binding population (Priestley et al., 2002). In addition, results from Chapter 2 and 
4 demonstrated that GFRα3-IR is expressed by small-medium diameter sized neurons, 
and very few contain NF200-IR (Chapter 2)(Bennett et al., 2006). GFRα3-IR neurons 
are therefore unlikely to contain TRPM8-IR. However, a recent study (Wang et al., 
2013) reports that genetically modified mice that over-express neurturin in the skin 
show increased behavioural sensitivity to innocuous cold and mechanical stimuli in 
the hindpaw. In addition, these mice show enhanced oral sensitivity to the cooling 
compound menthol (Wang et al., 2013). The enhanced cold sensitivity correlated to a 
significant increase in TRPM8 mRNA in DRG neurons and an increase in the number 
of TRPM8 neurons binding IB4 (therefore non-peptidergic) compared to wild type 
mice. An increase in the number of neurons containing GFRα2 and Ret was also 
reported. It is possible that TRPM8-IR was increased in neurons containing GFRα2-
IR (Wang et al., 2013). These results suggest that neurturin over-expression in the 
skin enhances TRPM8 expression in cutaneous afferent neurons, modulating 
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behavioural sensitivity to thermal, chemical and mechanical stimuli. While the 
function of GFRα2-positive neurons is less clear than those containing GFRα1 and 
GFRα3, the study by Wang et al., (2013) is in agreement with an earlier report that 
found IB4-binding DRG neurons from GFRα2 knock out mice show reduced heat 
currents (Stucky et al., 2002). Together, these results indicate that neurturin is likely 
to have an important role in modulating cutaneous thermal responses.  
 
6.9 GFL signalling and Ret 
Despite the limited information about the source of the GFLs, it raises the question of 
how and when they are activated. GFL signalling is activated if it is first bound to its 
specific GFR, which then activates Ret (Airaksinen and Saarma, 2002). On this basis, 
it is expected that the distribution of Ret will closely match that of the GFRs. Many of 
these studies have been performed in primary sensory neurons where most GFR-
expressing neurons contain Ret (Bennett et al., 1998; Kashiba et al., 1998; Kashiba et 
al., 2003; Lindfors et al., 2006; Orozco et al., 2001). This is not the case in the spinal 
cord where results from this thesis (Chapter 2-4) found that in both control and 
animals that underwent nerve injury or inflammation, the reported Ret expression 
(Jongen et al., 2007) did not match the sum of the GFRs. In naïve animals, Ret-IR 
fibres are found in lamina II, the majority targeting lamina II inner (Golden et al., 
2010; Jongen et al., 2007), whereas the GFRs terminate in laminae I (GFRα3), and 
lamina II outer (GFRα1) and inner (GFRα2). In addition, GFRα1-IR fibres are 
associated with the lateral collateral pathway and sacral preganglionic neurons 
(Chapters 2-4)(Forrest and Keast, 2008), and GFRα3-IR fibres are also associated 
with the lateral collateral pathway (Chapters 2-4)(Forrest and Keast, 2008). In 
addition, the profound changes reported in GFR expression in the spinal cord 
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following sciatic nerve injury (Chapter 2), also did not match reported Ret expression 
in the spinal cord following the same injury (Jongen et al., 2007). Following sciatic 
nerve injury in rats, Jongen et al., (2007) report close to a 50% reduction in the 
density of Ret-IR fibres in the medial half of lamina II on the side ipsilateral to injury. 
In addition, only a small increase in Ret-IR fibres in the medial aspect of laminae III 
and IV occurred on the injured side. This suggests that areas of Ret-independent 
signalling are present in the spinal cord or that Ret immunolabelling underestimates 
the distribution of Ret protein. It is also a possibility that Ret expression determines 
when GFRs are functional. In contrast, less is known about the distribution of Ret in 
the periphery. One study demonstrated the presence of Ret in the rat bladder, but a 
detailed description was not provided (Yang et al., 2006). Further investigation is 
required to determine the distribution of Ret in the spinal cord and periphery. 
 
Since the neurotrophins have been extensively studied, there is much information 
available about their source, both neuronal and non-neuronal, including immune cells  
(Heppenstall and Lewin, 2001; Pezet and McMahon, 2006; Vizzard, 2000b; 
Yamamoto et al., 1996). In contrast, the source of the endogenous ligands for the 
GFRs is largely unknown. GDNF is synthesised by DRG neurons, which could be 
released at their terminals (Holstege et al., 1998; Jongen et al., 1999; Nagano et al., 
2003), and by motoneurons in the spinal cord (Choi-Lundberg and Bohn, 1995; 
Pochon et al., 1997; Yamamoto et al., 1996). Schwann cells have also been reported 
to produce GDNF (Springer et al., 1994; Trupp et al., 1997; Zhang et al., 2009). A 
neuronal source of both neurturin and artemin are yet to be identified. NGF, GDNF 
and neurturin are synthesised by the bladder and a number of other pelvic organs 
(Kawakami et al., 2003; Laurikainen et al., 2000; Vizzard, 2000b; Widenfalk et al., 
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1997; Widenfalk et al., 2000). Many smooth muscle cells of the vasculature have 
been reported to express artemin (Damon et al., 2007; Honma et al., 2002; McIlvried 
et al., 2010), consistent with artemin being a vascular-derived neurotrophic factor 
(Honma et al., 2002). The source of artemin in pelvic visceral organs has not been 
investigated. 
 
Questions also arise about the conditions under which the GFLs are up-regulated and 
released. GDNF mRNA is increased in the bladder during chronic bladder 
inflammation in rats (Vizzard, 2000b) and in the urine of patients with interstitial 
cystitis (Okragly et al., 1999). In addition, GDNF and artemin mRNA are increased in 
the colon during inflammation induced by TNBS (Malin et al., 2011). Members of the 
GFLs are up-regulated at the site of peripheral nerve injury (Baloh et al., 1998; Trupp 
et al., 1995) and in the spinal cord following spinal cord injury (Satake et al., 2000; 
Widenfalk et al., 2001). These increased neurotrophic factor levels at the site of injury 
could modulate regenerative growth and support of injured axons (Navarro et al., 
2007). More recent studies have demonstrated that artemin mRNA is increased in the 
skin during inflammation of the hindpaw induced by injection of complete Freud’s 
adjuvant. No increase in GDNF or neurturin mRNA was detected (Malin et al., 2006). 
The up-regulation of artemin in skin during cutaneous inflammation suggests a role of 
artemin in mediating inflammatory hyperalgesia (Malin et al., 2006). Relatively few 
studies have focused on the biological activity of GFLs on nociceptors, but while 
these studies have been intriguing, they are also confusing. For example, a number of 
studies have demonstrated a pro-nociceptive function of the GFLs where they can 
sensitise nociceptors and contribute to pain (Elitt et al., 2006; Malin et al., 2011; 
Malin et al., 2006). In contrast, other studies demonstrate regenerative and anti-
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nociceptive effects of the GFLs (Bennett et al., 2000a; Gardell et al., 2003; Wang et 
al., 2008). Further studies are required to reconcile these discrepancies, however, it 
must be noted that the GFLs can also have powerful effects on autonomic neurons 
and glial cells (Keast, 2006). 
 
Neurotrophic factors, in particular NGF, have well established roles in pain 
modulation and transmission. NGF and the GFLs can be released from target tissues 
and up-regulated at the site of nerve injury or inflammation (Elitt et al., 2006; Malin 
et al., 2006). NGF acts as a sensitiser by activating trkA and p75 receptors in the 
peripheral nociceptor terminal (Pezet and McMahon, 2006). NGF signalling not only 
occurs at the peripheral nociceptor terminal, but also provides retrograde transport to 
the soma. This function allows NGF to function differently to other sensitisers 
released from axon terminals such as SP and CGRP, during inflammation (Navarro et 
al., 2007). NGF binds to trkA or p75, which becomes internalised and transported 
along the axon to the nociceptor cell body, where it continues to signal. This 
mechanism enables NGF to regulate gene expression in nociceptors and produce 
nociceptor sensitisation (Pezet and McMahon, 2006). NGF can also be potentially 
transported from the nociceptor soma to their central terminals, inducing synaptic 
plasticity in the spinal cord (Pezet and McMahon, 2006). While not specifically 
investigated, after mechanical injury to a visceral nerve it is likely  that NGF and the 
GFLs are up-regulated at the site of injury. After binding to their respective receptors 
(NGF to trkA and p75, GFLs to GFR and Ret), these neurotrophic factors could be 
internalised and transported back to the soma to alter gene expression. GDNF, 
neurturin and artemin have been shown to regulate gene transcription in DRG neurons 
(Bennett et al., 2000a; Gardell et al., 2003; Wang et al., 2008; Wang et al., 2013). 
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This is likely to have important implications for nociceptor sensitisation and the 
development of neuropathic pain following injury to somatic or visceral nerves. The 
GFLs could also be released from central terminals expressing their receptors, 
potentially stimulating their receptors in the spinal cord, impacting plasticity 
following injury in a similar manner as NGF. 
 
6.10 Conclusions 
In summary, the work presented in this thesis has provided evidence that the three 
populations of nociceptors expressing the GFRs show unique responses to nerve 
injury and inflammation. This suggests that the functional impact of injury and 
inflammation may differ between these groups of neurons and their responses to 
neurotrophic factors. Results from this study are also in agreement with the emerging 
view that somatic and visceral nociceptors are regulated differently by the GFLs. This 
suggests that somatic and visceral afferents will have different growth factor 
sensitivities that may impact the degree of regeneration or the development of 
sensitisation. Together these findings suggest that the GFLs and their receptors 
represent a promising new target for regeneration or the treatment of pain following 
nerve injury or visceral inflammation. 
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Appendix: antibody characterisation 
 
Rabbit anti-ATF-3 (C-19) polyclonal antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA; Cat. No. sc-188; Batch No. J2209) was raised against a peptide at the 
C-terminus of ATF-3 human origin. Western blot analysis of RAW 264.7 whole cell 
lysate reveals a single band at ~27 kDa (manufacturers technical information). This 
antibody produced nuclear immunoreactivity as previously described (Peddie and 
Keast, 2011; Starkey et al., 2009; Tsujino et al., 2000). 
 
Goat anti-calcitonin gene-related peptide (CGRP) polyclonal antibody (AbD Serotec, 
East Brisbane, QLD, Australia; Cat. No. 1720-9007; Batch No. 906) is derived from 
synthetic rat Tyr-CGRP (23-37) conjugated to gamma globulin. This antibody reacts 
with the whole molecule (1-37) and 23-37 fragment (C-terminus) and cross-reacts 
with mouse (manufacturer’s technical information). We found a similar pattern of 
immunoreactivity in DRG and spinal cord as previously described (Ivanusic, 2009; 
Kalous et al., 2007; 2009; Keast et al., 2010). 
 
Rabbit anti-CGRP polyclonal antibody (Sigma, Castle Hill, NSW, Australia; Cat. No. 
AB5920; Batch No. LV1520807) was raised against synthetic CGRP conjugated to 
KLH as the immunogen. This antibody reacts with rat CGRP but does not cross-react 
(<0.01%) with substance P, vasoactive intestinal peptide, neuropeptide Y (porcine), or 
with human calcitonin, somatostatin or amylin 8-37 (manufacturer’s technical 
information). Specific reactivity of this antibody can be eliminated by pre-incubation 
with 10 µM of rat CGRP (manufacturer’s technical information). This antibody 
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produced a similar pattern of immunoreactivity in DRG and spinal cord as previously 
described (Chao et al., 2008; Kalous et al., 2007; Keast et al., 2010). 
 
Mouse anti-CD68 (clone ED-1) monoclonal antibody (Millipore; Cat. No. C8198; 
Batch No. 059K4841) was isolated from rat spleen cells. This antibody recognises a 
single chain glycoprotein of 90-100 kDa. Cross reactivity with other species has not 
been determined (manufacturer’s technical information). We found similar 
immunoreactivity in macrophages in control and inflamed bladders as previously 
described (Damoiseaux et al., 1994; Vizzard, 2000a). 
 
Mouse cytokeratin-17, Clone E3 (CYTO-17) monoclonal antibody (DakoCytomation, 
Vancouver, BC, Canada; Cat. No. M7046; Batch No. 00038224) was raised against a 
cytoskeletal fraction of rat colon epithelium. According to the manufacturer’s 
technical information, this antibody reacts with the CYTO-17 equivalent protein in 
both rabbit and rat. This antibody produced a similar pattern of immunoreactivity in 
basal and intermediate urothelial cells as numerous previous publications (Moll et al., 
1995; Romih et al., 1998). 
 
Mouse anti-Cytokeratin-20, Clone KS20.8 (CYTO-20) monoclonal antibody 
(DakoCytomation; Cat. NO. M7019; Batch No. 00045829) was raised against CK-20 
isolated from cytoskeletal material from human duodenal mucosa. In Western blot 
this antibody recognises a single band at 46 kDa (manufacturer’s technical 
information). This antibody produced a similar pattern of immunoreactivity in 
superficial urothelial cells as previously described (Krimm et al., 2006; Moll et al., 
1995; Romih et al., 1998; Romih et al., 2005). 
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 Rabbit anti-estrogen receptor alpha (ERα Affinity) polyclonal antibody (Affinity 
Bioreagents, Scoresby, VIC, Australia; Cat. No. PA1-308; Batch No. 270-006) was 
raised against synthetic peptide M(1)TMTLHTKASGMALLHQIQGN(21)C. This 
antibody detects a single band at ~64 kDa on Western blot and reacts with ERα from 
both human and rat tissues and cells (manufacturer’s technical information). Pre-
absorption of the antibody in an excess of the purified nutralising peptide inhibits all 
positive immunoreactivity in rat DRG (Bennett et al., 2003). We found a similar 
pattern of immunoreactivity localised in the nucleus as previous publications (Bennett 
et al., 2003; Hager et al., 2000). 
 
Rabbit anti-estrogen receptor alpha (ERα Millipore) polyclonal antibody (Millipore; 
Cat. No. 06-935; Batch No. NG1838275) is derived from KLH-conjugated synthetic 
peptide representing the last 15 amino acids of rat ERα (TYYIPPEAEGFPNTI). This 
antibody cross reacts with rat and mouse ERα but does not cross-react with ER-beta. 
According to the manufacturer’s technical information, this antibody recognises a 
single band in Western blot at 66 kDa. We found a similar pattern of 
immunoreactivity localised in the nucleus as previously reported (Bennett et al., 2003; 
Kiasalari et al., 2010). 
 
Goat anti-GFRα1 polyclonal, affinity purified antibody (R&D Systems, Minneapolis, 
MN, USA; Cat. No. AF560; Batch No. BQE024081) was raised against a 
recombinant rat GFRα1 extracellular domain (Access. No. U59486). The immunogen 
consisted of amino acid residues Ala 19-Leu445 of the rat GFRα1 extracellular 
domain fused to an Fc with a linker sequence CSIEGRMD; the Fc was cleaved, 
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leaving Ala 19-Leu445-CSIEGR (manufacturer’s technical information). According 
to the manufacturer’s technical information, this antibody is specific for GFRα1 in 
direct ELISA and Western blot. In Western blot, approximately 10% cross-reactivity 
with recombinant human GFRα2 and no cross-reactivity with recombinant mouse Ret 
or recombinant human GFRα3 is observed. In the current study, this antibody shows 
distinct patterns of immunoreactivity within DRG and spinal cord that demonstrate a 
lack of cross-reactivity with GFRα2 and GFRα3. This antibody produced a similar 
pattern of immunoreactivity in DRG and spinal cord as described previously (Forrest 
and Keast, 2008; Kalous et al., 2009; Keast et al., 2010). 
 
Goat anti-GFRα2 polyclonal, affinity purified antibody (R&D Systems; Cat. No. 
AF429; Batch No. BTM01) was raised against recombinant mouse GFRα2 
extracellular domain (Access. No. NM008115). The immunogen consisted of amino 
acid residues Thr160-Ser441 of the GFRα2 extracellular domain fused to Fc with 
linker sequence DIEGRMD; the Fc was cleaved, leaving Thr160-Ser441-CSIEGR 
(manufacturer’s technical information). In direct ELISA and Western blot, this 
antibody shows less than 5% cross-reactivity with recombinant human GFRα3 
(manufacturer’s technical information). We found a similar pattern of 
immunoreactivity in DRG and spinal cord as reported (Forrest and Keast, 2008; 
Kalous et al., 2007; 2009). 
 
Goat anti-GFRα3 polyclonal, affinity purified antibody (R&D Systems; Cat. No. 
AF2645; Batch No. VFU01) was raised against recombinant mouse GFRα3 protein 
(amino acid sequence 17-386; Access. No. O35118), linked to an Fc sequence as 
described above. In direct ELISA and Western blot, this antibody detects mouse 
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GFRα3. In direct ELISA, this antibody shows approximately 10% cross-reactivity 
with recombinant human GFRα3 and less than 2% cross-reactivity with recombinant 
mouse GFRα2, recombinant mouse GFRα4 and recombinant rat GFRα1 
(manufacturer’s technical information). This antibody produced a similar pattern of 
immunoreactivity in DRGs and spinal cord as previously described (Forrest and 
Keast, 2008; Keast et al., 2010; Orozco et al., 2001). 
 
Rabbit anti-glial fibrillary acidic protein (GFAP) polyclonal antibody 
(DakoCytomation; Cat. No. Z0334; Batch No. 072(102)) was isolated from cow 
spinal cord. This antibody cross-reacts with GFAP in cat, dog, mouse, rat, sheep, cow 
and humans (manufacturer’s technical information). According to the manufacturer’s 
technical information, in indirect ELISA, this antibody shows no reaction with human 
plasma and cow serum. This antibody produced similar staining in glial cells as 
described previously (Cheng et al., 2010; Feig and Haberly, 2011; Inglis et al., 2007; 
Vessey et al., 2011). 
 
Mouse anti-neurofilament 200 (NF200, clone N52) monoclonal antibody (Sigma; Cat. 
No. N0142; Batch No. 017K4802) was raised from a hybridoma produced by the 
fusion of mouse myeloma cells and splenocytes from an immunised mouse. The 
carboxyterminal tail segment of enzymatically dephosphorylated pig neurofilament 
H-subunit was used as the immunogen (manufacturer’s technical information).  In 
western blot this antibody specifically localises the neurofilament of molecular weight 
200 kDa in rat spinal cord using an immunoblotting technique and does not cross-
react with other intermediate filament proteins. According to the manufacturer’s 
technical information, this antibody shows broad species cross-reactivity by 
334
recognising neurofilament in the central and peripheral nervous system in human, 
monkey, pig, rabbit, hamster, rat and mouse. We found a similar pattern of 
immunoreactivity using this antibody in rat DRG as previously described (Keast et 
al., 2010; Scherrer et al., 2010; Zylka et al., 2005). 
 
Rabbit anti-neuropeptide Y (NPY) polyclonal antibody (DiaSorin, North Ryde, NSW, 
Australia; Cat. No. 61-7000; Batch No. 208001) was raised against synthetic porcine 
NPY conjugated to methylated bovine serum albumin. This antibody also reacts with 
NPY in a range of species including fish, newt, frog, bird, rat, cat and human (107) 
(manufacturer’s technical information). This antibody produced a similar pattern of 
staining in the bladder as numerous previous publications (Gnanamanickam and 
Llewellyn-Smith, 2011; Henrich et al., 2003; Iuchi et al., 1994). 
 
Rabbit anti-protein gene product 9.5 (PGP) polyclonal antibody (Millipore, Kilsyth, 
VIC; Cat. No. AB5925; Batch No. 0510012083) was raised against synthetic peptide 
from human PGP 9.5. This antibody also cross reacts with human, rat, mouse and 
porcine PGP 9.5 (manufacturer’s data sheet). This antibody produced a similar pattern 
of immunoreactivity in the detrusor as previously described (Davidson and 
McCloskey, 2005; Grol et al., 2008).  
 
Rabbit anti-nitric oxide synthase (NOS) polyclonal antibody (Zymed, now Invitrogen, 
Mulgrave, VIC, Australia; Cat. No. 61-7000; Batch No. 441121A) is derived from a 
recombinant protein consisting of 195 amino acids from the N-terminal of rat nNOS 
protein. According to the manufacturer’s technical information, this antibody reacts 
with ~160 kDa nNOS and does not cross-react with related eNOS or iNOS proteins. 
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This antibody reacts with a ~160 kDa band on Western blot of rat and mouse tissue 
lysates (manufacturer’s technical information). This antibody produced a similar 
pattern of immunoreactivity in rat spinal cord as previously described (Forrest and 
Keast, 2008; Vizzard et al., 1995). 
 
Mouse anti-S100 monoclonal antibody (Millipore; Cat. No. MAB079; Batch No. 
18070419) was raised against purified bovine S100 protein. This antibody reacts with 
intact alpha and beta subunits of bovine, human and murine S100 protein as 
determined by immunoprecipitation profiles (manufacturer’s technical information). 
This antibody produced a similar pattern of immunoreactivity as described previously 
(Chao et al., 2008; Yan and Keast, 2008). 
 
Mouse anti-smooth muscle actin-α, clone 1A4 (SMA) monoclonal antibody (Sigma-
Aldrich, Castle Hill, NSW, Australia; Cat. No. A5228) is derived from the 1A4 
hybridoma produced by the fusion of mouse myeloma cells and splenocytes from 
mice immunised with the NH2 terminal synthetic decapeptide of α-smooth muscle 
actin, coupled to keyhole limpet hemocyanin (manufacturer’s technical information). 
This antibody is specific to the α-actin single isoform and cross-reacts with human, 
rabbit, rat, mouse, bovine, frog, goat, guinea pig, dog, sheep, snake and chicken 
(manufacturer’s technical information). This antibody produced a similar pattern of 
immunoreactivity as described previously (Faggian et al., 1998; Goldshmit et al., 
2006). 
 
Mouse anti-synaptophysin (SYN) monoclonal antibody (DakoCytomation; Cat. No. 
M0776; Batch No. 013) is derived from crude fractions of coated vesicles from 
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bovine brain. This antibody cross-reacts with the SYN equivalent protein in human, 
cow, mouse, rat, guinea pig and rabbit (manufacturer’s technical information). In 
Western blots this antibody recognises a band of Mr 38,000 (manufacturer’s technical 
information). This antibody labelled a similar number of axons and produced a similar 
pattern of immunoreactivity in the bladder as described by others (Gabella and Davis, 
1998). 
 
Guinea pig anti-vanilloid receptor 1 (TRPV1, C-terminal) polyclonal antibody 
(Millipore; Cat. No. AB5566; Batch No. 20080714) is derived from a 22 amino acid 
peptide corresponding to the C-terminus of the rat capsaicin receptor protein. This 
antibody cross-reacts with rat but cross-reactivity with other species has not been 
tested (manufacturer’s technical information). We found a similar pattern of 
immunoreactivity in DRG neurons as previously described (Amadesi et al., 2009; 
Bennett et al., 2003; Braz and Basbaum, 2010). 
 
Rabbit anti-TRPV1 (N-terminal) polyclonal antibody (Neuromics; Cat. No. 
RA10110; Batch No. 200070) was raised against the sequence 
RASLDSEESESPPQENSC corresponding to residues 4-21 of the amino-terminus of 
rat vanilloid receptor 1 (manufacturer’s technical information). According to the 
manufacturer’s technical information, this antibody shows cross-reactivity in rat, 
mouse and primate and recognises a 90-100 kDa band in Western blot of DRG cell 
extracts (Kiasalari et al., 2010). This antibody produced a similar pattern of 
immunoreactivity in rat DRG as previously described (Bennett et al., 2003; Guo et al., 
1999; Kiasalari et al., 2010). 
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Rabbit anti-tyrosine hydroxylase (TH) polyclonal antibody (Millipore; Cat. No. 
AB152; Batch No. NG1830749) was raised against denatured TH from rat 
pheochromocytoma.  This antibody cross-reacts with most mammalian and many 
non-mammalian species including rat, mouse, ferret and Aplysia (marine mollusc) 
(manufacturer’s technical information). In Western blot this antibody specifically 
labels a single band at approximately 62 kDa (manufacturer’s technical information). 
In the bladder, this antibody produced a similar pattern of immunoreactivity as 
reported previously (Llewellyn-Smith and Gnanamanickam, 2010; Wakabayashi et 
al., 1994; Wakabayashi et al., 1993). 
 
Mouse anti-vimentin, Clone V9 (Vim) monoclonal antibody (Sigma-Aldrich; Cat. No. 
V6630; Batch No. 090M4817) was raised against Vim in pig eye lens. This antibody 
cross reacts with a variety of species including horse, monkey, bovine, rabbit, pig, 
canine, gerbil, rat, chicken, human, cat and hamster (manufacturer’s technical 
information). This antibody produced a similar pattern of immunoreactivity as 
previously described (Davidson and McCloskey, 2005; Grol et al., 2008; McCloskey, 
2010). 
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